0000950170-22-015737.txt : 20220809 0000950170-22-015737.hdr.sgml : 20220809 20220809070124 ACCESSION NUMBER: 0000950170-22-015737 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 75 CONFORMED PERIOD OF REPORT: 20220630 FILED AS OF DATE: 20220809 DATE AS OF CHANGE: 20220809 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Verve Therapeutics, Inc. CENTRAL INDEX KEY: 0001840574 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 824800132 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-40489 FILM NUMBER: 221146327 BUSINESS ADDRESS: STREET 1: 500 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: (978) 501-3026 MAIL ADDRESS: STREET 1: 500 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 10-Q 1 verv-20220630.htm 10-Q 10-Q
---12-31Q2 may also terminatefalse00018405740001840574us-gaap:RetainedEarningsMember2022-06-300001840574us-gaap:SubsequentEventMemberverv:VertexPharmaceuticalsMember2022-07-180001840574us-gaap:GeneralAndAdministrativeExpenseMember2021-04-012021-06-300001840574verv:StrategicLicenseAndCollaborationAgreementMembersrt:MinimumMemberus-gaap:SubsequentEventMember2022-07-182022-07-180001840574verv:OutstandingOptionsToPurchaseCommonStockMember2022-01-012022-06-300001840574verv:USTreasuryBillsAndNotesMemberus-gaap:FairValueInputsLevel3Member2021-12-310001840574us-gaap:SalesMemberverv:BeamLicenseAgreementMember2022-01-012022-06-300001840574us-gaap:AccountingStandardsUpdate201602Member2022-01-012022-06-3000018405742021-10-012021-10-310001840574verv:UnvestedRestrictedStockUnitsMember2021-01-012021-06-300001840574us-gaap:OtherExpenseMemberverv:AntidilutionRightsLiabilityMember2021-04-012021-06-300001840574us-gaap:FairValueInputsLevel2Memberverv:SuccessPaymentLiabilityMember2021-12-310001840574us-gaap:ResearchAndDevelopmentExpenseMember2022-04-012022-06-300001840574us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-06-300001840574us-gaap:IPOMember2021-06-300001840574us-gaap:EmployeeStockOptionMember2022-01-012022-06-300001840574us-gaap:EquipmentMember2022-06-300001840574us-gaap:RestrictedStockMember2022-06-300001840574us-gaap:FairValueInputsLevel1Memberverv:SuccessPaymentLiabilityMember2021-12-310001840574us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2021-12-310001840574us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-06-300001840574verv:AcuitasAgreementsMember2022-01-012022-06-300001840574verv:USTreasuryBillsAndNotesMemberus-gaap:FairValueInputsLevel1Member2021-12-310001840574us-gaap:RetainedEarningsMember2021-12-310001840574us-gaap:CommonStockMember2022-04-012022-06-300001840574verv:StrategicLicenseAndCollaborationAgreementMembersrt:MinimumMemberus-gaap:SubsequentEventMemberverv:VertexPharmaceuticalsMember2022-07-180001840574us-gaap:LicenseAgreementTermsMember2020-01-012020-10-310001840574us-gaap:GeneralAndAdministrativeExpenseMember2022-04-012022-06-300001840574us-gaap:AdditionalPaidInCapitalMember2021-03-310001840574us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2022-06-300001840574us-gaap:FairValueInputsLevel2Member2022-06-300001840574us-gaap:IPOMember2021-06-210001840574us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001840574verv:USTreasuryBillsAndNotesMemberus-gaap:FairValueInputsLevel2Member2022-06-300001840574us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001840574verv:SuccessPaymentLiabilityMemberus-gaap:FairValueInputsLevel3Member2021-12-310001840574verv:BroadLicenseAgreementMember2019-01-012019-12-310001840574verv:USAgencySecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-06-300001840574verv:BroadLicenseAgreementMemberverv:AntidilutionRightsMember2022-06-300001840574verv:StrategicLicenseAndCollaborationAgreementMemberus-gaap:SubsequentEventMemberverv:VertexPharmaceuticalsMember2022-07-182022-07-180001840574verv:AntidilutionRightsLiabilityMember2021-01-012021-06-300001840574verv:USAgencySecuritiesMemberus-gaap:FairValueInputsLevel3Member2021-12-310001840574us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001840574us-gaap:MeasurementInputPriceVolatilityMember2022-01-012022-06-300001840574us-gaap:MoneyMarketFundsMember2022-06-300001840574verv:UnvestedRestrictedStockMember2022-01-012022-06-3000018405742022-01-012022-03-310001840574us-gaap:USTreasurySecuritiesMember2022-06-300001840574us-gaap:CommonStockMember2022-03-310001840574verv:NewAmendmentMember2022-01-3100018405742022-06-300001840574us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001840574us-gaap:RestrictedStockMember2022-01-012022-06-300001840574verv:BeamLicenseAgreementMember2022-01-012022-06-3000018405742022-03-310001840574us-gaap:ComputerEquipmentMember2021-12-310001840574us-gaap:PreferredStockMember2021-01-012021-03-310001840574verv:BroadLicenseAgreementMember2022-06-300001840574us-gaap:OtherIncomeMember2022-04-012022-06-300001840574us-gaap:RetainedEarningsMember2022-01-012022-03-310001840574verv:PremisesMember2021-08-192021-08-190001840574us-gaap:SubsequentEventMemberverv:VertexPharmaceuticalsMember2022-07-202022-07-2000018405742022-08-0400018405742022-01-012022-06-300001840574us-gaap:FairValueInputsLevel1Member2021-12-310001840574us-gaap:FairValueInputsLevel1Memberverv:SuccessPaymentLiabilityMember2022-06-300001840574verv:StockPurchaseAgreementMemberus-gaap:SubsequentEventMemberverv:VertexPharmaceuticalsMember2022-07-180001840574country:NZverv:BeamLicenseAgreementMember2022-01-012022-06-300001840574verv:USTreasuryBillsAndNotesMember2022-06-300001840574us-gaap:FairValueInputsLevel1Memberverv:USAgencySecuritiesMember2022-06-300001840574verv:USTreasuryBillsAndNotesMemberus-gaap:FairValueInputsLevel2Member2021-12-310001840574us-gaap:FairValueInputsLevel2Member2021-12-310001840574us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001840574verv:PremisesMember2021-10-310001840574verv:SuccessPaymentLiabilityMemberus-gaap:FairValueInputsLevel3Member2022-06-300001840574us-gaap:FairValueInputsLevel1Member2022-06-300001840574us-gaap:AccountingStandardsUpdate201602Member2022-04-012022-06-300001840574us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-3100018405742020-12-310001840574us-gaap:CommonStockMember2021-06-3000018405742021-01-012021-12-310001840574us-gaap:LicenseAgreementTermsMember2021-10-012021-10-310001840574verv:HarvardAndBroadLicenseAgreementMember2022-06-300001840574verv:AcuitasAgreementsMember2022-04-012022-06-300001840574us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-06-300001840574us-gaap:CommonStockMember2022-01-012022-03-310001840574verv:HarvardAndBroadLicenseAgreementMember2021-09-300001840574us-gaap:OtherIncomeMember2022-01-012022-06-300001840574us-gaap:OtherExpenseMemberverv:AntidilutionRightsLiabilityMember2021-01-012021-06-300001840574verv:SuccessPaymentLiabilityMember2022-06-300001840574us-gaap:SalesMemberverv:BeamLicenseAgreementMember2021-04-012021-06-300001840574us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300001840574verv:UnvestedRestrictedStockMember2021-01-012021-06-300001840574verv:SuccessPaymentLiabilityMember2022-01-012022-06-300001840574verv:SuccessPaymentLiabilityMember2021-06-300001840574us-gaap:RetainedEarningsMember2022-04-012022-06-300001840574verv:PremisesMember2022-01-012022-06-300001840574verv:AcuitasAgreementsMember2021-01-012021-06-300001840574us-gaap:SubsequentEventMemberverv:VertexPharmaceuticalsMember2022-07-182022-07-180001840574us-gaap:RestrictedStockMemberverv:TwoThousandAndTwentyOneStockIncentivePlanMember2022-06-300001840574us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001840574us-gaap:AccountingStandardsUpdate201602Member2021-04-012021-06-300001840574us-gaap:CommonStockMember2022-06-300001840574us-gaap:AccountingStandardsUpdate201602Member2021-01-012021-06-300001840574us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2022-06-300001840574verv:BroadLicenseAgreementMember2020-01-012020-12-310001840574us-gaap:PreferredStockMember2020-12-310001840574us-gaap:RetainedEarningsMember2021-04-012021-06-300001840574verv:TwoThousandAndTwentyOneStockIncentivePlanMember2021-06-160001840574us-gaap:ResearchAndDevelopmentExpenseMember2021-04-012021-06-300001840574verv:StrategicLicenseAndCollaborationAgreementMembersrt:MaximumMemberus-gaap:SubsequentEventMember2022-07-180001840574us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-06-300001840574verv:AntidilutionRightsLiabilityMember2021-06-300001840574us-gaap:CommonStockMemberverv:TwentyTwentyOneEmployeeStockPurchasePlanMember2022-01-012022-06-300001840574verv:SuccessPaymentLiabilityMember2021-01-012021-06-300001840574us-gaap:OtherIncomeMember2021-04-012021-06-300001840574us-gaap:NonUsMemberverv:BeamLicenseAgreementMember2019-04-012019-04-300001840574us-gaap:RestrictedStockUnitsRSUMember2022-06-300001840574verv:BroadLicenseAgreementMemberus-gaap:LicenseAgreementTermsMember2022-01-012022-06-300001840574us-gaap:CommonStockMemberus-gaap:IPOMember2021-06-300001840574srt:MaximumMemberverv:HarvardLicenseAgreementMember2022-06-300001840574us-gaap:PreferredStockMember2021-03-310001840574us-gaap:MoneyMarketFundsMember2021-12-310001840574verv:USAgencySecuritiesMember2021-12-310001840574verv:SuccessPaymentLiabilityMember2020-12-310001840574us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2021-12-310001840574verv:USAgencySecuritiesMember2022-06-300001840574verv:USTreasuryBillsAndNotesMemberus-gaap:FairValueInputsLevel1Member2022-06-300001840574us-gaap:FairValueInputsLevel3Member2022-06-300001840574verv:StrategicLicenseAndCollaborationAgreementMemberus-gaap:SubsequentEventMember2022-07-202022-07-2000018405742021-06-300001840574us-gaap:CommonStockMember2021-01-012021-03-3100018405742021-01-012021-06-300001840574us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300001840574us-gaap:SubsequentEventMemberverv:StockPurchaseAgreementMemberverv:VertexPharmaceuticalsMember2022-07-182022-07-180001840574verv:PremisesMemberus-gaap:LetterOfCreditMember2021-08-190001840574verv:USTreasuryBillsAndNotesMember2021-12-310001840574us-gaap:CommonStockMember2021-04-012021-06-300001840574us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300001840574verv:StrategicLicenseAndCollaborationAgreementMembersrt:MaximumMemberus-gaap:SubsequentEventMemberverv:VertexPharmaceuticalsMember2022-07-1800018405742022-04-012022-06-300001840574verv:OutstandingOptionsToPurchaseCommonStockMember2021-01-012021-06-300001840574us-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-06-300001840574verv:PremisesMember2021-10-012021-10-310001840574verv:StrategicLicenseAndCollaborationAgreementMembersrt:MaximumMemberus-gaap:SubsequentEventMember2022-07-182022-07-180001840574us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2021-12-310001840574verv:UnvestedRestrictedStockUnitsMember2022-01-012022-06-300001840574us-gaap:AdditionalPaidInCapitalMember2020-12-310001840574verv:StrategicLicenseAndCollaborationAgreementMemberus-gaap:SubsequentEventMemberverv:VertexPharmaceuticalsMember2022-07-180001840574verv:TwentyTwentyOneEmployeeStockPurchasePlanMember2022-01-012022-06-300001840574us-gaap:IPOMember2022-01-012022-06-300001840574us-gaap:PreferredStockMemberus-gaap:SeriesBPreferredStockMember2021-01-310001840574us-gaap:FairValueInputsLevel2Memberverv:USAgencySecuritiesMember2021-12-310001840574us-gaap:CommonStockMemberverv:TwentyEighteenMember2022-06-300001840574us-gaap:USTreasurySecuritiesMember2021-12-310001840574verv:HarvardAndBroadLicenseAgreementMember2022-03-310001840574us-gaap:FurnitureAndFixturesMember2021-12-310001840574us-gaap:AdditionalPaidInCapitalMember2021-06-300001840574us-gaap:FairValueInputsLevel3Member2021-12-310001840574verv:HarvardAndBoardMember2021-06-300001840574us-gaap:LeaseholdImprovementsMember2022-06-300001840574us-gaap:LeaseholdImprovementsMember2021-12-310001840574us-gaap:CommonStockMemberverv:TwoThousandAndTwentyOneStockIncentivePlanMember2022-01-012022-01-010001840574verv:PremisesMember2022-06-300001840574verv:SuccessPaymentLiabilityMember2021-12-310001840574us-gaap:CommonStockMember2021-12-310001840574verv:BroadLicenseAgreementMember2022-01-012022-06-300001840574us-gaap:OtherIncomeMember2021-01-012021-06-300001840574us-gaap:EquipmentMember2021-12-310001840574us-gaap:USGovernmentAgenciesDebtSecuritiesMember2021-12-310001840574us-gaap:IPOMember2021-01-012021-06-300001840574us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-06-300001840574verv:BeamLicenseAgreementMember2022-04-012022-06-300001840574us-gaap:FairValueInputsLevel2Memberverv:SuccessPaymentLiabilityMember2022-06-300001840574us-gaap:FairValueInputsLevel1Memberverv:USAgencySecuritiesMember2021-12-310001840574verv:BeamLicenseAgreementMember2019-04-012019-04-300001840574us-gaap:SubsequentEventMemberverv:PublicOfferingMember2022-07-250001840574verv:BeamLicenseAgreementMember2019-04-300001840574verv:USTreasuryBillsAndNotesMemberus-gaap:FairValueInputsLevel3Member2022-06-300001840574us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300001840574us-gaap:SalesMemberverv:BeamLicenseAgreementMember2021-01-012021-06-300001840574us-gaap:RetainedEarningsMember2022-03-310001840574us-gaap:SubsequentEventMemberverv:PublicOfferingMember2022-07-252022-07-2500018405742021-03-310001840574us-gaap:ComputerEquipmentMember2022-06-300001840574us-gaap:EmployeeStockOptionMember2022-06-300001840574us-gaap:AdditionalPaidInCapitalMember2022-03-310001840574us-gaap:RetainedEarningsMember2021-01-012021-03-310001840574us-gaap:FairValueInputsLevel2Memberverv:USAgencySecuritiesMember2022-06-3000018405742021-12-310001840574verv:TwoThousandAndTwentyOneStockIncentivePlanMember2022-01-010001840574verv:TwentyTwentyOneEmployeeStockPurchasePlanMember2022-01-010001840574us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001840574us-gaap:CommonStockMemberverv:TwentyTwentyOneEmployeeStockPurchasePlanMember2022-06-300001840574us-gaap:SalesMemberverv:BeamLicenseAgreementMember2022-04-012022-06-300001840574us-gaap:RetainedEarningsMember2021-06-300001840574us-gaap:AdditionalPaidInCapitalMember2022-06-300001840574us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2022-06-300001840574verv:BeamLicenseAgreementMember2021-01-012021-06-300001840574us-gaap:CommonStockMember2021-03-310001840574verv:TwentyTwentyOneEmployeeStockPurchasePlanMember2022-06-300001840574verv:AntidilutionRightsLiabilityMember2020-12-310001840574us-gaap:PreferredStockMemberus-gaap:SeriesBPreferredStockMember2021-01-012021-01-3100018405742021-04-012021-06-300001840574us-gaap:LicenseAgreementTermsMember2022-01-012022-06-300001840574us-gaap:PreferredStockMember2021-04-012021-06-300001840574us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001840574verv:PremisesMember2021-08-190001840574us-gaap:FurnitureAndFixturesMember2022-06-300001840574verv:BeamMemberverv:MaterialsExchangeAgreementMemberus-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-06-300001840574verv:AcuitasAgreementsMember2021-04-012021-06-300001840574us-gaap:CommonStockMember2020-12-310001840574us-gaap:RetainedEarningsMember2020-12-310001840574verv:TwoThousandAndTwentyOneStockIncentivePlanMember2022-06-3000018405742021-01-012021-03-310001840574us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001840574verv:BeamLicenseAgreementMember2021-04-012021-06-300001840574us-gaap:RestrictedStockUnitsRSUMember2021-12-310001840574us-gaap:AdditionalPaidInCapitalMember2021-12-310001840574us-gaap:MeasurementInputPriceVolatilityMember2021-01-012021-12-310001840574us-gaap:PreferredStockMember2021-06-300001840574us-gaap:RetainedEarningsMember2021-03-310001840574verv:TwoThousandAndTwentyOneStockIncentivePlanMember2022-01-012022-06-300001840574verv:StrategicLicenseAndCollaborationAgreementMemberus-gaap:SubsequentEventMember2022-07-182022-07-18xbrli:pureutr:sqftxbrli:sharesiso4217:USDxbrli:sharesiso4217:USD

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2022

OR

 

TRANSITION REPORT PURSUANT TO 2SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to ____________

Commission File Number: 001-40489

 

VERVE THERAPEUTICS , INC.

(Exact Name of Registrant as Specified in its Charter)

 

 

Delaware

82-4800132

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer
Identification No.)

 

 

500 Technology Square, Suite 901

Cambridge, Massachusetts

02139

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (617) 603-0070

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common stock, par value $0.001 per share

 

VERV

 

Nasdaq Global Select Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

 

Accelerated filer

 

Non-accelerated filer

 

 

Smaller reporting company

 

 

 

 

 

Emerging growth company

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No

As of August 4, 2022, the registrant had 59,942,339 shares of common stock, par value $0.001 per share, outstanding.

 

 

 


 

FORWARD-LOOKING STATEMENTS

 

This Quarterly Report on Form 10-Q includes forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” or the negative of these words or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

 

The forward-looking statements in this Quarterly Report on Form 10-Q include, among other things, statements about:

the initiation, timing, progress and results of our research and development programs, preclinical studies and clinical trials, including the timing of our submissions of investigational new drug applications, or INDs, and clinical trial applications to regulatory authorities;
the timing and conduct of our heart-1 clinical trial, a Phase 1b clinical trial of VERVE-101, including statements regarding the timing of enrollment and completion of the clinical trials and the period during which the results of the clinical trials will become available;
our estimates regarding expenses, future revenue, capital requirements, need for additional financing and the period over which we believe our existing cash, cash equivalents and marketable securities will be sufficient to fund our operating expenses and capital expenditure requirements;
the timing of and our ability to submit applications for and obtain and maintain regulatory approvals for our current and future product candidates;
the potential therapeutic attributes and advantages of our current and future product candidates;
our expectations about the translatability of non-human primates results into humans;
our plans to develop and, if approved, subsequently commercialize any product candidates we may develop;
the rate and degree of market acceptance and clinical utility of our products, if approved;
our estimates regarding the addressable patient population and potential market opportunity for our current and future product candidates;
our commercialization, marketing and manufacturing capabilities and strategy;
our expectations regarding our ability to obtain and maintain intellectual property protection;
our ability to identify additional products, product candidates or technologies with significant commercial potential that are consistent with our commercial objectives;
the impact of government laws and regulations;
our competitive position and expectations regarding developments and projections relating to our competitors and any competing therapies that are or become available;
developments relating to our competitors and our industry;
our ability to establish and maintain collaborations or obtain additional funding;
the impact of the ongoing COVID-19 pandemic and our response to the pandemic; and
our expectations regarding the time during which we will be an emerging growth company under the Jumpstart Our Business Startups Act.

We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this Quarterly Report on Form 10-Q, particularly in the “Risk Factors” section, that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, collaborations, joint ventures or investments we may make or enter into.

You should read this Quarterly Report on Form 10-Q and the documents that we reference in this Quarterly Report on Form 10-Q and have filed as exhibits to our other filings with the Securities and Exchange Commission completely and

 


 

with the understanding that our actual future results may be materially different from what we expect. The forward-looking statements contained in this Quarterly Report on Form 10-Q are made as of the date of this Quarterly Report on Form 10-Q, and we do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Except where the context otherwise requires or where otherwise indicated, the terms “we,” “us,” “our,” “our company,” “the company,” and “our business” in this Quarterly Report on Form 10-Q refer to Verve Therapeutics, Inc. and its consolidated subsidiary.

 

 


 

 

RISK FACTOR SUMMARY

 

Our business is subject to a number of risks of which you should be aware before making an investment decision. Below we summarize what we believe to be the principal risks facing our business, in addition to the risks described more fully in Item 1A, “Risk Factors” of Part II of this Quarterly Report on Form 10-Q and other information included in this report. The risks and uncertainties described below are not the only risks and uncertainties we face. Additional risks and uncertainties not presently known to us or that we presently deem less significant may also impair our business operations.

If any of the following risks occurs, our business, financial condition and results of operations and future growth prospects could be materially and adversely affected, and the actual outcomes of matters as to which forward-looking statements are made in this report could be materially different from those anticipated in such forward-looking statements:

We will need substantial additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts;
Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability;
We are very early in our development efforts, and we only recently initiated our first clinical trial of a product candidate, VERVE-101. As a result, we expect it will be many years before we commercialize any product candidate, if ever. If we are unable to advance our current or future product candidates into and through clinical trials, obtain marketing approval and ultimately commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed;
Gene editing, including base editing, is a novel technology in a rapidly evolving field that is not yet clinically validated as being safe and efficacious for human therapeutic use. The approaches we are taking to discover and develop novel therapeutics are unproven and may never lead to marketable products. We are focusing our research and development efforts for VERVE-101 and VERVE-201, our development candidate targeting ANGPTL3, on gene editing using base editing technology, but other gene editing technologies may be discovered that provide significant advantages over base editing and we may not be able to access or use those technologies, which could materially harm our business. We are also seeking to discover new gene editing technologies and may not be successful in doing so;
The outcome of preclinical studies and earlier-stage clinical trials may not be predictive of future results or the success of later preclinical studies and clinical trials;
If any of the product candidates we may develop, or the delivery modes we rely on to administer them, cause serious adverse events, undesirable side effects or unexpected characteristics, such events, side effects or characteristics could delay or prevent regulatory approval of the product candidates, limit the commercial potential or result in significant negative consequences following any potential marketing approval;
Adverse public perception of genetic medicines, and gene editing and base editing in particular, may negatively impact regulatory approval of, and/or demand for, our potential products;
Genetic medicines are complex and difficult to manufacture. We could experience delays in satisfying regulatory authorities or production problems that result in delays in our development programs, limit the supply of our product candidates we may develop, or otherwise harm our business;
We rely, and expect to continue to rely, on third parties to conduct some or all aspects of our product manufacturing, research and preclinical and clinical testing, and these third parties may not perform satisfactorily;
We have entered into collaborations, and may enter into additional collaborations, with third parties for the research, development, manufacture and commercialization of programs or product candidates. If these collaborations are not successful, our business could be adversely affected;
If we or our licensors are unable to obtain, maintain, defend and enforce patent rights that cover our gene editing technology and product candidates or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully develop and commercialize our technology and product candidates may be adversely affected;
If we fail to comply with our obligations in our intellectual property license arrangements with third parties, or otherwise experience disruptions to our business relationships with our licensors, we could lose intellectual property rights that are important to our business;
The intellectual property landscape around genome editing technology, including base editing, is highly dynamic, and third parties may initiate legal proceedings alleging that we are infringing, misappropriating, or otherwise violating their

 


 

intellectual property rights, the outcome of which would be uncertain and may prevent, delay or otherwise interfere with our product discovery, development and commercialization efforts;
We face substantial competition, which may result in others discovering, developing or commercializing products before us or more successfully than we do; and
The ongoing COVID-19 pandemic may affect our ability to initiate and complete preclinical studies, delay the initiation of future clinical trials, disrupt regulatory activities or have other adverse effects on our business and operations. In addition, this pandemic has adversely impacted economies worldwide, which could result in adverse effects on our business, operations and ability to raise capital.

 

 


 

 

Table of Contents

 

 

 

Page

PART I.

FINANCIAL INFORMATION

1

Item 1.

Financial Statements (Unaudited)

1

 

Condensed Consolidated Balance Sheets

1

 

Condensed Consolidated Statements of Operations and Comprehensive Loss

2

 

Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit)

3

 

Condensed Consolidated Statements of Cash Flows

4

 

Notes to Unaudited Condensed Consolidated Financial Statements

5

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

19

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

33

Item 4.

Controls and Procedures

33

 

 

 

PART II.

OTHER INFORMATION

34

Item 1.

Legal Proceedings

34

Item 1A.

Risk Factors

34

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

95

Item 6.

Exhibits

96

Signatures

97

 

 

 


 

Part I ─ Financial Information

Item 1. Financial Statements

Verve Therapeutics, Inc.

Condensed consolidated balance sheets

 

(in thousands, except share and per share amounts)
(unaudited)

 

June 30,
2022

 

 

December 31,
2021

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

72,889

 

 

$

64,330

 

Marketable securities

 

 

220,672

 

 

 

296,112

 

Prepaid expenses and other current assets

 

 

5,083

 

 

 

6,686

 

Total current assets

 

 

298,644

 

 

 

367,128

 

Property and equipment, net

 

 

12,354

 

 

 

7,224

 

Restricted cash

 

 

5,237

 

 

 

5,237

 

Operating lease right-of-use assets

 

 

839

 

 

 

1,839

 

Other long term assets

 

 

7,193

 

 

 

2,696

 

Total assets

 

$

324,267

 

 

$

384,124

 

Liabilities and stockholders’ equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

6,320

 

 

$

7,077

 

Accrued expenses

 

 

18,620

 

 

 

12,992

 

Operating lease obligations, current portion

 

 

907

 

 

 

1,955

 

Total current liabilities

 

 

25,847

 

 

 

22,024

 

Success payment liability

 

 

1,756

 

 

 

4,371

 

Other long term liabilities

 

 

331

 

 

 

377

 

Total liabilities

 

 

27,934

 

 

 

26,772

 

Commitments and contingencies (See Note 7 and Note 8)

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively

 

 

 

 

 

 

Common stock, $0.001 par value; 200,000,000 shares authorized, 48,709,652 and 48,511,735 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively

 

 

49

 

 

 

49

 

Additional paid-in capital

 

 

555,184

 

 

 

544,381

 

Accumulated other comprehensive loss

 

 

(938

)

 

 

(228

)

Accumulated deficit

 

 

(257,962

)

 

 

(186,850

)

Total stockholders’ equity

 

 

296,333

 

 

 

357,352

 

Total liabilities and stockholders’ equity

 

$

324,267

 

 

$

384,124

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

1


 

Verve Therapeutics, Inc.

Condensed consolidated statements of operations and comprehensive loss

 

 

 

Three months ended June 30,

 

 

Six months ended June 30,

 

(in thousands, except share and per share amounts)
(unaudited)

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

$

33,125

 

 

$

13,423

 

 

$

57,614

 

 

$

24,768

 

General and administrative

 

 

9,067

 

 

 

3,541

 

 

 

16,503

 

 

 

6,257

 

Total operating expenses

 

 

42,192

 

 

 

16,964

 

 

 

74,117

 

 

 

31,025

 

Loss from operations

 

 

(42,192

)

 

 

(16,964

)

 

 

(74,117

)

 

 

(31,025

)

Other income (expense):

 

 

 

 

 

 

 

 

 

 

 

 

Change in fair value of antidilution rights liability

 

 

-

 

 

 

(25,970

)

 

 

-

 

 

 

(25,574

)

Change in fair value of success payment liability

 

 

938

 

 

 

(10,036

)

 

 

2,615

 

 

 

(9,654

)

Interest and other income, net

 

 

308

 

 

 

5

 

 

 

390

 

 

 

25

 

Total other income (expense), net

 

 

1,246

 

 

 

(36,001

)

 

 

3,005

 

 

 

(35,203

)

Net loss

 

$

(40,946

)

 

$

(52,965

)

 

$

(71,112

)

 

$

(66,228

)

Net loss per common share attributable to common stockholders, basic and diluted

 

$

(0.84

)

 

$

(6.66

)

 

$

(1.46

)

 

$

(12.46

)

Weighted-average common shares used in net loss per share attributable to common stockholders, basic and diluted

 

 

48,674,873

 

 

 

7,948,110

 

 

 

48,623,330

 

 

 

5,316,084

 

Comprehensive Loss:

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(40,946

)

 

$

(52,965

)

 

$

(71,112

)

 

$

(66,228

)

Other comprehensive loss:

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized loss on marketable securities

 

 

(206

)

 

 

(4

)

 

 

(710

)

 

 

(5

)

Comprehensive loss

 

$

(41,152

)

 

$

(52,969

)

 

$

(71,822

)

 

$

(66,233

)

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

2


 

Verve Therapeutics, Inc.

Condensed consolidated statements of convertible preferred stock and stockholders’ equity (deficit)

 

 

 

Convertible preferred stock

 

 

Common stock

 

 

 

 

 

 

 

 

 

 

 

 

 

(in thousands, except share amounts)
(unaudited)

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

Additional
paid-in
capital

 

 

Accumulated
other
comprehensive
income (loss)

 

 

Accumulated
deficit

 

 

Total
stockholders’
equity (deficit)

 

Balance at December 31, 2020

 

 

179,519,032

 

 

$

125,160

 

 

 

2,585,789

 

 

$

3

 

 

$

2,616

 

 

$

8

 

 

$

(66,536

)

 

$

(63,909

)

Issuance of Series B convertible preferred stock, net of issuance costs of $241

 

 

77,163,022

 

 

 

93,759

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Vesting of restricted common stock

 

 

 

 

 

 

 

 

134,409

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exercise of stock options

 

 

 

 

 

 

 

 

48,745

 

 

 

 

 

 

72

 

 

 

 

 

 

 

 

 

72

 

Unrealized loss on available-for-sale securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(1

)

 

 

 

 

 

(1

)

Stock-based compensation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

670

 

 

 

 

 

 

 

 

 

670

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(13,263

)

 

 

(13,263

)

Balance at March 31, 2021

 

 

256,682,054

 

 

$

218,919

 

 

 

2,768,943

 

 

$

3

 

 

$

3,358

 

 

$

7

 

 

$

(79,799

)

 

$

(76,431

)

Conversion of convertible preferred stock to common stock upon closing of initial public offering

 

 

(256,682,054

)

 

 

(218,919

)

 

 

27,720,923

 

 

 

28

 

 

 

218,891

 

 

 

 

 

 

 

 

 

218,919

 

Issuance of common stock from initial public offering, net of issuance costs of $25,098

 

 

 

 

 

 

 

 

16,141,157

 

 

 

16

 

 

 

281,568

 

 

 

 

 

 

 

 

 

281,584

 

Issuance of common stock to licensor institutions

 

 

 

 

 

 

 

 

878,098

 

 

 

1

 

 

 

32,489

 

 

 

 

 

 

 

 

 

32,490

 

Vesting of restricted common stock

 

 

 

 

 

 

 

 

134,408

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exercise of stock options

 

 

 

 

 

 

 

 

303,467

 

 

 

 

 

 

452

 

 

 

 

 

 

 

 

 

452

 

Unrealized loss on available-for-sale securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(4

)

 

 

 

 

 

(4

)

Stock-based compensation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1,351

 

 

 

 

 

 

 

 

 

1,351

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(52,965

)

 

 

(52,965

)

Balance at June 30, 2021

 

 

 

 

$

 

 

 

47,946,996

 

 

$

48

 

 

$

538,109

 

 

$

3

 

 

$

(132,764

)

 

$

405,396

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at December 31, 2021

 

 

 

 

$

 

 

 

48,511,735

 

 

$

49

 

 

$

544,381

 

 

$

(228

)

 

$

(186,850

)

 

$

357,352

 

Exercise of stock options

 

 

 

 

 

 

 

 

143,506

 

 

 

 

 

 

505

 

 

 

 

 

 

 

 

 

505

 

Unrealized loss on available-for-sale securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(504

)

 

 

 

 

 

(504

)

Stock-based compensation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

4,203

 

 

 

 

 

 

 

 

 

4,203

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(30,166

)

 

 

(30,166

)

Balance at March 31, 2022

 

 

 

 

$

 

 

 

48,655,241

 

 

$

49

 

 

$

549,089

 

 

$

(732

)

 

$

(217,016

)

 

$

331,390

 

Exercise of stock options

 

 

 

 

 

 

 

 

29,193

 

 

 

 

 

 

120

 

 

 

 

 

 

 

 

 

120

 

Issuance of common stock under employee stock purchase plan

 

 

 

 

 

 

 

 

25,218

 

 

 

 

 

 

325

 

 

 

 

 

 

 

 

 

325

 

Unrealized loss on available-for-sale securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(206

)

 

 

 

 

 

(206

)

Stock-based compensation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

5,650

 

 

 

 

 

 

 

 

 

5,650

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(40,946

)

 

 

(40,946

)

Balance at June 30, 2022

 

 

 

 

$

 

 

 

48,709,652

 

 

$

49

 

 

$

555,184

 

 

$

(938

)

 

$

(257,962

)

 

$

296,333

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

3


 

Verve Therapeutics, Inc.

Condensed consolidated statements of cash flows

 

 

 

Six months ended June 30,

 

(unaudited, in thousands)

 

2022

 

 

2021

 

Cash flows from operating activities:

 

 

 

 

 

 

Net loss

 

$

(71,112

)

 

$

(66,228

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

Depreciation

 

 

1,162

 

 

 

651

 

Non-cash lease expense

 

 

999

 

 

 

865

 

Amortization of premium on marketable securities

 

 

1,231

 

 

 

356

 

Stock-based compensation

 

 

9,853

 

 

 

2,021

 

Change in fair value of antidilution rights

 

 

 

 

 

25,574

 

Change in fair value of success payments liabilities

 

 

(2,615

)

 

 

9,654

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

Prepaid expenses and other assets

 

 

(2,894

)

 

 

(159

)

Accounts payable

 

 

(1,017

)

 

 

1,283

 

Accrued expenses and other liabilities

 

 

5,176

 

 

 

(1,584

)

Operating lease liabilities

 

 

(1,048

)

 

 

(915

)

Net cash used in operating activities

 

 

(60,265

)

 

 

(28,482

)

Cash flows from investing activities:

 

 

 

 

 

 

Purchases of property and equipment

 

 

(5,627

)

 

 

(2,376

)

Purchases of marketable securities

 

 

(74,249

)

 

 

(11,176

)

Maturities of marketable securities

 

 

147,750

 

 

 

43,755

 

Net cash provided by investing activities

 

 

67,874

 

 

 

30,203

 

Cash flows from financing activities:

 

 

 

 

 

 

Proceeds from issuance of Series B convertible preferred stock, net

 

 

-

 

 

 

93,759

 

Proceeds from initial public offering, net of underwriting discount

 

 

-

 

 

 

285,214

 

Payment of initial public offering costs

 

 

-

 

 

 

(2,765

)

Proceeds from exercise of stock options

 

 

625

 

 

 

524

 

Issuance of shares through employee stock purchase plan

 

 

325

 

 

 

 

Net cash provided by financing activities

 

 

950

 

 

 

376,732

 

Increase in cash, cash equivalents and restricted cash

 

 

8,559

 

 

 

378,453

 

Cash, cash equivalents and restricted cash—beginning of period

 

 

69,567

 

 

 

9,456

 

Cash, cash equivalents and restricted cash—end of period

 

$

78,126

 

 

$

387,909

 

Supplemental disclosure of noncash investing and financing activities:

 

 

 

 

 

 

Property and equipment additions included in accounts payable and accrued expenses

 

$

1,169

 

 

$

794

 

Initial public offering costs included in accounts payable and accrued liabilities

 

$

 

 

$

865

 

Conversion of convertible preferred stock to common stock upon closing of initial public offering

 

$

 

 

$

218,919

 

Settlement of antidilution rights liability by issuing common stock

 

$

 

 

$

32,490

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

4


 

Verve Therapeutics, Inc.

Notes to condensed consolidated financial statements (unaudited)

1. Nature of the business and basis of presentation

Organization

Verve Therapeutics, Inc. (the “Company” or “Verve”) is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The Company was incorporated on March 9, 2018 as Endcadia, Inc., a Delaware corporation, and began operations shortly thereafter. In January 2019, the Company amended its certificate of incorporation to change its name to Verve Therapeutics, Inc. The Company’s principal offices are located in Cambridge, Massachusetts.

Liquidity and capital resources

Since its inception, the Company has devoted its efforts principally to research and development and raising capital. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry including, but not limited to, technical risks associated with the successful research, development and manufacturing of product candidates, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Current and future programs will require significant research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.

In connection with the Company's initial public offering, or IPO, in June 2021, the Company effected a one-for-9.2595 reverse stock split of the Company’s issued and outstanding common stock. Accordingly, all shares of common stock and per share amounts, as well as the conversion ratio of the Company’s outstanding convertible preferred stock, for all periods presented in the accompanying condensed consolidated financial statements and notes thereto have been retroactively adjusted, where applicable, to reflect the reverse stock split, including reclassification of par and additional paid-in capital amounts as a result of the reverse stock split.

Subsequent to June 30, 2022, on July 18, 2022, the Company entered into a Strategic Collaboration and License Agreement (the “Vertex Agreement”) with Vertex Pharmaceuticals Incorporated (“Vertex”) for an exclusive, four-year worldwide research collaboration focused on developing in vivo gene editing candidates toward an undisclosed target for the treatment of a single liver disease, as further described in Note 14, “Subsequent events.” Pursuant to the Vertex Agreement, Vertex paid the Company $25.0 million in an upfront payment on July 20, 2022. The Company is eligible to receive (i) success payments of up to $22 million for each product candidate (up to a maximum of $66 million) that achieves the applicable development criteria and (ii) up to an aggregate of $340 million in development and commercial milestone payments. The Company is also eligible to receive tiered single-digit royalties on net sales, subject to specified reductions.

On July 18, 2022, in connection with the execution of the Vertex Agreement, the Company also entered into a stock purchase agreement with Vertex (the “Stock Purchase Agreement”) for the sale and issuance of 1,519,756 shares of the Company’s common stock to Vertex at a price of $23.03 per share, which was equal to the five-day volume-weighted average share price as of July 15, 2022, for an aggregate purchase price of $35.0 million (the “Private Placement”). The Private Placement closed on July 20, 2022.

On July 25, 2022, the Company issued and sold 9,583,334 shares of its common, including an additional 1,250,000 shares its common stock sold pursuant to the underwriters’ full exercise of their option to purchase additional shares of common stock, at a public offering price of $27.00 per share, for aggregate net proceeds of approximately $242.9 million after deducting underwriting discounts and commissions of approximately $15.5 million and offering costs of approximately $0.3 million.

The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company expects that its cash, cash equivalents and marketable securities of $293.6 million as of June 30, 2022, together with the net proceeds of approximately $242.9 million from the July 2022 follow-on public offering, $35.0

5


 

million from the Private Placement with Vertex, and $25.0 million upfront payment from Vertex pursuant to the Vertex Agreement, will be sufficient to fund its operations and capital expenditure requirements beyond the next 12 months from the date of issuance of these financial statements. The Company will need additional financing to support its continuing operations and pursue its growth strategy. Until such time as the Company can generate significant revenue from product sales, if ever, it expects to finance its operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. The Company may be unable to raise additional funds or enter into such other agreements when needed on favorable terms or at all. The inability to raise capital as and when needed could have a negative impact on the Company’s financial condition and its ability to pursue its business strategy. The Company will need to generate significant revenue to achieve profitability, and it may never do so.

Basis of presentation

The accompanying condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC"). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations.

The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements. In the opinion of the Company’s management, the accompanying unaudited interim condensed consolidated financial statements contain all adjustments that are necessary to present fairly the Company’s financial position as of June 30, 2022, the results of its operations and other comprehensive loss for the three and six months ended June 30, 2022 and 2021, convertible preferred stock and stockholders’ equity for the three and six months ended June 30, 2022 and 2021 and cash flows for the six months ended June 30, 2022 and 2021. Such adjustments are of a normal and recurring nature. The results for the three and six months ended June 30, 2022 are not necessarily indicative of the results for the year ending December 31, 2022, or for any future period. These interim financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended December 31, 2021, and the notes thereto, included in the Company’s Annual Report on Form 10-K filed with the SEC on March 14, 2022.

2. Summary of significant accounting policies

The Company's significant accounting policies are disclosed in Note 2, "Summary of significant accounting policies," in the audited consolidated financial statements for the year ended December 31, 2021, and notes thereto, included in the Company’s Annual Report on Form 10-K filed with the SEC on March 14, 2022. Since the date of those financial statements, there have been no changes to its significant accounting policies.

Cash, cash equivalents and restricted cash

Restricted cash represents collateral provided for letters of credit issued as security deposits in connection with the Company’s leases of its corporate facilities. A reconciliation of the cash, cash equivalents, and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the statement of cash flows is as follows:

 

 

 

June 30,

 

 

June 30,

 

(in thousands)

 

2022

 

 

2021

 

Cash and cash equivalents

 

$

72,889

 

 

$

387,446

 

Restricted cash

 

 

5,237

 

 

 

463

 

Total cash, cash equivalents and restricted cash

 

$

78,126

 

 

$

387,909

 

Recently adopted accounting pronouncements

During the quarter ended September 30, 2021, the Company early adopted ASC Topic 842, “Leases” (“ASC 842”) using the revised modified retrospective approach as of January 1, 2021. The unaudited interim condensed consolidated financial statements for the three and six months ended June 30, 2021 have been retroactively adjusted to reflect the adoption of ASC 842, including retroactive adjustments to the unaudited interim condensed consolidated statement of cash flows and certain additional footnote disclosures as included herein. The adoption of ASC 842 had no material impact to the Company’s unaudited condensed consolidated statement of operations and comprehensive loss for the three and six months ended June 30, 2021.

6


 

At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on specific facts and circumstances, the existence of an identified asset(s), if any, and the Company’s control over the use of the identified asset(s), if applicable. The lease liability is measured at the present value of future lease payments, discounted using the discount rate as of the lease commencement date. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the incremental borrowing rate, which is the rate incurred to borrow, on a collateralized basis over a similar term, an amount equal to the lease payments in a similar economic environment. The Company recognizes a corresponding lease right of use (“ROU”) asset, initially measured as the amount of lease liability, adjusted for any initial lease costs or lease payments made before or at the commencement of the lease, and reduced by any lease incentives.

The Company’s leases consist of only operating leases. Operating leases are recognized on the balance sheet as ROU lease assets, lease liabilities current and lease liabilities non-current. Fixed rents are included in the calculation of the lease balances while certain variable costs paid for certain operating and pass-through costs are excluded. Lease expense is recognized over the expected term on a straight-line basis.

 

3. Marketable securities

Marketable securities by security type consisted of the following:

 

 

 

June 30, 2022

 

(in thousands)

 

Amortized
cost

 

 

Gross
unrealized
gains

 

 

Gross
unrealized
losses*

 

 

Fair
value

 

U.S. treasury bills and notes

 

$

215,407

 

 

$

 

 

$

(930

)

 

$

214,477

 

U.S. agency securities

 

 

6,203

 

 

 

 

 

 

(8

)

 

 

6,195

 

Total

 

$

221,610

 

 

$

 

 

$

(938

)

 

$

220,672

 

 

 

 

December 31, 2021

 

(in thousands)

 

Amortized
cost

 

 

Gross
unrealized
gains

 

 

Gross
unrealized
losses*

 

 

Fair
value

 

U.S. treasury bills and notes

 

$

277,559

 

 

$

 

 

$

(218

)

 

$

277,341

 

U.S. agency securities

 

 

18,781

 

 

 

 

 

 

(10

)

 

 

18,771

 

Total

 

$

296,340

 

 

$

 

 

$

(228

)

 

$

296,112

 

*The Company reviews its marketable securities for impairment each period whenever the fair value of a marketable security is less than the amortized cost and evidence indicates that a marketable security’s carrying amount is not recoverable. As of June 30, 2022 and December 31, 2021, the Company expected its investments to recover through the remaining term of the security and concluded no impairment existed.

The remaining contractual maturities of all marketable securities were less than one year as of June 30, 2022 and December 31, 2021.

4. Property and equipment, net

Property and equipment, net, consist of the following:

 

(in thousands)

 

June 30, 2022

 

 

December 31, 2021

 

Lab equipment

 

$

13,509

 

 

$

8,567

 

Furniture and fixtures

 

 

1,618

 

 

 

566

 

Computer equipment

 

 

448

 

 

 

158

 

Leasehold improvements

 

 

274

 

 

 

266

 

Total property and equipment

 

 

15,849

 

 

 

9,557

 

Less accumulated depreciation

 

 

(3,495

)

 

 

(2,333

)

Property and equipment, net

 

$

12,354

 

 

$

7,224

 

 

Depreciation expense for the three and six months ended June 30, 2022 was $0.6 million and $1.2 million, respectively.

Depreciation expense for the three and six months ended June 30, 2021 was $0.4 million and $0.7 million, respectively.

7


 

5. fair value of financial instruments

The Company’s financial instruments that are measured at fair value on a recurring basis consist of money market funds, marketable securities, and a derivative liability (success payment liability) pursuant to our license agreements with the President and Fellows of Harvard College, or Harvard, and The Broad Institute, Inc., or Broad, which license agreements are referred to herein as the Harvard/Broad License Agreement and Broad License Agreement.

The following tables set forth the fair value of the Company’s financial instruments by level within the fair value hierarchy:

 

 

 

As of June 30, 2022

 

(in thousands)

 

Fair
value

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

36,302

 

 

$

36,302

 

 

$

 

 

$

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury bills and notes

 

 

214,477

 

 

 

 

 

 

214,477

 

 

 

 

U.S. agency securities

 

 

6,195

 

 

 

 

 

 

6,195

 

 

 

 

Total assets

 

$

256,974

 

 

$

36,302

 

 

$

220,672

 

 

$

 

Liabilities

 

 

 

 

 

 

 

 

 

 

 

 

Success payment liability

 

$

1,756

 

 

$

 

 

$

 

 

$

1,756

 

Total liabilities

 

$

1,756

 

 

$

 

 

$

 

 

$

1,756

 

 

 

 

 

As of December 31, 2021

 

(in thousands)

 

Fair
value

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

58,127

 

 

$

58,127

 

 

$

 

 

$

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury bills and notes

 

 

277,341

 

 

 

 

 

 

277,341

 

 

 

 

U.S. agency securities

 

 

18,771

 

 

 

 

 

 

18,771

 

 

 

 

Total assets

 

$

354,239

 

 

$

58,127

 

 

$

296,112

 

 

$

 

Liabilities

 

 

 

 

 

 

 

 

 

 

 

 

Success payment liability

 

$

4,371

 

 

$

 

 

$

 

 

$

4,371

 

Total liabilities

 

$

4,371

 

 

$

 

 

$

 

 

$

4,371

 

 

Cash Equivalents—Cash equivalents of $36.3 million and $58.1 million as of June 30, 2022 and December 31, 2021, respectively, consisted of money market funds and are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices in active markets.

Marketable Securities—The Company measures its marketable securities at fair value on a recurring basis and classifies those instruments within Level 2 of the fair value hierarchy. Marketable securities are classified within Level 2 of the fair value hierarchy because pricing inputs are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date, and fair value is determined through the use of models or other valuation methodologies.

Antidilution Rights Liability—The antidilution rights liability represented the obligation to issue additional shares of common stock to Harvard and Broad following the completion of (1) a defined aggregate level of preferred stock financing and (2) either a sale of the Company’s preferred stock, an initial public offering, or a company sale meeting a certain value threshold. The antidilution rights liability is stated at fair value and is considered Level 3 in the fair value hierarchy because its fair value measurement is based, in part, on significant inputs not observed in the market. The antidilution rights liability related to meeting a defined aggregate level of preferred stock financing was valued using a probability-weighted present value model that considered the probability of meeting the defined aggregate level of preferred stock financing, as well as the fair value of the Company’s common stock. The antidilution rights liability related to the achievement of a specified valuation through either a sale of the Company’s preferred stock, an initial public offering, or a company sale was valued using a Monte Carlo simulation model, which models the value of the liability based on several key variables, including probability of event occurrence, timing of event occurrence, as well as the fair value of the Company’s common stock.

In June 2021, upon completion of its IPO, the Company settled the antidilution rights liability in full through the issuance of 878,098 shares of the Company's common stock for a settlement amount of $32.5 million. Prior to settlement, the Company remeasured the liability with a corresponding increase of $26.0 million and $25.6 million to other expense for

8


 

the three and six months ended June 30, 2021, respectively. As the antidilution rights liability was settled in full in June 2021, there were no amounts for such liability included in the condensed consolidated balance sheet as of June 30, 2022 or December 31, 2021.

Success Payment Liability—The Company is obligated to pay to Harvard and Broad tiered success payments in the event its average market capitalization exceeds specified thresholds for a specified period of time ascending from a high nine-digit dollar amount to $10.0 billion, or sale of the Company for consideration in excess of those thresholds. In the event of a change of control or a sale of the Company, the Company is required to pay success payments in cash within a specified period following such event. Otherwise, the success payments may be settled at the Company’s option in either cash or shares of its common stock, or a combination of cash and shares of its common stock. The maximum aggregate success payments that could be payable by the Company is $31.3 million (after termination of the Broad License Agreement).

The success payments liability is stated at fair value and is considered Level 3 because its fair value measurement is based, in part, on significant inputs not observed in the market. The Company used a Monte Carlo simulation model, which models the value of the liability based on several key variables, including probability of event occurrence, timing of event occurrence, as well as the value of the Company’s common stock. The Company also estimated the likelihood that it would maintain the Harvard/Broad License Agreement based on its ongoing research efforts.

The Company remeasured the liability at fair value with decreases of $0.9 million and $2.6 million recorded to other income for the three and six months ended June 30, 2022, respectively, and increases of $10.0 million and $9.7 million recorded to other expense for the three and six months ended June 30, 2021, respectively.

In September 2021, multiple success payments were triggered and amounts due to Harvard and Broad totaled $6.3 million. These amounts were settled in cash in November 2021. The Company will continue to adjust the remaining success payment liability for changes in fair value until the earlier of the achievement or expiration of the obligation.

The primary inputs used in valuing the success payments liability associated with the Company’s realization of a certain valuation threshold, were as follows:

 

 

 

At
June 30,
2022

 

 

At
December 31,
2021

 

Fair value of common stock (per share)

 

$

15.28

 

 

$

36.87

 

Equity volatility

 

 

88

%

 

 

77

%

 

In February 2021, the Company provided written notice to Broad of its election to terminate the Broad License Agreement, which termination became effective in June 2021.

The reconciliation of changes in the fair value of financial instruments based on Level 3 inputs for the six months ended June 30, 2022 is as follows:

 

(in thousands)

 

Success
payment
liability

 

Balance at December 31, 2021

 

$

4,371

 

Changes in fair value

 

 

(2,615

)

Balance at June 30, 2022

 

$

1,756

 

 

The reconciliation of changes in the fair value of financial instruments based on Level 3 inputs for the six months ended June 30, 2021 is as follows:

 

(in thousands)

 

Antidilution rights liability

 

 

Success
payment
liability

 

 

Total

 

Balance at December 31, 2020

 

$

6,916

 

 

$

2,806

 

 

$

9,722

 

Issuance of common stock

 

 

(32,490

)

 

 

-

 

 

 

(32,490

)

Changes in fair value

 

 

25,574

 

 

 

9,654

 

 

 

35,228

 

Balance at June 30, 2021

 

$

 

 

$

12,460

 

 

$

12,460

 

 

9


 

6. Accrued expenses

Accrued expenses consist of the following:

 

(in thousands)

 

June 30,
2022

 

 

December 31,
2021

 

Accrued external research and development expenses

 

$

6,657

 

 

$

5,041

 

Employee compensation and related benefits

 

 

3,682

 

 

 

6,050

 

License and milestone payments

 

 

3,330

 

 

 

 

Professional fees

 

 

1,961

 

 

 

1,109

 

Other

 

 

2,990

 

 

 

792

 

Total

 

$

18,620

 

 

$

12,992

 

 

7. Leases

The Company’s operating lease activity is comprised of non-cancelable facility leases for office and laboratory space in Cambridge, Massachusetts.

The Company has also entered into multiple contract research and contract manufacturing service agreements with third parties which contain embedded leases within the scope of ASC 842. The embedded leases are considered short term leases, as the contractual terms are 12 months or less. Accordingly, no lease liability or ROU asset has been recorded. The Company has recognized $1.0 million and $1.3 million of short term lease costs associated with the embedded leases during the three and six months ended June 30, 2022, respectively. The Company recognized $0.7 million and $1.2 million of short term lease costs associated with the embedded leases during the three and six months ended June 30, 2021, respectively.

The components of operating lease cost were as follows:

 

 

Three months ended June 30,

 

 

Six months ended June 30,

 

(in thousands)

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Operating lease costs

 

$

505

 

 

$

475

 

 

$

1,010

 

 

$

924

 

Variable lease costs

 

 

198

 

 

 

154

 

 

 

409

 

 

 

343

 

Total

 

$

703

 

 

$

629

 

 

$

1,419

 

 

$

1,267

 

Supplemental cash flow information related to operating leases was as follows:

 

 

Six months ended June 30,

 

(in thousands)

 

2022

 

 

2021

 

Cash paid for amounts included in the measurements of lease liabilities:

 

 

 

 

 

 

Operating cash flows related to operating leases

 

$

1,058

 

 

$

973

 

As of June 30, 2022, the Company’s operating leases were measured using a weighted-average incremental borrowing rate of 1.57% over a weighted-average remaining lease term of 0.4 years. As of June 30, 2021, the Company’s operating leases were measured using a weighted-average incremental borrowing rate of 4.69% over a weighted-average remaining lease term of 1.1 years.

On August 19, 2021, the Company entered into a lease agreement with ARE-MA Region No. 87 Tenant, LLC, a Delaware limited liability company (the “Landlord”), pursuant to which the Company will lease approximately 104,933 square feet of office and laboratory space located at 201 Brookline Avenue, Boston, Massachusetts (the “Boston Lease”), further amended in January 2022 to include an additional 211 square feet, for a total of 105,144 square feet (the “Premises”). In June 2022, the Company entered into a second amendment to specify separate target commencement dates for certain areas of the Premises. The Premises have not been made available to the Company as of June 30, 2022 and therefore the Boston Lease has not commenced.

The term of the Boston Lease will commence on the earlier of (1) the date the Landlord delivers the Premises to the Company, which the parties expect to be on or prior to August 18, 2022 for the initial premises and October 1, 2022, for the second floor premises, or (2) the date the Landlord could have delivered the Premises but for any delays attributable to the Company (the “Commencement Date”). The Company’s obligation for the payment of base rent for the Premises begins 90 days after the Commencement Date (the “Rent Commencement Date”) and will initially be $0.8 million per month, which will increase by approximately 3% per annum. The Boston Lease has a term of 10 years, measured from the Rent Commencement Date. The Company has the option to extend the term of the Boston Lease for a period of an additional five years. Under the terms of the Boston Lease, the Landlord has agreed to make up to $21.0 million in certain

10


 

tenant improvements to the Premises to suit the Company’s use (the “Tenant Improvement Allowance”), which amount is included in the base rent set forth in the Boston Lease. In addition to the Tenant Improvement Allowance, the Company may receive up to $5.2 million for additional improvements to the Premises, which amount is subject to an 8% annual interest charge and may be paid in equal monthly installments.

In connection with its entry into the Boston Lease and as a security deposit, the Company has provided the Landlord a letter of credit in the amount of approximately $4.8 million, which may be reduced to approximately $3.5 million on the expiration of the 36-month anniversary of the Rent Commencement Date so long as there are, and have been, no defaults by the Company under the terms of the Boston Lease. The Company also paid a deposit in the amount of $0.8 million, which is equal to the first month of base rent.

The Landlord has the right to terminate the Boston Lease upon customary events of default. The Company may also terminate the Boston Lease if the Premises are not ready for occupancy within a specified time period after September 1, 2022.

The Boston Lease requires the Landlord to perform a scope of work to build-out the base building prior to the construction of the Premises. The Company concluded the accounting commencement date will occur when the Landlord completes the build-out of the base building and control passes to the Company. The Company will assess the classification of the Boston Lease at the accounting commencement date, and measure the ROU asset and lease liability. Payments made by the Company prior to commencement will be treated as prepaid rent which will increase the ROU asset. As of June 30, 2022 the Company has incurred an aggregate of $6.2 million related to the build out of the Premises prior to the Commencement Date.

In October 2021, the Company entered into a sublease for 11,931 square feet of office and laboratory space in Cambridge, Massachusetts. The sublease commenced in December 2021 and has an initial noncancelable term of 12 months. The Company had the option to extend the sublease for one extension term of three months by written notice not less than six months prior to the expiration of the sublease term. The Company did not exercise this option. Therefore, this sublease is treated as a short term lease. The total fixed lease payments over the sublease term are approximately $1.4 million and the Company is also required to pay its proportional share of operating expenses.

Future minimum commitments under non-cancellable leases as of June 30, 2022 were as follows:

Years ending December 31,

 

Amount

 

 

 

(in thousands)

 

Remainder of 2022

 

$

2,337

 

2023

 

 

9,691

 

2024

 

 

9,982

 

2025

 

 

10,281

 

2026

 

 

10,590

 

Thereafter

 

 

65,196

 

Total lease payments

 

$

108,077

 

Less: interest

 

 

(2

)

Present value of operating lease liabilities

 

$

108,075

 

During the three and six months ended June 30, 2022, the Company incurred rent expense of $0.8 million and $1.7 million, respectively. During the three and six months ended June 30, 2021, the Company incurred rent expense of $0.5 million and $0.9 million, respectively.

8. License agreements

The Company's significant license agreements are disclosed in Note 8, "License agreements," in the audited consolidated financial statements for the year ended December 31, 2021, and notes thereto, included in the Company’s Annual Report on Form 10-K filed with the SEC on March 14, 2022. Since the date of those financial statements, there have been no changes to its license agreements, except as noted below and as noted in Note 14, "Subsequent events."

Harvard/Broad license agreement and Broad license agreement

In March 2019, the Company simultaneously entered into the Harvard/Broad License Agreement and Broad License Agreement (the “license agreements”) for certain base editing technologies pursuant to which the Company received exclusive, worldwide, sublicensable, royalty-bearing licenses under specified patent rights to develop and commercialize licensed products and nonexclusive, worldwide, sublicensable, royalty-bearing licenses under certain patent rights to research and develop licensed products. The Company agreed to use commercially reasonable efforts to develop licensed products in accordance with the development plans, to introduce any licensed products that gain regulatory approval into the commercial market, to market licensed products that have gained regulatory approval following such

11


 

introduction into the market, and to make licensed products that have gained regulatory approval reasonably available to the public. The term of the agreements will continue until the expiration of the last to expire valid claim. The Company may terminate either of the license agreements without cause upon four months’ prior written notice to Harvard and Broad, unless terminated earlier. In February 2021, the Company provided written notice to Broad of its intent to terminate the Broad License Agreement, which termination was effective in June 2021.

As partial consideration for the rights granted under the Harvard/ Broad License Agreement and Broad License Agreement, the Company paid $0.3 million in non-refundable upfront license fees and also issued 276,075 shares of its common stock with a fair value of $0.3 million. Additional consideration under the license agreements is as follows:

Antidilution Rights—The initial shares of common stock issued to Harvard and Broad were subject to antidilution provisions as further described in Note 5, "Fair value of financial instruments." The antidilution rights associated with the Company achieving a defined aggregate level of preferred stock financing were partially satisfied in 2019 and fully satisfied in 2020, which settlement amounts totaled $0.1 million and $0.5 million, respectively, and which amounts were settled through issuances of 121,411 and 187,867 shares of common stock, respectively. The remaining antidilution rights obligation was fully satisfied in the three months ended June 30, 2021 with the Company’s IPO. The settlement amount totaled $32.5 million, and was settled through issuance of 878,098 shares of common stock.

Success Payments—The Company is required to make success payments under the license agreements as further described in Note 5, "Fair value of financial instruments." In September 2021, certain success payments were triggered and amounts due to Harvard and Broad totaled $6.3 million. These amounts were settled in cash in November 2021.

Other Payments—The Company agreed to pay an annual license maintenance fee ranging from low-to-mid five figures to low six figures, depending on the particular calendar year, for each of the license agreements. The Company is responsible for the payment of certain patent prosecution and maintenance costs incurred by Harvard and Broad related to licensed patents. To the extent achieved, the Company is obligated to pay up to an aggregate of $46.2 million and $108 million in development and sales-based milestones, respectively. During the three months ended March 31, 2022, the first milestone was triggered and amounts due to Harvard and Broad totaled $0.3 million. These amounts remain payable as of June 30, 2022 and will be settled in cash. If the Company undergoes a change of control during the term of the license agreements, then certain of the milestone payments would be increased by a mid-double-digit percentage. To the extent there are sales of a licensed product, the Company is required to pay low single digit royalties on net sales, for each of the license agreements. The Company is entitled to certain reductions and offsets on these royalties with respect to a licensed product in a given country.

Beam license agreement

In April 2019, the Company and Beam Therapeutics, Inc. ("Beam") entered into a collaboration and license agreement (the “Beam Agreement”). Pursuant to the Beam Agreement, the Company received an exclusive, worldwide, sublicensable license under certain of Beam’s base editing technology, gene editing, and delivery technologies to develop, make, use, offer for sale, sell and import base editing products and nuclease products using Beam’s CRISPR associated protein 12b, or Cas12b technology, in each case, directed to any of four gene targets, including the PCSK9 and ANGPTL3 genes, that are associated with an increased risk of coronary diseases. In addition, the Company granted Beam an exclusive, worldwide, sublicensable license under certain of its delivery technology to develop, manufacture, sell and import product candidates and products, except for base editor products licensed to Verve.

Both parties may conduct certain activities in accordance with an agreed-upon research and/or development plan. Following the dosing of the final patient in a Phase 1 clinical trial of a given licensed product, Beam has the right to opt in to share 33% of worldwide expenses of the development of such licensed product, as well as jointly commercialize and share profits and expenses of commercializing such licensed product in the United States on a 50/50 basis. If Beam exercises its opt-in right for a given licensed product, which we refer to following such opt-in as a collaboration product, it will be obligated to pay for a specified percentage of the development and commercialization costs of such collaboration product and will have the right to receive a specified percentage of the profits from any sales of such collaboration product. The term of the Beam Agreement continues until the last to expire of any royalty term for any product. The Company has the right to terminate the Beam Agreement as to any licensed product, but not for any collaboration product, by delivering a 90-day termination notice to Beam, provided that Beam has elected not to exercise its opt-in right or the period to exercise such opt-in right has expired. The Company is responsible for all costs and expenses incurred in the conduct of activities under the research plan, any development plan and any costs and expenses for the development of a licensed product for which Beam has not elected to opt-in.

As partial consideration for the license rights granted by Beam under the Beam Agreement, the Company paid a one-time, nonrefundable fee through issuing 276,075 shares of its common stock with a fair value of $0.3 million. To the extent achieved, for each licensed product, the Company is also obligated to pay up to $11.3 million in development and regulatory-based milestones and $15.0 million in sales-based milestones. To the extent there are sales of a licensed

12


 

product, the Company is required to pay low-to-mid single digit royalties on net sales. To the extent achieved, for each collaboration product outside of the United States, the Company is obligated to pay up to $5.6 million in development and regulatory-based milestones and $7.5 million in sales-based milestones. To the extent there are ex-U.S. sales of a collaboration product, the Company is required to pay low-to-mid single digit royalties on net sales. Due to the submission of the Company's CTA in New Zealand, a milestone payment of $0.2 million was triggered during the period ending June 30, 2022.

On July 5, 2022, the Company entered into an Amended and Restated Collaboration and License Agreement with Beam (the “Amended Beam Agreement”), which is further described in Note 14, “Subsequent events.”

To the extent there are sales of a delivery technology product, each party will pay the other party low-to-mid single digit royalties based on the annual aggregate worldwide net sales resulting from the sale of each delivery technology product of such paying party; provided, however, that such royalty payments will not apply to net sales of the collaboration products or licensed products. The Company concluded the receipt of any milestone or royalty payments under the Beam Agreement was not probable as of June 30, 2022.

Beam materials exchange letter agreement

In October 2020, the Company and Beam entered into a materials exchange agreement wherein the parties agreed that Beam would provide certain mRNA, gRNA, and protein to the Company and that the Company would provide certain gRNAs to Beam at an agreed upon price per each material provided.

For the three and six months ended June 30, 2022 and 2021, the Company did not purchase any materials from Beam.

For the three and six months ended June 30, 2022, the Company did not sell any materials to Beam. For the three months ended June 30, 2021, the Company did not sell any materials to Beam. For the six months ended June 30, 2021, the Company recognized $0.2 million as a reduction to research and development expense related to reimbursements received for materials sold to Beam.

Acuitas agreements

Development and option agreement

In December 2019, the Company and Acuitas Therapeutics, Inc. ("Acuitas") entered into a development and collaboration agreement, which agreement was amended and restated in October 2020. The Company agreed to reimburse Acuitas on a quarterly basis for its services performed related to the program activities based on an agreed upon number of fulltime employees committed to work on the program at an annual rate per employee, including reimbursement of reasonable external costs. The Company recognized research and development expense of less than $0.1 million and $0.1 million during the three and six months ended June 30, 2022, respectively, and $0.3 million and $0.6 million for the three and six months ended June 30, 2021, respectively, related to the reimbursement of research and development services provided by Acuitas and technology maintenance fees.

License agreement

In October 2020, the Company paid Acuitas a non-refundable, upfront license fee of $2.0 million (less a previously paid target reservation fee) to exercise an option with respect to a licensed product and a licensed genome target and entered into a non-exclusive, worldwide license with Acuitas, with a right to sub-license through multiple tiers, under the licensed LNP technology to research, develop and commercialize the licensed products using the LNP technology in connection with the PCSK9 gene target for all human therapeutic or prophylactic uses.

To the extent achieved, the Company is also obligated to pay up to an aggregate of $9.8 million in clinical and regulatory milestones and $9.5 million in sales-based milestones. The milestones have not been achieved and no expense has been recorded for these milestones as of June 30, 2022.

Third-party license agreements

In October 2021, the Company entered into a license agreement with a third party to obtain a non-exclusive license to certain technology the Company is using for research and development. As consideration for the license and rights granted under the agreement, the Company made a one-time, non-refundable, upfront payment of $0.8 million during the three months ended December 31, 2021. The license agreement provides for specified development milestones relating to the licensed technology and requires the Company to make payments upon achievement of each milestone up to an aggregate amount of $10.0 million. The milestones have not been achieved and no expense has been recorded for these milestones as of June 30, 2022.

In June 2022, the Company amended the agreement to include three additional licensed products to the scope of the non-exclusive license. In consideration of the additional licensed products, the Company was required to make a one-time,

13


 

non-refundable upfront payment of $2.8 million to such third party. This amount remained payable as of June 30, 2022 and was settled in cash in July 2022.

9. Preferred and common stock

In January 2021, the Company issued 77,163,022 shares of Series B Preferred Stock at a price of $1.2182 per share for gross proceeds of $94.0 million. The Company incurred issuance costs in connection with this transaction of $0.2 million.

In June 2021, the Company amended and restated its certificate of incorporation to authorize 5,000,000 shares of preferred stock, which shares of preferred stock are currently undesignated, and 200,000,000 shares of common stock, $0.001 par value per share.

In June 2021, the Company completed its IPO, pursuant to which the Company issued and sold 16,141,157 shares of its common stock, including 2,105,368 shares pursuant to the full exercise of the underwriters' option to purchase additional shares, at a public offering price of $19.00 per share, for aggregate gross proceeds of $306.7 million. The Company received approximately $281.6 million in net proceeds, after deducting underwriting discounts and offering expenses payable by the Company.

Upon the closing of the IPO, all outstanding shares of the Company's preferred stock automatically converted into 27,720,923 shares of the Company's common stock.

In June 2021, the Company issued 878,098 shares of its common stock to Harvard and Broad as final settlement of its antidilution rights obligation.

The holders of common stock are entitled to one vote for each share of common stock.

10. Stock-based compensation

The 2018 Equity Incentive Plan, or the 2018 Plan, adopted by the board of directors in August 2018 provided for the grant of qualified incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock and restricted stock units to the Company’s employees, officers, directors, advisors, and outside consultants for the issuance or purchase of shares of the Company’s common stock. The maximum number of shares of common stock that were authorized for issuance under the 2018 Plan was 6,885,653.

In June 2021, the Company's board of directors adopted, and the Company's stockholders approved, the 2021 Stock Incentive Plan, or the 2021 Plan, which became effective on June 16, 2021. The 2021 Plan provides for grant of qualified and nonqualified stock options, stock appreciation rights, restricted and unrestricted stock and stock units, performance awards, and other share-based awards to the Company's employees, directors, advisors and outside consultants. Under the 2021 Plan, the number of shares of common stock initially reserved for issuance was the sum of: (1) 3,466,530; plus (2) the number of shares as was equal to the sum of (x) the number of shares of common stock reserved for issuance under the 2018 Plan that remained available for grant under the 2018 Plan on June 16, 2021 and (y) the number of shares of common stock subject to outstanding awards granted under the 2018 Plan that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right; plus (3) an annual increase, to be added on the first day of each fiscal year, commencing on January 1, 2022 and continuing until, and including, January 1, 2031, equal to the lesser of (i) 5% of the number of shares of common stock outstanding on such date and (ii) the number of shares of common stock determined by the Company’s board of directors.

On January 1, 2022, 2,425,587 shares of the Company's common stock were added to the amount reserved for issuance under the 2021 Plan in accordance with the 2021 Plan described above. As of June 30, 2022, the Company had reserved 7,057,629 shares of the Company's common stock for issuance of equity awards, of which 3,456,180 shares remained available for future grant under the 2021 Plan. Upon effectiveness of the 2021 Plan, the Company ceased granting additional awards under the 2018 Plan.

Stock-based compensation expense recorded in the condensed consolidated statements of operations and comprehensive loss is as follows:

 

 

 

Three months ended June 30,

 

 

Six months ended June 30,

 

(in thousands)

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Research and development

 

$

2,955

 

 

$

708

 

 

$

5,421

 

 

$

1,021

 

General and administrative

 

 

2,694

 

 

 

643

 

 

 

4,432

 

 

 

1,000

 

Total stock-based compensation expense

 

$

5,649

 

 

$

1,351

 

 

$

9,853

 

 

$

2,021

 

 

14


 

Stock options

The following table provides a summary of stock option activity during the six months ended June 30, 2022:

 

 

 

Number of
options

 

 

Weighted
average
exercise
price per
share

 

 

Weighted
average
remaining
contractual
life (in years)

 

 

Aggregate
intrinsic
value
(2)
(in thousands)

 

Outstanding at December 31, 2021

 

 

6,119,295

 

 

$

9.44

 

 

 

 

 

 

 

Granted

 

 

2,103,350

 

 

 

27.34

 

 

 

 

 

 

 

Exercised

 

 

(172,699

)

 

 

3.62

 

 

 

 

 

 

 

Forfeited

 

 

(164,729

)

 

 

25.77

 

 

 

 

 

 

 

Outstanding at June 30, 2022

 

 

7,885,217

 

 

$

14.09

 

 

 

8.5

 

 

$

52,868

 

Exercisable at June 30, 2022

 

 

2,301,148

 

 

$

4.40

 

 

 

7.8

 

 

$

25,676

 

Expected to vest after June 30, 2022(1)

 

 

5,584,069

 

 

$

18.08

 

 

 

8.8

 

 

$

27,192

 

 

(1)
This represents the number of unvested options outstanding as of June 30, 2022 that are expected to vest in the future.
(2)
The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the common stock for the options that were in the money as of June 30, 2022.

As of June 30, 2022, there was $66.3 million of unrecognized compensation cost related to unvested stock options, which is expected to be recognized over a weighted-average period of approximately 2.8 years.

Restricted stock units

During the six months ended June 30, 2022, the Company granted 524,875 restricted stock units under the 2021 Plan. These restricted stock units vest annually over a four-year period.

A summary of the status of and change in unvested restricted stock units as of June 30, 2022 was as follows:

 

 

 

Shares

 

 

Weighted-
average grant
date fair
value per share

 

Unvested restricted stock units as of December 31, 2021

 

 

32,000

 

 

$

36.58

 

Restricted stock units granted

 

 

524,875

 

 

$

20.48

 

Restricted stock units forfeited

 

 

(4,500

)

 

$

30.94

 

Unvested restricted stock units as of June 30, 2022

 

 

552,375

 

 

$

21.33

 

 

As of June 30, 2022, there was $11.0 million of unrecognized stock-based compensation expense related to restricted stock units that are expected to vest. These costs are expected to be recognized over a weighted-average remaining vesting period of approximately 3.9 years.

2021 Amended and Restated Employee Stock Purchase Plan

In June 2021, the board of directors adopted, and the Company's stockholders approved, the 2021 Employee Stock Purchase Plan, or the ESPP, as amended and restated, which became effective on June 16, 2021. The Company initially reserved 433,316 shares of common stock for sale under the ESPP. The aggregate number of shares reserved for sale under the ESPP increases automatically on the first day of each fiscal year commencing on January 1, 2022 through January 1, 2031, by the number of shares equal to the least of (a) 1,083,290 shares, (b) 1% of the total outstanding shares of common stock on such date, and (c) a number of shares as may be determined by the board of directors in any particular year. The first offering period under the ESPP commenced on June 16, 2021 and ended on December 13, 2021. On January 1, 2022, 485,117 shares of common stock were added to the amount reserved for sale under the ESPP. As of June 30, 2022, 844,918 shares remained available for issuance under the ESPP. The second offering period ended on May 31, 2022, for which offering period the Company issued 25,218 shares. The next offering period commenced on June 1, 2022 and will end on November 30, 2022.

11. Net loss per share attributable to common stockholders

 

The Company’s potential dilutive securities, which include convertible preferred stock, unvested restricted stock, unvested restricted stock units and common stock options, have been excluded from the computation of diluted net loss per share as the effects would be anti-dilutive. Therefore, the weighted average number of common shares outstanding used to

15


 

calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders for the period indicated because including them would have had an anti-dilutive effect:

 

 

 

As of June 30,

 

 

 

2022

 

 

2021

 

Unvested restricted stock

 

 

 

 

268,816

 

Unvested restricted stock units

 

 

552,375

 

 

 

 

Outstanding options to purchase common stock

 

 

7,885,217

 

 

 

5,720,987

 

Total

 

 

8,437,592

 

 

 

5,989,803

 

 

12. Income taxes

Deferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using statutory rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized. Due to the uncertainty surrounding the realization of the favorable tax attributes in future tax returns, the Company has recorded a full valuation allowance against the Company’s otherwise recognizable net deferred tax assets.

13. Related party transactions

An executive officer of Beam is a board member of the Company. In October 2020, the Company and Beam entered into a materials exchange agreement wherein the parties agreed that Beam would provide certain mRNA, gRNA, and protein to the Company and that the Company would provide certain gRNAs to Beam at an agreed upon price per each material provided. For the three months ended June 30, 2021, the Company did not sell any materials to Beam. For the six months ended June 30, 2021, the Company recognized $0.2 million as a reduction to research and development expense related to reimbursements received for materials sold to Beam. For the three and six months ended June 30, 2022, the Company did not sell any materials to Beam.

In October 2021, the Company entered into a sublease agreement with Beam for laboratory and office space in Cambridge, Massachusetts. The sublease commenced in December 2021. Total expenses incurred under this sublease were $0.5 million and $1.0 million for the three and six months ended June 30, 2022, respectively.

An executive of Broad was a board member of the Company until May 2021. In March 2019, the Company simultaneously entered into the Harvard/Broad License Agreement and Broad License Agreement for certain base editing technologies pursuant to which the Company received exclusive, worldwide, sublicensable, royalty-bearing licenses under specified patent rights to develop and commercialize licensed products and nonexclusive, worldwide, sublicensable, royalty-bearing licenses under certain patent rights to research and develop licensed products. Additional consideration under the license agreements include success payments. See Note 8, "License agreements."

14. Subsequent events

Amended and Restated Collaboration and License Agreement

On July 5, 2022, the Company entered into the Amended Beam Agreement.

Pursuant to the Amended Beam Agreement, Beam granted the Company an exclusive, worldwide, sublicensable license under certain of Beam’s base editing technology to develop and commercialize products directed towards an additional liver-mediated, cardiovascular disease target. The Company will be responsible for the development and commercialization of products targeting such gene, subject to Beam’s opt-in right. Following the dosing of the final patient in a Phase 1 clinical trial of a licensed product for such gene, Beam has the right to opt-in to share 35% of worldwide expenses of the development of such licensed product, as well as jointly commercialize and share 35% of the profits and expenses of commercializing such licensed product worldwide. If Beam does not elect to opt-in, Beam would be entitled to receive milestones and royalties on the same basis as other collaboration products as provided in the Beam Agreement.

In exchange, the Company granted to Beam an exclusive, worldwide, sublicensable, fully paid-up license under the Company's intellectual property, including under the Company's GalNAc-LNP delivery technology, relating to a preclinical program developed by the Company.

In addition, the Amended Beam Agreement:

clarifies intellectual property rights with respect to the Company's GalNAc-LNP delivery technology;

16


 

grants Beam, on a target-by-target basis, the option to obtain a non-exclusive, worldwide, sublicensable license to the Company's GalNAc-LNP delivery technology for the development and commercialization of certain base editor products, as to which Beam would owe the Company a fee upon exercise of each option, certain regulatory and commercial sale milestones as well as low single-digit royalties on net sales for base editor products using the GalNAc-LNP delivery technology;
terminates the Company's rights and economic obligations under the Beam Agreement with respect to the undisclosed genes, allowing the Company and Beam to independently develop and commercialize products directed to such gene targets; and
concludes other licenses that applied under the Beam Agreement with respect to delivery and other technologies developed by the parties for the development and commercialization of base editor products.

The Amended Beam Agreement also contains representations and warranties, covenants, and other negotiated provisions, including confidentiality obligations, customary for transactions of this nature.

Strategic License and Collaboration Agreement

On July 18, 2022, the Company entered into the Vertex Agreement for an exclusive, four-year worldwide research collaboration focused on developing in vivo gene editing candidates toward an undisclosed target for the treatment of a single liver disease. Additionally, on July 18, 2022, the Company entered into the Stock Purchase Agreement with Vertex, pursuant to which the Company agreed to sell and issue shares of its common stock to Vertex.

Pursuant to the Vertex Agreement, the Company will be responsible for discovery, research and certain preclinical development of novel in vivo gene editing development candidates for the target of interest. The Company’s research activities will be focused on (i) identifying and engineering specific gene editing systems and in vivo delivery systems directed to the target and (ii) evaluating and optimizing development candidates to achieve criteria specified in the Vertex Agreement. Vertex will reimburse the Company’s research expenses consistent with an agreed-upon budget. The research term has an initial term of four years and may be extended by Vertex for up to one additional year.

Vertex will be solely responsible for subsequent development, manufacturing and commercialization of any product candidate resulting from the Company’s research efforts. The Company received an upfront payment from Vertex of $25 million on July 20, 2022. The Company is eligible to receive (i) success payments of up to $22 million for each product candidate (up to a maximum of $66 million) that achieves the applicable development criteria and (ii) up to an aggregate of $340 million in development and commercial milestone payments. The Company is also eligible to receive tiered single-digit royalties on net sales, subject to specified reductions. Such royalty payments will terminate on a country-by-country and product-by-product basis upon the later to occur of (i) the expiration of the last to expire valid claim under the patent rights covering such product in such country, (ii) the period of regulatory exclusivity associated with such product in such country or (iii) ten years after the first commercial sale of such product in such country.

Prior to the first patient dosing of the first Phase 1 clinical trial for the first product candidate developed under the Vertex Agreement, the Company also has the right to opt-in to a profit share arrangement pursuant to which Vertex and the Company would share the costs and net profits for all product candidates emerging from the collaboration. If the Company exercises its opt-in right, in lieu of milestones and royalties, the Company will be obligated to pay for a specified percentage of the development and commercialization costs, and it will have the right to receive a specified percentage of the profits from any sales of any product candidates advanced under the collaboration. At the time the Company exercises the option, it may elect a profit/cost share of up to 40% (with Vertex retaining a minimum of 60%). In order to exercise its opt-in right, the Company is required to pay a fee ranging from $25-70 million, depending on the profit/cost percentage elected by the Company and the licensed technology of the Company included in the most advanced product candidate at the time the Company exercises its opt-in right. Under all profit share scenarios, Vertex will control the worldwide development and commercialization of any product candidates resulting from the collaboration.

The Vertex Agreement includes customary representations and warranties, covenants and indemnification obligations for a transaction of this nature. The Company and Vertex each have the right to terminate the agreement for material breach by, or insolvency of, the other party following notice, and if applicable, a cure period. Vertex may also terminate the Vertex Agreement in its entirety for convenience upon 90 days’ notice.

Stock Purchase Agreement

On July 18, 2022, in connection with the execution of the Vertex Agreement, the Company and Vertex also entered into the Stock Purchase Agreement for the sale and issuance of 1,519,756 shares of the Company’s common stock to Vertex at a price of $23.03 per share, which is equal to the five-day volume-weighted average share price as of July 15, 2022, for an aggregate purchase price of $35.0 million. The sale of the Company’s common stock closed on July 20, 2022.

17


 

The Stock Purchase Agreement includes lock-up restrictions with respect to the shares of common stock issued to Vertex. Pursuant to the terms of the Stock Purchase Agreement, Vertex has agreed not to, and to cause its affiliates not to, sell or transfer any of the shares for a period of 12 months following the date of issuance of the shares, subject to specified conditions and exceptions.

Follow-on public offering

On July 25, 2022, the Company issued and sold 9,583,334 shares of its common stock, including 1,250,000 shares of its common stock sold pursuant to the underwriters’ full exercise of their option to purchase additional shares of common stock, at a public offering price of $27.00 per share. The Company received net proceeds of approximately $242.9 million from the sale of shares in the follow-on offering after deducting underwriting discounts and commissions of approximately $15.5 million and offering costs of approximately $0.3 million.

 

18


 

Item 2. Management’s discussion and analysis of financial condition and results of operations

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our condensed consolidated financial statements and the related notes to those statements included elsewhere in this Quarterly Report on Form 10-Q and in our Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on March 14, 2022. In addition to historical financial information, the following discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors, including those discussed in “Risk Factors” in Part II, Item 1A. You should carefully read the section entitled “Risk Factors” to gain an understanding of the important factors that could cause actual results to differ materially from our forward- looking statements.

Overview

We are a clinical-stage genetic medicines company pioneering a new approach to the care of cardiovascular disease, or CVD, transforming treatment from chronic management to single-course gene editing medicines. Despite advances in treatment over the last 50 years, CVD remains the leading cause of death worldwide. The current paradigm of chronic care is fragile—requiring rigorous patient adherence, extensive healthcare infrastructure and regular healthcare access—and leaves many patients without adequate care. Our goal is to disrupt the chronic care model for CVD by providing a new therapeutic approach with single-course in vivo gene editing treatments focused on addressing the root causes of this highly prevalent and life-threatening disease. Our initial two programs target PCSK9 and ANGPTL3, respectively, genes that have been extensively validated as targets for lowering blood lipids, such as low-density lipoprotein cholesterol, or LDL-C. We believe that editing these genes could potently and durably lower LDL-C throughout the lifetime of patients with or at risk for atherosclerotic cardiovascular disease, or ASCVD, the most common form of CVD.

Our approach leverages multiple breakthroughs in 21st century biomedicine—human genetic analysis, gene editing, messenger RNA, or mRNA, -based therapies and lipid nanoparticle, or LNP, delivery—to target genes that are predominantly expressed in the liver and disrupt the production of proteins that cause CVD. We are advancing a pipeline of single-course in vivo gene editing programs, each designed to mimic natural disease resistance mutations and turn off specific genes in order to lower blood lipids, thereby reducing the risk of ASCVD. We intend to initially develop these programs for the treatment of patients with familial hypercholesterolemia, or FH, a genetic disease that causes life-long severely elevated blood LDL-C, leading to increased risk of early-onset ASCVD. If our programs are successful in FH, we believe they could also provide a potential treatment for the broader population of patients with established ASCVD. Ultimately, we believe that these treatments could potentially be developed for administration to people at risk for ASCVD as a preventative measure similar to the way that certain vaccines offer long-term protection against infectious diseases.

We were incorporated in March 2018 and commenced operations shortly thereafter. Since our inception, we have devoted substantially all of our resources to building our gene editing and LNP technology and advancing development of our portfolio of programs, establishing and protecting our intellectual property, conducting research and development activities, organizing and staffing our company, business planning, raising capital and providing general and administrative support for these operations. To date, we have financed our operations primarily through the sales of our preferred stock and through the sale of our common stock in our initial public offering, or IPO, and our follow-on public offering.

On June 21, 2021, we completed our IPO in which we issued and sold an aggregate of 16,141,157 shares of our common stock, including 2,105,368 shares of common stock sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a public offering price of $19.00 per share, for aggregate net proceeds of $281.6 million, after deducting underwriting discounts and offering expenses payable by us. Upon completion of the IPO, all 256,682,054 shares of outstanding convertible preferred stock automatically converted into 27,720,923 shares of common stock. Through June 30, 2022, we had raised an aggregate of $523.2 million in gross proceeds from the sale of our preferred stock in private placements and common stock in our IPO.

On July 18, 2022, we entered into a Strategic Collaboration and License Agreement, or the Vertex Agreement, with Vertex Pharmaceuticals Incorporated, or Vertex, for an exclusive, four-year worldwide research collaboration focused on developing in vivo gene editing candidates toward an undisclosed target for the treatment of a single liver disease. Pursuant to the Vertex Agreement, Vertex paid us $25.0 million in an upfront payment on July 20, 2022. We are eligible to receive (i) success payments of up to $22 million for each product candidate (up to a maximum of $66 million) that achieves the applicable development criteria and (ii) up to an aggregate of $340 million in development and commercial milestone payments. We are also eligible to receive tiered single-digit royalties on net sales, subject to specified reductions.

19


 

On July 18, 2022, in connection with the execution of the Vertex Agreement, we also entered into a stock purchase agreement with Vertex, or the Stock Purchase Agreement, for the sale and issuance of 1,519,756 shares of our common stock to Vertex at a price of $23.03 per share, which is equal to the five-day volume-weighted average share price as of July 15, 2022, for an aggregate purchase price of $35.0 million, or the Private Placement. The Private Placement closed on July 20, 2022.

On July 25, 2022, we issued and sold 9,583,334 shares of our common stock, including an additional 1,250,000 shares of common stock sold pursuant to the underwriters’ full exercise of their option to purchase additional shares of common stock, at a public offering price of $27.00 per share, for aggregate net proceeds of approximately $242.9 million after deducting underwriting discounts and commissions of approximately $15.5 million and offering costs of approximately $0.3 million.

We are a clinical-stage company. To date, we have not generated any revenue from product sales and do not expect to generate revenue from the sale of products for the foreseeable future. Prior to the execution of the Vertex Agreement, on July 18, 2022, we had not recorded any revenue. Since our inception, we have incurred significant operating losses. Our net losses for the three and six months ended June 30, 2022 were $40.9 million and $71.1 million, respectively. Our net losses for the three and six months ended June 30, 2021 were $53.0 million and $66.2 million, respectively. As of June 30, 2022, we had an accumulated deficit of $258.0 million.

We expect to continue to incur significant expenses and increasing operating losses in connection with ongoing development activities related to our portfolio of programs as we advance VERVE-101 in our heart-1 clinical trial; continue our preclinical development of other product candidates; advance these product candidates toward clinical development; further develop base editing and novel gene editing technology, delivery technology and manufacturing capabilities; seek to discover and develop additional product candidates including VERVE-201, our development candidate targeting ANGPTL3; maintain, expand enforcement, defend, and protect our intellectual property portfolio; hire research and development and clinical personnel; ultimately establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval; establish a commercial manufacturing source and secure supply chain capacity sufficient to provide commercial quantities of any product candidates for which we may obtain regulatory approval; and add operational, legal, compliance, financial and management information systems and personnel to support our research, product development, future commercialization efforts and operations as a public company.

As a result, we will need substantial additional funding to support our continuing operations and pursue our strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of equity offerings, debt financings and other sources of capital, which may include collaborations or licensing arrangements with other companies or other strategic transactions. If we are unable to raise capital or obtain adequate funds when needed or on acceptable terms, we may be required to delay, limit, reduce or terminate our research and development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.

Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve profitability. Even if we are able to generate revenue from product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.

As of June 30, 2022, we had cash, cash equivalents and marketable securities of $293.6 million. We believe that our existing cash, cash equivalents and marketable securities, including the net proceeds of approximately $242.9 million from the July 2022 follow-on public offering, $35.0 million from the Private Placement with Vertex and $25.0 million upfront payment pursuant to the Vertex Agreement, will enable us to fund our operating expenses and capital expenditure requirements into the second half of 2025. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. To finance our operations beyond that point we will need to raise additional capital, which cannot be assured. See “Liquidity and capital resources.”

Recent Developments

VERVE-101

Our lead product candidate, VERVE-101, is designed to permanently turn off the PCSK9 gene in the liver. PCSK9 is a highly validated target that plays a critical role in controlling blood LDL-C through its regulation of the LDL receptor, or LDLR. Reduction of PCSK9 protein in the blood improves the ability of the liver to clear LDL-C from the blood. VERVE-101 utilizes LNP-mediated delivery to target the liver and base editing technology to make a single base change at a specific site in the PCSK9 gene in order to disrupt PCSK9 protein production.

20


 

VERVE-101 is being developed for the treatment of patients with heterozygous familial hypercholesterolemia, or HeFH, which affects approximately 1.3 million people in the United States and approximately 31 million worldwide. We are strategically developing VERVE-101 initially in patients with HeFH, recognizing that the unmet need is highest in those patients and the benefit-risk profile may be more favorable. We intend to use a stepwise clinical development plan for VERVE-101, evaluating efficacy and safety in higher-risk populations first, and then if successful, expanding into broader population of patients with established ASCVD, and ultimately to those at risk for ASCVD in the general population.

In an ongoing in vivo proof-of-concept study of a precursor formulation of VERVE-101 in non-human primates, or NHPs, we observed substantial lowering of LDL-C levels that was sustained over an extended period of time following treatment. In this study, following a single intravenous infusion of a base editor targeting PCSK9, we observed an average reduction of blood PCSK9 protein of 89% accompanied by an average reduction of blood LDL-C levels of 59% at two weeks after treatment. This LDL-C reduction was maintained at an average of greater than 60% for 20 months following treatment. If we are able to achieve similar reductions in PCSK9 protein levels in humans, we believe this could result in marked and sustained LDL-C reductions of approximately 60%, which would potentially offer superior cumulative LDL-C lowering to what has been clinically demonstrated with other PCSK9-targeting treatment modalities.

In an ongoing preclinical study with VERVE-101 in NHPs, we observed 70% mean editing following a single administration of 1.5 mg/kg dose at the PCSK9 target gene site in liver biopsies taken at day 15. In this study, we also observed an average reduction in blood PCSK9 protein of 86% accompanied by an average reduction of blood LDL-C levels of 62% at two weeks after treatment. These reductions were durable when assessed 12 months after treatment, with mean reduction in blood PCSK9 protein of 89% and blood LDL-C levels of 68%.

In our preclinical studies in NHPs to date, VERVE-101 has been well tolerated following a single administration with only mild elevations in liver function tests that resolved within two weeks.

In GLP toxicology studies, we observed that the highest dose that did not produce a significant increase in adverse effects relative to control was 2.0 mg/kg and 5.0 mg/kg in NHPs and a mouse model, respectively. In the toxicology studies in NHPs, we observed transient mild elevations in liver function tests and evidence of minimal to mild single cell hepatocyte necrosis two days after dosing and all findings were reversible and observed to be resolved at a 90-day measurement. In the mouse model, we did not observe any differences between wild-type mice or the HeFH mouse disease model.

In April 2022, we presented data from a comprehensive preclinical assessment of the potential for VERVE-101 to cause unintended, or off-target, DNA edits in primary human liver cells from multiple donors. We used multiple methods consistent with recent guidance from the U.S. Food and Drug Administration to identify more than 3,000 sites with the greatest experimental or bioinformatic similarity to the on-target site. We then used a sequencing assay to determine whether administration of VERVE-101 resulted in off-target editing at those sites. We did not observe any statistically significant off-target editing after treatment with VERVE-101 at the identified sites. We also evaluated the potential for off-target editing in non-target cells (spleen cells, adrenal cells, and hematopoietic stem cells) and other cellular contexts (pediatric human liver cells and human liver cell lines) and identified only two sites with statistically significant editing above untreated controls. The two instances of off-target editing occurred at doses greater than the dose we expect to achieve saturation for on-target editing. Based on these assessments, we believe that VERVE-101 has a low risk of off-target genomic modifications that would be expected to have an associated clinical adverse effect.

We have received clearance of our first clinical trial application, or CTA, for VERVE-101 in New Zealand and in July 2022, we announced that the first patient has been dosed with VERVE-101 in our heart-1 clinical trial. The trial is underway and is enrolling patients with HeFH in New Zealand. We anticipate obtaining regulatory clearances for a CTA in the United Kingdom and an investigational new drug application, or IND, in the United States in the second half of 2022. We are on track to complete the remaining IND-enabling studies in the third quarter of 2022.

The heart-1 clinical trial is designed to enroll approximately 40 adult HeFH patients with established ASCVD and evaluate the safety and tolerability of VERVE-101 administration, with additional analyses for pharmacokinetics and reductions in blood PCSK9 protein and LDL-C. The trial includes three parts – (A) a single ascending dose portion, followed by (B) an expansion single-dose cohort, in which additional participants will receive the selected potentially therapeutic dose and (C) an optional second-dose cohort, in which eligible participants in lower dose cohorts in Part A have the option to receive a second treatment at the selected potentially therapeutic dose. We expect to report interim clinical data from the heart-1 clinical trial including safety parameters, blood PCSK9 level, and blood LDL-C level in 2023.

 

ANGPTL3 Program

VERVE-201, our development candidate targeting ANGPTL3, is designed to permanently turn off the ANGPTL3 gene in the liver. We plan to develop this program initially for the treatment of homozygous familial hypercholesterolemia, or HoFH, which affects approximately 1,300 patients in the United States. Similar to our approach with VERVE-101, we plan to expand the clinical development of VERVE-201 in a stepwise fashion beyond HoFH to patients with established

21


 

ASCVD who may need additional LDL-C and/or triglycerides reduction. Ultimately, we believe that VERVE-201 may also be useful to people at risk for ASCVD as a preventative measure in the general population. We plan to present updated preclinical data supporting VERVE-201’s advancement at the ESC 2022 Congress. We expect to begin IND-enabling studies in the second half of 2022.

We plan to utilize internally developed GalNAc-LNP technology in VERVE-201 to deliver a base editor targeting the ANGPTL3 gene to the liver. In patients with HoFH, delivery of base editors with standard LNPs to the liver is challenging due to the deficiency of LDLR, which is known to mediate LNP uptake. We have developed proprietary LNPs with a GalNAc ligand designed to bind to asialoglycoprotein receptors, in the liver, which bypass LDLR, thereby enabling uptake into the liver in HoFH patients.

In an ongoing proof of concept study of an ANGPTL3 base editor in NHPs (n=4), we observed a 96% reduction in blood ANGPTL3 protein from baseline, with follow-up out to approximately 20 months. In addition, no long-term impacts were observed on markers of liver toxicity, as measured by alanine aminotransferase (ALT) and bilirubin levels following treatment administration.

In addition, in our preclinical studies of our ANGPTL3 program using a single treatment of two different formulations of our proprietary GalNAc-LNPs to deliver an ANGPTL3-targeted base editor we observed approximately 94% (n=3) and 97% (n=3) reduction in blood ANGPTL3 protein, and reductions in LDL-C of nearly 100 mg/dL, which was an approximately 35% reduction from baseline. We conducted these studies in an internally developed NHP model of HoFH, which we created by editing the LDLR gene in wild-type NHPs and eliminating LDLR expression in the livers of NHPs using a Cas9 and dual guide RNA strategy encapsulated in standard LNPs, which led to nearly 70% whole liver DNA editing at the LDLR gene and resulted in an approximately 94% reduction in LDLR protein in the liver and a six-fold increase in blood LDL-C.

We have also assessed the potential broad utility of our proprietary GalNAc-LNP approach for delivery of our ANGPTL3-targeted base editor, in a preclinical study evaluating delivery efficiency of an ANGPTL3 base editor using either a GalNAc-LNP or a standard LNP without GalNAc in wild-type NHPs with normal livers. In these studies, we observed that wild-type NHPs treated with our ANGPTL3-targeted base editor delivered via our GalNAc-LNP had an approximately 89% reduction in ANGPTL3 protein compared to an approximately 74% reduction in wild-type NHPs treated with a standard LNP. A follow up study in which we performed dose-response assessments at three dose levels (0.75 mg/kg, 1.5 mg/kg and 3.0 mg/kg) in wild-type NHPs confirmed the observation that the addition of GalNAc-lipid to a standard LNP enhanced potency of liver base editing. In this study, we observed greater editing potency of a ANGPTL3 precursor formulation with our GalNAc-LNP than with standard LNPs at day 14. We also observed that the use of a GalNAc-LNP led to reductions in blood ANGPTL3 protein at each dose level at day 14, including a 51% reduction at 0.75mg/kg, an 83% reduction at 1.5 mg/kg and a 98% reduction at 3.0 mg/kg. In this study, the alanine aminotransferase profiles over 14 days following treatment did not differ between NHPs treated with GalNAc-LNP versus a standard LNP. We also evaluated the biodistribution of editing following administration of an ANGPTL3 precursor at a dose of 1.5 mg/kg using our GalNAc-LNP and observed editing to be localized to the liver with minimal biodistribution to other organs.

We believe this data suggests that GalNAc-LNP delivery may have broad utility for liver editing in other indications.

We are continuing to invest and build out capabilities in the development of novel and optimized GalNAc-targeting ligands, optimal lipid anchors, optimal compositions and ratios of LNP components, and optimal processes of addition and LNP formation with targeting ligands. We believe GalNAc provides a delivery platform for patients with both forms of FH and potentially may be applicable in other applications where liver-directed delivery is advantageous.

Impact of COVID-19 on our business

In March 2020, COVID-19 was declared a global pandemic by the World Health Organization and to date, the COVID-19 pandemic continues to present a substantial public health and economic challenge around the world. The length of time and full extent to which the COVID-19 pandemic may directly or indirectly impact our business, results of operations and financial condition will depend on future developments that are highly uncertain, subject to change and difficult to predict. We, our contract manufacturing organizations, or CMOs, and our contract research organizations, or CROs, experienced temporary reductions in the capacity to undertake research-scale production and to execute some preclinical studies. While these operations have since normalized, we, together with our CMOs and CROs, continue to closely monitor the impact of the COVID-19 pandemic on these operations.

We also plan to continue to closely monitor the ongoing impact of the COVID-19 pandemic on our employees and our other business operations. In an effort to provide a safe work environment for our employees, we have, among other things, limited employees in our office and lab facilities to those where on-site presence is needed for their job activities, increased the cadence of sanitization of our office and lab facilities, implemented various social distancing measures in our offices and labs including replacing all in-person meetings with virtual interactions. Recently, additional employees

22


 

have returned to our office and lab facilities in limited capacities. We continue to provide personal protective equipment and recommend regular COVID-19 testing for employees and visitors present in our office and lab facilities. We continue to monitor the impact and effects of the COVID-19 pandemic and our response to it, and we expect to continue to take actions as may be required or recommended by government authorities or as we determine are in the best interests of our employees and other business partners in light of the pandemic.

While the COVID-19 pandemic did not significantly impact our business or results for the three and six months ended June 30, 2022 and 2021, the length and extent of the pandemic, its consequences, and containment efforts will determine the future impact on our operations and financial condition.

License and collaboration agreements

We have obligations under various license and collaboration agreements to make potentially significant milestone and success payments in the future and to pay royalties on sales of any product candidates covered by those agreements that eventually achieve regulatory approval and commercialization. For information regarding these agreements, see Note 8, "License agreements" and Note 14, "Subsequent events" to our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.

Components of our results of operations

Revenue

Through June 30, 2022 and prior to the execution of the Vertex Agreement, we had not recorded any revenue. We do not expect to generate any revenue from the sale of products in the near future and unless and until we successfully complete development and obtain regulatory approval for one or more of our product candidates. If our development efforts for our product candidates are successful and result in regulatory approval or we successfully enter into license or collaboration agreements with third parties, in addition to the Vertex Agreement, we may generate revenue in the future from product sales, payments from such additional third-party collaboration or license agreements, or any combination thereof.

Operating expenses

Research and development expenses

Research and development expenses consist of costs incurred in performing research and development activities, which include:

the cost to obtain and maintain licenses to intellectual property, such as those with the President and Fellows of Harvard College, or Harvard, The Broad Institute, Inc., or Broad, Beam Therapeutics Inc., or Beam, Acuitas Therapeutics, Inc., or Acuitas, and others, and related future payments should certain development and regulatory milestones be achieved;
personnel-related expenses, including salaries, bonuses, benefits and stock-based compensation for employees engaged in research and development functions;
expenses incurred in connection with the discovery and preclinical development of our research programs, including under agreements with third parties, such as consultants, contractors and CROs;
the cost of developing and validating our manufacturing process for use in our preclinical studies and ongoing, planned and future clinical trials, including the cost of raw materials used in our research and development activities;
the cost of laboratory supplies and research materials; and
facilities, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities and insurance.

We expense research and development costs as incurred. Nonrefundable advance payments that we make for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the benefits are consumed.

In the early phases of development, our research and development costs are often devoted to proof-of-concept studies that are not necessarily allocable to a specific target; therefore, we have not yet begun tracking our expenses on a program-by-program basis.

Research and development activities are central to our business model. We expect that our research and development expenses will continue to increase for the foreseeable future as we advance our programs and product candidates into and through clinical development, as we continue to develop additional product candidates, and as we continue to

23


 

develop our gene editing and LNP technology. We also expect our discovery research efforts and our related personnel costs will increase and, as a result, we expect our research and development expenses, including costs associated with stock-based compensation, will increase above historical levels. In addition, we may incur additional expenses related to milestone and royalty payments payable to third parties with whom we may enter into license, acquisition and option agreements to acquire the rights to future product candidates.

At this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the preclinical and clinical development of, and obtain regulatory approval for, any of our product candidates or programs. The successful development of our product candidates is highly uncertain. This is due to the numerous risks and uncertainties associated with product development, including the following:

the timing and progress of preclinical and clinical development activities;
the number and scope of preclinical and clinical programs we decide to pursue;
raising additional funds necessary to complete preclinical and clinical development of our product candidates;
the timing of filing and acceptance of INDs or comparable foreign applications that allow commencement of planned and future clinical trials for our product candidates;
the successful initiation, enrollment and completion of clinical trials;
our ability to achieve positive results from our ongoing and future clinical programs that support a finding of safety and effectiveness and an acceptable risk-benefit profile in the intended patient populations of any product candidates we may develop;
our ability to successfully develop, obtain regulatory approval for, and then successfully commercialize, our product candidates for the expected indications and patient populations;
our ability to hire and retain key research and development personnel;
the costs associated with the development of any additional product candidates we develop or acquire through collaborations;
our ability to establish and maintain agreements with third-party manufacturers for clinical supply for our clinical trials and commercial manufacturing, if our product candidates are approved;
the terms and timing of any existing or future collaboration, license or other arrangement, including the terms and timing of any milestone payments thereunder;
our ability to establish and obtain intellectual property protection and regulatory exclusivity for our product candidates and enforce and defend our intellectual property rights and claims;
our ability to commercialize products, if and when approved, whether alone or in collaboration with others;
our ability to maintain a continued acceptable safety, tolerability and efficacy profile of our product candidates following approval; and
the effects of the COVID-19 pandemic.

A change in any of these variables with respect to any of our current or future product candidates could significantly change the costs, timing and viability associated with the development of that product candidate. We may never succeed in obtaining regulatory approval for any product candidate we may develop.

General and administrative expenses

General and administrative expenses consist primarily of personnel-related costs, including salaries, benefits and stock-based compensation, for personnel in our executive, intellectual property, business development, and administrative functions. General and administrative expenses also include legal fees relating to intellectual property and corporate matters, professional fees for accounting, auditing, tax and consulting services, insurance costs, travel, and direct and allocated facility-related expenses and other operating costs.

We anticipate that our general and administrative expenses will increase in the future to support increased research and development activities. We also expect to continue to incur increased costs associated with being a public company, including costs of accounting, audit, legal, regulatory and tax-related services associated with maintaining compliance with Nasdaq and SEC requirements, director and officer insurance costs, and investor and public relations costs.

24


 

Other income

Change in fair value of antidilution rights liability

Change in fair value of antidilution rights liability consists of remeasurement gains or losses associated with changes in the antidilution rights liability associated with our license agreements with Harvard and Broad, or the Harvard/Broad License Agreement, and Broad, or the Broad License Agreement.

The antidilution rights represented the obligation to issue additional shares of common stock to Harvard and Broad following the completion of preferred stock financings and other equity financings, which was fully satisfied upon the closing of our IPO. At the inception of the agreements, the liability for the antidilution rights was recorded at fair value with the cost recorded as research and development expense and were remeasured at each reporting period with changes recorded in other income (expense) while the instruments are outstanding.

The antidilution rights liability was partially satisfied in 2019 and 2020 and was satisfied in full in June 2021 upon the closing of our IPO with the issuance of an additional 878,098 shares of our common stock.

Change in fair value of success payment liability

We are also obligated to pay to Harvard and Broad tiered success payments in the event our average market capitalization exceeds specified thresholds ascending from a high nine-digit dollar amount to $10.0 billion, or sale of our company for consideration in excess of those thresholds. In the event of a change of control of our company or a sale of our company, we are required to pay any related success payment in cash within a specified period following such event. Otherwise, the success payments may be settled at our option in either cash or shares of our common stock, or a combination of cash and shares of our common stock. The maximum aggregate success payments that could be payable by us are $31.3 million. At inception of the agreements, the success payment liabilities were recorded at fair value with the cost recorded as research and development expense and are being remeasured at each reporting period with charges recorded in other income (expense) while the instrument is outstanding.

Depending on our valuation, the fair value of the success payment liability, and the corresponding changes in fair value that we record in our statements of operations, could fluctuate significantly from period to period.

During the year ended December 31, 2021, certain success payment obligations were triggered, and amounts due to Harvard and Broad totaled $6.3 million. These amounts were settled in cash in November 2021. The remaining success payment obligations will continue to be revalued at the end of each reporting period.

Interest and other income, net

Interest and other income primarily consisted of interest earned on our marketable securities and other miscellaneous income and expenses unrelated to our core operations.

Income tax

During the three and six months ended June 30, 2022 and 2021, we recorded a full valuation allowance on federal and state deferred tax assets since management does not forecast that we will be in a taxable position in the near future.

25


 

Results of operations

Comparison of three months ended June 30, 2022 and 2021

The following table summarizes our results of operations for the three months ended June 30, 2022 and 2021:

 

 

 

Three months ended
June 30,

 

 

 

 

(in thousands)

 

2022

 

 

2021

 

 

Change

 

Operating expenses:

 

 

 

 

 

 

 

 

 

Research and development

 

$

33,125

 

 

$

13,423

 

 

$

19,702

 

General and administrative

 

 

9,067

 

 

 

3,541

 

 

 

5,526

 

Total operating expenses

 

$

42,192

 

 

$

16,964

 

 

$

25,228

 

Other income (expense):

 

 

 

 

 

 

 

 

 

Change in fair value of antidilution rights liability

 

 

-

 

 

 

(25,970

)

 

 

25,970

 

Change in fair value of success payment liability

 

 

938

 

 

 

(10,036

)

 

 

10,974

 

Interest and other income, net

 

 

308

 

 

 

5

 

 

 

303

 

Total other income (expense)

 

$

1,246

 

 

$

(36,001

)

 

$

37,247

 

Net loss

 

$

(40,946

)

 

$

(52,965

)

 

$

12,019

 

 

Research and development expenses

The following table summarizes our research and development expenses for the three months ended June 30, 2022 and 2021:

 

 

 

Three months ended
June 30,

 

 

 

 

(in thousands)

 

2022

 

 

2021

 

 

Change

 

Employee-related expenses

 

$

10,917

 

 

$

4,113

 

 

$

6,804

 

External expenses associated with preclinical studies performed by outside consultants, including third-party CROs

 

 

7,462

 

 

 

3,681

 

 

 

3,781

 

Raw material costs and external expenses associated with manufacturing activities, including third-party CMOs

 

 

5,552

 

 

 

2,990

 

 

 

2,562

 

License and milestone payments

 

 

3,047

 

 

 

25

 

 

 

3,022

 

Lab supplies

 

 

2,369

 

 

 

1,138

 

 

 

1,231

 

Facility-related costs (including depreciation)

 

 

1,602

 

 

 

821

 

 

 

781

 

Clinical trial costs

 

 

1,305

 

 

 

-

 

 

 

1,305

 

Other research and development costs

 

 

871

 

 

 

655

 

 

 

216

 

Total research and development expenses

 

$

33,125

 

 

$

13,423

 

 

$

19,702

 

 

Research and development expenses were $33.1 million for the three months ended June 30, 2022, compared to $13.4 million for the three months ended June 30, 2021. The increase of $19.7 million was primarily due to the following:

an increase in personnel-related costs of $6.8 million, including stock-based compensation driven by an increase in headcount of employees involved in research and development activities;
an increase in external expenses associated with preclinical studies (primarily animal-study costs) performed by outside consultants, including third-party CROs, of $3.8 million;
an increase in raw material costs and external expenses associated with developing and validating our manufacturing activities, including third-party CMOs, for use in our preclinical studies and clinical trial of $2.6 million;
an increase in research and development expense attributed to license and milestone payments of $3.0 million in 2022;
an increase in lab supplies of $1.2 million due to increased headcount and company growth;
an increase in facility-related costs (including depreciation) and other allocated miscellaneous expenses of $0.8 million due to increased investment in research and development;
an increase in clinical trial costs of $1.3 million associated with our heart-1 clinical trial, a Phase 1b clinical trial of VERVE-101; and
an increase in other research and development costs of $0.2 million, primarily due to an increase in professional fees and consulting fees in support of increased investment in research and development activities.

26


 

We expect that our research and development expenses will continue to increase for the foreseeable future as we advance our programs and product candidates into and through clinical development, and as we continue to develop additional product candidates and invest in our technology and manufacturing capabilities.

General and administrative expenses

General and administrative expenses were $9.1 million for the three months ended June 30, 2022, compared to $3.5 million for the three months ended June 30, 2021. The increase of approximately $5.5 million was primarily attributable to the following:

an increase of $3.5 million in personnel, facility and other expenses stemming from an increase in headcount to support our growth;
an increase of $1.4 million in legal and professional service fees, primarily due to increased professional fees for audit, tax and consulting services; and
an increase in other miscellaneous expenses of $0.6 million, primarily due to increased insurance expense for our directors and officers insurance policy and other increases in software, IT, and other miscellaneous charges.

We anticipate that our general and administrative expenses will increase in the future to support increased research and development activities.

Other income (expense)

Change in fair value of antidilution rights liability

The decrease in the change in the fair value of the antidilution rights liability was as a result of the liability being fully settled during the three months ended June 30, 2021 with the issuance of 878,098 shares of our common stock.

Change in fair value of success payments liability

During the three months ended June 30, 2022, the change in fair value of the success payments liability was primarily due to the decrease in the fair value of our common stock, which resulted in a fair value adjustment of $0.9 million to other income. During the three months ended June 30, 2021, the change in fair value for the success payments liability of $10.0 million was primarily due to the increase in the fair value of our common stock.

Interest and other income, net

The increase of $0.3 million in interest and other income, net for the three months ended June 30, 2022 compared to the three months ended June 30, 2021 was primarily attributable to increasing interest rates on marketable security balances.

Comparison of six months ended June 30, 2022 and 2021

The following table summarizes our results of operations for the six months ended June 30, 2022 and 2021:

 

 

Six months ended
June 30,

 

 

 

 

(in thousands)

 

2022

 

 

2021

 

 

Change

 

Operating expenses:

 

 

 

 

 

 

 

 

 

Research and development

 

 

57,614

 

 

$

24,768

 

 

$

32,846

 

General and administrative

 

 

16,503

 

 

 

6,257

 

 

 

10,246

 

Total operating expenses

 

$

74,117

 

 

$

31,025

 

 

$

43,092

 

Other income (expense):

 

 

 

 

 

 

 

 

 

Change in fair value of antidilution rights liability

 

 

 

 

 

(25,574

)

 

 

25,574

 

Change in fair value of success payment liability

 

 

2,615

 

 

 

(9,654

)

 

 

12,269

 

Interest and other income, net

 

 

390

 

 

 

25

 

 

 

365

 

Total other income (expense)

 

$

3,005

 

 

$

(35,203

)

 

$

38,208

 

Net loss

 

$

(71,112

)

 

$

(66,228

)

 

$

(4,884

)

 

27


 

Research and development expenses

The following table summarizes our research and development expenses for the six months ended June 30, 2022 and 2021:

 

 

Six months ended
June 30,

 

 

 

 

(in thousands)

 

2022

 

 

2021

 

 

Change

 

Employee-related expenses

 

$

19,849

 

 

$

6,806

 

 

$

13,043

 

External expenses associated with preclinical studies performed by outside consulting services, including third-party CROs

 

 

13,702

 

 

 

7,691

 

 

 

6,011

 

Raw material costs and external expenses associated with manufacturing activities, including third-party CMOs

 

 

9,657

 

 

 

5,385

 

 

 

4,272

 

Lab supplies

 

 

3,775

 

 

 

1,869

 

 

 

1,906

 

License and milestone payments

 

 

3,400

 

 

 

80

 

 

 

3,320

 

Facility-related costs (including depreciation)

 

 

3,031

 

 

 

1,600

 

 

 

1,431

 

Clinical trial costs

 

 

1,317

 

 

 

-

 

 

 

1,317

 

Other research and development costs

 

 

2,883

 

 

 

1,337

 

 

 

1,546

 

Total research and development expenses

 

$

57,614

 

 

$

24,768

 

 

$

32,846

 

 

Research and development expenses were $57.6 million for the six months ended June 30, 2022, compared to $24.8 million for the six months ended June 30, 2021. The increase of $32.8 million was primarily due to the following:

an increase in personnel-related costs of $13.0 million, including stock-based compensation, driven by an increase in headcount of employees involved in research and development activities;
an increase in external expenses associated with preclinical studies (primarily animal-study costs) performed by outside consultants, including third-party CROs, of $6.0 million;
an increase in raw material costs and external expenses associated with developing and validating our manufacturing activities, including third-party CMOs, for use in our preclinical studies and clinical trial of $4.3 million;
an increase in lab supplies of $1.9 million due to increased headcount and company growth;
an increase in research and development expense attributed to license and milestone payments of $3.3 million in 2022;
an increase in facility-related costs (including depreciation) and other allocated miscellaneous expenses of $1.4 million due to increased investment in research and development;
an increase in clinical trial costs of $1.3 million associated with our heart-1 clinical trial, a Phase 1b clinical trial of VERVE-101; and
an increase in other research and development costs of approximately $1.6 million, primarily due to an increase in professional fees and consulting fees in support of increased investment in research and development activities.

We expect that our research and development expenses will continue to increase for the foreseeable future as we advance our programs and product candidates into and through clinical development, and as we continue to develop additional product candidates and invest in our technology and manufacturing capabilities.

General and administrative expenses

General and administrative expenses were $16.5 million for the six months ended June 30, 2022,compared to $6.3 million for the six months ended June 30, 2021. The increase of $10.2 million was primarily attributable to the following:

an increase of $6.5 million in personnel, facility and other expenses stemming from an increase in headcount to support our growth;
an increase of $2.1 million in legal and professional service fees, primarily due to increased professional fees for audit, tax and consulting services; and
an increase in other miscellaneous expenses of $1.6 million, primarily due to increased insurance expense of $1.3 million for our directors and officers insurance policy and other increases in software, IT, and other miscellaneous charges.

We anticipate that our general and administrative expenses will increase in the future to support increased research and development activities.

28


 

Other income (expense)

Change in fair value of antidilution rights liability

The decrease in the change in the fair value of the antidilution rights liability was as a result of the liability being fully settled during the six months ended June 30, 2021 with the issuance of 878,098 shares of our common stock.

Change in fair value of success payments liability

During the six months ended June 30, 2022, the change in fair value of the success payments liability was primarily due to the decrease in the fair value of our common stock, which resulted in a fair value adjustment of $2.6 million to other income. During the six months ended June 30, 2021, the change in fair value for the success payments liability of $9.7 million was primarily due to the increase in the fair value of our common stock.

Interest and other income, net

The increase of $0.4 million in interest and other income, net for the six months ended June 30, 2022 compared to the six months ended June 30, 2021 was primarily attributable to higher balances and increasing interest rates on marketable security balances.

Liquidity and capital resources

Sources of liquidity and capital

Since our inception in 2018, we have incurred significant operating losses. We expect to incur significant expenses and operating losses for the foreseeable future as we advance the preclinical and, if successful, clinical development of our programs. To date, we have funded our operations primarily through equity offerings. Through June 30, 2022, we had raised an aggregate of $523.2 million in gross proceeds from sales of our preferred stock in private placements and common stock in our IPO.

In June 2021, we completed our IPO in which we issued 16,141,157 shares of our common stock, including 2,105,368 shares of common stock sold pursuant to the underwriters' full exercise of their option to purchase additional shares, at a public offering price of $19.00 per share. We received net proceeds from our IPO of $281.6 million, after deducting underwriting discounts and offering expenses payable by us. In June 2021, we issued 878,098 shares of our common stock to Harvard and Broad as final settlement of the antidilution rights liability.

As of June 30, 2022, we had $293.6 million in cash, cash equivalents and marketable securities. On July 20, 2022, we received $25.0 million from Vertex pursuant to the Vertex Agreement. Additionally, on July 20, 2022, we sold and issued 1,519,756 shares of our common stock to Vertex in connection with the Private Placement at a price of $23.03 per share for an aggregate purchase price of $35.0 million. On July 25, 2022, we issued and sold 9,583,334 shares of our common stock, including an additional 1,250,000 shares of common stock sold pursuant to the underwriters’ full exercise of their option to purchase additional shares of common stock, at a public offering price of $27.00 per share, for aggregate net proceeds of approximately $242.9 million after deducting underwriting discounts and commissions of approximately $15.5 million and offering costs of approximately $0.3 million.

On July 1, 2022, we entered into an Open Market Sale AgreementSM, or the Sales Agreement, with Jefferies LLC, or Jefferies, as agent, pursuant to which we may offer and sell shares of our common stock having an aggregate offering price of up to $150.0 million from time to time through Jefferies under an “at-the-market offering” program. Upon delivery of a placement notice and subject to the terms and conditions of the Sales Agreement, Jefferies may sell the shares of our common stock by any method permitted by law deemed to be an "at-the-market offering" as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended. We may sell the shares in amounts and at times to be determined by us from time to time subject to the terms and conditions of the Sales Agreement, but we have no obligation to sell any shares under the Sales Agreement. We agreed to pay Jefferies a commission of up to 3% of the gross proceeds of any sales of common stock pursuant to the Sales Agreement. We or Jefferies may suspend or terminate the offering of shares upon notice to the other party and subject to other conditions. On July 20, 2022, we delivered written notice to Jefferies that we were suspending and terminating the prospectus, or the ATM Prospectus, related to the sale of our common stock pursuant to the Sales Agreement. As a result, we will not make any sales of our common stock pursuant to the Sales Agreement unless and until a new prospectus, prospectus supplement or registration statement is filed. The Sales Agreement remains in full force and effect. As of the termination of the at-the-market offering, we had not issued and sold any shares of our common stock under the ATM Prospectus.

29


 

Cash flows

The following table summarizes our sources and uses of cash for each period presented:

 

 

 

 

Six months ended
June 30,

 

(in thousands)

 

2022

 

 

2021

 

Cash used in operating activities

 

$

(60,265

)

 

$

(28,482

)

Cash provided by investing activities

 

 

67,874

 

 

 

30,203

 

Cash provided by financing activities

 

 

950

 

 

 

376,732

 

Net increase in cash, cash equivalents and restricted cash

 

$

8,559

 

 

$

378,453

 

 

Operating activities

For the six months ended June 30, 2022, net cash used in operating activities was $60.3 million, consisting primarily of our net loss of $71.1 million, partially offset by changes in our operating assets and liabilities of approximately $0.1 million and by the following non-cash changes: stock-based compensation of $9.9 million, depreciation expense of $1.2 million, non-cash lease expense of $1.0 million and amortization of investment premiums of $1.2 million offset by the non-cash change in the fair value of the success payment liability of $2.6 million.

For the six months ended June 30, 2021, net cash used in operating activities was $28.5 million, consisting primarily of our net loss of $66.2 million and a decrease in our operating assets and liabilities of approximately $1.5 million. These amounts were partially offset by the following non-cash changes: $25.6 million associated with the fair value change in antidilution rights liability, $9.7 million associated with the fair value change in success payments liability, stock-based compensation of $2.0 million, non-cash lease expense of approximately $0.8 million, depreciation expense of $0.7 million and amortization of investment premiums of $0.4 million.

Investing activities

For the six months ended June 30, 2022, net cash provided by investing activities was $67.9 million and consisted of maturities of marketable securities of approximately $147.7 million, partially offset by purchases of marketable securities of $74.2 million and purchases of property and equipment of $5.6 million, primarily related to lab equipment.

For the six months ended June 30, 2021, net cash provided by investing activities was $30.2 million and consisted of maturities of marketable securities of $43.8 million, offset partially by purchases of marketable securities of $11.2 million and purchases of property and equipment of $2.4 million, primarily related to lab equipment.

Financing activities

For the six months ended June 30, 2022, net cash provided by financing activities was $1.0 million, consisting of proceeds from exercises of stock options of approximately $0.7 million and issuance of shares through our employee stock purchase plan of $0.3 million.

For the six months ended June 30, 2021, net cash provided by financing activities was $376.7 million, consisting primarily of the net proceeds from the issuance of Series B Preferred Stock of $93.8 million, net proceeds from our IPO of $285.2 million and proceeds from exercises of stock options of $0.5 million, offset partially by payment of IPO expenses of $2.8 million.

Funding requirements

Our operating expenses and future funding requirements are expected to increase substantially as we continue to advance our portfolio of programs.

Specifically, our expenses will increase if and as we:

conduct our ongoing heart-1 clinical trial for VERVE-101 in New Zealand and, if the IND and CTA are cleared, as applicable, in the United States and United Kingdom;
continue our current research programs and our preclinical development of product candidates from our current research programs;
seek to identify additional research programs and additional product candidates;
advance our existing and future product candidates into clinical development;

30


 

initiate preclinical studies and clinical trials for any additional product candidates we identify and develop or expand development of existing programs into additional patient populations;
maintain, expand, enforce, defend and protect our intellectual property portfolio and provide reimbursement of third-party expenses related to our patent portfolio;
seek regulatory and marketing approvals for any of our product candidates that we develop;
seek to identify, establish and maintain additional collaborations and license agreements, and the success of those collaborations and license agreements;
make milestone payments to Beam under our amended and restated collaboration and license agreement with Beam, milestone payments to Acuitas under our non-exclusive license agreement with Acuitas, and milestone payments or success payments to Harvard and Broad under the Harvard/ Broad License Agreements, and potential payments to other third parties under our other collaboration agreements or under any additional future collaboration or license agreements that we obtain;
ultimately establish a sales, marketing, and distribution infrastructure to commercialize any drug products for which we may obtain marketing approval, either by ourselves or in collaboration with others;
generate revenue from commercial sales of product candidates we may develop for which we receive marketing approval;
further develop base editing and novel gene editing technology;
hire additional personnel including research and development, clinical and commercial personnel;
add operational, financial and management information systems and personnel, including personnel to support our product development;
acquire or in-license products, intellectual property, medicines and technologies;
satisfy any post-marketing requirements, such as a cardiovascular outcomes trial;
establish commercial-scale current good manufacturing practices capabilities through a third-party or our own manufacturing facility; and
continue to operate as a public company.

As of June 30, 2022, we had cash, cash equivalents and marketable securities of $293.6 million. We believe that our existing cash, cash equivalents and marketable securities, including the net proceeds of approximately $242.9 million from the July 2022 follow-on public offering, $35.0 million from the Private Placement with Vertex and the $25.0 million upfront payment from Vertex pursuant to the Vertex Agreement, will enable us to fund our operating expenses and capital expenditure requirements into the second half of 2025. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect.

Identifying potential product candidates and conducting preclinical testing and clinical trials is a time consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for several years, if ever. Accordingly, we will need to obtain substantial additional funds to achieve our business objectives.

Our expectation with respect to our ability to fund current planned operations is based on estimates that are subject to risks and uncertainties. Our operating plan may change as a result of many factors currently unknown to management and there can be no assurance that the current operating plan will be achieved in the time frame anticipated by us, and we may need to seek additional funds sooner than planned.

Adequate additional funds may not be available to us on acceptable terms, or at all. We do not have any source of committed external funds. Market volatility could also adversely impact our ability to access capital as and when needed. Additional capital raised through the sale of equity or convertible debt securities may include liquidation or other preferences. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, selling or licensing our assets, making capital expenditures or declaring dividends and may require the issuance of warrants.

If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research

31


 

programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed or on terms acceptable to us, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.

Contractual obligations

During the three months ended June 30, 2022, there were no material changes to our contractual obligations and commitments from those described under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Contractual obligations” in our Annual Report on Form 10-K filed with the SEC on March 14, 2022. Refer to Note 7, “Leases,” to the condensed consolidated financial statements appearing in Part I, Item 1 in this Quarterly Report on Form 10-Q for more information on our lease obligations.

Emerging growth company status

As an emerging growth company, or EGC, under the Jumpstart Our Business Startups Act of 2012, or JOBS Act, we may delay the adoption of certain accounting standards until such time as those standards apply to private companies. Other exemptions and reduced reporting requirements under the JOBS Act for EGCs include presentation of only two years of audited financial statements in a registration statement for an IPO, an exemption from the requirement to provide an auditor’s report on internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act of 2002, an exemption from any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation, and less extensive disclosure about our executive compensation arrangements.

In addition, the JOBS Act provides that an EGC can take advantage of an extended transition period for complying with new or revised accounting standards. This provision allows an EGC to delay the adoption of some accounting standards until those standards would otherwise apply to private companies. We have elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our consolidated financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.

We may remain classified as an EGC until December 31, 2026, although if the market value of our common stock that is held by non-affiliates exceeds $700 million as of any June 30 before that time or if we have annual gross revenues of $1.07 billion or more in any fiscal year, we would cease to be an emerging growth company as of December 31 of the applicable year. We also would cease to be an EGC if we issue more than $1 billion of non-convertible debt over a three-year period.

Critical accounting policies and significant judgments

This management’s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which we have prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements and related disclosures requires us to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.

During the three and six months ended June 30, 2022, there were no material changes to our critical accounting policies from those described in our Annual Report on Form 10-K filed with the SEC on March 14, 2022.

Recently issued accounting pronouncements

See Note 2, “Summary of significant accounting policies – Recently issued accounting pronouncements” to our consolidated financial statements included in our Annual Report on Form 10-K filed with the SEC on March 14, 2022.

32


 

Item 3. Quantitative and qualitative disclosures about market risk

Interest rate risk

We are exposed to market risk related to changes in interest rates. As of June 30, 2022, we had cash and cash equivalents of $72.9 million, which consisted of standard checking accounts and money market account funds that invest primarily in U.S. government-backed securities and treasuries. In addition, as of June 30, 2022, we also had marketable securities of $220.7 million, which consist of U.S. treasury securities and agency securities. Interest income is sensitive to change in the general level of interest rates, however, due to the short-term maturities of our cash equivalents and the low risk profile of our marketable securities, an immediate 10% change in interest rates would not have a material effect on the fair market value of our cash equivalents and marketable securities.

Foreign currency exchange risk

We are not currently exposed to significant market risk related to changes in foreign currency exchange rates; however, we do contract with vendors that are located outside of the United States and may be subject to fluctuations in foreign currency rates. We may enter into additional contracts with vendors located outside of the United States in the future, which may increase our foreign currency exchange risk.

Inflation generally affects us by increasing our cost of labor and target development costs. We do not believe that inflation had a material effect on our business, financial condition or results of operations during the three and six months ended June 30, 2022.

Item 4. Controls and procedures

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our principal executive officer and our principal financial officer, evaluated, as of the end of the period covered by this Quarterly Report on Form 10-Q, the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Based on the evaluation of our disclosure controls and procedures as of June 30, 2022, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures as of such date were effective at the reasonable assurance level.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended June 30, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

33


 

Part II ─ Other Information

We are currently not a party to any material legal proceedings.

Item 1A. Risk factors

Our future operating results could differ materially from the results described in this Quarterly Report on Form 10-Q due to the risks and uncertainties described below. You should consider carefully the following information about risks below in evaluating our business. If any of the following risks actually occur, our business, financial conditions, results of operations and future growth prospects would likely be materially and adversely affected. In these circumstances, the market price of our common stock would likely decline. In addition, we cannot assure investors that our assumptions and expectations will prove to be correct. Important factors could cause our actual results to differ materially from those indicated or implied by forward-looking statements. See page i of this Quarterly Report on Form 10-Q for a discussion of some of the forward-looking statements that are qualified by these risk factors. Factors that could cause or contribute to such differences include those factors discussed below.

Risks related to our financial position and need for additional capital

We have incurred significant losses since our inception and have no products approved for sale. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability.

Since our inception, we have devoted substantially all of our financial resources and efforts to research and development, including preclinical studies, and have incurred significant operating losses. Our net losses were $71.1 million for the six months ended June 30, 2022 and $120.3 million for the year ended December 31, 2021. As of June 30, 2022, we had an accumulated deficit of $258.0 million. Through June 30, 2022 and prior to the execution of the Strategic Collaboration and License Agreement, or the Vertex Agreement, with Vertex Pharmaceuticals Incorporated, or Vertex, we had generated no revenue. We have financed our operations primarily through private placements of our preferred stock and common stock and from the sale of common stock in public offerings and payments received in connection with the Vertex Agreement. We have devoted all of our efforts to research and development and are still in the early stages of development of our research programs. We expect to continue to incur significant expenses and operating losses for the foreseeable future. Our operating expenses and net losses may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially if and as we:

conduct our ongoing heart-1 clinical trial for VERVE-101 in New Zealand and, if the investigational new drug application, or IND, and clinical trial application, or CTA, are cleared, as applicable, in the United States and United Kingdom;
continue our current research programs and our preclinical development of product candidates from our current research programs;
seek to identify additional research programs and additional product candidates;
advance our existing and future product candidates into clinical development;
initiate preclinical studies and clinical trials for any additional product candidates we identify and develop or expand development of existing programs into additional patient populations;
maintain, expand, enforce, defend and protect our intellectual property portfolio and provide reimbursement of third-party expenses related to our patent portfolio;
seek regulatory and marketing approvals for any of our product candidates that we develop;
seek to identify, establish and maintain additional collaborations and license agreements, and the success of those collaborations and license agreements;
make milestone payments to Beam Therapeutics Inc., or Beam, under our amended and restated collaboration and license agreement with Beam, or the Beam Agreement, milestone payments to Acuitas Therapeutics Inc., or Acuitas, under our non-exclusive license agreement with Acuitas, or the Acuitas Agreement, and milestone payments or success payments to The Broad Institute, Inc., or Broad, and the President and Fellows of Harvard College, or Harvard, under our license agreement with Broad and Harvard (as amended, the Cas9 License Agreement), and

34


 

potential payments to other third parties under our other collaboration agreements or any additional future collaboration or license agreements that we obtain;
ultimately establish a sales, marketing, and distribution infrastructure to commercialize any drug products for which we may obtain marketing approval, either by ourselves or in collaboration with others;
generate revenue from commercial sales of product candidates we may develop for which we receive marketing approval;
further develop base editing and novel gene editing technology;
hire additional personnel including research and development, clinical and commercial personnel;
add operational, financial and management information systems and personnel, including personnel to support our product development;
acquire or in-license products, intellectual property, medicines and technologies;
satisfy any post-marketing requirements, such as a cardiovascular outcomes trial, or CVOT;
establish commercial-scale current good manufacturing practices capabilities, or cGMP, through a third-party or our own manufacturing facility; and
continue to operate as a public company.

In addition, our expenses will increase if, among other things:

we are required by the U.S. Food and Drug Administration, or the FDA, the European Medicines Agency, or the EMA, or other regulatory authorities to perform trials or studies in addition to, or different than, those expected;
there are any delays in completing our clinical trials or the development of any of our product candidates; or
there are any third-party challenges to our intellectual property or we need to defend against any intellectual property-related claim.

Even if we obtain marketing approval for, and are successful in commercializing, one or more of our product candidates, we expect to incur substantial additional research and development and other expenditures to develop and market additional product candidates and/or to expand the approved indications of any marketed product. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue.

We have never generated revenue from product sales and may never achieve or maintain profitability.

We have only recently initiated clinical development of our first product candidate and expect that it will be many years, if ever, before we have a product candidate ready for commercialization. To become and remain profitable, we must succeed in developing, obtaining the necessary regulatory approvals for and eventually commercializing a product or products that generate significant revenue. The ability to achieve this success will require us to be effective in a range of challenging activities, including:

completing preclinical testing and clinical trials;
identifying additional product candidates;
obtaining marketing approval for these product candidates;
manufacturing, marketing and selling any products for which we may obtain marketing approval; and
achieving market acceptance of products for which we may obtain marketing approval as viable treatment options.

We are only in the preliminary stages of these activities and there is no assurance that we will be successful in these activities and, even if we are, may never generate revenues that are significant enough to achieve profitability. Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to generate revenue or achieve profitability.

Even if we are able to generate revenue from the sale of any approved products, we may not become profitable and may need to obtain additional funding to continue operations. Our revenue will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval, the accepted price for the product, the ability to obtain coverage and reimbursement, and whether we own the commercial rights for that territory. If the number of our

35


 

addressable patients is not as significant as we estimate, the indication approved by regulatory authorities is narrower than we expect, or the treatment population is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of such products, even if approved.

We will need substantial additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.

We expect to devote substantial financial resources to our ongoing and planned activities, particularly as we conduct our ongoing Phase 1b clinical trial of VERVE-101, continue research, development and preclinical testing, initiate additional clinical trials and potentially seek marketing approval for VERVE-101 and any other product candidates we may develop. We expect our expenses to increase substantially in connection with our ongoing and planned activities, particularly as we advance our preclinical activities and our ongoing and planned clinical trials. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, sales, marketing and distribution. Furthermore, we expect to continue to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. We currently do not have a credit facility or any committed sources of capital. If we are unable to raise capital or obtain adequate funds when needed or on acceptable terms, we may be forced to delay, limit, reduce or terminate our research and development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.

Our future capital requirements will depend on many factors, including:

the costs of acquiring licenses for the delivery modalities that will be used with our product candidates;
the progress, costs and results of our ongoing Phase 1b clinical trial of VERVE-101 and any future clinical development of VERVE-101;
the scope, progress, results and costs of discovery, preclinical and clinical development for any product candidates we may develop;
the cost and timing of completion of commercial-scale manufacturing activities;
the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property and proprietary rights, and defending intellectual property-related claims, including claims of infringement, misappropriation or other violation of third-party intellectual property;
the costs, timing and outcome of regulatory review of the product candidates we may develop;
the costs of future commercialization activities, either by ourselves or in collaboration with others, including product sales, marketing, manufacturing, and distribution for any product candidates for which we receive marketing approval;
the costs of satisfying any post-marketing requirements, such as a CVOT;
the revenue, if any, received from commercial sales of product candidates we may develop for which we receive marketing approval;
the success of our license agreements and our collaborations;
our ability to establish and maintain additional collaborations on favorable terms, if at all;
the achievement of milestones or occurrence of other developments that trigger payments under any additional collaboration agreements we obtain;
the extent to which we acquire or in-license products, intellectual property and technologies;
the costs of operational, financial and management information systems and associated personnel; and
the costs of operating as a public company.

Identifying potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, even if we successfully identify and develop product candidates and those are approved, we may not achieve commercial success. Our commercial revenues, if any, may not be sufficient to sustain our operations. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives.

As of June 30, 2022, we had cash, cash equivalents and marketable securities of approximately $293.6 million. We believe that our existing cash, cash equivalents and marketable securities, together with the net proceeds of

36


 

approximately $242.9 million from the July 2022 follow-on public offering, $35.0 million from Vertex in the private placement and $25.0 million upfront payment from Vertex pursuant to the Vertex Agreement, will enable us to fund our operating expenses and capital expenditure requirements into the second half of 2025. However, we have based this estimate on assumptions that may prove to be wrong, and our operating plan may change as a result of many factors currently unknown to us. As a result, we could deplete our capital resources sooner than we currently expect and could be forced to seek additional funding sooner than planned.

Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize any product candidates. We cannot be certain that additional funding will be available on acceptable terms, or at all. For example, while the potential impact and duration of the COVID-19 pandemic on the global economy and our business in particular may be difficult to assess or predict, the pandemic has resulted in, and may continue to result in, significant disruption of global financial markets, which could in the future negatively affect our liquidity. We have no committed source of additional capital and, if we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of our product candidates or other research and development initiatives. We could be required to seek collaborators for product candidates we may develop at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available or relinquish or license on unfavorable terms our rights to product candidates we may develop in markets where we otherwise would seek to pursue development or commercialization ourselves.

Any of the above events could significantly harm our business, prospects, financial condition and results of operations and cause the price of our common stock to decline.

Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.

Until such time, if ever, as we can generate substantial revenues from product sales, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. We do not have any source of committed external funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, our stockholders’ interests will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders’ rights as a common stockholder. Any debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, selling or licensing our assets, making capital expenditures, declaring dividends or encumbering our assets to secure future indebtedness.

If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed or on terms acceptable to us, we would be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.

Our limited operating history may make it difficult for stockholders to evaluate the success of our business to date and to assess our future viability.

We commenced operations in 2018 and are a clinical-stage company. Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, developing our technology, identifying potential product candidates, securing intellectual property rights, conducting preclinical studies and an early-stage clinical trial. In July 2022, we initiated our first clinical trial, a Phase 1b clinical trial for VERVE-101, in New Zealand. Our other research programs are still in the research or preclinical stage of development, and their risk of failure is high. We have not yet demonstrated our ability to complete any clinical trials, obtain marketing approvals, manufacture a clinical development or commercial scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. In part because of this lack of experience, we cannot be certain that our ongoing preclinical studies and clinical trial will be completed on time or if the planned preclinical studies and clinical trials will begin or be completed on time, if at all. Consequently, any predictions stockholders make about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing gene editing products.

Our limited operating history, particularly in light of the rapidly evolving genetic medicines field, may make it difficult to evaluate our technology and industry and predict our future performance. Our limited history as an operating company makes any assessment of our future success or viability subject to significant uncertainty. We will encounter risks and

37


 

difficulties frequently experienced by early-stage companies in rapidly evolving fields. If we do not address these risks successfully, our business will suffer.

In addition, as our business grows, we may encounter unforeseen expenses, restrictions, difficulties, complications, delays and other known and unknown factors. We will need to transition at some point from a company with a research and development focus to a company capable of supporting commercial activities. We may not be successful in such a transition.

Our ability to use our net operating losses and research and development tax credit carryforwards to offset future taxable income or taxes may be subject to certain limitations.

We have a history of cumulative losses and anticipate that we will continue to incur significant losses in the foreseeable future; thus, we do not know whether or when we will generate taxable income necessary to utilize our net operating losses, or NOLs, or research and development tax credit carryforwards. As of December 31, 2021, we had federal NOL carryforwards of $124.7 million and state NOL carryforwards of $114.4 million.

In general, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, and corresponding provisions of state law, a corporation that undergoes an “ownership change,” generally defined as a greater than 50 percentage point change (by value) in its equity ownership by certain stockholders over a three-year period, is subject to limitations on its ability to utilize its pre-change NOLs and research and development tax credit carryforwards to offset post-change taxable income or taxes. We have not conducted a study to assess whether any such ownership changes have occurred. We may have experienced such ownership changes in the past and may experience such ownership changes in the future as a result of subsequent changes in our stock ownership (which may be outside our control). As a result, if, and to the extent that, we earn net taxable income, our ability to use our pre-change NOLs and research and development tax credit carryforwards to offset such taxable income may be subject to limitations. Our NOLs or credits may also be impaired under state law.

There is also a risk that due to regulatory changes, such as suspensions on the use of NOLs, or other unforeseen reasons, our existing NOLs could expire or otherwise become unavailable to offset future income tax liabilities. As described below in “Changes in tax laws or in their implementation or interpretation may adversely affect our business and financial condition,” the Tax Cuts and Jobs Act, or the Tax Act, as amended by the Coronavirus Aid, Relief, and Economic Security Act, or CARES Act, included changes to U.S. federal tax rates and the rules governing NOL carryforwards that may significantly impact our ability to utilize our NOLs to offset taxable income in the future. For these reasons, even if we attain profitability, we may be unable to use a material portion of our NOLs and other tax attributes.

Risks related to discovery and development

 

We are very early in our development efforts, and we have not yet completed IND- enabling studies of any product candidate. As a result, we expect it will be many years before we commercialize any product candidate, if ever. If we are unable to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed.

We are very early in our development efforts and have focused our research and development efforts to date primarily on research efforts and preclinical development. In July 2022, we initiated our first clinical trial, a Phase 1b clinical trial for VERVE-101, in New Zealand. We anticipate obtaining regulatory clearances for a CTA in the United Kingdom and an IND application in the United States in the second half of 2022, but we cannot provide assurances that such clearances will be obtained. Our ability to generate product revenues, which we do not expect will occur for many years, if ever, will depend heavily on the successful development, marketing approval and eventual commercialization of our product candidates, which may never occur. We have not yet generated revenue from product sales, and we may never be able to develop or commercialize a marketable product.

Commencing clinical trials in the United States is subject to acceptance by the FDA of an IND and finalizing the trial design based on discussions with the FDA and other regulatory authorities. We have had initial discussions with the FDA and other regulatory authorities with respect to our clinical trial design for our planned Phase 1 clinical trial of VERVE-101, but we have not yet made regulatory submissions to the FDA with respect to the planned trial design and that trial design may change subject to those discussions. While we received clearance of our first CTA for VERVE-101 in New Zealand, there can be no assurance that other regulatory agencies, including the FDA, will accept an IND or CTAs.

The FDA or other regulatory agencies may require us to complete additional preclinical studies or require us to satisfy other requests prior to commencing clinical trials in the respective countries, which may delay our clinical trials beyond our planned timeline. As a result, we cannot be certain that we will be able to obtain clearance of an IND application in the United States or a CTA in the United Kingdom in the second half of 2022. Even after we receive and incorporate guidance

38


 

from these regulatory authorities, the FDA or other regulatory authorities could disagree that we have satisfied their requirements to commence any clinical trial or change their position on the acceptability of our trial design or the clinical endpoints selected, which may require us to complete additional preclinical studies or clinical trials, delay the enrollment of our clinical trials or impose stricter approval conditions than we currently expect. There are equivalent processes and risks applicable to CTAs in other countries, including countries in the European Union.

Commercialization of any product candidates we may develop will require preclinical and clinical development; regulatory and marketing approval in multiple jurisdictions, including by the FDA and the EMA; manufacturing supply, capacity and expertise; a commercial organization; and significant marketing efforts. The success of VERVE-101 and any other product candidates we may identify and develop will depend on many factors, including the following:

timely and successful completion of preclinical studies, including toxicology studies, biodistribution studies and minimally efficacious dose studies in animals, where applicable;
effective INDs or comparable foreign applications that allow commencement of our planned clinical trials or future clinical trials for any product candidates we may develop;
successful enrollment and completion of clinical trials, including under the FDA’s current Good Clinical Practices, or GCPs, current Good Laboratory Practices and any additional regulatory requirements from foreign regulatory authorities;
positive results from our ongoing and future clinical trials that support a finding of safety and effectiveness and an acceptable risk-benefit profile in the intended populations;
receipt of marketing approvals from applicable regulatory authorities;
establishment of arrangements through our own facilities or with third-party manufacturers for clinical supply and, where applicable, commercial manufacturing capabilities;
establishment, maintenance, defense and enforcement of patent, trademark, trade secret and other intellectual property protection or regulatory exclusivity for any product candidates we may develop;
commercial launch of any product candidates we may develop, if approved, whether alone or in collaboration with others;
acceptance of the benefits and use of our product candidates we may develop, including method of administration, if and when approved, by patients, the medical community and third-party payers;
effective competition with other therapies;
maintenance of a continued acceptable safety, tolerability and efficacy profile of any product candidates we may develop following approval; and
establishment and maintenance of healthcare coverage and adequate reimbursement by payers.

If we do not succeed in one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize any product candidates we may develop, which would materially harm our business. If we are unable to advance our product candidates through clinical development, obtain regulatory approval and ultimately commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed.

Gene editing, including base editing, is a novel technology that is not yet clinically validated as being safe and efficacious for human therapeutic use. The approaches we are taking to discover and develop novel therapeutics are unproven and may never lead to marketable products.

We are focused on developing medicines utilizing gene editing technology, which is new and largely unproven. The base editing technologies that we have licensed and that we are utilizing with VERVE-101 and in our ANGPTL3 program have not yet been clinically tested, nor are we aware of any clinical trials for safety or efficacy having been completed by third parties using our base editing or similar technologies. The scientific evidence to support the feasibility of developing product candidates based on gene editing technologies is both preliminary and limited. Successful development of our product candidates will require us to safely deliver a gene editor into target cells, optimize the efficiency and specificity of such product candidates and ensure the therapeutic selectivity of such product candidates. There can be no assurance that base editing technology, or other gene editing technology, will lead to the development of genetic medicines or that we will be successful in solving any or all of these issues.

Our future success is highly dependent on the successful development of gene editing technologies, delivery technology methods and therapeutic applications of that technology. We may decide to alter or abandon our initial programs as new

39


 

data become available and we gain experience in developing gene editing therapeutics. We cannot be sure that our technologies will yield satisfactory products that are safe and effective, scalable or profitable in our initial indications or any other indication we pursue. Adverse developments in the clinical development efforts of other gene editing technology companies could adversely affect our efforts or the perception of our product candidates by both investors and regulatory authorities.

Similarly, another new gene editing technology that has not been discovered yet may be developed by third parties and may be determined to be more attractive than base editing for the gene targets that we are pursuing with base editing technology. We also are seeking to develop a novel gene editing development candidate as part of our collaboration with Vertex, including seeking to identify and engineer specific gene editing systems and delivery systems directed to a target of interest. We have not previously developed novel gene editing technology on our own and have in-licensed gene editing technology from third parties. We cannot be certain that we will be able to successfully develop novel gene editing systems for the target or for any other targets.

Moreover, we cannot be certain we will be able to obtain any necessary rights to develop other gene editing technologies. Although all of our founders who currently provide consulting and advisory services to us in the area of base editing technologies have assignment of inventions obligations to us with respect to the services they perform for us, these assignment of inventions obligations are subject to limitations and do not extend to their work in other fields or to the intellectual property arising from their employment with their respective academic and research institutions. To obtain intellectual property rights assigned by these founders to such institutions, we would need to enter into license agreements with such institutions, which may not be available on commercially reasonable terms or at all. Any of these factors could reduce or eliminate our commercial opportunity and could have a material adverse effect on our business, financial condition, results of operations and prospects.

Development activities in the field of gene editing are currently subject to a number of risks related to the ownership and use of certain intellectual property rights that are subject to patent interference proceedings in the United States and opposition proceedings in Europe. For additional information regarding the risks that may apply to our and our licensors’ intellectual property rights, see the section entitled “—Risks related to our intellectual property” for more information.

Additionally, public perception and related media coverage relating to the adoption of new therapeutics or novel approaches to treatment, as well as ethical concerns related specifically to gene editing, may adversely influence the willingness of subjects to participate in clinical trials, or, if any therapeutic is approved, of physicians and patients to accept these novel and personalized treatments. Physicians, health care providers and third-party payors often are slow to adopt new products, technologies and treatment practices, particularly those that may also require additional upfront costs and training. Physicians may not be willing to undergo training to adopt these novel and potentially personalized therapies, may decide the particular therapy is too complex or potentially risky to adopt without appropriate training, and may choose not to administer the therapy. Further, due to health conditions, genetic profile or other reasons, certain patients may not be candidates for the therapies. In addition, responses by federal and state agencies, Congressional committees and foreign governments to negative public perception, ethical concerns or financial considerations may result in new legislation, regulations or medical standards that could limit our ability to develop or commercialize any product candidates, obtain or maintain regulatory approval or otherwise achieve profitability. New government requirements may be established that could delay or prevent regulatory approval of our product candidates under development. It is impossible to predict whether legislative changes will be enacted, regulations, policies or guidance changed, or interpretations by agencies or courts changed, or what the impact of such changes, if any, may be. Based on these and other factors, health care providers and payors may decide that the benefits of these new therapies do not or will not outweigh their costs.

The gene editing field is relatively new and is evolving rapidly. We are focusing our research and development efforts on gene editing using base editing technology, but other gene editing technologies may be discovered that provide significant advantages over base editing, which could materially harm our business.

To date, we have focused our efforts on gene editing technologies using base editing. Other companies have previously undertaken research and development of gene editing technologies using zinc finger nucleases, engineered meganucleases and transcription activator-like effector nucleases, but to date none have obtained marketing approval for a product candidate. There can be no certainty that base editing technology will lead to the development of genetic medicines or that other gene editing technologies will not be considered better or more attractive for the development of medicines. For example, Feng Zhang’s group at the Massachusetts Institute of Technology, or MIT, and Broad, and, separately, Samuel Sternberg’s group at Columbia University recently announced the discovery of the use of transposons, or “jumping genes.” Transposons can insert themselves into different places in the genome and can be programmed to carry specific DNA sequences to specific sites, without the need for making double-stranded breaks in DNA. Beam uses prime editing technology, which utilizes a CRISPR protein to target a mutation site in DNA and to nick a single strand of the target DNA. Guide RNA allows the CRISPR protein to recognize a DNA sequence that is

40


 

complementary to the guide RNA and also carries a primer for reverse transcription and a replacement template. The reverse transcriptase copies the template sequence in the nicked site, installing the edit.

A number of alternative approaches are being developed by others, including, for example, Intellia Therapeutics, Inc., which recently reported clinical data from a Phase 1 trial of a CRISPR/Cas9-based gene editing product candidate for the treatment of hereditary transthyretin amyloidosis with polyneuropathy. Similarly, other new gene editing technologies that have not been discovered yet may be more attractive than base editing. Moreover, we cannot be certain we will be able to obtain rights to develop or use other gene editing technologies. Any of these factors could reduce or eliminate our commercial opportunity, and could have a material adverse effect on our business, financial condition, results of operations and prospects.

We may not be successful in our efforts to identify and develop potential product candidates. If these efforts are unsuccessful, we may never become a commercial stage company or generate any revenues.

The success of our business depends primarily upon our ability to identify, develop and commercialize product candidates using gene editing technologies. We have only just initiated our first clinical trial in New Zealand and we have not yet completed IND-enabling studies or submitted an IND in the United States for any product candidate. Our research programs may fail to identify potential product candidates for clinical development for a number of reasons. Our research methodology may be unsuccessful in identifying additional potential product candidates, our potential product candidates may be shown to have harmful side effects in preclinical in vitro experiments or animal model studies, they may not show promising signals of therapeutic effect in such experiments or studies or they may have other characteristics that may make the product candidates impractical to manufacture, unmarketable or unlikely to receive marketing approval.

If any of these events occur, we may be forced to abandon our research or development efforts for a program or programs, which would have a material adverse effect on our business, financial condition, results of operations and prospects. Research programs to identify new product candidates require substantial technical, financial and human resources. We may focus our efforts and resources on potential programs or product candidates that ultimately prove to be unsuccessful, which would be costly and time-consuming.

The COVID-19 pandemic may affect our ability to initiate and complete current or future preclinical studies and clinical trials, disrupt regulatory activities or have other adverse effects on our business and operations. In addition, this pandemic has adversely impacted economies worldwide, which could result in adverse effects on our business, operations and prospects.

The COVID-19 pandemic has caused, and may continue to cause, many governments to implement measures to slow the spread of the pandemic through quarantines, travel restrictions, heightened border scrutiny and other measures. The pandemic and government measures taken in response have also had a significant impact, both direct and indirect, on businesses and commerce, as worker shortages have occurred; supply chains have been disrupted; facilities and production have been suspended; and demand for certain goods and services, such as medical services and supplies, has spiked, while demand for other goods and services, such as travel, has fallen.

The future progression of the pandemic and its effects on our business and operations are uncertain. We and our contract manufacturing organizations, or CMOs, and contract research organizations, or CROs, have experienced a reduction in the capacity to undertake research-scale production and to execute some preclinical studies, and we have faced and may face disruptions that affect our ability to initiate and complete preclinical studies and clinical trials, and disruptions in procuring items that are essential for our research and development activities, including:

raw materials and supplies used in the production and purification of messenger RNA, or mRNA, nucleic acids as well as lipids used in the production of lipid nanoparticles, or LNPs;
raw materials and supplies used in the manufacture of any product candidates we may develop;
laboratory supplies used in our preclinical studies and clinical trials; and
animals that are used for preclinical testing for which there are shortages because of ongoing efforts to address components of the pandemic.

We and our CROs and CMOs may also face disruptions related to our ongoing and future IND-enabling studies and clinical trials arising from delays in preclinical studies, manufacturing disruptions, and the ability to obtain necessary institutional review board, or IRB, institutional biosafety committee, or IBC, or other necessary site approvals, as well as other delays at clinical trial sites.

The response to the COVID-19 pandemic may also redirect resources with respect to regulatory and intellectual property matters in a way that would adversely impact our ability to progress regulatory approvals and protect our intellectual property, for example by causing interruptions or delays in the operations of the FDA or other regulatory authorities, which

41


 

may impact review and approval timelines. We have experienced delays with the FDA as a result of the COVID-19 pandemic. In addition, we may face impediments or delays to regulatory meetings and approvals due to measures intended to limit in-person interactions. We cannot be certain what the overall impact of the COVID-19 pandemic will be on our business, although for the reasons described above it has the potential to adversely affect our business, financial condition, results of operations and prospects.

Clinical drug development involves a lengthy and expensive process, with an uncertain outcome. If we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.

The risk of failure for each of our product candidates is high. It is impossible to predict when or if any of our product candidates will prove effective or safe in humans or will receive marketing approval. The time required to obtain approval from the FDA, EMA or other comparable foreign regulatory authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of regulatory authorities. Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. We have only recently initiated a clinical trial for VERVE-101 and have not yet completed any clinical trials. Clinical trials may fail to demonstrate that our product candidates are safe for humans and effective for indicated uses. Even if initial clinical trials in any of our product candidates we may develop are successful, these product candidates we may develop may fail to show the desired safety and efficacy in later stages of clinical development despite having successfully advanced through preclinical studies and initial clinical trials. There is a high failure rate for drugs and biologics proceeding through clinical trials. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in later stage clinical trials even after achieving promising results in earlier stage clinical trials. Furthermore, even if the clinical trials are successful, changes in marketing approval policies during the development period, changes in or the enactment or promulgation of additional statutes, regulations or guidance or changes in regulatory review for each submitted product application may cause delays in the approval or rejection of an application.

Before we can commence clinical trials for a product candidate, we must complete extensive preclinical testing and studies that support our planned INDs and other regulatory filings in the United States and abroad. We cannot be certain of the timely completion or outcome of our preclinical testing and studies and cannot predict if the outcome of our preclinical testing and studies will ultimately support the further development of our current or future product candidates or whether regulatory authorities will accept our proposed clinical programs. As a result, we may not be able to submit an IND in the United States or comparable foreign applications to initiate clinical development on the timelines we expect, if at all, and the submission of these applications may not result in regulatory authorities allowing clinical trials to begin. Furthermore, product candidates are subject to continued preclinical safety studies, which may be conducted concurrently with our clinical testing. The outcomes of these safety studies may delay the launch of or enrollment in future clinical trials and could impact our ability to continue to conduct our clinical trials.

Clinical testing is expensive, is difficult to design and implement, can take many years to complete and is uncertain as to outcome. We cannot guarantee that any of our clinical trials will be conducted as planned or completed on schedule, or at all. A failure of one or more clinical trials can occur at any stage of testing, which may result from a multitude of factors, including, but not limited to, flaws in study design, dose selection issues, placebo effects, patient enrollment criteria and failure to demonstrate favorable safety or efficacy traits.

Preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. Furthermore, the failure of any of our product candidates to demonstrate safety and efficacy in any clinical trial could negatively impact the perception of our other product candidates and/or cause the FDA, EMA or other regulatory authorities to require additional testing before approving any of our product candidates.

Our current and future product candidates could fail to receive regulatory approval for many reasons, including the following:

the FDA, EMA or other foreign regulatory authorities may disagree with the design or implementation of our clinical trials;
we may be unable to demonstrate to the satisfaction of the FDA, EMA or other foreign regulatory authorities that a product candidate is safe, pure and potent or effective for its proposed indication;
the results of clinical trials may not meet the level of statistical significance required by the FDA, EMA or other foreign regulatory authorities for approval;
we may be unable to demonstrate that a product candidate’s clinical and other benefits outweigh its safety risks;

42


 

the FDA, EMA or other foreign regulatory authorities may disagree with our interpretation of data from clinical trials or preclinical studies;
the data collected from clinical trials of our product candidates may not be sufficient to support the submission of a Biologics License Application, or BLA, to the FDA, or similar foreign submission to the EMA or other foreign regulatory authority, to obtain approval in the United States, the European Union or elsewhere;
the FDA, EMA or other foreign regulatory authorities may find deficiencies with or fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and
the approval policies or regulations of the FDA, EMA or other foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.

This lengthy approval process as well as the unpredictability of clinical trial results may result in our failing to obtain regulatory approval to market any product candidate we develop, which would significantly harm our business, financial condition, results of operations and prospects.

The FDA, EMA and other comparable foreign regulatory authorities have substantial discretion in the approval process and determining when or whether regulatory approval will be obtained for any product candidate that we develop. Even if we believe the data collected from our ongoing or future clinical trials of our product candidates are promising, such data may not be sufficient to support approval by the FDA, EMA or any other comparable foreign regulatory authorities.

Even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may grant approval contingent on the performance of costly post-marketing clinical trials or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Additionally, outside of the United States, regulatory authorities may not approve the price we intend to charge for our products. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.

In response to the COVID-19 pandemic, the FDA issued guidance on March 18, 2020, and subsequently updated it on July 2, 2020, January 27, 2021, and August 30, 2021, to address the conduct of clinical trials during the pandemic. The guidance sets out a number of considerations for sponsors of clinical trials impacted by the pandemic, including the requirement to include in the clinical study report (or as a separate document) contingency measures implemented to manage the study, and any disruption of the study as a result of COVID-19; a list of all study participants affected by COVID-19-related study disruptions by a unique subject identifier and by investigational site, and a description of how the individual’s participation was altered; and analyses and corresponding discussions that address the impact of implemented contingency measures (e.g., participant discontinuation from investigational product and/or study, alternative procedures used to collect critical safety and/or efficacy data) on the safety and efficacy results reported for the study. In its most recent update to this guidance, FDA addresses questions received during the past year from clinical practitioners who are adapting their operations in a pandemic environment. These questions focused on, among other things, when to suspend, continue or initiate a trial and how to submit changes to protocols for INDs and handle remote site monitoring visits. There is no assurance that this guidance governing clinical studies during the pandemic will remain in effect or, even if it does, that it will help address the risks and challenges enumerated above. Accordingly, our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays or might require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidates, slow down or halt our product candidate development and approval process and jeopardize our ability to seek and obtain the marketing approval required to commence product sales and generate revenue, which would cause the value of our company to decline and limit our ability to obtain additional financing if needed.

Accordingly, the COVID-19 pandemic may continue to significantly impact economies and financial markets worldwide, which could result in adverse effects on our business and operations, impact our ability to raise additional funds through public offerings and impact the volatility of our stock price and trading in our stock. We cannot be certain what the overall impact of the COVID-19 pandemic will be on our business and it has the potential to adversely affect our business, financial condition, results of operations, and prospects.

The outcome of preclinical studies and earlier-stage clinical trials may not be predictive of future results or the success of later preclinical studies and clinical trials.

We have only recently initiated and begun conducting a clinical trial. As a result, our belief in the potential capabilities of our programs is based on early research and preclinical studies. However, the results of preclinical studies may not be predictive of the results of later preclinical studies or clinical trials, and the results of any early-stage clinical trials may not be predictive of the results of later clinical trials. In addition, initial success in clinical trials may not be indicative of results obtained when such trials are completed. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in

43


 

preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. We have conducted several preclinical studies of our product candidates in non-human primates, but we cannot be certain that the results observed in such studies will translate into similar results in clinical trials of our product candidates in humans. Our ongoing or future clinical trials may not ultimately be successful or support further clinical development of any product candidates we may develop. There is a high failure rate for product candidates proceeding through clinical trials. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving encouraging results in earlier studies. Any such setbacks in our clinical development could materially harm our business and results of operations.

We may incur unexpected costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.

We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including:

regulators, IRBs or independent ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;
we may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites;
regulators may decide that longer follow-up data are needed before they will consider our marketing application, which would delay our ability to obtain approval;
regulators may decide the design of our clinical trials is flawed, for example if regulators do not agree with our chosen primary endpoints;
regulators may decide to slow patient enrollment, resulting in delays to our ability to meet our timelines;
clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs;
preclinical testing may produce results based on which we may decide, or regulators may require us, to conduct additional preclinical studies before we proceed with certain clinical trials, limit the scope of our clinical trials, halt ongoing clinical trials or abandon product development programs;
the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate;
our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;
regulators, IRBs or ethics committees may require us to perform additional or unanticipated clinical trials to obtain approval or we may be subject to additional post-marketing testing requirements to maintain regulatory approval, such as a CVOT;
regulators may revise the requirements for approving our product candidates, or such requirements may not be as we anticipate;
the cost of clinical trials of our product candidates may be greater than we anticipate;
the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate;
our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators, IRBs or ethics committees to suspend or terminate the trials; and
regulators may withdraw their approval of a product or impose restrictions on its distribution, such as in the form of a risk evaluation and mitigation strategy, or REMS.

We could encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are conducted or their ethics committees, by the data review committee or data safety monitoring board for such trial or by the FDA, EMA or other foreign regulatory authorities. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA, EMA or other foreign regulatory

44


 

authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, including those relating to the class of products to which our product candidates belong.

If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may:

be delayed in obtaining marketing approval for our product candidates;
not obtain marketing approval at all;
obtain approval for indications or patient populations that are not as broad as intended or desired;
obtain approval with labeling or a REMS that includes significant use or distribution restrictions or safety warnings;
be subject to additional post-marketing testing requirements; or
have the product removed from the market after obtaining marketing approval.

Our development costs will also increase if we experience delays in preclinical studies or clinical trials or in obtaining marketing approvals. We do not know whether any of our preclinical studies or clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. We may also determine to change the design or protocol of one or more of our clinical trials, including to add additional patients or arms, which could result in increased costs and expenses and/or delays. Significant preclinical study or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.

Preclinical drug development is uncertain. Some or all of our preclinical programs may experience delays or may never advance to clinical trials, which would adversely affect our ability to obtain marketing approvals or commercialize these product candidates on a timely basis or at all, which would have an adverse effect on our business.

In order to obtain FDA approval to market a new biological product, we must demonstrate product purity (or product quality) as well as proof of safety and potency or efficacy in humans. To satisfy these requirements, we will have to conduct adequate and well-controlled clinical trials. Before we can commence clinical trials for a product candidate, we must complete extensive preclinical testing and studies that support an IND in the United States. We have not yet submitted an IND to the FDA for any of our product candidates. We cannot be certain of the timely completion or outcome of our preclinical testing and studies, and we cannot predict if the FDA will accept our proposed clinical programs or if the outcome of our preclinical testing and studies will ultimately support the further development of these product candidates. As a result, we cannot be sure that we will be able to submit INDs or similar applications for any preclinical programs on the timelines we expect, if at all, and we cannot be sure that submission of INDs or similar applications will result in the FDA or other regulatory authorities allowing clinical trials to begin.

Conducting preclinical testing is a lengthy, time-consuming and expensive process. The length of time may vary substantially according to the type, complexity, novelty and intended use of the product candidate, and often can be several years or more per product candidate. Delays associated with product candidates for which we are conducting preclinical testing and studies ourselves may cause us to incur additional operating expenses. Moreover, we may be affected by delays associated with the preclinical testing and studies of certain product candidates conducted by our potential partners over which we have no control. The commencement and rate of completion of preclinical studies and clinical trials for a product candidate may be delayed by many factors, including, for example:

inability to generate sufficient preclinical or other in vivo or in vitro data to support the initiation of clinical trials; and
delays in reaching a consensus with regulatory agencies on study design.

Moreover, even if we do initiate clinical trials for other product candidates, our development efforts may not be successful, and clinical trials that we conduct or that third parties conduct on our behalf may not demonstrate product purity (or quality) as well as proof of safety and potency or efficacy necessary to obtain the requisite marketing approvals for any of our product candidates or product candidates employing our technology. Even if we obtain positive results from preclinical studies or initial clinical trials, we may not achieve the same success in future trials.

45


 

If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.

Identifying and qualifying patients to participate in clinical trials for our product candidates is critical to our success. We recently initiated our heart-1 clinical trial for VERVE-101 in New Zealand. Successful and timely completion of clinical trials will require that we enroll a sufficient number of patients who remain in the trial until its conclusion. We may not be able to initiate or continue additional clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside of the United States. Given the large patient population for atherosclerotic cardiovascular disease, or ASCVD, if we expand clinical development of VERVE-101 for the treatment of patients with established ASCVD, the number of patients that may be required for clinical trials could be high, we may not be able to enroll a sufficient number of patients and we may not be able to initiate or complete clinical trials of VERVE-101 for the treatment of patients with established ASCVD. Because of the small patient population for homozygous familial hypercholesterolemia, or HoFH, we may have difficulty enrolling patients and we may not be able to initiate or complete clinical trials for our ANGPTL3 program for the treatment of HoFH.

Patient enrollment is affected by a variety of other factors, including:

the prevalence and severity of the disease under investigation;
the eligibility criteria for the trial in question;
the perceived risks and benefits of the product candidate under trial;
the requirements of the trial protocols, which for products targeting cardiovascular disease, or CVD, could include up to 15 years of long-term patient follow-up;
the availability of existing treatments for the indications for which we are conducting clinical trials;
the ability to recruit clinical trial investigators with the appropriate competencies and experience;
the efforts to facilitate timely enrollment in clinical trials;
the patient referral practices of physicians;
the ability to monitor patients adequately during and after treatment;
the proximity and availability of clinical trial sites for prospective patients;
perceived negative public perception of gene editing;
the conduct of clinical trials by competitors for product candidates that treat the same indications or address the same patient populations as our product candidates; and
the cost to, or lack of adequate compensation for, prospective patients.

Other pharmaceutical and biotechnology companies have reported experiencing delays in enrollment in their ongoing clinical trials as a result of the COVID-19 pandemic, and we could also experience such delays. Our inability to locate and enroll a sufficient number of patients for our clinical trials would result in significant delays, could require us to abandon one or more clinical trials altogether and could delay or prevent our receipt of necessary regulatory approvals. Enrollment delays in our clinical trials may result in increased development costs for our product candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing.

Even if we are able to enroll a sufficient number of patients for our future clinical trials, we may have difficulty maintaining patients in our clinical trials. Many of the patients who end up receiving placebo may perceive that they are not receiving the product candidate being tested, and they may decide to withdraw from our clinical trials to pursue alternative therapies rather than continue the trial. If we have difficulty enrolling or maintaining a sufficient number of patients to conduct our clinical trials, we may need to delay, limit or terminate clinical trials, any of which would harm our business, financial condition, results of operations and prospects.

If any of the product candidates we may develop, or the delivery modes we rely on to administer them, cause serious adverse events, undesirable side effects or unexpected characteristics, such events, side effects or characteristics could delay or prevent regulatory approval of the product candidates, limit the commercial potential or result in significant negative consequences following any potential marketing approval.

We only recently initiated our heart-1 clinical trial for VERVE-101. Moreover, there have been only a limited number of clinical trials involving the use of gene editing technologies and none involving base editing technology similar to our technology. Furthermore, there has not been any gene editing product candidate that has received regulatory approval for

46


 

use in humans. It is impossible to predict when or if any product candidates we may develop will prove safe in humans. There can be no assurance that gene editing technologies will not cause undesirable side effects, as improper editing of a patient’s DNA could lead to lymphoma, leukemia or other cancers or other aberrantly functioning cells.

A significant risk in any gene editing product candidate is that “off-target” edits may occur, which could cause serious adverse events, undesirable side effects or unexpected characteristics. We cannot be certain that off-target editing will not occur in any of our ongoing or future clinical studies, and the lack of observed side effects in preclinical studies does not guarantee that such side effects will not occur in human clinical studies. There is also the potential risk of delayed or late presentation of adverse events following exposure to gene editors due to the potential permanence of edits to DNA or due to other components of product candidates used to carry the genetic material. Further, because gene editing makes a permanent change, the therapy cannot be withdrawn, even after a side effect is observed.

We intend to use LNPs to deliver our gene editors to the liver. LNPs have recently been used to deliver mRNA in humans, including the COVID-19 vaccines developed by Pfizer Inc., or Pfizer, and BioNTech SE and by Moderna, Inc., and LNPs are being used to deliver mRNA for therapeutic use in clinical trials. LNPs have the potential to induce liver injury and/or initiate a systemic inflammatory response, either of which could potentially be fatal. While we aim to continue to optimize our LNPs, there can be no assurance that our LNPs will not have undesired effects. Our LNPs could contribute, in whole or in part, to one or more of the following: liver injury, immune reactions, infusion reactions, complement reactions, opsonization reactions, antibody reactions including IgA, IgM, IgE or IgG or some combination thereof, or reactions to the polyethylene glycol, or PEG, from some lipids or PEG otherwise associated with the LNP. Certain aspects of our investigational medicines may induce immune reactions from either the mRNA or the lipid as well as adverse reactions within liver pathways or degradation of the mRNA or the LNP, any of which could lead to significant adverse events in one or more of our ongoing or future clinical trials. Some of these types of adverse effects have been observed for other LNPs. There may be uncertainty as to the underlying cause of any such adverse event, which would make it difficult to accurately predict side effects in ongoing or future clinical trials and would result in significant delays in our programs.

Our GalNAc-LNPs are a novel delivery mechanism for delivery of gene editors to the liver and have not yet been studied in humans.

If any product candidates we develop are associated with serious adverse events, undesirable side effects or unexpected characteristics, we may need to abandon their development or limit development to certain uses or subpopulations in which the serious adverse events, undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective, any of which would have a material adverse effect on our business, financial condition, results of operations and prospects.

If in the future we are unable to demonstrate that any of the above adverse events were caused by factors other than our product candidate, the FDA, the EMA or other regulatory authorities could order us to cease further development of, or deny approval of, any product candidates we are able to develop for any or all targeted indications. They could also revoke a marketing authorization if a serious safety concern is identified in any post-marketing follow up studies. Even if we are able to demonstrate that all future serious adverse events are not product-related, such occurrences could affect patient recruitment or the ability of enrolled patients to complete the trial. Moreover, if we elect, or are required, to delay, suspend or terminate any clinical trial of any product candidate we may develop, the commercial prospects of such product candidates may be harmed and our ability to generate product revenues from any of these product candidates may be delayed or eliminated. Any of these occurrences may harm our ability to identify and develop product candidates, and may harm our business, financial condition, result of operations, and prospects significantly.

Adverse public perception of genetic medicines, and gene editing and base editing in particular, may negatively impact regulatory approval of, and/or demand for, our potential products.

Our programs involve editing the human genome. The clinical and commercial success of our product candidates will depend in part on public understanding and acceptance of the use of gene editing therapy for the prevention or treatment of human diseases. Public attitudes may be influenced by claims that gene editing is unsafe, unethical or immoral, and, consequently, our product candidates may not gain the acceptance of the public or the medical community. Adverse public attitudes may adversely impact our ability to enroll clinical trials. Moreover, our success will depend upon physicians prescribing, and their patients being willing to receive, treatments that involve the use of product candidates we may develop in lieu of, or in addition to, existing treatments with which they are already familiar and for which greater clinical data may be available.

In addition, gene editing technology is subject to public debate and heightened regulatory scrutiny due to ethical concerns.

More restrictive government regulations or negative public opinion would have a negative effect on our business or financial condition and may delay or impair our development and commercialization of product candidates or demand for any product candidates we may develop. Adverse events in our preclinical studies or clinical trials or those of our

47


 

licensors, partners or competitors or of academic researchers utilizing gene editing technologies, even if not ultimately attributable to product candidates we may identify and develop, and the resulting publicity could result in increased governmental regulation, unfavorable public perception, potential regulatory delays in the testing or approval of potential product candidates we may identify and develop, stricter labeling requirements for those product candidates that are approved and a decrease in demand for any such product candidates. Use of gene editing technology by a third party or government to develop biological agents or products that threaten U.S. national security could similarly result in such negative impacts to us.

Interim and preliminary results from our clinical trials that we announce or publish from time to time may change as more participant data become available and are subject to audit and verification procedures, which could result in material changes in the final data.

From time to time, we may publish or report interim or preliminary results from our clinical trials. Interim results from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as participant enrollment continues and more participant data become available. For example, our clinical trial design for our Phase 1b clinical trial of VERVE-101 includes an interim analysis of three-month data from the trial and these data could be materially different than the data reported at the end of the study. We also make assumptions, estimations, calculations, and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully evaluate all data. Preliminary, interim or top-line data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary or interim data we previously published. As a result, preliminary, interim or top-line data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could be material and could significantly harm our reputation and business prospects and may cause the trading price of our common stock to fluctuate significantly.

Genetic medicines are complex and difficult to manufacture. We could experience delays in satisfying regulatory authorities or production problems that result in delays in our development programs, limit the supply of our product candidates we may develop, or otherwise harm our business.

Any product candidates we may develop will likely require processing steps that are more complex than those required for most chemical pharmaceuticals. Moreover, unlike chemical pharmaceuticals, the physical and chemical properties of a biologic such as the product candidates we intend to develop generally cannot be fully characterized. As a result, assays of the finished product candidate may not be sufficient to ensure that the product candidate will perform in the intended manner. Problems with the manufacturing process, even minor deviations from the normal process, could result in product defects or manufacturing failures that result in lot failures, product recalls, product liability claims or insufficient inventory or potentially delay progression of our potential IND filings. If we successfully develop product candidates, we may encounter problems achieving adequate quantities and quality of clinical-grade materials that meet FDA, EMA or other comparable applicable foreign standards or specifications with consistent and acceptable production yields and costs. In addition, the product candidates we may develop will require complicated delivery modalities, such as LNPs, which will introduce additional complexities in the manufacturing process.

In addition, the FDA, the EMA and other regulatory authorities may require us to submit samples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, the EMA or other regulatory authorities may require that we not distribute a lot until the agency authorizes its release. Slight deviations in the manufacturing process, including those affecting quality attributes and stability, may result in unacceptable changes in the product that could result in lot failures or product recalls. Lot failures or product recalls could cause us to delay clinical trials or product launches, which could be costly to us and otherwise harm our business, financial condition, results of operations and prospects.

We also may encounter problems hiring and retaining the experienced scientific, quality control and manufacturing personnel needed to manage our manufacturing process, which could result in delays in our production or difficulties in maintaining compliance with applicable regulatory requirements.

Given the nature of biologics manufacturing, there is a risk of contamination during manufacturing. Any contamination could materially harm our ability to produce product candidates on schedule and could harm our results of operations and cause reputational damage. Some of the raw materials that we anticipate will be required in our manufacturing process are derived from biologic sources. Such raw materials are difficult to procure and may be subject to contamination or recall. A material shortage, contamination, recall or restriction on the use of biologically derived substances in the manufacture of any product candidates we may develop could adversely impact or disrupt the commercial manufacturing or the production of clinical material, which could materially harm our development timelines and our business, financial condition, results of operations and prospects.

48


 

Any problems in our manufacturing process or the facilities with which we contract could make us a less attractive collaborator for potential partners, including larger pharmaceutical companies and academic research institutions, which could limit our access to additional attractive development programs. Problems in third-party manufacturing process or facilities also could restrict our ability to ensure sufficient clinical material for any clinical trials we may be conducting or are planning to conduct and meet market demand for any product candidates we develop and commercialize.

If any of our product candidates receives marketing approval and we, or others, later discover that the drug is less effective than previously believed or causes undesirable side effects that were not previously identified, our ability to market the drug could be compromised.

Clinical trials of our product candidates are conducted in carefully defined subsets of patients who have agreed to enter into clinical trials. Consequently, it is possible that our clinical trials may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any, or alternatively fail to identify undesirable side effects. If one or more of our product candidates receives regulatory approval, and we, or others, later discover that they are less effective than previously believed, or cause undesirable side effects, a number of potentially significant negative consequences could result, including:

withdrawal or limitation by regulatory authorities of approvals of such product;
seizure of the product by regulatory authorities;
recall of the product;
restrictions on the marketing of the product or the manufacturing process for any component thereof;
requirement by regulatory authorities of additional warnings on the label, such as a “black box” warning or contraindication;
requirement that we implement a REMS or create a medication guide outlining the risks of such side effects for distribution to patients;
commitment to expensive post-marketing studies as a prerequisite of approval by regulatory authorities of such product;
the product may become less competitive;
initiation of regulatory investigations and government enforcement actions;
initiation of legal action against us to hold us liable for harm caused to patients; and
harm to our reputation and resulting harm to physician or patient acceptance of our products.

Any of these events could prevent us from achieving or maintaining market acceptance of a particular product candidate, if approved, and could significantly harm our business, financial condition, and results of operations.

We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.

Because we have limited financial and managerial resources, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. Failure to allocate resources or capitalize on strategies in a successful manner will have an adverse impact on our business, financial condition and results of operations.

 

We are conducting a clinical trial, and plan to conduct additional clinical trials, at sites outside the United States. The FDA may not accept data from trials conducted in such locations, and the conduct of trials outside the United States could subject us to additional delays and expense.

We are conducting and plan to conduct one or more of additional clinical trials with one or more trial sites that are located outside the United States, including our ongoing Phase 1 trial of VERVE-101 in New Zealand and other foreign countries. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of these data is

49


 

subject to conditions imposed by the FDA. For example, the clinical trial must be well designed and conducted and be performed by qualified investigators in accordance with ethical principles. The FDA must be able to validate the data from the trial through an onsite inspection, if necessary. The trial population must also adequately represent the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful. In addition, while these clinical trials are subject to the applicable local laws, whether the FDA accepts the data will depend on its determination that the trials also complied with all applicable U.S. laws and regulations. There can be no assurance that the FDA will accept data from trials conducted outside of the United States. If the FDA does not accept the data from any trial that we conduct outside the United States, it would likely result in the need for additional trials, which would be costly and time-consuming and could delay or permanently halt our development of the applicable product candidates.

In addition, conducting clinical trials outside the United States could have a significant adverse impact on us. Risks inherent in conducting international clinical trials include:

clinical practice patterns and standards of care that vary widely among countries;
non-U.S. regulatory authority requirements that could restrict or limit our ability to conduct our clinical trials;
administrative burdens of conducting clinical trials under multiple non-U.S. regulatory authority schema;
foreign exchange fluctuations; and
diminished protection of intellectual property in some countries.

Risks related to our dependence on third parties

We rely, and expect to continue to rely, on third parties to conduct some or all aspects of our product manufacturing, research and preclinical and clinical testing, and these third parties may not perform satisfactorily.

We do not expect to independently conduct all aspects of our product manufacturing, research and preclinical and clinical testing. We currently rely, and expect to continue to rely, on third parties with respect to many of these items, including CMOs for the manufacturing of any product candidates we test in preclinical or clinical development, as well as CROs for the conduct of our animal testing and research. Any of these third parties may terminate their engagements with us at any time. If we need to enter into alternative arrangements, it could delay our product development activities. Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibility to ensure compliance with all required regulations and study protocols. For example, for product candidates that we develop and commercialize on our own, we will remain responsible for ensuring that each of our IND-enabling studies and clinical trials are conducted in accordance with the study plan and protocols.

Although we intend to design the clinical trials for any product candidates we may develop, CROs will conduct some or all of the clinical trials. As a result, many important aspects of our development programs, including their conduct and timing, will be outside of our direct control. Our reliance on third parties to conduct ongoing and future preclinical studies and clinical trials will also result in less direct control over the management of data developed through preclinical studies and clinical trials than would be the case if we were relying entirely upon our own staff. Communicating with outside parties can also be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. Outside parties may:

have staffing difficulties;
fail to comply with contractual obligations;
experience regulatory compliance issues;
undergo changes in priorities or become financially distressed; or
form relationships with other entities, some of which may be our competitors.

These factors may materially adversely affect the willingness or ability of third parties to conduct our preclinical studies and clinical trials and may subject us to unexpected cost increases that are beyond our control. If the CROs and other third parties do not perform preclinical studies and ongoing and future clinical trials in a satisfactory manner, breach their obligations to us or fail to comply with regulatory requirements, the development, regulatory approval and commercialization of any product candidates we may develop may be delayed, we may not be able to obtain regulatory approval and commercialize our product candidates or our development programs may be materially and irreversibly harmed. If we are unable to rely on preclinical and clinical data collected by our CROs and other third parties, we could be

50


 

required to repeat, extend the duration of or increase the size of any preclinical studies or clinical trials we conduct and this could significantly delay commercialization and require greater expenditures.

If third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our studies in accordance with regulatory requirements or our stated study plans and protocols, we will not be able to complete, or may be delayed in completing, the preclinical studies and clinical trials required to support future IND submissions and approval of any product candidates we may develop.

Manufacturing biologic products is complex and subject to product loss for a variety of reasons. We contract with third parties for the manufacture of our product candidates for preclinical and clinical testing and expect to continue to do so for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts.

We do not own or operate, and currently have no plans to establish, any manufacturing facilities. We rely, and expect to continue to rely, on third parties for the manufacture of VERVE-101 and our other product candidates for preclinical and clinical testing, as well as for commercial manufacture if any of our product candidates receive marketing approval. We also rely on these third parties for packaging, labeling, sterilization, storage, distribution and other production logistics. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts. We may be unable to establish any agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:

reliance on the third party for regulatory compliance and quality assurance;
the possible breach of the manufacturing agreement by the third party;
the possible misappropriation of our proprietary information, including our trade secrets and know-how; and
the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.

We or our third-party manufacturers may encounter shortages in the raw materials or active pharmaceutical ingredients, or API, necessary to produce our product candidates in the quantities needed for our clinical trials or, if our product candidates are approved, in sufficient quantities for commercialization or to meet an increase in demand, as a result of capacity constraints or delays or disruptions in the market for the raw materials or API, including shortages caused by the purchase of such raw materials or API by our competitors or others. The failure of us or our third-party manufacturers to obtain the raw materials or API necessary to manufacture sufficient quantities of our product candidates may have a material adverse effect on our business.

Components of a finished therapeutic product approved for commercial sale or used in late-stage clinical trials must be manufactured in accordance with cGMP. Our third-party manufacturers are subject to inspection and approval by regulatory authorities before we can commence the manufacture and sale of any of our product candidates, and thereafter subject to ongoing inspection from time to time. Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside of the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in regulatory actions, such as the issuance of FDA Form 483 notices of observations, warning letters or sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products.

Manufacturing biologic products, such as VERVE-101, is complex, especially in large quantities. Biologic products must be made consistently and in compliance with a clearly defined manufacturing process. Accordingly, it is essential to be able to validate and control the manufacturing process to assure that it is reproducible. The manufacture of biologics is extremely susceptible to product loss due to contamination, equipment failure or improper installation or operation of equipment, vendor or operator error, inconsistency in yields, variability in product characteristics and difficulties in scaling the product process. We have not yet scaled up the manufacturing process for any of our product candidates for potential commercialization. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination, which could harm our results of operations and cause potential reputational damage. Our product candidates and any products that we may develop may compete with other product candidates and products for access to manufacturing facilities. As a result, we

51


 

may not obtain access to these facilities on a priority basis or at all. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us.

Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval. We do not currently have arrangements in place for redundant supply or a source for bulk drug substance nor do we have any agreements with third-party manufacturers for long-term commercial supply. If any of our future contract manufacturers cannot perform as agreed, we may be required to replace such manufacturers. Although we believe that there are several potential alternative manufacturers who could manufacture our product candidates, we may incur added costs and delays in identifying and qualifying any such replacement or be unable to reach agreement with an alternative manufacturer.

Our current and anticipated future dependence upon others for the manufacture of our product candidates or products may adversely affect our future profit margins and our ability to commercialize any products that receive marketing approval on a timely and competitive basis.

If any third-party manufacturer of our product candidates is unable to increase the scale of its production of our product candidates, and/or increase the product yield of its manufacturing, then our costs to manufacture the product candidate may increase and commercialization may be delayed.

In order to produce sufficient quantities to meet the demand for clinical trials and, if approved, subsequent commercialization of any current or future product candidates that we may develop, our third-party manufacturers will be required to increase their production and optimize their manufacturing processes while maintaining the quality of the product. The transition to larger scale production could prove difficult. In addition, if our third-party manufacturers are not able to optimize their manufacturing processes to increase the product yield for our product candidates, or if they are unable to produce increased amounts of our product candidates while maintaining the quality of the product, then we may not be able to meet the demands of our ongoing or future clinical trials or market demands, which could decrease our ability to generate profits and have a material adverse impact on our business and results of operation.

We have entered into collaborations, and may enter into additional collaborations, with third parties for the research, development, manufacture and commercialization of programs or product candidates. If these collaborations are not successful, our business could be adversely affected.

As part of our strategy, we have entered into collaborations and intend to seek to enter into additional collaborations with third parties for one or more of our programs or product candidates. For example, in April 2019, we entered into the Beam Agreement to exclusively license certain of Beam’s base editing, gene editing and delivery technology against certain cardiovascular targets for use in our product candidates, which agreement was amended and restated in July 2022; in October 2020, we entered into the Acuitas Agreement to license from Acuitas its LNP delivery technology; and in July 2022, we entered into the Vertex Agreement for a four-year worldwide research collaboration focused on developing in vivo gene editing candidates toward an undisclosed target for the treatment of a single liver disease. Our likely collaborators for any other collaboration arrangements include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies. We have under the Beam Agreement, and we may have under any other arrangements that we may enter into with any third parties, limited control over the amount and timing of resources that collaborators dedicate to the development or commercialization of our product candidates. Our ability to generate revenue from these arrangements may depend on our collaborators’ abilities to successfully perform the functions assigned to them in these arrangements.

Collaborations that we enter into may not be successful, and any success will depend heavily on the efforts and activities of such collaborators. Collaborations pose a number of risks, including the following:

collaborators have significant discretion in determining the amount and timing of efforts and resources that they will apply to these collaborations;
collaborators may not perform their obligations as expected;
collaborators may not pursue development of our product candidates or may elect not to continue or renew development programs based on results of clinical trials or other studies, changes in the collaborators’ strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities;
collaborators may not pursue commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew commercialization programs based on results of clinical trials or other studies, changes in the collaborators’ strategic focus or available funding, or external factors, such as an acquisition, that may divert resources or create competing priorities;

52


 

collaborators may delay preclinical studies and clinical trials, provide insufficient funding for a preclinical study or clinical trial program, stop a preclinical study or clinical trial or abandon a product candidate, repeat or conduct new preclinical studies or clinical trials or require a new formulation of a product candidate for preclinical or clinical testing;
we may not have access to, or may be restricted from disclosing, certain information regarding product candidates being developed or commercialized under a collaboration and, consequently, may have limited ability to inform our stockholders about the status of such product candidates on a discretionary basis;
collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates and products if the collaborators believe that the competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;
product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates;
a collaborator may fail to comply with applicable regulatory requirements regarding the development, manufacture, distribution or marketing of a product candidate or product;
a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product or products;
disagreements with collaborators, including disagreements over intellectual property or proprietary rights, contract interpretation or the preferred course of development, might cause delays or terminations of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive;
collaborators may not properly obtain, maintain, enforce, defend or protect our intellectual property or proprietary rights or may use our proprietary information in such a way as to potentially lead to disputes or legal proceedings that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation;
disputes may arise with respect to the ownership of intellectual property developed pursuant to our collaborations;
collaborators may infringe, misappropriate or otherwise violate the intellectual property or proprietary rights of third parties, which may expose us to litigation and potential liability; and
collaborations may be terminated for the convenience of the collaborator, and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates.

Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner, or at all. If any current or future collaborations do not result in the successful development and commercialization of products or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. If we do not receive the funding we expect under these agreements, our development of our product candidates could be delayed and we may need additional resources to develop our product candidates. All of the risks relating to product development, regulatory approval and commercialization described in this "Risk Factors" section also apply to the activities of our collaborators.

Collaboration agreements may require us to incur non-recurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our existing stockholders, or disrupt our management and business. For example, upon execution of the Beam Agreement, we issued 276,075 shares of our common stock to Beam and in connection with the execution of the Vertex Agreement, we completed a private placement with Vertex pursuant to which we issued 1,519,756 shares of our common stock to Vertex. In addition, under the Cas9 License Agreement, we issued 138,037 shares of our common stock to Broad and Harvard. Broad and Harvard also had anti-dilution rights, pursuant to which we issued Broad and Harvard an additional 309,278 shares of our common stock in the aggregate following the completion of preferred stock financings. We also issued 878,098 additional shares of common stock to Broad and Harvard upon the closing of our IPO pursuant to the Cas9 License Agreement. We are also obligated to pay to Harvard and Broad tiered success payments in the event our average market capitalization exceeds specified thresholds ascending from a high nine-digit dollar amount to $10.0 billion, or sale of our company for consideration in excess of those thresholds. In the event of a change of control of our company or a sale of our company, we are required to pay any related success payment in cash within a specified period following such event. Otherwise, the success payments may be settled at our option in either cash or shares of our common stock, or a combination of cash and shares of our common stock. In September 2021, we notified Harvard and Broad that our average market capitalization exceeded three specified thresholds as of a relevant measurement date and aggregate success payments of approximately $6.3 million became payable under the Cas9 License Agreement, which we settled in cash in November 2021.

53


 

We could face significant competition in seeking appropriate collaborators, and the negotiation process is time-consuming and complex. Our ability to reach a definitive collaboration agreement will depend, among other things, upon our assessment of the collaborator’s resources and expertise, the terms and conditions of the proposed collaboration, and the proposed collaborator’s evaluation of several factors. If we license rights to any product candidates we or our collaborators may develop, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture.

Additionally, subject to its contractual obligations to us, if a collaborator of ours is involved in a business combination, the collaborator might deemphasize or terminate the development or commercialization of any product candidate licensed to it by us. If one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators and our perception in the business and financial communities could be adversely affected.

If we are not able to establish or maintain collaborations on commercially reasonable terms, we may have to alter our development and commercialization plans and our business could be adversely affected.

We face significant competition in attracting appropriate collaborators, and a number of more established companies may also be pursuing strategies to license or acquire third-party intellectual property rights that we consider attractive. These established companies may have a competitive advantage over us due to their size, financial resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator’s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator’s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA, EMA or other regulatory authorities, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge, the terms of any existing collaboration agreements, and industry and market conditions generally. The collaborator may also have the opportunity to collaborate on other product candidates or technologies for similar indications and will have to evaluate whether such a collaboration could be more attractive than the one with us for our product candidate.

We may also be restricted under existing or future license agreements from entering into agreements on certain terms with potential collaborators.

Collaborations are complex and time-consuming to negotiate, document and execute. In addition, consolidation among large pharmaceutical and biotechnology companies has reduced the number of potential future collaborators.

We may not be able to negotiate additional collaborations on a timely basis, on acceptable terms or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our product candidates or bring them to market.

We depend on single-source suppliers for some of the components and materials used in our product candidates.

We depend on single-source suppliers for some of the components and materials used in our product candidates. We cannot ensure that these suppliers or service providers will remain in business, have sufficient capacity or supply to meet our needs or that they will not be purchased by one of our competitors or another company that is not interested in continuing to work with us. Our use of single-source suppliers of raw materials, components, key processes and finished goods exposes us to several risks, including disruptions in supply, price increases or late deliveries. There are, in general, relatively few alternative sources of supply for substitute components. These vendors may be unable or unwilling to meet our future demands for our clinical trials or commercial sale. Establishing additional or replacement suppliers for these components, materials and processes could take a substantial amount of time and it may be difficult to establish replacement suppliers who meet regulatory requirements. Any disruption in supply from any single-source supplier or service provider could lead to supply delays or interruptions, which would damage our business, financial condition, results of operations and prospects.

If we have to switch to a replacement supplier, the manufacture and delivery of any product candidates we may develop could be interrupted for an extended period, which could adversely affect our business. Establishing additional or

54


 

replacement suppliers, if required, may not be accomplished quickly. If we are able to find a replacement supplier, the replacement supplier would need to be qualified and may require additional regulatory authority approval, which could result in further delay. While we seek to maintain adequate inventory of the single source components and materials used in our products, any interruption or delay in the supply of components or materials, or our inability to obtain components or materials from alternate sources at acceptable prices in a timely manner, could impair our ability to meet the demand for our product candidates.

Risks related to our intellectual property

If we or our licensors are unable to obtain, maintain, defend and enforce patent rights that cover our gene editing technology and product candidates or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully develop and commercialize our technology and product candidates may be adversely affected.

Our success depends in large part on our ability to obtain, maintain, defend, and enforce protection of the intellectual property we may own solely and jointly with others or may license from others, particularly patents, in the United States and other countries with respect to proprietary technology and product candidates we develop. It is difficult and costly to protect our gene editing technologies and product candidates, and we may not be able to ensure their protection. Our ability to stop unauthorized third parties from making, using, selling, offering to sell, importing or otherwise commercializing our product candidates we may develop, or operatively similar products, is dependent upon the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities.

We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our product candidates that are important to our business and by in-licensing intellectual property related to our technologies and product candidates. If we are unable to obtain or maintain patent protection with respect to any proprietary technology or product candidate, our business, financial condition, results of operations and prospects could be materially harmed. Failure to obtain protection including patent protection, may be a result of specific legal and factual circumstances that may preclude the availability of protection for our product candidates in the United States or any given country. For example, inadequate, faulty or erroneous patent prosecution may result in diminution, loss or unavailability of patent rights that adequately cover our products. Patent disclosures and claims that are intended to cover our product candidates that are sufficient or allowable in one country may not be sufficient or allowable in another country. The requirements for filing a patent application in the United States may not be sufficient to support a patent filing in a country or region outside the United States.

The patent prosecution process is expensive, time-consuming and complex, and we may not be able to file, prosecute, maintain, defend or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. In addition, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our inventions and the prior art allow our inventions to be patentable over the prior art. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we do not have the right to control the preparation, filing and prosecution of patent applications, or to maintain, enforce and defend the patents, covering technology that we license from third parties. Therefore, these in-licensed patents and applications may not be prepared, filed, prosecuted, maintained, defended and enforced in a manner consistent with the best interests of our business.

The patent position of pharmaceutical and biotechnology companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. The field of gene editing especially has been the subject of extensive patenting activity and litigation. In addition, the scope of patent protection outside of the United States is uncertain and laws of foreign countries may not protect our rights to the same extent as the laws of the United States or vice versa. For example, European patent law restricts the patentability of methods of treatment of the human body more than United States law does. Further, no earlier than October 1, 2022, European applications will soon have the option, upon grant of a patent, of becoming a Unitary Patent which will be subject to the jurisdiction of the Unitary Patent Court (“UPC"). This will be a significant change in European patent practice. As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty of any litigation.

With respect to both owned and in-licensed patent rights, we cannot predict whether the patent applications we and our licensors are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors. Further, we may not be aware of all third-party intellectual property rights potentially relating to our product candidates.

In addition, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not published at all. Therefore, neither we nor our licensors can know with certainty whether either we or our

55


 

licensors were the first to make the inventions claimed in the patents and patent applications we own or in-license now or in the future, or that either we or our licensors were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our owned and in-licensed patent rights are highly uncertain. Moreover, our owned and in-licensed pending and future patent applications may not result in patents being issued which protect our technology and product candidates, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents and our ability to obtain, protect, maintain, defend and enforce our patent rights, narrow the scope of our patent protection and, more generally, could affect the value or narrow the scope of our patent rights.

Moreover, we or our licensors may be subject to a third-party preissuance submission of prior art to the United States Patent and Trademark Office, or USPTO, or become involved in opposition, derivation, revocation, reexamination, inter partes review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or product candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize drugs without infringing third-party patent rights. If the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.

Additionally, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if our owned and in-licensed patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and in-licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and product candidates. Such proceedings also may result in substantial cost and require significant time from our management and employees, even if the eventual outcome is favorable to us. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. Furthermore, our competitors may be able to circumvent our owned or in-licensed patents by developing similar or alternative technologies or products in a non-infringing manner. As a result, our owned and in-licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing technology and products similar or identical to any of our technology and product candidates.

Our rights to develop and commercialize our gene editing technology and product candidates are subject, in part, to the terms and conditions of licenses granted to us by others.

We depend on intellectual property licensed from third parties, and our licensors may not always act in our best interest. If we fail to comply with our obligations under our intellectual property licenses, if the licenses are terminated, or if disputes regarding these licenses arise, we could lose significant rights that are important to our business.

We have licensed and are dependent on certain patent rights and proprietary technology from third parties that are important or necessary to the development of our gene editing technology and product candidates. For example, we are a party to the Beam Agreement, the Cas9 License Agreement, the Acuitas Agreement and other license agreements, pursuant to which we in-license and have acquired key patents and patent applications for our gene editing technology, LNP technology and product candidates. These license agreements impose various diligence, milestone payment, royalty, insurance and other obligations on us. If we fail to comply with these obligations, our licensors may have the right to terminate our license, in which event we would not be able to develop or market our gene editing technology or product candidates covered by the intellectual property licensed under these agreements.

These and other licenses may not provide exclusive rights to use such intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our gene editing technology and product candidates in the future. Some licenses and acquired patents granted to us are expressly subject to certain preexisting rights held by the licensor or certain third parties. As a result, we may not be able to prevent competitors from developing and commercializing competitive products in certain territories or fields. If we determine that rights to such excluded fields are necessary to commercialize our product candidates or maintain our competitive advantage, we may need to obtain a license from such third party in order to continue developing, manufacturing or marketing our product candidates. We may not be able to obtain such a license on an exclusive basis, on commercially reasonable terms, or at

56


 

all, which could prevent us from commercializing our product candidates or allow our competitors or others the chance to access technology that is important to our business.

In addition, pursuant to the Cas9 License Agreement, under certain specific circumstances, Harvard and Broad may grant a license to the patents that are the subject of such license agreements to a third party in the same field as such patents are licensed to us. Such third party may then have full rights that are the subject of the Cas9 License Agreement, which could impact our competitive position and enable a third party to commercialize products similar to our potential future product candidates and technology. Any grant of rights to a third party in this scenario would narrow the scope of our exclusive rights to the patents and patent applications we have in-licensed from Harvard and Broad.

We do not have complete control in the preparation, filing, prosecution, maintenance, enforcement and defense of patents and patent applications covering the technology that we license or have acquired from third parties. It is possible that our licensors’ enforcement of patents against infringers or defense of such patents against challenges of validity or claims of enforceability may be less vigorous than if we had conducted them ourselves, or may not be conducted in accordance with our best interests. We cannot be certain that these patents and patent applications will be prepared, filed, prosecuted, maintained, enforced and defended in a manner consistent with the best interests of our business. If our licensors fail to prosecute, maintain, enforce and defend such patents, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated, our right to develop and commercialize any of our product candidates we may develop that are the subject of such licensed rights could be adversely affected and we may not be able to prevent competitors from making, using and selling competing products.

Our licensors may have relied on third-party consultants or collaborators or on funds from third parties such that our licensors are not the sole and exclusive owners of the patents we in-licensed. If other third parties have ownership rights to our in-licensed patents, the license granted to us in jurisdictions where the consent of a co-owner is necessary to grant such a license may not be valid and such co-owners may be able to license such patents to our competitors, and our competitors could market competing products and technology. In addition, our rights to our in-licensed patents and patent applications are dependent, in part, on inter-institutional or other operating agreements between the joint owners of such in-licensed patents and patent applications. If one or more of such joint owners breaches such inter-institutional or operating agreements, our rights to such in-licensed patents and patent applications may be adversely affected. Any of these events could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.

Furthermore, inventions contained within some of our in-licensed patents and patent applications were made using U.S. government funding. We rely on our licensors to ensure compliance with applicable obligations arising from such funding, such as timely reporting, an obligation associated with our in-licensed patents and patent applications. The failure of our licensors to meet their obligations may lead to a loss of rights or the unenforceability of relevant patents. For example, the U.S. government could have certain rights in such in-licensed patents, including a non-exclusive license authorizing the U.S. government to use the invention or to have others use the invention on its behalf. If the U.S. government decides to exercise these rights, it is not required to engage us as its contractor in connection with doing so. The U.S. government’s rights may also permit it to disclose the funded inventions and technology to third parties and to exercise march-in rights to use or allow third parties to use the technology we have licensed that was developed using U.S. government funding. The U.S. government may also exercise its march-in rights if it determines that action is necessary because we or our licensors failed to achieve practical application of the U.S. government-funded technology, because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations or to give preference to U.S. industry. In addition, our rights in such in-licensed U.S. government-funded inventions may be subject to certain requirements to manufacture product candidates embodying such inventions in the United States. Any of the foregoing could harm our business, financial condition, results of operations and prospects significantly.

In the event any of our third-party licensors determine that, in spite of our efforts, we have materially breached a license agreement or have failed to meet certain obligations thereunder, it may elect to terminate the applicable license agreement or, in some cases, one or more license(s) under the applicable license agreement, and such termination would result in us no longer having the ability to develop and commercialize product candidates and technology covered by that license agreement or license. In the event of such termination of a third-party in-license, or if the underlying patents under a third-party in-license fail to provide the intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market, products identical to ours. Any of these events could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.

Our owned patent applications and in-licensed patents and patent applications and other intellectual property may be subject to priority or inventorship disputes, interferences and similar proceedings. If we or our licensors are unsuccessful in any of these proceedings, we may be required to obtain licenses from third parties, which may not be available on commercially reasonable terms or at all, or to cease the development, manufacture, and

57


 

commercialization of one or more of the product candidates we may develop, which could have a material adverse impact on our business.

Certain of the U.S. patents and one U.S. patent application to which we hold an option are co-owned by Broad and MIT, and in some cases co-owned by Broad, MIT and Harvard, which we refer to together as the Boston Licensing Parties, and were involved in U.S. Interference No. 106,048 with one U.S. patent application co-owned by the University of California, the University of Vienna, and Emmanuelle Charpentier, which we refer to together as CVC. On September 10, 2018, the Court of Appeals for the Federal Circuit, or the CAFC, affirmed the Patent Trial and Appeal Board of the USPTO’s, or PTAB’s, holding that there was no interference-in-fact. An interference is a proceeding within the USPTO to determine priority of invention of the subject matter of patent claims filed by different parties.

On June 24, 2019, the PTAB declared an interference (U.S. Interference No. 106,115) between 10 U.S. patent applications that are co-owned by CVC, and 13 U.S. patents and one U.S. patent application (that are co-owned by the Boston Licensing Parties). In the declared interference, CVC has been designated as the junior party and the Boston Licensing Parties have been designated as the senior party. On February 28, 2022, the PTAB held that the Boston Licensing Parties had priority over CVC with respect to Count 1 of the interference: a single RNA CRISPR-Cas9 system that functions in eukaryotic cells. As a result, CVC’s patent applications involved in this interference were deemed unpatentable.

On December 20, 2020, the PTAB declared an interference (U.S. Interference No. 106,126) between one U.S. patent application owned by Toolgen, Inc. and 14 U.S. patents and two U.S. patent applications that are co-owned by the Boston Licensing Parties. In the declared interference, Boston Licensing Parties have been designated as the junior party and Toolgen, Inc. has been designated as the senior party.

On June 21, 2021, the PTAB declared an interference (U.S. Interference No. 106,133) between one U.S. patent application owned by Sigma-Aldrich Co., LLC and 14 U.S. patents and two U.S. patent applications that are co-owned by the Boston Licensing Parties. In the declared interference, Boston Licensing Parties have been designated as the junior party and Sigma-Aldrich Co., LLC has been designated as the senior party

As a result of the declaration of interference, an adversarial proceeding in the USPTO before the PTAB has been initiated, which is declared to ultimately determine priority, specifically and which party was first to invent the claimed subject matter. An interference is typically divided into two phases. The first phase is referred to as the motions or preliminary motions phase while the second is referred to as the priority phase. In the first phase, each party may raise issues including but not limited to those relating to the patentability of a party’s claims based on prior art, written description, and enablement. A party also may seek an earlier priority benefit or may challenge whether the declaration of interference was proper in the first place. Priority, or a determination of who first invented the commonly claimed invention, is determined in the second phase of an interference. Although we cannot predict with any certainty how long each phase will actually take, each phase may take approximately a year or longer before a decision is made by the PTAB. It is possible for motions filed in the preliminary motions phase to be dispositive of the interference proceeding, such that the second priority phase is not reached.

There can be no assurance that these pending U.S. interference proceedings will be resolved in favor of the Boston Licensing Parties. If the 106,126, or 106,133 interference resolves in favor of Toolgen, Inc. or Sigma-Aldrich Co., LLC, respectively, or if the Boston Licensing Parties’ patents and patent application are narrowed, invalidated, or held unenforceable, we will lose the ability to license the optioned patents and patent application and our ability to commercialize our product candidates may be adversely affected if we cannot obtain a license to relevant third-party patents that cover our product candidates. We may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be nonexclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, we may be unable to commercialize our gene editing technology or product candidates or such commercialization efforts may be significantly delayed, which could in turn significantly harm our business.

We or our licensors may also be subject to claims that former employees, collaborators, or other third parties have an interest in our owned patent applications or in-licensed patents or patent applications or other intellectual property as an inventor or co-inventor. If we are unable to obtain an exclusive license to any such third-party co-owners’ interest in such patent applications, such co-owners rights may be subject, or in the future subject, to assignment or license to other third parties, including our competitors. In addition, we may need the cooperation of any such co-owners to enforce any patents that issue from such patent applications against third parties, and such cooperation may not be provided to us.

If we or our licensors are unsuccessful in any interference proceedings or other priority, validity (including any patent oppositions) or inventorship disputes to which we or they are subject, we may lose valuable intellectual property rights through the loss of one or more of our owned, licensed or optioned patents, or such patent claims may be narrowed,

58


 

invalidated or held unenforceable, or through loss of exclusive ownership of or the exclusive right to use our owned or in-licensed patents. In the event of loss of patent rights as a result of any of these disputes, we may be required to obtain and maintain licenses from third parties, including parties involved in any such interference proceedings or other priority or inventorship disputes. Such licenses may not be available on commercially reasonable terms or at all, or may be non-exclusive. If we are unable to obtain and maintain such licenses, we may need to cease the development, manufacture and commercialization of one or more of the product candidates we may develop. The loss of exclusivity or the narrowing of our patent claims could limit our ability to stop others from using or commercializing similar or identical technology and product candidates. Even if we or our licensors are successful in an interference proceeding, other similar priority disputes, or inventorship or ownership disputes, it could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could result in a material adverse effect on our business, financial condition, results of operations or prospects.

If we fail to comply with our obligations in our intellectual property licenses arrangements with third parties, or otherwise experience disruptions to our business relationships with our licensors, we could lose intellectual property rights that are important to our business.

We are party to agreements, and we may enter into additional arrangements, with third parties that may impose diligence, development and commercialization timelines, milestone payment, royalty, insurance and other obligations on us. We have existing agreements, pursuant to which we are obligated to pay royalties on net product sales of product candidates or related technologies to the extent they are covered by the agreements. If we fail to comply with such obligations under current or future agreements, our counterparties may have the right to terminate these agreements or require us to grant them certain rights. Such an occurrence could materially adversely affect the value of any product candidate being developed under any such agreement. Termination of these agreements or reduction or elimination of our rights under these agreements may result in our having to negotiate new or reinstated agreements with less favorable terms, or cause us to lose our rights under these agreements, including our rights to important intellectual property or technology, which would have a material adverse effect on our business, financial condition, results of operations and prospects. While we still face all of the risks described herein with respect to those agreements, we cannot prevent third parties from also accessing those technologies. In addition, our licenses may place restrictions on our future business opportunities.

Disputes may arise regarding intellectual property subject to a licensing agreement, including:

the scope of rights granted under the agreement and other interpretation related issues;
the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;
the sublicensing of patent and other rights under our collaborative development relationships;
our diligence obligations under the agreement and what activities satisfy those diligence obligations;
the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and
the priority of invention of patented technology.

In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected technology and product candidates, which could have a material adverse effect on our business, financial conditions, results of operations and prospects.

Our current or future licensors may have relied on third-party consultants or collaborators or on funds from third parties such that our licensors are not the sole and exclusive owners of the intellectual property or intellectual property rights we in-license. If other third parties have ownership rights to intellectual property or intellectual property rights we in-license, they may be able to license such intellectual property or intellectual property rights to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.

In spite of our best efforts, our licensors might conclude that we have materially breached our license agreements and might therefore terminate the license agreements, thereby removing our ability to develop and commercialize product candidates and technology covered by these license agreements. If these in-licenses are terminated, or if the underlying

59


 

intellectual property fails to provide the intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market, products and technologies identical to ours. This could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects.

If we are unable to obtain licenses from third parties on commercially reasonable terms or fail to comply with our obligations under such agreements, our business could be harmed.

We currently have rights to intellectual property, through licenses from third parties, to identify and develop product candidates, and we expect to seek to expand our product candidate pipeline in part by in-licensing the rights to key technologies. Although we have succeeded in licensing technologies from third-party licensors including Harvard, Broad, Beam, and Acuitas in the past, we cannot assure our stockholders that we will be able to in-license or acquire the rights to any product candidates or technologies from third parties on acceptable terms or at all.

Various third parties practice in competitive technology areas and may have issued patents or patent applications that will issue as patents in the future, which could impede or preclude our ability to commercialize our product candidates. For any third-party patents that could be relevant to our product candidates, we rely in part on the “safe harbor” or research exemption under 35 U.S.C. § 271(e)(1), which exempts from patent infringement activities related to pursuing FDA approval for a drug product. However, while U.S. patent law provides such a “safe harbor” to our clinical product candidates under this provision, that exemption expires when an IND or BLA is submitted. Given the uncertainty of clinical trials, we cannot be certain of the timing of their completion and it is possible that we may submit a BLA for one of our product candidates at a time when one or more relevant third-party patents is in force.

It may therefore be necessary for us to use the patented or proprietary technology of third parties to commercialize our products, in which case we would be required to obtain a license from these third parties. If we are unable to license such technology, or if we are forced to license such technology on unfavorable terms, our business could be materially harmed. If we are unable to obtain a necessary license, we may be unable to develop or commercialize the affected product candidates, which could materially harm our business and the third parties owning such intellectual property rights could seek either an injunction prohibiting our sales or an obligation on our part to pay royalties and/or other forms of compensation. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us.

Furthermore, there has been extensive patenting activity in the field of gene editing, and pharmaceutical companies, biotechnology companies, and academic institutions are competing with us or are expected to compete with us in the field of gene editing technology and filing patent applications potentially relevant to our business, and there may be third-party patent applications that, if issued, may allow the third party to circumvent our patent rights. Because of the large number of patents issued and patent applications filed in our field, these and other third parties could allege they have patent rights encompassing our product candidates, technologies or methods. In order to market our product candidates, we may find it necessary or prudent to obtain licenses from such third-party intellectual property holders. However, we may be unable to secure such licenses or otherwise acquire or in-license any compositions, methods of use, processes, or other intellectual property rights from third parties that we identify as necessary for product candidates and gene editing technology we may develop. We may also require licenses from third parties for certain gene editing technologies including certain delivery and gene editing compositions and methods that we are evaluating, or may in the future evaluate, for use with product candidates we may develop. In addition, some of our owned patent applications and in-licensed patents and patent applications may be determined to be co-owned with third parties. With respect to any patents co-owned with third parties, we may require licenses to such co-owners’ interest to such patents. If we are unable to obtain an exclusive license to any such third-party co-owners’ interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us.

Additionally, we may collaborate with academic institutions to accelerate our preclinical research or development under written agreements with these institutions. In certain cases, these institutions provide us with an option to negotiate a license to any of the institution’s rights in technology resulting from the collaboration. Even if we hold such an option, we may be unable to negotiate a license from the institution within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to others, potentially blocking our ability to pursue our program.

In addition, the licensing or acquisition of third-party intellectual property rights is a highly competitive area, and a number of more established companies are also pursuing strategies to license or acquire third party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or

60


 

acquire third party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or product candidate, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.

If we are unable to obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may be required to expend significant time and resources to redesign our technology, product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected technology and product candidates, which could harm our business, financial condition, results of operations and prospects significantly.

Additionally, if we fail to comply with our obligations under license agreements, our counterparties may have the right to terminate these agreements, in which event we might not be able to develop, manufacture or market, or may be forced to cease developing, manufacturing or marketing, any product that is covered by these agreements or may face other penalties under such agreements. Such an occurrence could materially adversely affect the value of the product candidate being developed under any such agreement. Termination of these agreements or reduction or elimination of our rights under these agreements, or restrictions on our ability to freely assign or sublicense our rights under such agreements when it is in the interest of our business to do so, may result in our having to negotiate new or reinstated agreements with less favorable terms, cause us to lose our rights under these agreements, including our rights to important intellectual property or technology or impede, or delay or prohibit the further development or commercialization of one or more product candidates that rely on such agreements.

The intellectual property landscape around genome editing technology, including base editing, is highly dynamic, and third parties may initiate legal proceedings alleging that we are infringing, misappropriating, or otherwise violating their intellectual property rights, the outcome of which would be uncertain and may prevent, delay or otherwise interfere with our product discovery and development efforts.

Our commercial success depends upon our ability and the ability of our collaborators to research, develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property rights of third parties. The field of genome editing, especially in the area of base editing technology, is still in its infancy, and no such product candidates have reached the market. Due to the intense research and development that is taking place by several companies, including us and our competitors, in this field, the intellectual property landscape is evolving and in flux, and it may remain uncertain for the coming years. The biotechnology and pharmaceutical industries are characterized by extensive and complex litigation regarding patents and other intellectual property rights as well as administrative proceedings for challenging patents, including interference, derivation, inter partes review, post grant review, and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. There may be significant intellectual property related litigation and proceedings relating to our owned and in-licensed, and other third party, intellectual property and proprietary rights in the future. We may be subject to and may in the future become party to, or threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our gene editing platform technology and any product candidates we may develop, including interference proceedings, post-grant review, inter partes review, and derivation proceedings before the USPTO and similar proceedings in foreign jurisdictions such as oppositions before the European Patent Office. Numerous U.S. and foreign issued patents and pending patent applications that are owned by third parties exist in the fields in which we are developing our product candidates and they may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of their merit.

As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our gene editing technology and product candidates may give rise to claims of infringement of the patent rights of others. Moreover, it is not always clear to industry participants, including us, which patents cover various types of therapies, products or their methods of use or manufacture. We are aware of certain third-party patent applications that, if issued, may be construed to cover our gene editing technology and product candidates. There may also be third-party patents of which we are currently unaware with claims to technologies, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents.

It is possible that we have failed to identify relevant third-party patents or applications that our product candidates and programs may infringe. Because patent applications can take many years to issue, may be confidential for 18 months or more after filing and can be revised before issuance, there may be applications now pending which may later result in issued patents that may be infringed by the manufacture, use, sale or importation of any product candidates we may

61


 

develop or our technology, and we may not be aware of such patents. Furthermore, applications filed before November 29, 2000 and certain applications filed after that date that will not be filed outside the United States may remain confidential until a patent issues. Moreover, it is difficult for industry participants, including us, to identify all third-party patent rights that may be relevant to any product candidates we may develop and our technologies because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. We may fail to identify relevant patents or patent applications or may identify pending patent applications of potential interest but incorrectly predict the likelihood that such patent applications may issue with claims of relevance to our technology. In addition, we may incorrectly conclude that a third-party patent is invalid, unenforceable or not infringed by our activities. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our technologies, any product candidates we may develop or the use of any product candidates we may develop.

Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of their merit. There is a risk that third parties may choose to engage in litigation with us to enforce or to otherwise assert their patent rights against us. Even if we believe such claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, which could adversely affect our ability to commercialize our product candidates or any other of our product candidates or technologies covered by the asserted third-party patents. In order to successfully challenge the validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent.

Numerous third-party U.S. and foreign issued patents and pending patent applications exist in the fields in which we are developing product candidates. Our product candidates make use of CRISPR-based gene editing technology, which is a field that is highly active for patent filings. The extensive patent filings related to CRISPR and Cas make it difficult for us to assess the full extent of relevant patents and pending applications that may cover our gene editing technology and product candidates and their use or manufacture. There may be third-party patents or patent applications, including patents held or controlled by our competitors with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our gene editing technology and product candidates.

If we are found to infringe, misappropriate or otherwise violate a third party’s valid and enforceable intellectual property rights, we could be required to obtain a license from such third party to continue developing, manufacturing and marketing our product candidates and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. We could be forced, including by court order, to cease developing, manufacturing and commercializing the infringing technology or product candidates. In addition, we could be found liable for monetary damages, including treble damages and attorneys’ fees, if we are found to have willfully infringed a patent or other intellectual property right indemnify our customers or collaborators. A finding of infringement could prevent us from manufacturing and commercializing our product candidates or force us to cease some of our business operations, which could harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business, financial condition, results of operations and prospects.

Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.

Patents have a limited lifespan. The terms of individual patents depend upon the legal term for patents in the countries in which they are granted. In most countries, including the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest non-provisional filing date in the applicable country. However, the actual protection afforded by a patent varies from country to country, and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed

62


 

patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.

Our product candidates may face competition from biosimilars approved through an abbreviated regulatory pathway.

The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the PPACA, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-approved reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first approved by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first approved. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor’s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of the other company’s product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty.

We believe that any of our product candidates approved as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to Congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for biosimilar competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.

If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, thereby potentially extending the term of our marketing exclusivity for any product candidates we may develop, our business may be materially harmed.

In the United States, the patent term of a patent that covers an FDA-approved drug may be eligible for limited patent term extension, which permits patent term restoration as compensation for the patent term lost during the FDA regulatory review process. The Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Act, permits a patent term extension of up to five years beyond the expiration of the patent. The length of the patent term extension is related to the length of time the drug is under clinical development and regulatory review. Patent extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, and only one patent applicable to and that covers an approved drug may be extended. Similar provisions are available in Europe, such as supplementary protection certificates, and certain other non-United States jurisdictions to extend the term of a patent that covers an approved drug. While, in the future, if and when our product candidates receive FDA approval, we expect to apply for patent term extensions on patents covering those product candidates, there is no guarantee that the applicable authorities will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions. We may not be granted patent term extension either in the United States or in any foreign country because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the term of extension, as well as the scope of patent protection during any such extension, afforded by the governmental authority could be less than we request. If we are unable to obtain any patent term extension or the term of any such extension is less than we request, our competitors may obtain approval of competing products following the expiration of our patent rights, and our business, financial condition, results of operations and prospects could be materially harmed.

It is possible that we will not obtain patent term extension under the Hatch-Waxman Act for a U.S. patent covering any of our product candidates that we may identify even where that patent is eligible for patent term extension, or if we obtain such an extension, it may be for a shorter period than we had sought.

Changes to patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our gene editing platform technology and product candidates.

As is the case with other biotech and pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain.

63


 

Changes in either the patent laws or interpretation of patent laws in the United States, including patent reform legislation such as the Leahy-Smith America Invents Act, or the Leahy-Smith Act, could increase the uncertainties and costs surrounding the prosecution of our owned and in-licensed patent applications and the maintenance, enforcement or defense of our owned and in-licensed issued patents. The Leahy-Smith Act includes a number of significant changes to United States patent law. These changes include provisions that affect the way patent applications are prosecuted, redefine prior art, provide more efficient and cost-effective avenues for competitors to challenge the validity of patents, and enable third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent at USPTO-administered post-grant proceedings, including post-grant review, inter partes review, and derivation proceedings. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action.

Assuming that other requirements for patentability are met, prior to March 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. After March 2013, under the Leahy-Smith Act, the United States transitioned to a first-to-file system in which, assuming that the other statutory requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. As such, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.

In addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. Past U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our patent rights and our ability to protect, defend and enforce our patent rights in the future. For example, in the case, Assoc. for Molecular Pathology v. Myriad Genetics, Inc., the U.S. Supreme Court held that claims to certain DNA molecules are not patentable. More recently, in Amgen Inc. v. Sanofi, the Federal Circuit held that claims with functional language may pose high hurdles in fulfilling the enablement requirement for claims with broad functional language. We cannot predict how this and future decisions by the courts, the U.S. Congress or the USPTO may impact the value of our patents. Any similar adverse changes in the patent laws of other jurisdictions could also have a material adverse effect on our business, financial condition, results of operations and prospects.

Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court. We may not be able to protect our trade secrets in court.

If we or one of our licensing partners initiates legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, written description or non-enablement. In addition, patent validity challenges may, under certain circumstances, be based upon non-statutory obviousness-type double patenting, which, if successful, could result in a finding that the claims are invalid for obviousness-type double patenting or the loss of patent term, including a patent term adjustment granted by the USPTO, if a terminal disclaimer is filed to obviate a finding of obviousness-type double patenting. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld information material to patentability from the USPTO, or made a misleading statement, during prosecution. Third parties also may raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post grant review, inter partes review and equivalent proceedings in foreign jurisdictions. Such proceedings could result in the revocation or cancellation of or amendment to our patents in such a way that they no longer cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art of which the patent examiner and we or our licensing partners were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we could

64


 

lose at least part, and perhaps all, of the patent protection on one or more of our product candidates. Such a loss of patent protection could have a material adverse impact on our business.

In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our product candidate discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets can be difficult to protect, and some courts inside and outside the United States are less willing or unwilling to protect trade secrets. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors and contractors. We cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors.

Intellectual property litigation or other legal proceedings relating to intellectual property could cause us to spend substantial resources and distract our personnel from their normal responsibilities.

Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and may also have an advantage in such proceedings due to their more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of intellectual property litigation or other proceedings could compromise our ability to compete in the marketplace.

Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.

Periodic maintenance, renewal and annuity fees and various other government fees on any issued patent and pending patent application must be paid to the USPTO and foreign patent agencies in several stages or annually over the lifetime of our owned and in-licensed patents and patent applications. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In certain circumstances, we may rely on our licensing partners to pay these fees to, or comply with the procedural and documentary rules of, the relevant patent agency. With respect to our patents, we rely on outside firms and outside counsel to remind us of the due dates and to make payment after we instruct them to do so. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, potential competitors might be able to enter the market with similar or identical products or technology. If we or our licensors fail to maintain the patents and patent applications covering our product candidates, it would have a material adverse effect on our business, financial condition, results of operations and prospects.

We have limited foreign intellectual property rights and may not be able to protect our intellectual property and proprietary rights throughout the world.

We have limited intellectual property rights outside the United States. Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States, and even where such protection is nominally available, judicial and governmental enforcement of such intellectual property rights may be lacking. Consequently, we may not be able to prevent third parties from practicing our inventions in

65


 

all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection or licenses but enforcement is not as strong as that in the United States. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.

Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary rights generally. In addition, certain jurisdictions do not protect to the same extent or at all inventions that constitute new methods of treatment.

Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.

Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.

Furthermore, geo-political actions in the United States and in foreign countries could increase the uncertainties and costs surrounding the prosecution or maintenance of our patent applications or those of any current or future licensors and the maintenance, enforcement or defense of our issued patents or those of any current or future licensors. For example, the United States and foreign government actions related to Russia’s invasion of Ukraine may limit or prevent filing, prosecution and maintenance of patent applications in Russia. Government actions may also prevent maintenance of issued patents in Russia. These actions could result in abandonment or lapse of our licensed patents or patent applications, resulting in partial or complete loss of patent rights in Russia. If such an event were to occur, it could have a material adverse effect on our business. In addition, a decree was adopted by the Russian government in March 2022, allowing Russian companies and individuals to exploit inventions owned by patentees that have citizenship or nationality in, are registered in, or have a predominately primary place of business or profit-making activities in the United States and other countries that Russia has deemed unfriendly without consent or compensation. Consequently, we would not be able to prevent third parties from practicing our inventions in Russia or from selling or importing products made using our inventions in and into Russia. Accordingly, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.

We may be subject to claims by third parties asserting that our employees, consultants or contractors have wrongfully used or disclosed confidential information of third parties, or we have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.

Many of our employees, consultants and contractors were previously employed at universities or other pharmaceutical or biotechnology companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual’s current or former employer. Litigation may be necessary to defend against these claims.

In addition, while it is our policy to require our employees, consultants and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Our intellectual property assignment agreements with them may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the

66


 

ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial conditions, results of operations and prospects.

If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could have a material adverse effect on our competitive business position and prospects. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or products, which license may not be available on commercially reasonable terms, or at all, or such license may be non-exclusive. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to our management and employees.

If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.

In addition to seeking patents for our some of our technology and product candidates, we also rely on trade secrets and confidentiality agreements to protect our unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect our trade secrets and other proprietary technology, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, CROs, CMOs, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants, but we cannot guarantee that we have entered into such agreements with each party that may have or has had access to our trade secrets or proprietary technology. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Detecting the disclosure or misappropriation of a trade secret and enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable.

In addition to contractual measures, we try to protect the confidential nature of our proprietary information through other appropriate precautions, such as physical and technological security measures. However, trade secrets and know-how can be difficult to protect. These measures may not, for example, in the case of misappropriation of a trade secret by an employee or third party with authorized access, provide adequate protection for our proprietary information. Our security measures may not prevent an employee or consultant from misappropriating our trade secrets and providing them to a competitor, and any recourse we might take against this type of misconduct may not provide an adequate remedy to protect our interests fully. In addition, trade secrets may be independently developed by others in a manner that could prevent us from receiving legal recourse. If any of our confidential or proprietary information, such as our trade secrets, were to be disclosed or misappropriated, or if any of that information was independently developed by a competitor, our competitive position could be harmed.

In addition, some courts inside and outside of the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party, our competitive position would be materially and adversely harmed.

If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.

Any registered trademarks or trade names may be challenged, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely impact our financial condition or results of operations.

67


 

Intellectual property rights do not necessarily address all potential threats.

The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:

any product candidates we may develop will eventually become commercially available in generic or biosimilar product forms;
others may be able to make gene editing product that are similar to ours but that are not covered by the claims of the patents that we own;
we, or our license partners or current or future collaborators, might not have been the first to make the inventions covered by the issued patent or pending patent applications that we license or may own in the future;
we, or our license partners or current or future collaborators, might not have been the first to file patent applications covering certain of our or their inventions;
others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or in-licensed intellectual property rights;
it is possible that our pending owned and in-licensed patent applications or those we may own or in-license in the future will not lead to issued patents;
it is possible that there are prior public disclosures that could invalidate our owned or in-licensed patents, or parts of our owned or in-licensed patents;
it is possible that there are unpublished applications or patent applications maintained in secrecy that may later issue with claims covering our product candidates or technology similar to ours;
it is possible that our owned or in-licensed patents or patent applications omit individual(s) that should be listed as inventor(s) or include individual(s) that should not be listed as inventor(s), which may cause these patents or patents issuing from these patent applications to be held invalid or unenforceable;
issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors;
the laws of foreign countries may not protect our proprietary rights or the proprietary rights of license partners or current or future collaborators to the same extent as the laws of the United States;
the inventors of our owned or in-licensed patents or patent applications may become involved with competitors, develop products or processes that design around our patents, or become hostile to us or the patents or patent applications on which they are named as inventors;
our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;
we have engaged in scientific collaborations in the past and will continue to do so in the future and our collaborators may develop adjacent or competing products that are outside the scope of our patent rights;
we cannot ensure that any of our patents, or any of our pending patent applications, if issued, or those of our licensors, will include claims having a scope sufficient to protect our product candidates;
we cannot ensure that any patents issued to us or our licensors will provide a basis for an exclusive market for our commercially viable product candidates or will provide us with any competitive advantages;
we cannot ensure that our commercial activities or product candidates will not infringe upon the patents of others;
we cannot ensure that we will be able to successfully commercialize our product candidates on a substantial scale, if approved, before our relevant patents that we own or license expire;
we may not develop additional proprietary technologies that are patentable;
the patents of others may harm our business; and
we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property.

68


 

Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and prospects.

Risks related to commercialization

Even if any of our current or future product candidates receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success, and the market opportunity for any of such product candidates, if approved, may be smaller than we estimate.

If any of our current or future product candidates receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. For example, current CVD treatments such as statins, ezetimibe, bempedoic acid, lomitapide, mipomersen and icosapent ethyl are well-established in the medical community, and physicians may continue to rely on these treatments. Efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and may not be successful. If our current or future product candidates do not achieve an adequate level of acceptance, we may not generate significant product revenues and we may not become profitable. The degree of market acceptance of our current or future product candidates, if approved for commercial sale, will depend on a number of factors, including:

the efficacy and potential advantages of such product candidates compared to the advantages and relative risks of alternative treatments;
the effectiveness of sales and marketing efforts;
the cost of treatment in relation to alternative treatments, including any similar biosimilar treatments;
our ability to offer our products, if approved, for sale at competitive prices;
the clinical indications for which the product is approved;
the convenience and ease of administration compared to alternative treatments;
the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;
the strength of marketing and distribution support;
the timing of market introduction of competitive products;
the availability of third-party coverage and adequate reimbursement, and patients’ willingness to pay out of pocket for required co-payments or in the absence of third-party coverage or adequate reimbursement;
the prevalence and severity of any side effects; and
any restrictions on the use of our products, if approved, together with other medications.

Our assessment of the potential market opportunity for our current or future product candidates is based on industry and market data that we obtained from industry publications, research, surveys and studies conducted by third parties and our analysis of these data, research, surveys and studies. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. While we believe these industry publications and third-party research, surveys and studies are reliable, we have not independently verified such data. Our estimates of the potential market opportunities for our product candidates include a number of key assumptions based on our industry knowledge, industry publications and third-party research, surveys and studies, which may be based on a small sample size and fail to accurately reflect market opportunities. While we believe that our internal assumptions are reasonable, no independent source has verified such assumptions. If any of our assumptions or estimates, or these publications, research, surveys or studies prove to be inaccurate, then the actual market for any of our product candidates may be smaller than we expect, and as a result our revenues from product sales may be limited and it may be more difficult for us to achieve or maintain profitability.

We face substantial competition, which may result in others discovering, developing or commercializing products before us or more successfully than we do.

The development and commercialization of new drug or biologic products is highly competitive. It is particularly competitive with respect to new products for CVD, for which the standard of care is well-established. We face competition with respect to our current product candidates, and will face competition with respect to any product candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. There are a number of large pharmaceutical and biotechnology

69


 

companies that currently market and sell products or are pursuing the development of products for the treatment of many of the disease indications for which we are developing our product candidates. Some of these competitive products and therapies are based on scientific approaches that are similar to our approach, and others are based on entirely different approaches. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.

There are several approved products for low-density lipoprotein cholesterol, or LDL-C, lowering or cardiovascular risk reduction, such as statins, ezetimibe, bempedoic acid, lomitapide, mipomersen and icosapent ethyl.

There are several approved products that target PCSK9 protein as a mechanism to lower LDL-C and reduce the risk of ASCVD. Evolocumab, a monoclonal antibody, or mAb, marketed as Repatha by Amgen, is approved by the FDA for the treatment of patients with heterozygous familial hypercholesterolemia, or HeFH, patients with HoFH and in patients with ASCVD. Alirocumab, a mAb marketed as Praluent by Sanofi and Regeneron Pharmaceuticals, Inc., or Regeneron, is approved by the FDA for the treatment of patients with ASCVD and for the treatment of patients with primary hyperlipidemia, including HeFH. Regeneron has sole U.S. rights to alirocumab and Sanofi has sole ex-U.S. rights to alirocumab. The approved mAb treatments act through extracellular inhibition of PCSK9 protein. Inclisiran, a small interfering RNA, or siRNA, marketed as Leqvio by Novartis AG, is approved in the United States for the treatment of patients with clinical ASCVD or HeFH who require additional lowering of LDL-C and in Europe for the treatment of patients with hypercholesterolemia, including HeFH, or mixed dyslipidemia. Inclisiran acts by inhibiting the synthesis of PCSK9 within liver cells, which is distinct from extracellular protein inhibition.

We are aware of several product candidates in clinical development that target PCSK9 protein as a mechanism to lower LDL-C and reduce the risk of ASCVD, including peptide-based anti PCSK9 vaccination, small molecule oral PCSK9 inhibitors, small binding proteins, and antisense oligonucleotides. In 2021, Esperion in-licensed an oral small molecule PCSK9 inhibitor from Serometrix LLC for which it disclosed plans to submit an IND in 2022, and an oral PCSK9 inhibitor from Merck & Co., for which they plan to progress to Phase 2 in 2022.

We are aware of one other gene editing program targeting the PCSK9 gene in preclinical development. Precision Biosciences, Inc., or Precision, has published preclinical data showing long-term stable reduction of LDL-C levels in non-human primates following in vivo gene editing of the PCSK9 gene using its gene editing platform. In September 2021, Precision entered into a collaboration with iECURE under which iECURE plans to advance Precision’s PCSK9-directed nuclease product candidate into Phase 1 clinical trials for the treatment of familial hypercholesterolemia in 2022.

Evinacumab, a mAb targeting ANGPTL3 protein that is marketed by Regeneron, is approved by the FDA for the treatment of patients with HoFH. Evinacumab is also being evaluated by Regeneron in Phase 2 development for severe hypertriglyceridemia.

We are aware of several product candidates in clinical development that target ANGPTL3 protein as a mechanism to lower LDL-C and reduce the risk of ASCVD, including vupanorsen, an antisense oligonucleotide therapy being evaluated in a Phase 2 clinical trial by Ionis Pharmaceuticals, Inc. and Pfizer for the treatment of patients with elevated non-high-density lipoprotein cholesterol and triglycerides. ARO-ANG3, a siRNA targeting ANGPTL3 protein, is being evaluated in a Phase 1/2 clinical trial by Arrowhead Pharmaceuticals, Inc., or Arrowhead. In 2021, Arrowhead initiated a Phase 2b trial of ARO-ANG3 for the treatment of patients with mixed dyslipidemia. In addition, Eli Lilly and Company, or Eli Lilly, is evaluating a siRNA targeting ANGPTL3 protein in a Phase 1 study for the treatment of CVD.

Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of biosimilar products. If our product candidates achieve marketing approval, we expect that they will be priced at a significant premium over competitive biosimilar products.

Many of the companies against which we are competing or against which we may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do.

Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.

70


 

If we are unable to establish sales, marketing and distribution capabilities or enter into sales, marketing and distribution agreements with third parties, we may not be successful in commercializing our current and future product candidates if and when they are approved.

We do not have a sales or marketing infrastructure and have no experience as a company with the commercialization of products. To achieve commercial success for any product for which we have obtained marketing approval, we will need to establish a sales, marketing and distribution organization, either ourselves or through collaborations or other arrangements with third parties.

In the future, we expect to build a sales and marketing infrastructure to market some of our product candidates in the United States, if and when they are approved. There are risks involved with establishing our own sales, marketing and distribution capabilities. For example, recruiting and training a sales force is expensive and time-consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. These efforts may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.

Factors that may inhibit our efforts to commercialize our products on our own include:

our inability to recruit, train and retain adequate numbers of effective sales, marketing, coverage or reimbursement, customer service, medical affairs and other support personnel;
the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future products;
the inability of reimbursement professionals to negotiate arrangements for coverage, formulary access, reimbursement and other acceptance by payors;
the inability to price our products at a sufficient price point to ensure an adequate and attractive level of profitability;
restricted or closed distribution channels that make it difficult to distribute our products to segments of the patient population;
the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and
unforeseen costs and expenses associated with creating an independent sales and marketing organization.

If we are unable to establish our own sales, marketing and distribution capabilities and we enter into arrangements with third parties to perform these services, our product revenues and our profitability, if any, are likely to be lower than if we were to market, sell and distribute any products that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell, market and distribute our product candidates or may be unable to do so on terms that are acceptable to us. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we do not establish sales, marketing and distribution capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates.

We currently rely, and expect to continue to rely, on CMOs to manufacture our product candidates. If we are unable to enter into such arrangements as expected or if such organizations do not meet our supply requirements, development and/or commercialization of our product candidates may be delayed.

We currently rely, and expect to continue to rely, on third parties to manufacture clinical supplies of our product candidates and commercial supplies of our products, if and when approved for marketing by applicable regulatory authorities, as well as for packaging, sterilization, storage, distribution and other production logistics. If we are unable to enter into such arrangements on the terms or timeline we expect, development and/or commercialization of our product candidates may be delayed. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or manufacture our product candidates in accordance with regulatory requirements, if there are disagreements between us and such parties or if such parties are unable to expand capacities to support commercialization of any of our product candidates for which we obtain marketing approval, we may not be able to fulfill, or may be delayed in producing sufficient product candidates to meet, our supply requirements. These facilities may also be affected by catastrophic events, including pandemics, including the ongoing COVID-19 pandemic, terrorist attacks, wars or other armed conflicts, geopolitical tensions, such as the ongoing conflict between Russia and Ukraine, natural disasters, such as floods or fire, or such facilities could face manufacturing issues, such as contamination or regulatory concerns following a regulatory inspection of such facility. In such instances, we may need to locate an appropriate replacement third-party facility and establish a contractual relationship, which may not be readily available or on acceptable terms, which would cause

71


 

additional delay and increased expense, including as a result of additional required FDA approvals, and may have a material adverse effect on our business.

Our third-party manufacturers will be subject to inspection and approval by the FDA before we can commence the manufacture and sale of any of our product candidates, and thereafter subject to FDA inspection from time to time. Failure by our third-party manufacturers to pass such inspections and otherwise satisfactorily complete the FDA approval regimen with respect to our product candidates may result in regulatory actions such as the issuance of FDA Form 483 notices of observations, warning letters or injunctions or the loss of operating licenses.

We or our third-party manufacturers may also encounter shortages in the raw materials or API necessary to produce our product candidates in the quantities needed for our clinical trials or, if our product candidates are approved, in sufficient quantities for commercialization or to meet an increase in demand, as a result of capacity constraints or delays or disruptions in the market for the raw materials or API, including shortages caused by the purchase of such raw materials or API by our competitors or others. The failure of us or our third-party manufacturers to obtain the raw materials or API necessary to manufacture sufficient quantities of our product candidates may have a material adverse effect on our business.

Even if we are able to commercialize any product candidates, the products may become subject to unfavorable pricing regulations, third-party coverage or reimbursement practices or healthcare reform initiatives, which could harm our business.

The regulations that govern marketing approvals, pricing, coverage and reimbursement for new drug products vary widely from country to country. Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain marketing approval.

Our ability to commercialize any product candidates successfully also will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor’s determination that use of a product is:

a covered benefit under its health plan;
safe, effective and medically necessary;
appropriate for the specific patient;
cost-effective; and
neither experimental nor investigational.

In the United States, there is no uniform policy of coverage and reimbursement for products that exists among third-party payors. As a result, obtaining coverage and reimbursement approval of a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide to each payor supporting scientific, clinical and cost-effectiveness data for the use of our products on a payor-by-payor basis, with no assurance that coverage and adequate reimbursement will be obtained. The availability and adequacy of coverage and reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford our product candidates, if approved. Our ability to achieve acceptable levels of coverage and reimbursement for our product candidates, if approved, by governmental authorities, private health insurers and other organizations will have an effect on our ability to successfully commercialize, our product candidates. Assuming we obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require patient out-of-pocket costs that patients find unacceptably high.

A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Coverage and reimbursement may not be available

72


 

for any product that we commercialize and, even if these are available, the level of reimbursement may not be satisfactory. Reimbursement may affect the demand for, or the price of, any product candidate for which we obtain marketing approval. Obtaining and maintaining adequate reimbursement for our products may be difficult. We may be required to conduct expensive pharmacoeconomic studies to justify coverage and reimbursement or the level of reimbursement relative to other therapies. If coverage and adequate reimbursement are not available or reimbursement is available only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval.

There may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or similar regulatory authorities outside of the United States. Moreover, eligibility for coverage and reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution expenses. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.

There can be no assurance that our product candidates, even if they are approved for sale in the United States or in other countries, will be considered medically reasonable and necessary for a specific indication or cost-effective by third-party payors, or that coverage and an adequate level of reimbursement will be available or that third-party payors’ reimbursement policies will not adversely affect our ability to sell our product candidates profitably.

Our future growth depends, in part, on our ability to penetrate foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties that, if they materialize, could harm our business.

Our future profitability will depend, in part, on our ability to commercialize our product candidates in markets outside of the United States. If we commercialize our product candidates in foreign markets, we will be subject to additional risks and uncertainties, including:

economic weakness, including inflation, or political instability in particular economies and markets;
the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements, many of which vary between countries;
different medical practices and customs in foreign countries affecting acceptance in the marketplace;
tariffs and trade barriers, as well as other governmental controls and trade restrictions;
other trade protection measures, import or export licensing requirements or other restrictive actions by U.S. or foreign governments;
longer accounts receivable collection times;
longer lead times for shipping;
compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;
workforce uncertainty in countries where labor unrest is common;
language barriers for technical training;
reduced protection of intellectual property rights in some foreign countries, and related prevalence of biosimilar alternatives to therapeutics;
foreign currency exchange rate fluctuations and currency controls;
differing foreign reimbursement landscapes;
uncertain and potentially inadequate reimbursement of our products; and
the interpretation of contractual provisions governed by foreign laws in the event of a contract dispute.

73


 

If risks related to any of these uncertainties materializes, it could have a material adverse effect on our business.

Clinical trial and product liability lawsuits against us could divert our resources and could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.

We will face an inherent risk of clinical trial and product liability exposure related to the testing of our product candidates in human clinical trials, and we will face an even greater risk if we commercially sell any products that we may develop. While we currently have no products that have been approved for commercial sale, the ongoing, planned and future use of product candidates by us in clinical trials, and the sale of any approved products in the future, may expose us to liability claims. These claims might be made by patients that use the product, healthcare providers, pharmaceutical companies or others selling such products. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:

decreased demand for any product candidates or products that we may develop;
termination of clinical trials;
injury to our reputation and significant negative media attention;
withdrawal of clinical trial participants;
significant costs to defend any related litigation;
substantial monetary awards to trial participants or patients;
loss of revenue;
reduced resources of our management to pursue our business strategy; and
the inability to commercialize any products that we may develop.

We currently do not hold any clinical trial liability insurance coverage. We may need to obtain insurance coverage as we expand our clinical trials or if we commence commercialization of our product candidates. Insurance coverage is increasingly expensive. We may not be able to obtain and maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. If a successful clinical trial or product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims and our business operations could be impaired.

Risks related to regulatory approval and other legal compliance matters

Gene editing is novel and the regulatory landscape that will govern any product candidates we may develop is uncertain and may change. As a result, we cannot predict the time and cost of obtaining regulatory approval, if we receive it at all, for any product candidates we may develop.

The regulatory requirements that will govern any novel gene editing product candidates we develop are not entirely clear and may change. Within the broader genetic medicines field, we are aware of a limited number of gene therapy products that have received marketing authorization from the FDA and the EMA. Even with respect to more established products that fit into the categories of gene therapies or cell therapies, the regulatory landscape is still developing. Regulatory requirements governing gene therapy products and cell therapy products have changed frequently and will likely continue to change in the future. Moreover, there is substantial, and sometimes uncoordinated, overlap in those responsible for regulation of existing gene therapy products and cell therapy products. For example, in the United States, the FDA has established the Office of Tissues and Advanced Therapies within its Center for Biologics Evaluation and Research, or CBER, to consolidate the review of gene therapy and related products, and the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on its review. Gene therapy clinical trials may also be subject to review and oversight by an IBC, a local institutional committee that reviews and oversees basic and clinical research conducted at the institution participating in the clinical trial. Although the FDA decides whether individual gene therapy protocols may proceed, the review process and determinations of other reviewing bodies can impede or delay the initiation of a clinical trial, even if the FDA has reviewed the trial and approved its initiation.

The same applies in the European Union. In the European Union, the development and evaluation of a gene therapy medicinal product must be considered in the context of the relevant EU guidelines. The EMA may issue new guidelines concerning the development and marketing authorization for gene therapy medicinal products and require that we comply with these new guidelines. Additionally, for advanced therapy medicinal products, a marketing application authorization undergoes review by the EMA’s Committee for Advanced Therapies, or CAT, in addition to review by the Committee for Medicinal Products for Human Use, or CHMP. As a result, the procedures and standards applied to gene therapy

74


 

products and cell therapy products may be applied to any product candidates we may develop, but that remains uncertain at this point.

Adverse developments in post-marketing experience or in clinical trials conducted by others of gene therapy products, cell therapy products, or products developed through the application of a base editing or other gene editing technology may cause the FDA, the EMA, and other regulatory bodies to revise the requirements for development or approval of any product candidates we may develop or limit the use of products utilizing base editing technologies, either of which could materially harm our business. In addition, the clinical trial requirements of the FDA, the EMA, and other regulatory authorities and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty, and intended use and market of the potential products. The regulatory approval process for novel product candidates such as the product candidates we may develop can be more expensive and take longer than for other, better known, or more extensively studied pharmaceutical or other product candidates. Regulatory agencies administering existing or future regulations or legislation may not allow production and marketing of products utilizing base editing technology in a timely manner or under technically or commercially feasible conditions. In addition, regulatory action or private litigation could result in expenses, delays, or other impediments to our research programs or the commercialization of resulting products.

The regulatory review committees and advisory groups described above and the new guidelines they promulgate may lengthen the regulatory review process, require us to perform additional studies or trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of these treatment candidates, or lead to significant post-approval limitations or restrictions. As we advance our research programs and develop future product candidates, we will be required to consult with these regulatory and advisory groups and to comply with applicable guidelines. If we fail to do so, we may be required to delay or discontinue development of any product candidates we identify and develop.

Because we are developing product candidates in the field of genetic medicines, a field that includes gene therapy and gene editing, in which there is little clinical experience, there is increased risk that the FDA, the EMA, or other regulatory authorities may not consider the endpoints of our clinical trials to provide clinically meaningful results and that these results may be difficult to analyze.

During the regulatory review process, we will need to identify success criteria and endpoints such that the FDA, the EMA, or other regulatory authorities will be able to determine the clinical efficacy and safety profile of any product candidates we may develop. As we are seeking to identify and develop product candidates to treat diseases in which there is no clinical experience using a gene editing approach, there is heightened risk that the FDA, the EMA, or other regulatory authorities may not consider the clinical trial endpoints that we propose to provide clinically meaningful results (reflecting a tangible benefit to patients). In addition, the resulting clinical data and results may be difficult to analyze. Even if the FDA does find our success criteria to be sufficiently validated and clinically meaningful, we may not achieve the pre-specified endpoints to a degree of statistical significance. Further, even if we do achieve the pre-specified criteria, we may produce results that are unpredictable or inconsistent with the results of the non-primary endpoints or other relevant data. The FDA also weighs the benefits of a product against its risks, and the FDA may view the efficacy results in the context of safety as not being supportive of regulatory approval. Other regulatory authorities in the European Union and other countries may make similar comments with respect to these endpoints and data. Any product candidates we may develop will be based on a novel technology that makes it difficult to predict the time and cost of development and of subsequently obtaining regulatory approval. No gene editing therapeutic product has been approved in the United States or in Europe.

Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming and uncertain and may prevent us from obtaining approvals for the commercialization of any product candidates we develop. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize, or will be delayed in commercializing, product candidates we develop, and our ability to generate revenue will be materially impaired.

Any product candidates we develop and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive regulation by the FDA and other regulatory authorities in the United States and by comparable authorities in other countries. Failure to obtain marketing approval for a product candidate will prevent us from commercializing the product candidate in a given jurisdiction. We have not received approval to market any product candidates from regulatory authorities in any jurisdiction. We have no experience as a company in filing and supporting the applications necessary to gain marketing approvals and expect to rely on third-party CROs to assist us in this process. Securing regulatory approval requires the submission of extensive preclinical and clinical data and supporting information, including manufacturing information, to the various regulatory authorities for each therapeutic indication to establish the biologic product candidate’s safety, purity and potency. Securing regulatory approval also

75


 

requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Any product candidates we develop may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use.

The process of obtaining marketing approvals, both in the United States and abroad, is expensive, may take many years if additional clinical trials are required, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved and the specific disease or condition to be treated. Of the large number of products in development, only a small percentage successfully complete the FDA or foreign regulatory approval processes and are commercialized. Even if any product candidates we may develop demonstrate safety and efficacy in clinical trials, the regulatory agencies may not complete their review processes in a timely manner, or we may not be able to obtain regulatory approval. Additional delays may result if an FDA Advisory Committee or other regulatory authority recommends non-approval or restrictions on approval. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. The FDA and comparable authorities in other countries have substantial discretion in the approval process and may refuse to accept any application or may decide that our data is insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.

If we experience delays in obtaining approval or if we fail to obtain approval of any product candidates we develop, the commercial prospects for those product candidates may be harmed and our ability to generate revenues will be materially impaired.

Obtaining and maintaining marketing approval or commercialization of our product candidates in the United States does not mean that we will be successful in obtaining marketing approval of our product candidates in other jurisdictions. Failure to obtain marketing approval in foreign jurisdictions would prevent any product candidates we develop from being marketed in such jurisdictions, which, in turn, would materially impair our ability to generate revenue.

In order to market and sell any product candidates we may develop in the European Union and many other foreign jurisdictions, we or our collaborators must obtain separate marketing approvals and comply with numerous and varying local regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in that country. We or these third parties may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. We may not be able to file for marketing approvals and may not receive necessary approvals to commercialize our product candidates in any jurisdiction, which would materially impair our ability to generate revenue.

On June 23, 2016, the electorate in the United Kingdom voted in favor of leaving the European Union, commonly referred to as Brexit. Following protracted negotiations, the United Kingdom left the European Union on January 31, 2020 and European Union rules and regulations ceased to apply to the United Kingdom starting on January 1, 2021. The Medicines and Healthcare products Regulatory Agency, or the MHRA, is now the sole decision maker for marketing authorizations of pharmaceutical products in the United Kingdom, except for Northern Ireland. The MHRA will rely on the Human Medicines Regulations 2012 (SI 2012/1916) (as amended), or the HMR, as the basis for regulating medicines. The HMR has incorporated into the domestic law of the United Kingdom the body of European Union law governing medicinal products that pre-existed before the United Kingdom’s withdrawal from the European Union.

Since the regulatory framework for pharmaceutical products in the United Kingdom covering the quality, safety, and efficacy of pharmaceutical products, clinical trials, marketing authorization, commercial sales, and distribution of pharmaceutical products is derived from European Union directives and regulations, the consequences of Brexit and the impact the future regulatory regime that applies to products and the approval of product candidates in the United Kingdom remains unclear. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, may force us to restrict or delay efforts to seek regulatory approval in the United Kingdom for our product candidates, which could significantly and materially harm our business. As a result of Brexit, we expect we will need to

76


 

submit a separate application to the MHRA for marketing approval in the United Kingdom, in addition to any planned marketing authorisation applications for the EMA.

We expect that we will be subject to additional risks in commercializing any of our product candidates that receive marketing approval outside the United States, including tariffs, trade barriers and regulatory requirements; economic weakness, including inflation, or political instability in particular foreign economies and markets; compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country; and workforce uncertainty in countries where labor unrest is more common than in the United States.

We may seek certain designations for our product candidates, including Fast Track, Breakthrough Therapy, Regenerative Medicine Advanced Therapy and Priority Review designations in the United States, and PRIME Designation in the European Union, but we might not receive such designations, and even if we do, such designations may not lead to a faster development or regulatory review or approval process.

If a product candidate is intended for the treatment of a serious or life-threatening condition and the product candidate demonstrates the potential to address unmet medical need for this condition, the sponsor may apply to the FDA for Fast Track designation. For Fast Track products, sponsors may have greater interactions with the FDA and the FDA may initiate review of sections of a Fast Track product’s application before the application is complete. This rolling review may be available if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a Fast Track product may be effective.

In addition, an applicant may seek designation of its product as a breakthrough therapy, which is a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs and biologics that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens.

Additionally, a product is eligible for Regenerative Medicine Advanced Therapy, or RMAT, designation if it is intended to treat, modify, reverse or cure a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product candidate has the potential to address unmet medical needs for such disease or condition. The benefits of an RMAT designation are similar to a breakthrough therapy designation, and include early interactions with the FDA to expedite development and review, potential eligibility for priority review and accelerated approval based on surrogate or intermediate endpoints.

Further, if the FDA determines that a product candidate offers major advances in treatment or provides a treatment where no adequate therapy exists, the FDA may designate the product candidate for priority review. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting product reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, and evidence of safety and effectiveness in a new subpopulation. A priority review designation means that the goal for the FDA to review an application is six months, rather than the standard review period of ten months.

We may seek these and other designations for our product candidates. The FDA has broad discretion with respect to whether or not to grant these designations to a product candidate, so even if we believe a particular product candidate is eligible for such designation or status, the FDA may decide not to grant it. Moreover, a Fast Track, breakthrough therapy or RMAT designation does not necessarily mean a faster regulatory review process or necessarily confer any advantage with respect to approval compared to conventional FDA procedures. As a result, while we may seek and receive these designations for our product candidates, we may not experience a faster development process, review or approval compared to conventional FDA procedures. In addition, the FDA may withdraw these designations if it believes that the designation is no longer supported by data from our clinical development program.

In the European Union, we may seek PRIME designation for some of our product candidates in the future. PRIME is a voluntary program aimed at enhancing the EMA’s role to reinforce scientific and regulatory support in order to optimize development and enable accelerated assessment of new medicines that are of major public health interest with the potential to address unmet medical needs. The program focuses on medicines that target conditions for which there exists no satisfactory method of treatment in the European Union or even if such a method exists, it may offer a major therapeutic advantage over existing treatments. PRIME is limited to medicines under development and not authorized in the European Union and the applicant intends to apply for an initial marketing authorization application through the centralized procedure. To be accepted for PRIME, a product candidate must meet the eligibility criteria in respect of its major public health interest and therapeutic innovation based on information that is capable of substantiating the claims.

77


 

The benefits of a PRIME designation include the appointment of a CHMP rapporteur to provide continued support and help to build knowledge ahead of a marketing authorization application, early dialogue and scientific advice at key development milestones, and the potential to qualify products for accelerated review, meaning reduction in the review time for an opinion on approvability to be issued earlier in the application process. PRIME also encourages an applicant to request parallel EMA scientific advice and health technology assessment advice to facilitate timely market access. Even if we receive PRIME designation for any of our product candidates, the designation may not result in a materially faster development process, review or approval compared to conventional EMA procedures. Further, obtaining PRIME designation does not assure or increase the likelihood of EMA’s grant of a marketing authorization.

We may not be able to obtain orphan drug exclusivity for any product candidates we may develop, and even if we do, that exclusivity may not prevent the FDA or the EMA from approving other competing products.

Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug or biologic intended to treat a rare disease or condition. A similar regulatory scheme governs approval of orphan products by the EMA in the European Union. Generally, if a product candidate with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA or the EMA from approving another marketing application for the same product for the same therapeutic indication for that time period. The applicable period is seven years in the United States and ten years in the European Union. The exclusivity period in the European Union can be reduced to six years if a product no longer meets the criteria for orphan drug designation, in particular if the product is sufficiently profitable so that market exclusivity is no longer justified.

In order for the FDA to grant orphan drug exclusivity to one of our products, the agency must find that the product is indicated for the treatment of a condition or disease with a patient population of fewer than 200,000 individuals annually in the United States. The FDA may conclude that the condition or disease for which we seek orphan drug exclusivity does not meet this standard. Even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different products can be approved for the same condition. In particular, the concept of what constitutes the “same drug” for purposes of orphan drug exclusivity remains in flux in the context of gene therapies, and the FDA has issued recent final guidance suggesting that it would not consider two genetic medicine products to be different drugs solely based on minor differences in the transgenes or vectors. In addition, even after an orphan drug is approved, the FDA can subsequently approve the same product for the same condition if the FDA concludes that the later product is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. Orphan drug exclusivity may also be lost if the FDA or EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of the patients with the rare disease or condition.

In 2017, the Congress passed the FDA Reauthorization Act of 2017, or the FDARA. FDARA, among other things, codified the FDA’s pre-existing regulatory interpretation, to require that a drug sponsor demonstrate the clinical superiority of an orphan drug that is otherwise the same as a previously approved drug for the same rare disease in order to receive orphan drug exclusivity. Under Omnibus legislation signed by President Trump on December 27, 2020, the requirement for a product to show clinical superiority applies to drugs and biologics that received orphan drug designation before enactment of FDARA in 2017, but have not yet been approved or licensed by FDA.

The FDA and Congress may further reevaluate the Orphan Drug Act and its regulations and policies. This may be particularly true in light of a decision from the Court of Appeals for the 11th Circuit in September 2021 finding that, for the purpose of determining the scope of exclusivity, the term “same disease or condition” means the designated “rare disease or condition” and could not be interpreted by the FDA to mean the “indication or use.” Thus, the court concluded, orphan drug exclusivity applies to the entire designated disease or condition rather than the “indication or use.” We do not know if, when, or how the FDA may change the orphan drug regulations and policies in the future, and it is uncertain how any changes might affect our business. Depending on what changes the FDA may make to its orphan drug regulations and policies, our business could be adversely impacted.

Negative public opinion of gene editing and increased regulatory scrutiny of gene editing and genetic research may adversely impact public perception of our future product candidates.

Our potential therapeutic products involve introducing genetic material into patients’ cells. The clinical and commercial success of our potential products will depend in part on public acceptance of the use of gene editing and gene regulation for the prevention or treatment of human diseases. Public attitudes may be influenced by claims that gene editing and gene regulation are unsafe, unethical or immoral, and, consequently, our products may not gain the acceptance of the public or the medical community. Adverse public attitudes may adversely impact our ability to enroll clinical trials. Moreover, our success will depend upon physicians prescribing, and their patients being willing to receive, treatments that

78


 

involve the use of product candidates we may develop in lieu of, or in addition to, existing treatments with which they are already familiar and for which greater clinical data may be available.

More restrictive government regulations or negative public opinion would have a negative effect on our business or financial condition and may delay or impair the development and commercialization of our product candidates or demand for any products once approved. For example, in 2003, trials using early versions of murine gamma-retroviral vectors, which integrate with, and thereby alter, the host cell’s DNA, have led to several well-publicized adverse events, including reported cases of leukemia. Adverse events in our clinical trials, even if not ultimately attributable to our product candidates, and the resulting publicity could result in increased governmental regulation, unfavorable public perception, potential regulatory delays in the testing or approval of our product candidates, stricter labeling requirements for those product candidates that are approved and a decrease in demand for any such product candidates. The risk of cancer remains a concern for gene editing and we cannot assure that it will not occur in any of our planned or future clinical trials. If any such adverse events occur, commercialization of our product candidates or further advancement of our clinical trials could be halted or delayed, which would have a negative impact on our business and operations.

Even if we, or any collaborators we may have, obtain marketing approvals for any product candidates we develop, the terms of approvals and ongoing regulation of our products could require the substantial expenditure of resources and may limit how we, or they, manufacture and market our products, which could materially impair our ability to generate revenue.

Any product candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, advertising, and promotional activities for such product, will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, cGMP requirements relating to quality control, quality assurance and corresponding maintenance of records and documents, and requirements regarding the distribution of samples to physicians and recordkeeping. For example, the holder of an approved BLA is obligated to monitor and report adverse events and any failure of a product to meet the specifications in the BLA. The FDA typically advises that patients treated with genetic medicine undergo follow-up observations for potential adverse events for up to a 15-year period. The holder of an approved BLA must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the product.

Accordingly, assuming we, or any collaborators we may have, receive marketing approval for one or more product candidates we develop, we, and such collaborators, and our and their contract manufacturers will continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance, and quality control. If we and such collaborators are not able to comply with post-approval regulatory requirements, we and such collaborators could have the marketing approvals for our products withdrawn by regulatory authorities and our, or such collaborators’, ability to market any future products could be limited, which could adversely affect our ability to achieve or sustain profitability. Further, the cost of compliance with post-approval regulations may have a negative effect on our business, operating results, financial condition, and prospects.

Any product candidate for which we obtain marketing approval could be subject to restrictions or withdrawal from the market, and we may be subject to substantial penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products, when and if any of them are approved.

The FDA and other regulatory agencies closely regulate the post-approval marketing and promotion of medicines to ensure that they are marketed only for the approved indications and in accordance with the provisions of the approved labeling. Although physicians may prescribe products for uses not described in the product’s labeling, known as off-label uses, in their professional medical judgment, the FDA and other regulatory agencies impose stringent restrictions on manufacturers’ communications regarding off-label use, and if we market our products, if approved, in a manner inconsistent with their approved labeling, we may be subject to enforcement action for off-label marketing by the FDA and other federal and state enforcement agencies, including the Department of Justice, or DOJ. Violation of the Federal Food, Product, and Cosmetic Act and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription products may also lead to investigations or allegations of violations of federal and state health care fraud and abuse laws and state consumer protection laws. In September 2021, the FDA published final regulations that describe the types of evidence that the FDA will consider in determining the intended use of a drug or biologic.

79


 

In addition, later discovery of previously unknown problems with our product candidates, manufacturers, or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including:

restrictions on such products, manufacturers, or manufacturing processes;
restrictions on the labeling or marketing of a medicine;
restrictions on the distribution or use of a medicine;
requirements to conduct post-marketing clinical trials;
receipt of warning or untitled letters;
withdrawal of the medicines from the market;
refusal to approve pending applications or supplements to approved applications that we submit;
recall of medicines;
fines, restitution, or disgorgement of profits or revenue;
suspension or withdrawal of marketing approvals;
suspension of any ongoing clinical trials;
refusal to permit the import or export of our medicines;
product seizure; and
injunctions or the imposition of civil or criminal penalties.

Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize any product candidates we develop and adversely affect our business, financial condition, results of operations, and prospects.

Inadequate funding for the FDA, the SEC and other government agencies, including from government shut downs, or other disruptions to these agencies’ operations, could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.

The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result. Disruptions at the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. In addition, government funding of the Securities and Exchange Commission, or the SEC, and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.

Disruptions at the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.

Separately, in response to the COVID-19 pandemic, a number of companies announced in 2021 receipt of complete response letters due to the FDA’s inability to complete required inspections for their applications. Following a period of false starts and temporary suspensions due to the omicron variant, the FDA resumed domestic inspections in February 2022 and indicated that it would conduct foreign inspections beginning in April 2022 on a prioritized basis However, the FDA may not be able to continue its current pace and review timelines could be extended, including where a pre-approval inspection or an inspection of clinical sites is required and due to the ongoing COVID-19 pandemic and travel restrictions, the FDA is unable to complete such required inspections during the review period. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic and may experience delays in their regulatory activities. If a prolonged government shutdown or other disruption occurs, it could

80


 

significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Future shutdowns or other disruptions could also affect other government agencies such as the SEC, which may also impact our business by delaying review of our public filings, to the extent such review is necessary, and our ability to access the public markets.

Any relationships we may have with customers, healthcare providers and professionals, and third-party payors, among others, will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to penalties, including criminal sanctions, civil penalties, contractual damages, reputational harm, fines, disgorgement, exclusion from participation in government healthcare programs, curtailment or restricting of our operations, and diminished profits and future earnings.

Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any products for which we are able to obtain marketing approval. Any arrangements we have with healthcare providers, third-party payors and customers will subject us to broadly applicable fraud and abuse and other healthcare laws and regulations. The laws and regulations may constrain the business or financial arrangements and relationships through which we conduct clinical research, market, sell and distribute any products for which we obtain marketing approval. These include the following:

the federal healthcare anti-kickback statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order, or recommendation of, any good or service, for which payment may be made under federal and state healthcare programs such as Medicare and Medicaid;
the federal civil and criminal false claims laws, including the federal False Claims Act, which can be enforced through civil whistleblower or qui tam actions, and civil monetary penalty laws impose civil and criminal penalties against individuals or entities for knowingly presenting or causing to be presented, to the federal government, claims for payment or approval from Medicare, Medicaid or other government payers that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government, with potential liability including mandatory treble damages and significant per-claim penalties;
the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which prohibits, among other things, knowingly and willfully executing, or attempting to execute, a scheme or artifice to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private), and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false, fictitious or fraudulent statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters;
HIPAA, as further amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, which imposes certain requirements, including mandatory contractual terms, on covered entities subject to the rule, such as health plans, healthcare clearinghouses and certain healthcare providers, as well as their respective business associates and their subcontractors that perform services for them that involve the use, or disclosure of, individually identifiable health information, relating to the privacy, security, and transmission of such individually identifiable health information;
the federal transparency requirements under the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies to report to the Department of Health and Human Services, or HHS, information related to payments and other transfers of value to physicians, as defined by such law, and teaching hospitals and other covered recipients and ownership and investment interests held by healthcare providers and their immediate family members and applicable group purchasing organizations, and, beginning in 2022, will require applicable manufacturers to report information regarding payments and other transfers of value provided during the previous year to physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists, anesthesiologist assistants, and certified nurse midwives; and
analogous state laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payers, including private insurers, and certain state laws that require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to report information related to drug pricing and payments to physicians and other healthcare providers or marketing expenditures and state and local laws that require the registration of sales representatives; and state and foreign laws governing the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.

81


 

Efforts to ensure that any business arrangements we have with third parties, and our business generally, will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, individual imprisonment, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, exclusion of products from government funded healthcare programs, such as Medicare and Medicaid, disgorgement, contractual damages, reputational harm, and the curtailment or restructuring of our operations. Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. Further, if any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.

Current and future legislation may increase the difficulty and cost for us and any collaborators to obtain marketing approval and commercialize our product candidates and affect the prices we, or they, may obtain.

In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could, among other things, prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability, or the ability of any collaborators, to profitably sell or commercialize any product candidate for which we, or they, obtain marketing approval. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we, or any collaborators, may receive for any approved products.

In March 2010, President Obama signed into law the PPACA. In addition, other legislative changes have been proposed and adopted since the PPACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation’s automatic reduction to several government programs. These changes included aggregate reductions to Medicare payments to providers of up to two percent per fiscal year, which went into effect in April 2013 and will remain in effect through 2031. Pursuant to the CARES Act and subsequent legislation, these Medicare sequester reductions were suspended through the end of June 2022 but the full 2% cut resumed thereafter on July 1, 2022.The American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used.

Since enactment of the PPACA, there have been, and continue to be, numerous legal challenges and Congressional actions to repeal and replace provisions of the law. For example, the Tax Act repealed the “individual mandate.” The repeal of this provision, which requires most Americans to carry a minimal level of health insurance, became effective in 2019. Further, on December 14, 2018, a U.S. District Court judge in the Northern District of Texas ruled that the individual mandate portion of the PPACA is an essential and inseverable feature of the PPACA, and therefore because the mandate was repealed as part of the Tax Act, the remaining provisions of the PPACA are invalid as well. However, on June 17, 2021, the U.S. Supreme Court dismissed the case and sustained the PPACA. Litigation and legislation over the PPACA are likely to continue, with unpredictable and uncertain results.

The former Trump presidential administration also took executive actions to undermine or delay implementation of the PPACA, including directing federal agencies with authorities and responsibilities under the PPACA to waive, defer, grant exemptions from, or delay the implementation of any provision of the PPACA that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. On January 28, 2021, however, President Biden revoked those orders and issued a new Executive Order which directs federal agencies to reconsider rules and other policies that limit Americans’ access to health care, and consider actions that will protect and strengthen that access. Under this Executive Order, federal agencies are directed to re-examine: policies that undermine protections for people with pre-existing conditions, including complications related to COVID-19; demonstrations and waivers under Medicaid and the PPACA that may reduce coverage or undermine the programs, including work requirements; policies that undermine the Health Insurance Marketplace or other markets for health insurance; policies that make it more difficult to enroll in Medicaid and the PPACA; and policies that reduce

82


 

affordability of coverage or financial assistance, including for dependents. This Executive Order also directs the HHS to create a special enrollment period for the Health Insurance Marketplace in response to the COVID-19 pandemic.

We expect that these healthcare reform measures, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product and/or the level of reimbursement physicians receive for administering any approved product we might bring to market. Reductions in reimbursement levels may negatively impact the prices we receive or the frequency with which our products are prescribed or administered. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. Accordingly, such reforms, if enacted, could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which we may obtain marketing approval and may affect our overall financial condition and ability to develop or commercialize product candidates. It is also possible that additional governmental action will be taken in response to the COVID-19 pandemic.

The prices of prescription pharmaceuticals in the United States and foreign jurisdictions is subject to considerable legislative and executive actions and could impact the prices we obtain for our products, if and when licensed.

The prices of prescription pharmaceuticals have also been the subject of considerable discussion in the United States. There have been several recent U.S. congressional inquiries, as well as proposed and enacted state and federal legislation designed to, among other things, bring more transparency to pharmaceutical pricing, review the relationship between pricing and manufacturer patient programs, reduce the prices of pharmaceuticals under Medicare and Medicaid. Congress continues to consider various legislative measures to limit the costs of prescription drugs, including authorizing Medicare to negotiate the prices of certain pharmaceuticals with manufacturers each year, capping beneficiary out-of-pocket Part D drug costs at $2,000 a year, and penalizing drug manufacturers for price hikes that outpace inflation.

At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional health care organizations and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.

In the European Union, similar political, economic and regulatory developments may affect our ability to profitably commercialize our product candidates, if approved. In markets outside of the United States and the European Union, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. In some countries, particularly the countries of the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed, possibly materially.

We are subject to stringent privacy laws, information security laws, regulations, policies and contractual obligations related to data privacy and security and changes in such laws, regulations, policies, contractual obligations, and the failure to comply with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition or results of operations.

We are subject to data privacy and protection laws and regulations that apply to the collection, transmission, storage and use of personally-identifying information, which among other things, impose certain requirements relating to the privacy, security and transmission of personal information, including comprehensive regulatory systems in the United States, European Union and United Kingdom. The legislative and regulatory landscape for privacy and data protection continues to evolve in jurisdictions worldwide, and there has been an increasing focus on privacy and data protection issues with the potential to affect our business. Failure to comply with any of these laws and regulations could result in enforcement action against us, including fines, imprisonment of company officials and public censure, claims for damages by affected individuals, damage to our reputation and loss of goodwill, any of which could have a material adverse effect on our business, financial condition, results of operations or prospects.

83


 

There are numerous U.S. federal and state laws and regulations related to the privacy and security of personal information. In particular, regulations promulgated pursuant to HIPAA establish privacy and security standards that limit the use and disclosure of individually identifiable health information, or protected health information, and require the implementation of administrative, physical and technological safeguards to protect the privacy of protected health information and ensure the confidentiality, integrity and availability of electronic protected health information. Determining whether protected health information has been handled in compliance with applicable privacy standards and our contractual obligations can be complex and may be subject to changing interpretation. These obligations may be applicable to some or all of our business activities now or in the future.

If we are unable to properly protect the privacy and security of protected health information, we could be found to have breached certain contracts with our business partners. Further, if we fail to comply with applicable privacy laws, including applicable HIPAA privacy and security standards, we could face civil and criminal penalties. HHS enforcement activity can result in financial liability and reputational harm, and responses to such enforcement activity can consume significant internal resources. In addition, state attorneys general are authorized to bring civil actions seeking either injunctions or damages in response to violations that threaten the privacy of state residents. We cannot be sure how these regulations will be interpreted, enforced or applied to our operations. In addition to the risks associated with enforcement activities and potential contractual liabilities, our ongoing efforts to comply with evolving laws and regulations at the federal and state level may be costly and require ongoing modifications to our policies, procedures and systems.

In 2018, California passed into law the CCPA, which took effect on January 1, 2020 and imposed many requirements on businesses that process the personal information of California residents. Many of the CCPA’s requirements are similar to those found in the GDPR, including requiring businesses to provide notice to data subjects regarding the information collected about them and how such information is used and shared, and providing data subjects the right to request access to such personal information and, in certain cases, request the erasure of such personal information. The CCPA also affords California residents the right to opt-out of “sales” of their personal information. The CCPA contains significant penalties for companies that violate its requirements. On November 3, 2020, California voters passed the CPRA, which will significantly expand the CCPA to incorporate additional GDPR-like provisions including requiring that the use, retention, and sharing of personal information of California residents be reasonably necessary and proportionate to the purposes of collection or processing, granting additional protections for sensitive personal information, and requiring greater disclosures related to notice to residents regarding retention of information. Most CPRA provisions will take effect on January 1, 2023, though the obligations will apply to any personal information collected after January 1, 2022. These provisions may apply to some of our business activities. In addition, other states, including Virginia and Colorado, already have passed state privacy laws. Other states will be considering these laws in the future. These laws may impact our business activities, including our identification of research subjects, relationships with business partners and ultimately the marketing and distribution of our products.

Similar to the laws in the United States, there are significant privacy and data security laws that apply in Europe and other countries. The collection, use, disclosure, transfer, or other processing of personal data, including personal health data, regarding individuals who are located in the European Economic Area, or EEA, and the processing of personal data that takes place in the EEA, is regulated by the GDPR, which went into effect in May 2018 and imposes obligations on companies that operate in our industry with respect to the processing of personal data and the cross-border transfer of such data. The GDPR imposes onerous accountability obligations requiring data controllers and processors to maintain a record of their data processing and policies. If our or our partners’ or service providers’ privacy or data security measures fail to comply with the GDPR requirements, we may be subject to litigation, regulatory investigations, enforcement notices requiring us to change the way we use personal data and/or fines of up to 20 million Euros or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, as well as compensation claims by affected individuals, negative publicity, reputational harm and a potential loss of business and goodwill.

The GDPR places restrictions on the cross-border transfer of personal data from the EU to countries that have not been found by the European Commission to offer adequate data protection legislation, such as the United States. There are ongoing concerns about the ability of companies to transfer personal data from the EU to other countries. In July 2020, the Court of Justice of the European Union, or CJEU, invalidated the EU-U.S. Privacy Shield, one of the mechanisms used to legitimize the transfer of personal data from the EEA to the U.S. The CJEU’s decision also drew into question the long-term viability of an alternative means of data transfer, the standard contractual clauses, for transfers of personal data from the EEA to the U.S. While we were not self-certified under the EU-U.S. Privacy Shield, this CJEU decision may lead to increased scrutiny on data transfers from the EEA to the U.S. generally and increase our costs of compliance with data privacy legislation as well as our costs of negotiating appropriate privacy and security agreements with our vendors and business partners.

Following the withdrawal of the United Kingdom from the European Union, the United Kingdom’s Data Protection Act 2018, which “implements” and complements the GDPR and achieved Royal Assent on May 23, 2018, applies to the processing of personal data that takes place in the United Kingdom and includes parallel obligations to those set forth by

84


 

GDPR. While the Data Protection Act of 2018 is now effective in the United Kingdom, it is still unclear whether transfer of data from the EEA to the United Kingdom will remain lawful under GDPR. The United Kingdom has already determined that it considers all European Union and EEA member states to be adequate for the purposes of data protection, ensuring that data flows from the United Kingdom to the European Union and EEA remain unaffected. In addition, a recent decision from the European Commission appears to deem the United Kingdom as being “essentially adequate” for purposes of data transfer from the European Union to the United Kingdom, although this decision may be re-evaluated in the future.

Beyond GDPR, there are privacy and data security laws in a growing number of countries around the world. While many loosely follow GDPR as a model, other laws contain different or conflicting provisions. These laws will impact our ability to conduct our business activities, including both our clinical trials and any eventual sale and distribution of commercial products, through increased compliance costs, costs associated with contracting and potential enforcement actions.

While we continue to address the implications of the recent changes to data privacy regulations, data privacy remains an evolving landscape at both the domestic and international level, with new regulations coming into effect and continued legal challenges, and our efforts to comply with the evolving data protection rules may be unsuccessful. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our practices. We must devote significant resources to understanding and complying with this changing landscape. Failure to comply with laws regarding data protection would expose us to risk of enforcement actions taken by data protection authorities in the EEA and elsewhere and carries with it the potential for significant penalties if we are found to be non-compliant. Similarly, failure to comply with federal and state laws in the United States regarding privacy and security of personal information could expose us to penalties under such laws. Any such failure to comply with data protection and privacy laws could result in government-imposed fines or orders requiring that we change our practices, claims for damages or other liabilities, regulatory investigations and enforcement action, litigation and significant costs for remediation, any of which could adversely affect our business. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our reputation and our business, financial condition, results of operations or prospects.

Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.

We are exposed to the risk of fraud or other misconduct by our employees, vendors, consultants and partners, and, for our clinical trials, our principal investigators and CROs. Misconduct by these parties could include intentional failures to comply with FDA regulations or the regulations applicable in the European Union and other jurisdictions, provide accurate information to the FDA, the European Commission, and other regulatory authorities, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately, or disclose unauthorized activities to us. In particular, sales, marketing, and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs, and other business arrangements. Such misconduct also could involve the improper use of information obtained in the course of clinical trials or interactions with the FDA or other regulatory authorities, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of conduct applicable to all of our employees, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, financial condition, results of operations and prospects, including the imposition of significant fines or other sanctions.

Laws and regulations governing any international operations we may have in the future may preclude us from developing, manufacturing and selling certain product candidates outside of the United States and require us to develop and implement costly compliance programs.

We are subject to numerous laws and regulations in each jurisdiction outside the United States in which we operate. The creation, implementation and maintenance of international business practices compliance programs is costly and such programs are difficult to enforce, particularly where reliance on third parties is required.

The Foreign Corrupt Practices Act, or FCPA, prohibits any U.S. individual or business from paying, offering, authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party, or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of

85


 

internal accounting controls for international operations. The anti-bribery provisions of the FCPA are enforced primarily by the DOJ. The SEC is involved with enforcement of the books and records provisions of the FCPA.

Compliance with the FCPA and other anti-corruption laws potentially applicable to our business is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the compliance with the FCPA and other anti-corruption laws presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions.

We are also subject to other laws and regulations governing our international operations, including applicable export control laws, economic sanctions on countries and persons, and customs requirements. In addition, various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain non-U.S. nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. Our expansion outside of the United States has required, and will continue to require, us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain drugs and drug candidates outside of the United States, which could limit our growth potential and increase our development costs.

There is no assurance that we will be completely effective in ensuring our compliance with the FCPA and other applicable anti-corruption, export, sanctions, and customs laws. The failure to comply with laws governing international business practices may result in substantial penalties, including suspension or debarment from government contracting. Violations of these laws, including the FCPA, can result in significant civil and criminal penalties. Indictment alone under the FCPA can lead to suspension of the right to do business with the U.S. government until the pending claims are resolved. Conviction of a violation of the FCPA can result in long-term disqualification as a government contractor. The termination of a government contract or relationship as a result of our failure to satisfy any of our obligations under laws governing international business practices would have a negative impact on our operations and harm our reputation and ability to procure government contracts. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA’s accounting provisions.

If we or any third-party manufacturer we engage now or in the future fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs or liabilities that could have a material adverse effect on our business.

We and third-party manufacturers we engage now are, and any third-party manufacturer we may engage in the future will be, subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.

Although we maintain general liability insurance as well as workers’ compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.

In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or commercialization efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.

Further, with respect to the operations of our current and any future third-party contract manufacturers, it is possible that if they fail to operate in compliance with applicable environmental, health and safety laws and regulations or properly dispose of wastes associated with our products, we could be held liable for any resulting damages, suffer reputational harm or experience a disruption in the manufacture and supply of our product candidates or products. In addition, our supply chain may be adversely impacted if any of our third-party contract manufacturers become subject to injunctions or other sanctions as a result of their non-compliance with environmental, health and safety laws and regulations.

86


 

Risks related to employee matters and managing growth

Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.

We are highly dependent on the research and development, clinical, financial, operational and other business expertise of Sekar Kathiresan, M.D., our chief executive officer, Andrew Ashe, J.D., our president, chief operating officer and general counsel, Allison Dorval, our chief financial officer, and Andrew Bellinger, M.D., Ph.D., our chief scientific officer and chief medical officer, as well as the other principal members of our management, scientific and clinical teams. Although we have entered into employment agreements with our executive officers, each of them may terminate their employment with us at any time. We do not maintain “key person” insurance for any of our executives or other employees. Recruiting and retaining qualified scientific, clinical, manufacturing, accounting, legal and sales and marketing personnel will also be critical to our success.

The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain marketing approval of and commercialize products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. Our success also depends on implementing and maintaining internal controls and the accuracy and timeliness of our financial reporting. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited.

We expect to expand our development and regulatory capabilities and potentially implement sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.

As our development progresses, we expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of drug development, clinical, regulatory affairs, manufacturing and quality control and, if any of our product candidates receive marketing approval, sales, marketing and distribution. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.

Future acquisitions or strategic alliances could disrupt our business and harm our financial condition and results of operations.

We may acquire additional businesses, technologies or assets, form strategic alliances or create joint ventures with third parties that we believe will complement or augment our existing business. If we acquire businesses with promising markets or technologies, we may not be able to realize the benefit of acquiring such businesses if we are unable to successfully integrate them with our existing operations and company culture. We may encounter numerous difficulties in developing, manufacturing and marketing any new products or product candidates resulting from a strategic alliance or acquisition that may delay or prevent us from realizing their expected benefits or enhancing our business. We cannot assure our stockholders that, following any such acquisition, we will achieve the expected synergies to justify the transaction. The risks we face in connection with acquisitions include:

diversion of management time and focus from operating our business to addressing acquisition integration challenges;
coordination of research and development efforts;
retention of key employees from the acquired company;
changes in relationships with collaborators as a result of product acquisitions or strategic positioning resulting from the acquisition;

87


 

cultural challenges associated with integrating employees from the acquired company into our organization;
the need to implement or improve controls, procedures and policies at a business that prior to the acquisition may have lacked sufficiently effective controls, procedures and policies;
liability for activities of the acquired company before the acquisition, including intellectual property infringement claims, violation of laws, commercial disputes, tax liabilities and other known liabilities;
unanticipated write-offs or charges; and
litigation or other claims in connection with the acquired company, including claims from terminated employees, customers, former stockholders or other third parties.

Our failure to address these risks or other problems encountered in connection with our past or future acquisitions or strategic alliances could cause us to fail to realize the anticipated benefits of these transactions, cause us to incur unanticipated liabilities and harm the business generally. There is also a risk that future acquisitions will result in the incurrence of debt, contingent liabilities, amortization expenses or incremental operating expenses, any of which could harm our financial condition or results of operations.

Our internal information technology systems, or those of our collaborators, vendors or other contractors or consultants, may fail or suffer security breaches, loss of data and other disruptions, which could result in a material disruption of our product development programs, compromise sensitive information related to our business or prevent us from accessing critical information, trigger contractual and legal obligations, potentially exposing us to liability, reputational harm or otherwise adversely affecting our business and financial results.

We are dependent upon information technology systems, infrastructure and data to operate our business. In the ordinary course of business, we collect, store and transmit confidential information, including but not limited to intellectual property, proprietary business information and personal information. It is critical that we, our vendors, collaborators or other contractors or consultants, do so in a secure manner to maintain the availability, security, confidentiality, privacy and integrity of such confidential information.

Despite the implementation of security measures, our internal information technology systems and those of any collaborators, vendors, contractors or consultants are vulnerable to damage or interruption from computer viruses, computer hackers, malicious code, employee error, theft or misuse, denial-of-service attacks, sophisticated nation-state and nation-state-supported actors, unauthorized access, natural disasters, terrorism, wars or other armed conflict, telecommunication and electrical failures or other compromise. There could be an increase in cybersecurity attacks generally as a result of the ongoing conflict between Russia and Ukraine and the resulting sanctions imposed by the United States and European governments, together with any additional future sanctions or other actions by them.

Cyber-attacks are increasing in their frequency, sophistication and intensity, and have become increasingly difficult to detect. Cyber-attacks could include the deployment of harmful malware, ransomware, denial-of-service attacks, unauthorized access to or deletion of files, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information. Cyber-attacks also could include phishing attempts or e-mail fraud to cause payments or information to be transmitted to an unintended recipient. We may not be able to anticipate all types of security threats, and we may not be able to implement preventive measures effective against all such security threats. The techniques used by cyber criminals change frequently, may not be recognized until launched, and can originate from a wide variety of sources, including outside groups such as external service providers, organized crime affiliates, terrorist organizations or hostile foreign governments or agencies. We cannot guarantee that the measures we have taken to date, and actions we may take in the future, will be sufficient to prevent any future breaches.

To the extent we experience a material system failure, accident, cyber-attack or security breach, it could result in a material disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary or confidential information or other disruptions. For example, the loss of clinical trial data from ongoing or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. If we do not allocate and effectively manage the resources necessary to build and sustain the proper technology and cybersecurity infrastructure, we could suffer significant business disruption, including transaction errors, supply chain or manufacturing interruptions, processing inefficiencies, data loss or the loss of or damage to intellectual property or other proprietary information.

To the extent that any disruption or security breach were to result in a loss of, or damage to, our or our vendors’, collaborators’ or other contractors’ or consultants’ data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, including litigation exposure, penalties and fines, we could become the subject of regulatory action or investigation, our competitive position and reputation could be harmed and the further development and commercialization of our product candidates could be delayed. As a result of such an event, we may be

88


 

in breach of our contractual obligations. Furthermore, any such event that leads to unauthorized access, use, or disclosure of personal information, including personal information regarding our customers or employees, could harm our reputation, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action, and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information, which could result in significant legal and financial exposure and reputational damages. Any of the above could have a material adverse effect on our business, financial condition, results of operations or prospects.

The financial exposure from the events referenced above could either not be insured against or not be fully covered through any insurance that we maintain and could have a material adverse effect on our business, financial condition, results of operations or prospects. In addition, we cannot be sure that our existing insurance coverage will continue to be available on acceptable terms or that our insurers will not deny coverage as to any future claim. There can be no assurance that the limitations of liability in our contracts would be enforceable or adequate or would otherwise protect us from liabilities or damages as a result of the events referenced above.

Risks related to ownership of our common stock and our status as a public company

Our executive officers, directors and their affiliates, if they choose to act together, will have the ability to significantly influence all matters submitted to stockholders for approval.

Our executive officers and directors and their affiliates, in the aggregate, beneficially owned shares representing approximately 21.8% of our common stock as of August 4, 2022. As a result, if these stockholders were to choose to act together, they would effectively be able to significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, could significantly influence the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets.

This concentration of ownership control may:

delay, defer or prevent a change in control;
entrench our management and board of directors; or
delay or prevent a merger, consolidation, takeover or other business combination involving us that other stockholders may desire.

Provisions in our corporate charter documents and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current directors and members of management.

Provisions in our restated certificate of incorporation and our amended and restated bylaws may discourage, delay or prevent a merger, acquisition or other change in control of our company that stockholders may consider favorable, including transactions in which our stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:

establish a classified board of directors such that only one of three classes of directors is elected each year;
allow the authorized number of our directors to be changed only by resolution of our board of directors;
limit the manner in which stockholders can remove directors from our board of directors;
establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors;
require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent;
limit who may call stockholder meetings;
authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a “poison pill” that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and

89


 

require the approval of the holders of at least 75% of the votes that all our stockholders would be entitled to cast to amend or repeal specified provisions of our restated certificate of incorporation or amended and restated bylaws.

Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, or the DGCL, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.

An active trading market for our common stock may not continue to develop or be sustained.

Our common stock began trading on the Nasdaq Global Select Market on June 17, 2021. Given the limited trading history of our common stock, there is a risk that an active trading market for our shares may not continue to develop or be sustained. If an active market for our common stock does not continue to develop or is not sustained, it may be difficult for our stockholders to sell their shares without depressing the market price for the shares, or at all.

If securities analysts do not publish or cease publishing research or reports or publish misleading, inaccurate or unfavorable research about our business or if they publish negative evaluations of our stock, the price and trading volume of our stock could decline.

The trading market for our common stock relies, in part, on the research and reports that industry or financial analysts publish about us or our business. There can be no assurance that existing analysts will continue to cover us or that new analysts will begin to cover us. There is also no assurance that any covering analysts will provide favorable coverage. Although we have obtained analyst coverage, if one or more of the analysts covering our business downgrade their evaluations of our stock or publish inaccurate or unfavorable research about our business, or provides more favorable relative recommendations about our competitors, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price and trading volume to decline.

The price of our common stock has been volatile and may fluctuate substantially, which could result in substantial losses for our stockholders.

Our stock price has been and is likely to continue to be volatile. The stock market in general and the market for smaller biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, our stockholders may not be able to sell their common stock at or above the price they paid for their shares. The market price for our common stock may be influenced by many factors, including:

timing and results of or developments in preclinical studies and clinical trials of our product candidates or those of our competitors or potential collaborators;
adverse regulatory decisions, including failure to receive regulatory approvals for any of our product candidates;
our success in commercializing our product candidates, if and when approved;
developments with respect to competitive products or technologies;
regulatory or legal developments in the United States and other countries;
developments or disputes concerning patent applications, issued patents or other intellectual property or proprietary rights;
the recruitment or departure of key personnel;
the level of expenses related to any of our product candidates or clinical development programs;
the results of our efforts to discover, develop, acquire or in-license products, product candidates, technologies, the costs of commercializing any such products and the costs of development of any such product candidates or technologies;
actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;
variations in our financial results or the financial results of companies that are perceived to be similar to us;
sales of common stock by us, our executive officers, directors or principal stockholders, or others;

90


 

changes in the structure of healthcare payment systems;
market conditions in the pharmaceutical and biotechnology sectors;
general economic, industry and market conditions, such as the impact of the COVID-19 pandemic on our industry and market conditions; and
the other factors described in this “Risk factors” section.

In the past, following periods of volatility in the market price of a company’s securities, securities class-action litigation has often been instituted against that company. Any lawsuit to which we are a party, with or without merit, may result in an unfavorable judgment. We also may decide to settle lawsuits on unfavorable terms. Any such negative outcome could result in payments of substantial damages or fines, damage to our reputation or adverse changes to our offerings or business practices. Such litigation may also cause us to incur other substantial costs to defend such claims and divert management’s attention and resources. Furthermore, negative public announcements of the results of hearings, motions or other interim proceedings or developments could have a negative effect on the market price of our common stock.

We have broad discretion in the use of our cash and cash equivalents and may not use them effectively.

Our management has broad discretion in the application of our cash and cash equivalents and could use such funds in ways that do not improve our results of operations or enhance the value of our common stock. The failure by our management to apply these funds effectively could result in financial losses that could have a material adverse effect on our business, cause the price of our common stock to decline and delay the development of our product candidates. Pending their use, we may invest these funds in a manner that does not produce income or that loses value.

A significant portion of our total outstanding shares are eligible to be sold into the market in the near future, which could cause the market price of our common stock to drop significantly, even if our business is doing well.

Sales of a substantial number of shares of our common stock in the public market, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. Persons who were our stockholders prior to our IPO continue to hold a substantial number of shares of our common stock. If such persons sell, or indicate an intention to sell, substantial amounts of our common stock in the public market, the trading price of our common stock could decline.

In addition, certain of our executive officers, directors and stockholders affiliated with our directors have entered or may enter into Rule 10b5-1 plans providing for sales of shares of our common stock from time to time. Under a Rule 10b5-1 plan, a broker executes trades pursuant to parameters established by the executive officer, director or affiliated stockholder when entering into the plan, without further direction from the executive officer, director or affiliated stockholder. A Rule 10b5-1 plan may be amended or terminated in some circumstances. Our executive officers, directors and stockholders affiliated with our directors also may buy or sell additional shares outside of a Rule 10b5-1 plan when they are not in possession of material, nonpublic information.

Moreover, holders of a substantial number of shares of our common stock have rights, subject to specified conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. We have also filed a registration statement on Form S-8 to register all of the shares of common stock that we were able to issue under our equity compensation plans as of June 17, 2021 and we filed a registration statement on Form S-8 to register the additional 2,910,704 shares of our common stock that became issuable under our equity compensation plans on January 1, 2022. Shares registered under these registration statements on Form S-8 can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates, vesting arrangements, and exercise of options.

We are an “emerging growth company” and the reduced disclosure requirements applicable to emerging growth companies may make our common stock less attractive to investors.

We are an “emerging growth company,” or EGC, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. We may remain an EGC until the end of 2026, although if the market value of our common stock that is held by non-affiliates exceeds $700 million as of any June 30 before that time or if we have annual gross revenues of $1.07 billion or more in any fiscal year, we would cease to be an EGC as of December 31 of the applicable year. We also would cease to be an EGC if we issue more than $1 billion of non-convertible debt over a three-year period. For so long as we remain an EGC, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not EGCs. These exemptions include:

not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting;

91


 

not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements;
reduced disclosure obligations regarding executive compensation; and
exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

We cannot predict whether investors will find our common stock less attractive if we rely on certain or all of these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.

In addition, the JOBS Act permits an EGC to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have elected not to “opt out” of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we will adopt the new or revised standard at the time private companies adopt the new or revised standard and will do so until such time that we either (i) irrevocably elect to “opt out” of such extended transition period or (ii) no longer qualify as an EGC.

We have incurred and will continue to incur increased costs as a result of operating as a public company, and our management has devoted and will continue to be required to devote substantial time to new compliance initiatives and corporate governance practices.

As a public company, we have incurred and particularly after we are no longer an EGC, we will continue to incur significant legal, accounting and other expenses that we did not previously incur as a private company. The Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of the Nasdaq Global Select Market and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel devote and will need to continue to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs, particularly as we hire additional financial and accounting employees to meet public company internal control and financial reporting requirements, and will make some activities more time-consuming and costly compared to when we were a private company. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance, which in turn could make it more difficult for us to attract and retain qualified members of our board of directors.

We are evaluating these rules and regulations and cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.

Pursuant to Section 404, we will be required to furnish a report by our management on our internal control over financial reporting beginning with our filing of an Annual Report on Form 10-K with the SEC for the year ended December 31, 2022. However, while we remain an EGC, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section 404 within the prescribed period, we are engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, including through hiring additional financial and accounting personnel, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by Section 404. If we identify one or more material weaknesses in our internal control over financial reporting, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.

92


 

Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be our stockholders' sole source of gain.

We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. As a result, capital appreciation, if any, of our common stock will be our stockholders' sole source of gain for the foreseeable future.

Our restated certificate of incorporation designates the Court of Chancery of the State of Delaware and the federal district courts of the United States of America as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers and employees.

Our restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery of the State of Delaware does not have jurisdiction, the federal district court for the District of Delaware) will be the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law:

any derivative action or proceeding brought on our behalf;
any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, employees or stockholders to our company or our stockholders;
any action asserting a claim arising pursuant to any provision of the DGCL or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware; or
any action asserting a claim arising pursuant to any provision of our restated certificate of incorporation or amended and restated bylaws (in each case, as they may be amended from time to time) or governed by the internal affairs doctrine.

These choice of forum provisions will not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted by law, be the sole and exclusive forum for the resolution of any claims arising under the Securities Act. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.

These exclusive forum provisions may limit the ability of our stockholders to bring a claim in a judicial forum that such stockholders find favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees. If a court were to find either exclusive forum provision contained in our restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving such action in other jurisdictions, all of which could materially adversely affect our business, financial condition and results of operations.

General risk factors

Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.

We are subject to certain reporting requirements of the Exchange Act. Our disclosure controls and procedures are designed to reasonably assure that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to management, recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements or insufficient disclosures due to error or fraud may occur and not be detected.

93


 

Changes in tax laws or in their implementation or interpretation may adversely affect our business and financial condition.

Changes in tax law may adversely affect our business or financial condition. On December 22, 2017, the U.S. government enacted the Tax Act, which significantly reformed the Code. The Tax Act, as amended by the CARES Act, among other things, contains significant changes to corporate taxation, including reducing the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, limiting the tax deduction for net interest expense to 30% of adjusted taxable income (except for certain small businesses), limiting the deduction for NOLs arising in taxable years beginning after December 31, 2017 to 80% of current year taxable income in tax years beginning after December 31, 2020 and eliminating NOL carrybacks for losses arising in taxable years ending after December 31, 2017 (though any such NOLs may be carried forward indefinitely and such NOLs arising in taxable years beginning before January 1, 2021 are generally eligible to be carried back up to five years), imposing a one-time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, eliminating U.S. tax on foreign earnings (subject to certain important exceptions), allowing immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits.

In addition to the CARES Act, as part of Congress’ response to the COVID-19 pandemic, economic relief legislation has been enacted in 2020 and 2021 containing tax provisions. Regulatory guidance under the Tax Act and such additional legislation is and continues to be forthcoming, and such guidance could ultimately increase or lessen their impact on our business and financial condition. Also, as a result of the changes in the U.S. presidential administration and control of the U.S. Senate, additional tax legislation may be enacted; any such additional legislation could have an impact on us. In addition, it is uncertain if and to what extent various states will conform to the Tax Act and additional tax legislation. We urge prospective investors in our common stock to consult with their legal and tax advisors with respect to any recently enacted tax legislation, or proposed changes in law, and the potential tax consequences of investing in or holding our common stock.

Unfavorable global economic conditions could adversely affect our business, financial condition, stock price and results of operations.

Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets and uncertainty about economic stability. The global economy and financial markets may also be adversely affected by the current or anticipated impact of military conflict, including the conflict between Russia and Ukraine, terrorism or other geopolitical events. Sanctions imposed by the United States and other countries in response to such conflicts, including the sanctions relating to Russia, may also adversely impact the financial markets and the global economy, and the economic countermeasures by the affected countries or others could exacerbate market and economic instability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. A severe or prolonged economic downturn could result in a variety of risks to our business, including weakened demand for any product candidates we may develop and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption. If the equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly, and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could impair our ability to achieve our growth strategy, could harm our financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that our current or future service providers, manufacturers or other collaborators may not survive such difficult economic times, which could directly affect our ability to attain our operating goals on schedule and on budget. We cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.

94


 

Item 2. Unregistered sales of equity securities and use of proceeds

 

Recent sales of unregistered securities

None.

Use of proceeds from registered securities

On June 21, 2021, we completed our IPO pursuant to a Registration Statement on Form S-1 (File No. 333-256608), which was declared effective by the SEC on June 16, 2021 and Form S-1 (File No. 333-257158), which was filed pursuant to Rule 462(b) of the Securities Act and was declared effective by the SEC on June 16, 2021.

The net offering proceeds to us, after deducting underwriting discounts and offering expenses payable by us of $25.1 million, were $281.6 million. As of June 30, 2022, we had not used any of the net proceeds from the IPO. We have invested the net proceeds from the offering in money market funds and short-term investments. There has been no material change in our planned use of the net proceeds from our IPO as described in our final prospectus, dated June 16, 2021, filed with the SEC pursuant to Rule 424(b).

 

95


 

 

Item 6. Exhibits

 

Exhibit

Number

 

Description

 

 

 

3.1

 

Restated Certificate of Incorporation of Verve Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed with the SEC on June 21, 2021).

 

 

 

3.2

 

Amended and Restated Bylaws of Verve Therapeutics, Inc. (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K, filed with the SEC on June 21, 2021).

 

 

 

10.1

 

Open Market Sale AgreementSM, dated as of July 1, 2022, by and between the Registrant and Jefferies LLC (incorporated by reference to Exhibit 1.2 to the Company’s Registration Statement on Form S-3, filed with the SEC on July 1, 2022).

 

 

 

10.2*

 

Second Amendment to Lease, dated as of June 17, 2022, by and between the Registrant and ARE-MA Region No. 87 Tenant, LLC

 

 

 

31.1*

 

Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

 

 

31.2*

 

Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

 

 

32.1+

 

Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

32.2+

 

Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

101.INS

 

Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document

 

 

 

101.SCH

 

Inline XBRL Taxonomy Extension Schema Document

 

 

 

101.CAL

 

Inline XBRL Taxonomy Extension Calculation Linkbase Document

 

 

 

101.DEF

 

Inline XBRL Taxonomy Extension Definition Linkbase Document

 

 

 

101.LAB

 

Inline XBRL Taxonomy Extension Label Linkbase Document

 

 

 

101.PRE

 

Inline XBRL Taxonomy Extension Presentation Linkbase Document

 

 

 

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

* Filed herewith.

+ Furnished herewith.

96


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

VERVE THERAPEUTICS, INC.

 

 

 

 

Date: August 9, 2022

 

By:

/s/ Sekar Kathiresan

 

 

 

Sekar Kathiresan, M.D.

 

 

 

Chief Executive Officer

 

 

 

 Principal Executive Officer

Date: August 9, 2022

 

By:

/s/ Allison Dorval

 

 

 

Allison Dorval

 

 

 

Chief Financial Officer

 

 

 

Principal Financial Officer

 

97


EX-10.2 2 verv-ex10_2.htm EX-10.2 EX-10.2

Exhibit 10.2

SECOND AMENDMENT TO LEASE

THIS SECOND AMENDMENT TO LEASE (this “Second Amendment”) is made as of June 17, 2022, by and between ARE-MA REGION NO. 87 TENANT, LLC, a Delaware limited liability company (“Landlord”), and VERVE THERAPEUTICS, INC., a Delaware corporation (“Tenant”).

RECITALS

A.
Landlord and Tenant are parties to that certain Lease Agreement dated as of August 19, 2021, as amended by that certain First Amendment to Lease dated as of January 4, 2022 (as amended, the “Lease”). Pursuant to the Lease, Tenant leases approximately 105,182 rentable square feet (the “Premises”), consisting of (i) the entire 2nd floor of that certain to-be-constructed 14-story building to be known as 201 Brookline Avenue, Boston, Massachusetts (the “Building”), commonly known as Suite 201, containing approximately 21,104 rentable square feet (the “Second Floor Premises”), (ii) the entire 6th floor of the Building, commonly known as Suite 601, containing approximately 41,662 rentable square feet, (iii) the entire 7th floor of the Building, commonly known as Suite 701, containing approximately 41,585 rentable square feet, (iv) a portion of the first floor of the Building, commonly known as Suite S113, containing approximately 371 rentable square feet of chemical storage space, and (v) mechanical space in a portion of the penthouse floor of the Building, commonly known as (i) Suite S1501, containing approximately 250 rentable square feet, and (ii) Suite S1502, containing approximately 210 rentable square feet. The Premises are more particularly described in the Lease. The balance of the Premises other than the Second Floor Premises may be referred to herein as the “Initial Premises”. Capitalized terms used herein without definition shall have the meanings defined for such terms in the Lease.
B.
Landlord and Tenant desire, subject to the terms and conditions set forth below, to, among other things, amend the Lease to provide for the phased Delivery of the Premises.

NOW, THEREFORE, in consideration of the foregoing Recitals, which are incorporated herein by this reference, the mutual promises and conditions contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Landlord and Tenant hereby agree as follows:

1.
Target Commencement Date. As of the date hereof, the defined term “Target Commencement Date” on page 1 of the Lease shall be deleted in their entirety and replaced with the following:

“Initial Premises Target Commencement Date: August 18, 2022

Second Floor Premises Target Commencement Date: October 1, 2022”

2.
Delivery; Acceptance of Premises; Commencement Date. As of the date hereof, Section 2 of the Lease shall be deleted in its entirety and replaced with the following:

 

1

 


“2. Delivery; Acceptance of Premises; Commencement Date.

(a)
Initial Premises. Landlord shall use reasonable efforts to deliver the Initial Premises to Tenant (“Delivery” or “Deliver”) on or before the Initial Premises Target Commencement Date, with the Tenant Improvements in the Initial Premises Substantially Completed. If Landlord fails to timely Deliver the Initial Premises, Landlord shall not be liable to Tenant for any loss or damage resulting therefrom, and this Lease shall not be void or voidable except as provided herein. Notwithstanding anything to the contrary contained herein, if Landlord fails to Deliver the entirety of the Initial Premises to Tenant within 60 days after the Initial Premises Target Commencement Date (as such date may be extended by Force Majeure (as defined in Section 34) and Tenant Delays, the “Initial Premises Abatement Date”), Base Rent payable with respect to any the Initial Premises shall be permanently abated 1 day for each day after the Initial Premises Abatement Date that Landlord fails to Deliver the Initial Premises to Tenant. If Landlord does not Deliver the entirety of the Initial Premises within 180 days of the Initial Premises Target Commencement Date for any reason other than Force Majeure delays and Tenant Delays, this Lease may be terminated by Tenant by written notice to Landlord, and if so terminated by Tenant: (a) the Security Deposit, or any balance thereof (i.e., after deducting therefrom all amounts to which Landlord is entitled under the provisions of this Lease), shall be returned to Tenant, and (b) neither Landlord nor Tenant shall have any further rights, duties or obligations under this Lease, except with respect to provisions which expressly survive termination of this Lease. As used In this Section 2, the terms “Tenant Improvements,” “Tenant Delays” and “Substantially Completed” shall have the meanings set forth for such terms in the Work Letter. If Tenant does not elect to void this Lease within 10 business days of the lapse of such 180 day period, such right to void this Lease shall be waived and this Lease shall remain in full force and effect. To the extent that Tenant has not elected to void this Lease pursuant to the immediately preceding sentence, then each 60 days thereafter, if Landlord has not delivered the entirety of the Initial Premises for any reason other than Force Majeure delays and Tenant Delays, Tenant shall have the right (with 10 days after each such 60-day period) to terminate this Lease subject to the terms set forth above with respect to the initial 180 days period. Prior to the Substantial Completion of the Tenant Improvements in the entirety of the Initial Premises, within 5 days after receipt of written request from Tenant (not more than once in any calendar month), Landlord shall provide Tenant with a written status update regarding the then-currently anticipated Delivery date.

The “Commencement Date” shall be the earlier of: (i) the date Landlord Delivers the Initial Premises to Tenant; or (ii) the date Landlord could have Delivered the Initial Premises but for Tenant Delays. The “Rent Commencement Date” with respect to the Initial Premises shall be the date that is 90 days after the Commencement Date. The period commencing on the Commencement Date through the day immediately preceding the Rent Commencement Date may be referred to herein as the “Initial Premises Abatement Period.” Prior to the Second Floor Premises Commencement Date (as defined in Section 2(b) below), references in this Lease to the “Premises” shall mean the Initial Premises only.

Except as set forth in the Work Letter or as otherwise expressly set forth in this Lease: (x) Tenant shall accept the Initial Premises in their condition as of the

 

2

 


Commencement Date; (y) Landlord shall have no obligation for any defects in the Initial Premises; and (z) Tenant’s taking possession of the Initial Premises shall be conclusive evidence that Tenant accepts the Initial Premises and that the Initial Premises were in good condition at the time possession was taken. Any occupancy of the Initial Premises by Tenant before the Commencement Date shall be subject to all of the terms and conditions of this Lease, excluding, so long Tenant does not commence operating its business in all or a portion of the Initial Premises, the obligation to pay Base Rent and Operating Expenses. Tenant shall be entitled to receive the benefit of all construction warranties and manufacturer’s equipment warranties issued to Landlord as set forth in the Work Letter in connection with the Tenant Improvements.

(b)
Second Floor Premises. Landlord shall use reasonable efforts to Deliver the Second Floor Premises to Tenant on or before the Second Floor Premises Target Commencement Date, with the Tenant Improvements in the Second Floor Premises Substantially Completed. If Landlord fails to timely Deliver the Second Floor Premises, Landlord shall not be liable to Tenant for any loss or damage resulting therefrom, and this Lease shall not be void or voidable. Notwithstanding anything to the contrary contained herein, if Landlord fails to Deliver the entirety of the Second Floor Premises to Tenant within 60 days after the Second Floor Premises Target Commencement Date (as such date may be extended by Force Majeure and Tenant Delays, the “Second Floor Premises Abatement Date”), Base Rent payable with respect to the Second Floor Premises shall be permanently abated 2 days for each day after the Second Floor Premises Abatement Date that Landlord fails to Deliver the Second Floor Premises to Tenant. Prior to the Substantial Completion of the Tenant Improvements in the entirety of the Second Floor Premises, within 5 days after receipt of written request from Tenant (not more than once in any calendar month), Landlord shall provide Tenant with a written status update regarding the then-currently anticipated Delivery date.

The “Second Floor Premises Commencement Date” shall be the earlier of: (i) the date Landlord Delivers the Second Floor Premises to Tenant; or (ii) the date Landlord could have Delivered the Second Floor Premises but for Tenant Delays. The “Second Floor Premises Rent Commencement Date” with respect to the Second Floor Premises shall be the date that is 90 days after the Second Floor Premises Commencement Date. The period commencing on the Second Floor Premises Commencement Date through the day immediately preceding the Second Floor Premises Rent Commencement Date may be referred to herein as the “Second Floor Premises Abatement Period.”

Except as set forth in the Work Letter or as otherwise expressly set forth in this Lease: (x) Tenant shall accept the Second Floor Premises in their condition as of the Second Floor Premises Commencement Date; (y) Landlord shall have no obligation for any defects in the Second Floor Premises; and (z) Tenant’s taking possession of the Second Floor Premises shall be conclusive evidence that Tenant accepts the Second Floor Premises and that the Second Floor Premises were in good condition at the time possession was taken. Any occupancy of the Second Floor Premises by Tenant before the Commencement Date shall be subject to all of the terms and conditions of this Lease, excluding, so long Tenant does not commence operating its business in all or a portion of the Second Floor Premises, the obligation to pay Base Rent and Operating Expenses. Tenant shall be entitled to receive

 

3

 


the benefit of all construction warranties and manufacturer’s equipment warranties issued to Landlord as set forth in the Work Letter in connection with the Tenant Improvements.

(c)
General. Upon request of Landlord, Tenant shall execute and deliver a written acknowledgment of the Commencement Date, the Second Floor Commencement Date, the Rent Commencement Date, the Second Floor Rent Commencement Date, the expiration date of the Term and a schedule of Base Rent when such are established in the form of the “Acknowledgement of Commencement Date” attached to this Lease as Exhibit D; provided, however, Tenant’s failure to execute and deliver such acknowledgment shall not affect Landlord’s rights hereunder. The “Term” of this Lease shall be the Base Term, as defined above on the first page of this Lease and any Extension Terms which Tenant may elect pursuant to Section 40 hereof.

Tenant agrees and acknowledges that neither Landlord nor any agent of Landlord has made any representation or warranty with respect to the condition of all or any portion of the Premises or the Project, and/or the suitability of the Premises or the Project for the conduct of Tenant’s business, and Tenant waives any implied warranty that the Premises or the Project are suitable for the Permitted Use. This Lease constitutes the complete agreement of Landlord and Tenant with respect to the subject matter hereof and supersedes any and all prior representations, inducements, promises, agreements, understandings and negotiations which are not contained herein. Landlord in executing this Lease does so in reliance upon Tenant’s representations, warranties, acknowledgments and agreements contained herein.”

As of the date hereof, Exhibit D to the Lease shall be deleted in its entirety and replaced with Exhibit A to this Second Amendment.

3.
Operating Expenses. Notwithstanding anything to the contrary contained in the Lease, Tenant shall commence paying Operating Expenses with respect to the Initial Premises on the Commencement Date and with respect to the Second Floor Premises on the Second Floor Premises Commencement Date.
4.
Costs. Landlord and Tenant anticipate that certain costs in addition to the costs reflected in the Budget for the Tenant Improvements, as identified on Exhibit B attached to this Second Amendment (“Delay Costs”), will be incurred as a result of the delayed Delivery of the Second Floor Premises provided for in Section 2 above. Notwithstanding anything to the contrary contained in the Lease or in the Work Letter, Landlord shall be responsible for such Delay Costs and Landlord shall reimburse Tenant for such costs within thirty (30) days of the date on which Tenant submits to Landlord a request for reimbursement for the Delay Costs along with reasonable supporting documentation.
5.
OFAC. Tenant and all beneficial owners of Tenant are currently (a) in compliance with and shall at all times during the Term of the Lease remain in compliance with the regulations of the Office of Foreign Assets Control (“OFAC”) of the U.S. Department of Treasury and any statute, executive order, or regulation relating thereto (collectively, the “OFAC Rules”), (b) not listed on, and shall not during the term of the Lease be listed on, the Specially Designated Nationals and Blocked Persons List, Foreign Sanctions Evaders List, or the Sectoral Sanctions Identification List,

 

4

 


which are all maintained by OFAC and/or on any other similar list maintained by OFAC or other governmental authority pursuant to any authorizing statute, executive order, or regulation, and (c) not a person or entity with whom a U.S. person is prohibited from conducting business under the OFAC Rules.
6.
Brokers. Landlord and Tenant each represents and warrants that it has not dealt with any broker, agent or other person (collectively, “Broker”) in connection with the transaction reflected in this Second Amendment and that no Broker brought about this transaction, other than CBRE and Newmark. Landlord and Tenant each hereby agree to indemnify and hold the other harmless from and against any claims by any Broker, other than CBRE and Newmark, claiming a commission or other form of compensation by virtue of having dealt with Tenant or Landlord, as applicable, with regard to this Second Amendment.
7.
Miscellaneous.
a.
This Second Amendment is the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior and contemporaneous oral and written agreements and discussions. This Second Amendment may be amended only by an agreement in writing, signed by the parties hereto.
b.
This Second Amendment is binding upon and shall inure to the benefit of the parties hereto, their respective agents, employees, representatives, officers, directors, divisions, subsidiaries, affiliates, assigns, heirs, successors in interest and shareholders.
c.
This Second Amendment may be executed in 2 or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature process complying with the U.S. federal ESIGN Act of 2000) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. Electronic signatures shall be deemed original signatures for purposes of this Second Amendment and all matters related thereto, with such electronic signatures having the same legal effect as original signatures.
d.
Except as amended and/or modified by this Second Amendment, the Lease is hereby ratified and confirmed and all other terms of the Lease shall remain in full force and effect, unaltered and unchanged by this Second Amendment. Without limiting the generality of the foregoing, Landlord and Tenant acknowledge that nothing set forth in this Second Amendment shall alter or amend the Term and both the Initial Premises and Second Floor Premises shall expire conterminously upon the expiration or earlier termination of the Term in accordance with the provisions of the Lease. In the event of any conflict between the provisions of this Second Amendment and the provisions of the Lease, the provisions of this Second Amendment shall prevail. Whether or not specifically amended by this Second Amendment, all of the terms and provisions of the Lease are hereby amended to the extent necessary to give effect to the purpose and intent of this Second Amendment.

[ Signatures of following page ]

 

5

 


 

IN WITNESS WHEREOF, the parties hereto have executed this Second Amendment as of the day and year first above written.

LANDLORD: ARE-MA REGION NO. 87 TENANT, LLC,

a Delaware limited liability company

 

By: ARE-MA REGION NO. 87, LLC,

a Delaware limited liability company,

managing member

 

By: ARE-MA REGION NO. 87 MM, LLC,

a Delaware limited liability company,

managing member

 

By ALEXANDRIA REAL ESTATE EQUITIES, L.P.,

a Delaware limited partnership,

managing member

 

By: ARE-QRS CORP.,

a Maryland corporation,

general partner

 

By: /s/ Allison Grochola

Its: SVP – Real Estate Legal Affairs

 

 

 

TENANT: VERVE THERAPEUTICS, INC.,

a Delaware corporation

 

By: /s/ Andrew Ashe

Its: President & COO

I hereby certify that the signature, name, and title

Above are my signature, name and title.

 

6

 


EX-31.1 3 verv-ex31_1.htm EX-31.1 EX-31.1

 

Exhibit 31.1

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Sekar Kathiresan, certify that:

1.
I have reviewed this Quarterly Report on Form 10-Q of Verve Therapeutics, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(c)
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: August 9, 2022

 

By:

/s/ Sekar Kathiresan

 

 

 

Sekar Kathiresan, M.D.

 

 

 

Chief Executive Officer

(Principal Executive Officer)

 

 


EX-31.2 4 verv-ex31_2.htm EX-31.2 EX-31.2

 

Exhibit 31.2

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Allison Dorval, certify that:

1.
I have reviewed this Quarterly Report on Form 10-Q of Verve Therapeutics, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(c)
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: August 9, 2022

 

By:

/s/ Allison Dorval

 

 

 

Allison Dorval

 

 

 

Chief Financial Officer

(Principal Financial Officer)

 

 


EX-32.1 5 verv-ex32_1.htm EX-32.1 EX-32.1

 

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Verve Therapeutics, Inc. (the “Company”) for the period ending June 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Sekar Kathiresan, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Date: August 9, 2022

 

By:

/s/ Sekar Kathiresan

 

 

 

Sekar Kathiresan, M.D.

 

 

 

Chief Executive Officer

(Principal Executive Officer)

 

 


EX-32.2 6 verv-ex32_2.htm EX-32.2 EX-32.2

 

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Verve Therapeutics, Inc. (the “Company”) for the period ending June 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Allison Dorval, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Date: August 9, 2022

 

By:

/s/ Allison Dorval

 

 

 

Allison Dorval

 

 

 

Chief Financial Officer

(Principal Financial Officer)

 

 


EX-101.LAB 7 verv-20220630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT License and milestone payments License and milestone payments Lease Expiration Date Lease expiration date Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Vesting period Forecast Forecast [Member] Lease, Cost [Abstract] Preferred stock financing partially satisfied Preferred Stock Financing Partially Satisfied Preferred stock financing partially satisfied New Amendment [Member] New Amendment [Member] Operating lease related expenses prior to commencement. Operating Lease Related Expenses Prior To Commencement Lease space build out cost prior to commencement Operating Expenses [Abstract] Operating expenses: Operating Income (Loss) Loss from operations Increase (Decrease) in Operating Lease Liability Operating Lease Liabilities Operating lease liabilities Increase in operating lease liability Preferred and common stock disclosure text block. Preferred And Common Stock [Text Block] Preferred and Common Stock Increase in common stock capital shares, reserved for future issuance Increase In Common Stock Capital Shares Reserved For Future Issuance Increase in common stock capital shares, reserved for future issuance. Entity Emerging Growth Company Entity Emerging Growth Company Income Tax Disclosure [Abstract] Short term borrowings reduced value. Short Term Borrowings Reduced Value Letter of credit reduced value Financial Instrument [Axis] Financial Instrument Weighted-Average Grant-Date Fair Value, Granted Weighted-Average Grant-Date Fair Value, Granted Increase (Decrease) in Prepaid Expense and Other Assets, Total Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other assets Shares available for future grant Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Common Stock Offering Price Per Share Common Stock Offering Price Per Share Payments to Acquire Property, Plant, and Equipment, Total Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Geographical [Axis] Geographical Issuance of common stock, value Common Stock, Value, Issued, Ending Balance Common Stock, Value, Issued, Beginning Balance Common Stock, Value, Issued, Total Common Stock, Value, Issued Common stock, $0.001 par value; 200,000,000 and 255,000,000 shares authorized, 48,655,241 and 48,511,735 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively Entity Address, State or Province Entity Address, State or Province Liabilities Total liabilities License Agreement Abstract License Agreement [Abstract] Proceeds From Issuance Of Common Stock Under IPO, Gross. Proceeds From Issuance Of Common Stock Under I P O Gross Proceeds from common stock, gross Marketable Securities [Line Items] Marketable Securities [Line Items] Stockholders' Equity, Reverse Stock Split Reverse stock split Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Schedule of Future Minimum Lease Commitments under Non-Cancellable Leases Class of Stock [Domain] Class of Stock Common stock issued for partly satisfying preferred stock financing Common Stock Issued For Partly Satisfying Preferred Stock Financing Common stock issued for partly satisfying preferred stock financing Settlement of tranche right liability. Settlement Of Tranche Right Lliability Settlement of tranche right liability License Agreement License Agreement Terms [Member] Organization consolidation and presentation of financial statements. Organization Consolidation And Presentation Of Financial Statements [Table] Organization Consolidation And Presentation Of Financial Statements [Table] Convertible Preferred Stock, Shares Issued upon Conversion Shares issued upon conversion of preferred stock Harward. Harvard License Agreement [Member] Harvard Harvard License Agreement Weighted Average Number of Shares Outstanding, Basic and Diluted Weighted-average common shares used in net loss per share attributable to common stockholders, basic and diluted Legal Entity [Axis] Legal Entity Revenue from Related Parties Revenue from related parties General and Administrative General and Administrative Expense [Member] Accrued Employee Benefits, Current Employee compensation and related benefits Weighted average remaining contractual life (in years), Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Series B Preferred Stock Series B Preferred Stock [Member] U.S. Treasury Bills and Notes U.S. treasury bills and notes. U S Treasury Bills And Notes [Member] Short-term Debt, Total Short-term Debt Letter of credit issued Fair Value, Recurring and Nonrecurring [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Schedule of Related Party Transactions, by Related Party [Table] Schedule Of Related Party Transactions By Related Party [Table] City Area Code City Area Code Restricted stock units forfeited Restricted stock units forfeited Payment of initial public offering costs Payments for Repurchase of Initial Public Offering US Treasury Securities [Member] U.S. Treasury Bills and Notes [Member] Temporary equity, Conversion of convertible preferred stock to common stock upon closing of initial public offering (in shares) Temporary Equity Conversion Of Convertible Preferred Stock To Common Stock Upon Closing Of Initial Public Offering In Shares Temporary equity Conversion of convertible preferred stock to common stock upon closing of initial public offering (in shares) Change in Accounting Principle, Accounting Standards Update, Adopted [true false] Change in accounting principle, accounting standards update, adopted Commitments and Contingencies Commitments and contingencies (See Note 7 and Note 8) Twent Eighteen Twenty Eighteen [Member] Twenty eighteen Proceeds From sale Of Common Stock Percentage Proceeds From sale Of Common Stock Percentage Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Potential Common Shares, Based on Amounts Outstanding at Period End were Excluded From the Computation of Diluted Net Loss Per Share Attributable to Common Stockholders Issuance of common stock from initial public offering, net of issuance costs (in shares) Stock Issued During Period, Shares, New Issues Stock Issued During Period, Shares, New Issues Debt Securities, Available-for-sale, Total Debt Securities, Available-for-sale Fair value Scenario [Axis] Liabilities, Fair Value Disclosure [Abstract] Liabilities Issuance of common stock under Employee Stock Purchase Plan, shares Stock Issued During Period, Shares, Employee Stock Purchase Plans Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, cash equivalents and restricted cash—end of period Cash, cash equivalents and restricted cash—beginning of period Total cash, cash equivalents and restricted cash Related Party [Domain] Related Party Fair value net derivative asset liability measured on recurring basis unobservable inputs reconciliation success payment earned. Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Success Payment Earned Success payment earned Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false] Change in accounting principle, accounting standards update, immaterial effect Stock Issued During Period, Value, Conversion of Convertible Securities Conversion of convertible preferred stock to common stock upon closing of initial public offering Income Statement [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Harvard and Board. Harvard And Board [Member] Harvard and Board [Member] Measurement Input, Default Rate [Member] Probability of Termination Other Income [Member] Other Income Net Cash Provided by (Used in) Investing Activities Net cash provided by investing activities Percentage of outstanding stock, reserved for issuance Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum Number of installments for restricted shares vested. Number of Installments for Restricted Shares Vested General and Administrative Expense, Total General and Administrative Expense General and administrative General and administrative Total liabilities Financial Liabilities Fair Value Disclosure, Total Financial Liabilities Fair Value Disclosure Property, Plant and Equipment, Net, Ending Balance Property, Plant and Equipment, Net, Beginning Balance Property, Plant and Equipment, Net Property and equipment, net Property and equipment, net Common stock shares issued Common Stock, Shares, Issued Common Stock, Shares, Issued, Total Issuance Costs of Series A Convertible Preferred Stock Issuance Costs Of Series A Convertible Preferred Stock Issuance Costs of Series A Convertible Preferred Stock Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Restricted stock units forfeited Restricted stock units forfeited Lessee, Operating Lease, Lease Not yet Commenced, Existence of Option to Extend [true false] Option to extend true/false, lease not yet commenced Debt Securities, Available-for-sale, Amortized Cost, Total Debt Securities, Available-for-sale, Amortized Cost Amortized cost Operating Lease, Right-of-Use Asset Operating lease right-of-use assets Security Exchange Name Security Exchange Name Statistical Measurement [Domain] Statistical Measurement Furniture and Fixtures [Member] Furniture and Fixtures Payment of sales based milestone Payment of Sales Based Milestone Payment of sales based milestone. Other long term liabilities Other long term liabilities Measurement Input, Price Volatility [Member] Equity Volatility U.S. Agency Securities U.S. agency securities. U S Agency Securities [Member] Subsequent Event Type [Domain] Amortization of premium on marketable securities. Amortization Of Premium On Marketable Securities Amortization of premium on marketable securities Option License Agreement And Patent License Agreement Option License Agreement And Patent License Agreement [Member] Option License Agreement and Patent License Agreement [Member]. Document Period End Date Document Period End Date Restricted Cash, Noncurrent Restricted cash Income Statement Location [Axis] Income Statement Location Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table] Accrued Liabilities, Current Accrued expenses Total MASSACHUSETTS Cambridge, Massachusetts Related Party Transaction, Expenses from Transactions with Related Party Related party transaction, expenses from transactions with related party Other Expense [Member] Other Expense Issuance Costs of Series A-1 Convertible Preferred Stock Issuance Costs Of Series A1 Convertible Preferred Stock Issuance Costs of Series A-1 Convertible Preferred Stock Common stock, shares authorized Common Stock, Shares Authorized Common Stock, Shares Authorized Stock Issued During Period Shares Series A1 Convertible Preferred Stock Issuance of Series A-1 convertible preferred stock, net of issuance costs (in shares) Issuance of Series A-1 convertible preferred stock, net of issuance costs (in shares) Operating Lease, Liability, Current Operating lease obligations, current portion Related Party [Axis] Related Party Agreegate purchase price Agreegate Purchase Price Agreegate purchase price. Broad License Agreement Broad License Agreement [Member] Broad License Agreement [Member] Class of Stock [Axis] Class of Stock Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Sales Based Milestone Sales based milestone Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive securities Beam Beam [Member] Beam [Member]. Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings Changes in fair value Non-US Non-US [Member] Accrued expenses Accounts Payable and Accrued Liabilities Disclosure [Text Block] Additional Lessee Operating Lease Area Additional Lessee Operating Lease Area Additional Lease Area Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of Fair Value of Financial Instruments, Assets and Liabilities Current Fiscal Year End Date Current Fiscal Year End Date Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Increase in cash, cash equivalents and restricted cash Operating Lease, Cost Operating lease costs Public price. Public Price Public price Counterparty Name [Axis] Assets [Abstract] Assets Success payment recieved under collaboration agreement Success Payment Recieved Under Collaboration Agreement Success payment recieved under collaboration agreement Stock Issued During Period, Shares, Conversion of Convertible Securities Conversion of convertible preferred stock to common stock upon closing of initial public offering (in shares) Fair value assumptions expected term 1. Fair Value Assumptions Expected Term1 Expected term (in years) Lease Noncancelable Term. Lease Noncancelable Term Assets, Fair Value Disclosure [Abstract] Assets Lessee, Operating Lease, Liability, to be Paid, Year One 2023 Conversion of convertible preferred stock to common stock upon closing of initial public offering Temporary equity, Conversion of convertible preferred stock to common stock upon closing of initial public offering Temporary Equity Conversion Of Convertible Preferred Stock To Common Stock Upon Closing Of Initial Public Offering Accounts Payable, Current, Total Accounts Payable, Current Accounts payable US Government Agencies Debt Securities [Member] U.S. Agency Securities [Member] Common Stock, Par Value Common stock fair value Common Stock, Par or Stated Value Per Share Investments, Debt and Equity Securities [Abstract] Change in fair value of antidilution rights. Change In Fair Value Of Antidilution Rights Change in fair value of antidilution rights Change in fair value of antidilution rights liability Additional common stock issued Additional Paid in Capital, Common Stock, Ending Balance Additional Paid in Capital, Common Stock, Beginning Balance Additional Paid in Capital, Common Stock Additional paid-in capital Issuance Costs Of Common Stock from Initial Public Offering Issuance Costs Of Common Stock From Initial Public Offering Issuance Costs Of Common Stock from Initial Public Offering License agreement License Agreement Disclosure [Text Block] License Agreement Success payments for each product Success payments for each product Success payments for each product Fair Value by Liability Class [Domain] Fair Value by Liability Class Document Type Document Type Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Marketable Securities Preferred Stock, Value, Issued, Total Preferred Stock, Value, Issued, Beginning Balance Preferred Stock, Value, Issued, Ending Balance Preferred Stock, Value, Issued Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively Schedule of Accrued Liabilities [Table Text Block] Schedule of Accrued Expenses Assets, Current Total current assets Unvested Restricted Stock. Unvested Restricted Stock [Member] Unvested Restricted Stock Stock Available For Issuance Under Employee Stock Purchase Plan Stock Available For Issuance Under Employee Stock Purchase Plan Stock available for issuance under ESPP Liability Class [Axis] Liability Class ESPP Twenty Twenty One Employee Stock Purchase Plan [Member] Twenty twenty one employee stock purchase plan member Employee Stock Option Share-based Payment Arrangement, Option [Member] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type Clinical And Regulatory Milestone Clinical and regulatory milestone. Weighted average remaining contractual life (in years), Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Supplemental disclosure of noncash investing and financing activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Earnings Per Share, Basic and Diluted, Total Earnings Per Share, Basic and Diluted Net loss per common share attributable to common stockholders, basic and diluted Leases [Abstract] Antidilution Rights Antidilution Rights Member Antidilution rights. Unvested RSUs, ending balance, unvested Unvested RSUs, beginning balance, Unvested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Non-cash lease expense Provision for Lease Losses Common Stock, Shares, Outstanding Ending balance (in shares) Beginning Balance (in shares) Common Stock, Shares, Outstanding Plan Name [Axis] Plan Name Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less accumulated depreciation Change in fair value of success payments liabilities. Change In Fair Value Of Success Payments Liabilities Change in fair value of success payments liabilities Change in fair value of success payment liability Improvement allowance interest rate Interest rate for additional improvements allowance. Interest Rate For Additional Improvements Allowance Net proceeds from sale of common stock Sale of Stock, Consideration Received on Transaction Lease Commitment Amount Short-term Lease Commitment, Amount Lease Rent Payment Cash and Cash Equivalents [Domain] Cash and Cash Equivalents Operating Expenses Total operating expenses IPO [Member] IPO Lease, Cost Lease payment Total Financial Instruments [Domain] Financial Instruments Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Gross unrealized losses Preferred Stock Preferred Stock [Member] Preferred Stock [Member] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Weighted average exercise price, Ending balance Weighted average exercise price, Beginning balance Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flows from operating activities: Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Gross unrealized gains Marketable Securities [Table Text Block] Schedule of Marketable Securities by Security Earnings Per Share [Abstract] Awards description Share-based Compensation Arrangement by Share-based Payment Award, Description Issuance of common stock to licensor institutions (in shares) Stock Issued During Period Share Licensor Institutions Issuance of common stock to licensor institutions (in shares) Lessee, Operating Lease, Liability, to be Paid, Year Two 2024 Net Income (Loss) Attributable to Parent Net loss Net loss Net loss attributable to common stockholders Research and Development Research and Development Expense [Member] Document Fiscal Period Focus Document Fiscal Period Focus Issuance of Series A Preferred Stock Temporary Equity, Stock Issued During Period, Value, New Issues Issuance of Series A Preferred Accounting Policies [Abstract] Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive income Entity Address, Address Line One Entity Address, Address Line One Number of options, Outstanding, Ending balance Number of options, Outstanding, Beginning balance Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Liabilities, Current Total current liabilities Harvard and Broad license agreement. Harvard And Broad License Agreement [Member] Harvard and Board Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Entity Address, Postal Zip Code Entity Address, Postal Zip Code Materials Exchange Agreement Materials Exchange Agreement [Member] Materials Exchange Agreement [Member]. Preferred stock tranche liability disclosure text block. Preferred Stock Tranche Liability [Text Block] Preferred Stock Tranche Liability Total lease payments Lessee, Operating Lease, Liability, to be Paid Subsequent Event [Table] Product and Service [Domain] Stock Issued During Period Value Licensor Institutions Stock Issued During Period Value Licensor Institutions Issuance of common stock to licensor institutions Proceeds from Issuance Initial Public Offering Proceeds from initial public offering, net of underwriting discount Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Additional shares of common stock Equipment [Member] Equipment Lab equipment Convertible Preferred Stock Convertible Preferred Stock [Member] Additional tenant improvements allowance. Additional Tenant Improvements Allowance Additional tenant improvements allowance Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Schedule Of Research And Development Arrangement Contract To Perform For Others [Table] Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Thereafter Lessee operating lease liability payments due after year four. Lessee Operating Lease Liability Payments Due After Year Four Milestone related expenses Milestone Related Expenses Milestone related expenses. Equity Components [Axis] Equity Components Lease, Cost [Table Text Block] Components of Operating Lease Cost Assets, Current [Abstract] Current assets: Variable Lease, Cost Variable lease costs Restricted Cash and Cash Equivalents, Current, Total Restricted Cash and Cash Equivalents, Current Restricted cash Entity Registrant Name Entity Registrant Name Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Other comprehensive loss: Weighted-Average Grant-Date Fair Value, forfeited Weighted-Average Grant-Date Fair Value, forfeited NZ NEW ZEALAND Entity Interactive Data Current Entity Interactive Data Current Stock Purchase Agreement Stock Purchase Agreement [Member] Stock Purchase Agreement [Member] Entity Address, City or Town Entity Address, City or Town Common stock offering price Common stock offering price Common stock offering price Success Payment Liability, Payable Success Payment Liability, Payable Success payment liability, payable Lease Commencement Date. Lease Commencement Date Measurement Input, Expected Term [Member] Expected Term Trading Symbol Trading Symbol Related Party Transactions Disclosure [Text Block] Related Party Transactions Strategic License and Collaboration Agreement Strategic License and Collaboration Agreement [Member] Strategic License and Collaboration Agreement [Member] Development and commercial milestone payments under collaboration agreement Development and Commercial Milestone Payments Under Collaboration Agreement Development and commercial milestone payments under collaboration agreement Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flows from investing activities: Lessee, Operating Lease, Liability, Undiscounted Excess Amount Less: interest Less: interest Local Phone Number Local Phone Number ASC 842 Accounting Standards Update 2016-02 [Member] Number of options, Expected to vest Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Beginning Balance Stockholders' Equity Attributable to Parent Ending Balance Total stockholders equity Subsequent Event Type [Axis] Operating cash flows related to operating leases Operating Lease, Payments Preferred Stock, Shares Issued, Total Preferred Stock, Shares Issued Preferred stock, shares issued Total assets Assets, Fair Value Disclosure Statistical Measurement [Axis] Statistical Measurement Settlement of antidilution rights liability by issuing common stock Settlement of Antidilution Rights Liability By Issuing Common Stock Settlement of Antidilution Rights Liability By Issuing Common Stock Entity Small Business Entity Small Business Preferred Stock, Shares Outstanding, Beginning Balance Preferred Stock, Shares Outstanding, Ending Balance Preferred Stock, Shares Outstanding Preferred Stock, Shares Outstanding Increase Decrease In Operating Lease Right Of Use Of Asset Increase Decrease In Operating Lease Right Of Use Of Asset Increase in Right-Of-Use assets Organization, Consolidation and Presentation of Financial Statements [Abstract] Number of options, Forfeited Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Total Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Forfeited Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total APIC, Share-based Payment Arrangement, Increase for Cost Recognition Stock-based compensation Over-Allotment Option [Member] Underwriters Option Tenant improvements allowance. Tenant Improvements Allowance Tenant improvements allowance Credit Facility [Axis] Entity [Domain] Entity Verily License Agreement Verily License Agreement [Member] Verily License Agreement [Member] First Amendment Member. First Amendment [Member] First Amendment Third Amendment Member. Third Amendment [Member] Third Amendment Derivative Liability, Fair Value, Gross Liability, Total Derivative Liability, Fair Value, Gross Liability Success payments due Success payment liability, payable Weighted average exercise price, Granted Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Sale of Stock [Domain] Sale of Stock Other income (expense): Nonoperating Gains (Losses) [Abstract] Remaining contractual maturities of marketable securities term. Remaining Contractual Maturities Of Marketable Securities Term Remaining contractual maturities of marketable securities term Equity [Abstract] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Plan Name [Domain] Plan Name Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent, Total Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Unrealized gain on available-for-sale securities Unrealized loss on available-for-sale securities Lessee, Lease, Description [Table] Lessee, Operating Lease, Lease Not yet Commenced, Option to Extend Option to extend, lease not yet commenced sell Sales [Member] Depreciation, Total Depreciation Depreciation 2021 Stock Incentive Plan Two Thousand And Twenty One Stock Incentive Plan [Member] Two Thousand And Twenty One Stock Incentive Plan [Member] Lessee, Operating Lease, Term of Contract Lease term Issuance of common stock Stock Issued During Period, Value, New Issues Issuance of common stock from initial public offering, net of issuance costs of $25,098 Issuance Costs Of Series B Convertible Preferred Stock Issuance Costs Of Series B Convertible Preferred Stock Issuance Costs Of Series B Convertible Preferred Stock Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Reconciliation of cash, cash equivalents and restricted cash. Reconciliation Of Cash Cash Equivalents And Restricted Cash Table [Text Block] Reconciliation of Cash, Cash Equivalents and Restricted Cash Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Schedule of Fair Value Liabilities Measured on Recurring Basis Success payment liability. Success Payment Liability Success payment liability Success payment liability, net of current portion (See Notes 5, 8 and 14) Lessee operating lease incremental borrowing rate. Lessee Operating Lease Incremental Borrowing Rate Operating lease incremental borrowing rate Cash Equivalents, at Carrying Value, Total Cash Equivalents, at Carrying Value Cash equivalents Share-based Payment Arrangement, Noncash Expense, Total Share-based Payment Arrangement, Noncash Expense Stock-based compensation Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Profit share Profit cost share Profit cost share Preferred stock abstract. Preferred Stock [Abstract] Share-based Payment Arrangement, Option, Activity [Table Text Block] Schedule of Stock Option Activity Vertex Pharmaceuticals [Member] Vertex Pharmaceuticals [Member] Vertex pharmaceuticals member. Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset Related Party Transactions [Abstract] Maximum Success Payments For Each Product Maximum Success Payments For Each Product Increase (Decrease) in Other Current Liabilities Increase in liabilities Proceeds from Issuance of Preferred Stock and Preference Stock Proceeds from issuance of Series B convertible preferred stock, net Proceeds from issuance of Preferred Stock, net Number of options, Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Right-of-use assets obtained in exchange for new operating lease liabilities Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Weighted-Average Grant Date Fair Value Per Share, Vested Assets Total assets Level 2 Fair Value, Inputs, Level 2 [Member] Lessee, Operating Leases [Text Block] Leases Number of options, Exercised Exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercise of stock options (in shares) Unvested Restricted Stock Units [Member] Unvested Restricted Stock Units [Member] Unvested restricted stock units Statement [Line Items] Statement [Line Items] Total liabilities, convertible preferred stock, and stockholders' equity (deficit) Liabilities and Equity Document Quarterly Report Document Quarterly Report Property, Plant and Equipment [Abstract] Statement of Cash Flows [Abstract] Additional Paid-in Capital [Member] Additional Paid-In Capital Issuance of Series B convertible preferred stock, net of issuance costs (in shares) Stock Issued During Period Shares Series B Convertible Preferred Stock Issuance of Series B convertible preferred stock, net of issuance costs (in shares) Title of 12(b) Security Title of 12(b) Security Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss Level 3 Fair Value, Inputs, Level 3 [Member] Prepaid Rent Prepaid rent Award Type [Domain] Award Type Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV Nonvested Restricted Stock Shares Activity [Table Text Block] Schedule of Status and Change in Unvested Restricted Stock Property, Plant and Equipment [Table Text Block] Schedule of Property and Equipment, net Common stock issued for fully satisfying preferred stock financing Common Stock Issued For Fully Satisfying Preferred Stock Financing Common stock issued for fully satisfying preferred stock financing Level 1 Fair Value, Inputs, Level 1 [Member] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Research and Development Arrangement, Contract to Perform for Others, Type Issuance of Series B convertible preferred stock, net of issuance costs Stock Issued During Period Value Series B Convertible Preferred Stock Issuance of Series B convertible preferred stock, net of issuance costs of $241 Lessee, Operating Lease, Liability, to be Paid, Year Four 2026 Restricted Stock [Member] Restricted Stock Total other income (expense), net Nonoperating Income (Expense) Weighted average exercise price, Expected to vest Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Subsidiary, Sale of Stock [Line Items] Subsidiary Sale Of Stock [Line Items] Number of options, Granted Stock option granted during period Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Aggregate intrinsic value, Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding Entity Current Reporting Status Entity Current Reporting Status Payments to Acquire Marketable Securities, Total Payments to Acquire Marketable Securities Purchases of marketable securities Marketable Securities [Table] Marketable Securities [Table] Preferred stock tranche liability. Preferred Stock Tranche Liability [Member] Preferred Stock Tranche Liability Measurement Input Type [Domain] Measurement Input Type Scenario [Domain] Organization consolidation and presentation of financial statements. Organization Consolidation And Presentation Of Financial Statements [Line Items] Organization Consolidation And Presentation Of Financial Statements [Line Items] Money Market Funds Money Market Funds [Member] Public offering Public offering [Member] Public offering [Member] Lessee, Operating Lease, Option to Extend Antidilution rights liability. Antidilution Rights Liability [Member] Antidilution Rights Liability Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Summary of Stock Based Compensation Expense Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table] Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Remainder of 2022 Computer Equipment [Member] Computer Equipment AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Income (Loss) Lessee, Operating Lease, Lease Not yet Commenced, Variable Lease Payment, Terms and Conditions Operating lease payment term, lease not yet commenced, terms and conditions Officer [Member] Officer [Member] Income Statement Location [Domain] Income Statement Location Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Schedule of Reconciliation of Changes in Fair Value of Financial Instruments Ending balance Beginning balance Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs Underwriting discounts and commissions Investment Banking, Advisory, Brokerage, and Underwriting Fees and Commissions Investment Banking, Advisory, Brokerage, and Underwriting Fees and Commissions, Total Success Payment Liability Current Success Payment Liability Current Success payment liability, current portion Preferred Stock, Shares Authorized Preferred stock, shares authorized Cambridge lease. Cambridge Lease [Member] Cambridge Lease Minimum Minimum [Member] Property and equipment additions included in accounts payable and accrued expenses. Property And Equipment Additions Included In Accounts Payable And Accrued Expenses Property and equipment additions included in accounts payable and accrued expenses Weighted average remaining contractual life (in years), Expected to vest Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Stock Issued During Period, Value, Stock Options Exercised Exercise of stock options Payment received for license agreement reimbursement of costs incurred Payment Received for License Agreement Reimbursement of Costs Incurred Preferred stock financing were fully satisfied Preferred Stock Financing Fully Satisfied Preferred stock financing fully satisfied Amount recieved under collaboration agreement Amount Recieved Under Collaboration Agreement Amount recieved under collaboration agreement Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Restricted stock units granted Lessee, Operating Lease, Liability, Payment, Due [Abstract] Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows from financing activities: Entity Filer Category Entity Filer Category Document Fiscal Year Focus Document Fiscal Year Focus Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Stock issued during period shares series a convertible preferred stock. Stock Issued During Period Value Series A Convertible Preferred Stock Issuance of Series A convertible preferred stock, net of issuance costs of $22 Lease Rent Payment Lease Rent Payment Lease rent payment Retained Earnings (Accumulated Deficit), Ending Balance Retained Earnings (Accumulated Deficit), Beginning Balance Retained Earnings (Accumulated Deficit), Total Retained Earnings (Accumulated Deficit) Accumulated deficit Income Tax Disclosure [Text Block] Income Taxes Depreciation, Depletion and Amortization, Nonproduction, Total Depreciation, Depletion and Amortization, Nonproduction Depreciation Entity Ex Transition Period Entity Ex Transition Period Lease term remaining Lessee, Operating Lease, Remaining Lease Term Fair Value Disclosures [Abstract] Property, Plant and Equipment Disclosure [Text Block] Property and equipment, net Short-term Lease, Cost Maximum Maximum [Member] Entity Central Index Key Entity Central Index Key Cash paid for amounts included in the measurements of lease liabilities. Cash paid for amounts included in the measurements of lease liabilities [Abstract] Beam License Agreement Beam License Agreement [Member] Beam license agreement. Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Cash, Cash Equivalents and Restricted Cash Issuance of Series A-1 convertible preferred stock, net of issuance costs of $112 Stock Issued During Period Value Series A1 Convertible Preferred Stock Issuance of Series A-1 convertible preferred stock, net of issuance costs of $112 Payables and Accruals [Abstract] Measurement Input Type [Axis] Measurement Input Type Operating Lease, Expense Operating lease, rent expense Jefferies LLC [Member] Jefferies LLC [Member] Jefferies LLC [Member] Entity Tax Identification Number Entity Tax Identification Number Equity Component [Domain] Equity Component Offering Costs Offering Costs Offering Costs Preferred Stock, Par or Stated Value Per Share Preferred stock, value per share Non refundable upfront payment Non Refundable Upfront Payment Non-refundable upfront payment Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Weighted average period over which unrecognized compensation is expected to be recognized Open Market Sale Agreement Open Market Sale Agreement [Member] Open Market Sale Agreement [Member] Change in Accounting Principle, Accounting Standards Update, Adoption Date Change in accounting principle, accounting standards update, adoption date Subsequent Events [Abstract] Subsequent Event [Line Items] Leasehold Improvements [Member] Leasehold Improvements License [Member] License Agreement [Member] Weighted average exercise price, Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Statement [Table] Statement [Table] Operating Lease, Weighted Average Remaining Lease Term Weighted average remaining lease term Entity File Number Entity File Number Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Cumulative probability of triggering event. Cumulative Probability Of Triggering Event Cumulative probability of triggering event Lessee, Lease, Description [Line Items] Retained Earnings [Member] Accumulated Deficit Accounting Standards Update [Domain] Accounting Standards Update [Axis] Transaction costs on issuance Payments of Stock Issuance Costs Non Refundable Upfront License Fee Non refundable upfront license fee. Increase (Decrease) in Accounts Payable, Total Increase (Decrease) in Accounts Payable Accounts payable Liabilities, Current [Abstract] Current liabilities: Share-based Payment Arrangement [Text Block] Stock-based compensation Subsequent Event [Member] Subsequent Event Aggregate intrinsic value, Expected to vest Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Operating Lease, Liability, Total Operating Lease, Liability Present value of operating lease liabilities Operating lease liability Common Stock [Member] Common Stock Property, Plant and Equipment, Gross, Ending Balance Property, Plant and Equipment, Gross, Beginning Balance Property, Plant and Equipment, Gross, Total Property, Plant and Equipment, Gross Total property and equipment Accrued Professional Fees, Current Professional fees Accrued external research and development expenses Accrued External Research And Development Expenses Accrued external research and development expenses Cover [Abstract] Credit Facility [Domain] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Weighted-Average Grant Date Fair Value Per Share, ending balance, Unvested Weighted-Average Grant Date Fair Value Per Share, beginning balance, Unvested Issuance of Series A convertible preferred stock, net of issuance costs (in shares) Stock Issued During Period Shares Series A Convertible Preferred Stock Issuance of Series A convertible preferred stock, net of issuance costs (in shares) Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table] Statement of Stockholders' Equity [Abstract] Property, Plant and Equipment [Table] Schedule Of Property Plant And Equipment [Table] Stock Issued During Period, Shares, Restricted Stock Award, Gross Vesting of restricted common stock (in shares) Share-based Payment Arrangement [Abstract] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] Lessee operating lease area. Lessee Operating Lease Area Lease area Research and Development Arrangement, Contract to Perform for Others [Line Items] Research And Development Arrangement Contract To Perform For Others [Line Items] RSU Restricted Stock Units (RSUs) [Member] Cash, Cash Equivalents, and Short-term Investments, Total Cash, Cash Equivalents, and Short-term Investments Cash, cash equivalents, and marketable securities Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset Other Accrued Liabilities, Current Other Document Transition Report Document Transition Report Proceeds from Stock Options Exercised Proceeds from exercise of stock options Weighted average exercise price, Forfeited Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Letter of Credit [Member] Letter of Credit Fair value of common stock (per share) Fair value of common stock per share Fair value of common stock per share. Outstanding Options to Purchase Common Stock Outstanding Options To Purchase Common Stock [Member] Outstanding Options To Purchase Common Stock Lessee, Operating Lease, Renewal Term Operating lease renewal term Fair value inputs probability of termination. Fair Value Inputs Probability Of Termination Fair value inputs probability of termination Research and Development Expense Research and development Research and development expenses Research and Development Expense, Total Initial public offering costs included in accounts payable and accrued liabilities Initial Public Offering Costs Included In Accounts Payable And Accrued Liabilities Initial Public Offering Costs Included In Accounts Payable And Accrued Liabilities Sublease expiration date. Sublease Expiration Date Sublease expiration date Share-based Payment Arrangement, Expense Total stock-based compensation expense Success payment liability. Success Payment Liability [Member] Success Payment Liability Statement of Financial Position [Abstract] Unvested RSUs, Vested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Unvested RSUs, Vested Second Amendment Member. Second Amendment [Member] Second Amendment Non-refundable upfront license fees paid Non-Refundable Upfront License Fees Paid Non-refundable upfront license fees paid Stockholders' equity (deficit): Stockholders' Equity Attributable to Parent [Abstract] Premises. Premises [Member] Premises Nature of the Business and Basis of Presentation Nature of Operations [Text Block] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents Aggregate purchase price per share Aggregate purchase price per share Payment of milestone development Payment of Milestone Development Payment of milestone development. Weighted average exercise price, Exercised Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Lessee, Operating Lease, Liability, to be Paid, Year Three 2025 Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Maturities of marketable securities. Maturities Of Marketable Securities Maturities of marketable securities Derivative Liability, Total Derivative Liability Success payment liability Sale of common stock for future issuance Shares of common stock reserved for future issuance Common Stock, Capital Shares Reserved for Future Issuance Award Type [Axis] Award Type Entity Shell Company Entity Shell Company Other Comprehensive Income (Loss), Net of Tax [Abstract] Comprehensive Loss: Price Per Share Sale of Stock, Price Per Share Public offering price per share Liabilities and Equity [Abstract] Liabilities, convertible preferred stock, and stockholders’ deficit Schedule of supplemental cash flow information related to operating leases. Schedule of Supplemental Cash Flow Information Related to Operating Leases [Table Text Block] Supplemental Cash Flow Information Related to Operating Leases Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Issuance of common stock under Employee Stock Purchase Plan Issuance of shares through employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Stock Issued During Period, Value, Restricted Stock Award, Gross Vesting of restricted common stock Earnings Per Share [Text Block] Net Loss Per Share Attributable to Common Stockholders Counterparty Name [Domain] Amendment Flag Amendment Flag Product and Service [Axis] Other Nonoperating Income (Expense), Total Other Nonoperating Income (Expense) Interest and other income, net Sale of Stock, Number of Shares Issued in Transaction Shares issued and sold Cash and Cash Equivalents, at Carrying Value, Ending Balance Cash and Cash Equivalents, at Carrying Value, Beginning Balance Cash and Cash Equivalents, at Carrying Value, Total Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents New Accounting Pronouncements, Policy [Policy Text Block] Recently Adopted Accounting Pronouncements Lessee, Operating Lease, Lease Not yet Commenced, Existence of Option to Terminate [true false] Option to terminate, lease not yet commenced Issuance of shares through employee stock purchase plan Issuance Of Share Under Employee Stock Purchase Plan Issuance Of Share Under Employee Stock Purchase Plan Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract Lease not yet commenced , lease term Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Unrecognized stock-based compensation cost Acuitas Agreements Acuitas Agreements [Member] Acuitas agreements. Marketable Securities, Current, Total Marketable Securities, Current Marketable securities Subsequent Events [Text Block] Subsequent Events Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Accrued expenses and other liabilities Property, Plant and Equipment [Line Items] Property Plant And Equipment [Line Items] Other Assets, Noncurrent, Total Other Assets, Noncurrent Other long term assets OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Unrealized loss on marketable securities Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Geographical [Domain] Geographical Aggregate intrinsic value, Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Fair value assumption of equity volatility rate. Fair Value Assumption Of Equity Volatility Rate Equity volatility Sale of Stock [Axis] Sale of Stock Fair value of financial instruments Fair Value Disclosures [Text Block] Unrecognized stock-based compensation cost Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount EX-101.SCH 8 verv-20220630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 100010 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 100020 - Disclosure - Leases - Summary of Future Minimum Commitments under Non-Cancellable Operating Leases (Details) 2 link:presentationLink link:calculationLink link:definitionLink 100030 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100040 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 100050 - Statement - Condensed Consolidated Statement of Convertible Preferred Stock and Stockholders' Equity (Deficit) link:presentationLink link:calculationLink link:definitionLink 100060 - Statement - Condensed Consolidated Statement of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100070 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 100080 - Disclosure - Nature of the Business and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 100090 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 100100 - Disclosure - Marketable Securities link:presentationLink link:calculationLink link:definitionLink 100110 - Disclosure - Property and equipment, net link:presentationLink link:calculationLink link:definitionLink 100120 - Disclosure - Fair value of financial instruments link:presentationLink link:calculationLink link:definitionLink 100130 - Disclosure - Accrued expenses link:presentationLink link:calculationLink link:definitionLink 100140 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 100150 - Disclosure - License Agreements link:presentationLink link:calculationLink link:definitionLink 100160 - Disclosure - Preferred Stock Tranche Liability link:presentationLink link:calculationLink link:definitionLink 100170 - Disclosure - Preferred and Common Stock link:presentationLink link:calculationLink link:definitionLink 100180 - Disclosure - Stock-based compensation link:presentationLink link:calculationLink link:definitionLink 100190 - Disclosure - Net Loss Per Share Attributable to Common Stockholders link:presentationLink link:calculationLink link:definitionLink 100200 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 100210 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 100220 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 100230 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 100240 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 100250 - Disclosure - Marketable Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 100260 - Disclosure - Property and equipment, net (Tables) link:presentationLink link:calculationLink link:definitionLink 100270 - Disclosure - Fair Value of Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 100280 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 100290 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 100300 - Disclosure - Stock-based compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 100310 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables) link:presentationLink link:calculationLink link:definitionLink 100320 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100330 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 100340 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100350 - Disclosure - Marketable securities - Schedule of Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 100360 - Disclosure - Marketable securities - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100370 - Disclosure - Property and Equipment, net - Schedule of Property and Equipment, net (Details) link:presentationLink link:calculationLink link:definitionLink 100380 - Disclosure - Property and Equipment, net - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100390 - Disclosure - Fair value of financial instruments - Summary of Assets and Liabilities Measured at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 100400 - Disclosure - Fair value of financial instruments - Summary of Assets and Liabilities Measured at Fair Value (Parenthetical) (Details) link:presentationLink link:calculationLink link:definitionLink 100410 - Disclosure - Fair value of financial instruments - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100420 - Disclosure - Fair value of financial instruments - Schedule of Fair Value Liabilities Measured on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 100430 - Disclosure - Fair value of financial instruments - Schedule of Reconciliation of Changes in Fair Value of Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 100440 - Disclosure - Accrued expenses - Schedule of Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 100450 - Disclosure - Leases - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100460 - Disclosure - Leases - Summary of Components of Operating Lease Cost (Details) link:presentationLink link:calculationLink link:definitionLink 100470 - Disclosure - Leases - Summary of Supplemental Cash Flow Information Related to Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 100480 - Disclosure - Leases - Summary of Future Minimum Commitments under Non-Cancellable Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 100490 - Disclosure - License Agreements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100500 - Disclosure - Preferred and Common Stock - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100510 - Disclosure - Stock-based compensation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100520 - Disclosure - Stock-based compensation - Summary of Stock Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 100530 - Disclosure - Stock-based compensation - Schedule of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 100540 - Disclosure - Stock-based compensation - Summary of the Restricted Stock Units (Details) link:presentationLink link:calculationLink link:definitionLink 100550 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Potential Common Shares, Based on Amounts Outstanding at Period End were Excluded From the Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details) link:presentationLink link:calculationLink link:definitionLink 100560 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100570 - Disclosure - Related Party Transactions - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100580 - Disclosure - Subsequent Events - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 9 verv-20220630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.PRE 10 verv-20220630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.CAL 11 verv-20220630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT XML 12 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Document and Entity Information - shares
6 Months Ended
Jun. 30, 2022
Aug. 04, 2022
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Jun. 30, 2022  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q2  
Entity Registrant Name VERVE THERAPEUTICS , INC.  
Entity Central Index Key 0001840574  
Trading Symbol VERV  
Current Fiscal Year End Date --12-31  
Entity Current Reporting Status Yes  
Entity Shell Company false  
Entity Filer Category Non-accelerated Filer  
Entity Emerging Growth Company true  
Entity Ex Transition Period false  
Entity Small Business false  
Entity Common Stock, Shares Outstanding   59,942,339
Entity Interactive Data Current Yes  
Security Exchange Name NASDAQ  
Title of 12(b) Security Common stock, par value $0.001 per share  
Entity File Number 001-40489  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 82-4800132  
Entity Address, Address Line One 500 Technology Square, Suite 901  
Entity Address, City or Town Cambridge  
Entity Address, State or Province MA  
Entity Address, Postal Zip Code 02139  
City Area Code 617  
Local Phone Number 603-0070  
Document Quarterly Report true  
Document Transition Report false  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 72,889 $ 64,330
Marketable securities 220,672 296,112
Prepaid expenses and other current assets 5,083 6,686
Total current assets 298,644 367,128
Property and equipment, net 12,354 7,224
Restricted cash 5,237 5,237
Operating lease right-of-use assets 839 1,839
Other long term assets 7,193 2,696
Total assets 324,267 384,124
Current liabilities:    
Accounts payable 6,320 7,077
Accrued expenses 18,620 12,992
Operating lease obligations, current portion 907 1,955
Total current liabilities 25,847 22,024
Success Payment Liability 1,756 4,371
Other long term liabilities 331 377
Total liabilities 27,934 26,772
Commitments and contingencies (See Note 7 and Note 8)
Stockholders' equity (deficit):    
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively 0 0
Common stock, $0.001 par value; 200,000,000 and 255,000,000 shares authorized, 48,655,241 and 48,511,735 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively 49 49
Additional paid-in capital 555,184 544,381
Accumulated other comprehensive income (938) (228)
Accumulated deficit (257,962) (186,850)
Total stockholders equity 296,333 357,352
Total liabilities, convertible preferred stock, and stockholders' equity (deficit) $ 324,267 $ 384,124
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Jun. 30, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]    
Preferred stock, value per share $ 0.001 $ 0.001
Preferred stock, shares authorized 5,000,000 5,000,000
Preferred stock, shares issued 0 0
Preferred Stock, Shares Outstanding 0 0
Common stock fair value $ 0.001 $ 0.001
Common Stock, Shares Authorized 200,000,000 200,000,000
Common stock shares issued 48,709,652 48,511,735
Common Stock, Shares, Outstanding 48,709,652 48,511,735
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Operating expenses:        
Research and development $ 33,125 $ 13,423 $ 57,614 $ 24,768
General and administrative 9,067 3,541 16,503 6,257
Total operating expenses 42,192 16,964 74,117 31,025
Loss from operations (42,192) (16,964) (74,117) (31,025)
Other income (expense):        
Change in fair value of antidilution rights liability 0 (25,970) 0 (25,574)
Change in fair value of success payment liability 938 (10,036) 2,615 (9,654)
Interest and other income, net 308 5 390 25
Total other income (expense), net 1,246 (36,001) 3,005 (35,203)
Net loss $ (40,946) $ (52,965) $ (71,112) $ (66,228)
Net loss per common share attributable to common stockholders, basic and diluted $ (0.84) $ (6.66) $ (1.46) $ (12.46)
Weighted-average common shares used in net loss per share attributable to common stockholders, basic and diluted 48,674,873 7,948,110 48,623,330 5,316,084
Comprehensive Loss:        
Net loss $ (40,946) $ (52,965) $ (71,112) $ (66,228)
Other comprehensive loss:        
Unrealized loss on marketable securities (206) (4) (710) (5)
Comprehensive loss $ (41,152) $ (52,969) $ (71,822) $ (66,233)
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Statement of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)
$ in Thousands
Total
Preferred Stock
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Beginning Balance at Dec. 31, 2020 $ (63,909) $ 125,160 $ 3 $ 2,616 $ 8 $ (66,536)
Beginning Balance (in shares) at Dec. 31, 2020   179,519,032 2,585,789      
Issuance of Series B convertible preferred stock, net of issuance costs of $241   $ 93,759        
Issuance of Series B convertible preferred stock, net of issuance costs (in shares)   77,163,022        
Vesting of restricted common stock (in shares)     134,409      
Exercise of stock options 72     72    
Exercise of stock options (in shares)     48,745      
Unrealized loss on available-for-sale securities (1)       (1)  
Stock-based compensation 670     670    
Net loss (13,263)         (13,263)
Ending Balance at Mar. 31, 2021 (76,431) $ 218,919 $ 3 3,358 7 (79,799)
Ending balance (in shares) at Mar. 31, 2021   256,682,054 2,768,943      
Beginning Balance at Dec. 31, 2020 (63,909) $ 125,160 $ 3 2,616 8 (66,536)
Beginning Balance (in shares) at Dec. 31, 2020   179,519,032 2,585,789      
Conversion of convertible preferred stock to common stock upon closing of initial public offering 218,919          
Issuance of common stock from initial public offering, net of issuance costs of $25,098 (32,490)          
Net loss (66,228)          
Ending Balance at Jun. 30, 2021 405,396   $ 48 538,109 3 (132,764)
Ending balance (in shares) at Jun. 30, 2021     47,946,996      
Beginning Balance at Mar. 31, 2021 (76,431) $ 218,919 $ 3 3,358 7 (79,799)
Beginning Balance (in shares) at Mar. 31, 2021   256,682,054 2,768,943      
Conversion of convertible preferred stock to common stock upon closing of initial public offering (in shares)   (256,682,054) 27,720,923      
Issuance of common stock from initial public offering, net of issuance costs of $25,098 281,584   $ 16 281,568    
Issuance of common stock from initial public offering, net of issuance costs (in shares)     16,141,157      
Issuance of common stock to licensor institutions 32,490   $ 1 32,489    
Issuance of common stock to licensor institutions (in shares)     878,098      
Vesting of restricted common stock (in shares)     134,408      
Exercise of stock options 452     452    
Exercise of stock options (in shares)     303,467      
Unrealized loss on available-for-sale securities (4)       (4)  
Stock-based compensation 1,351     1,351    
Net loss (52,965)         (52,965)
Ending Balance at Jun. 30, 2021 405,396   $ 48 538,109 3 (132,764)
Ending balance (in shares) at Jun. 30, 2021     47,946,996      
Conversion of convertible preferred stock to common stock upon closing of initial public offering 218,919 $ (218,919) $ 28 218,891    
Beginning Balance at Dec. 31, 2021 $ 357,352   $ 49 544,381 (228) (186,850)
Beginning Balance (in shares) at Dec. 31, 2021 48,511,735   48,511,735      
Exercise of stock options $ 505     505    
Exercise of stock options (in shares)     143,506      
Unrealized loss on available-for-sale securities (504)       (504)  
Stock-based compensation 4,203     4,203    
Net loss (30,166)         (30,166)
Ending Balance at Mar. 31, 2022 331,390   $ 49 549,089 (732) (217,016)
Ending balance (in shares) at Mar. 31, 2022     48,655,241      
Beginning Balance at Dec. 31, 2021 $ 357,352   $ 49 544,381 (228) (186,850)
Beginning Balance (in shares) at Dec. 31, 2021 48,511,735   48,511,735      
Conversion of convertible preferred stock to common stock upon closing of initial public offering          
Exercise of stock options (in shares) 172,699          
Net loss $ (71,112)          
Ending Balance at Jun. 30, 2022 $ 296,333   $ 49 555,184 (938) (257,962)
Ending balance (in shares) at Jun. 30, 2022 48,709,652   48,709,652      
Beginning Balance at Mar. 31, 2022 $ 331,390   $ 49 549,089 (732) (217,016)
Beginning Balance (in shares) at Mar. 31, 2022     48,655,241      
Exercise of stock options 120     120    
Exercise of stock options (in shares)     29,193      
Issuance of common stock under Employee Stock Purchase Plan, shares     25,218      
Issuance of common stock under Employee Stock Purchase Plan 325     325    
Unrealized loss on available-for-sale securities (206)       (206)  
Stock-based compensation 5,650     5,650    
Net loss (40,946)         (40,946)
Ending Balance at Jun. 30, 2022 $ 296,333   $ 49 $ 555,184 $ (938) $ (257,962)
Ending balance (in shares) at Jun. 30, 2022 48,709,652   48,709,652      
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Statement of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) - USD ($)
$ in Thousands
3 Months Ended
Jun. 30, 2021
Mar. 31, 2021
Statement of Stockholders' Equity [Abstract]    
Issuance Costs Of Series B Convertible Preferred Stock   $ 241
Issuance Costs Of Common Stock from Initial Public Offering $ 25,098  
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Cash flows from operating activities:    
Net loss $ (71,112) $ (66,228)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 1,162 651
Non-cash lease expense 999 865
Amortization of premium on marketable securities 1,231 356
Stock-based compensation 9,853 2,021
Change in fair value of antidilution rights 0 25,574
Change in fair value of success payments liabilities (2,615) 9,654
Changes in operating assets and liabilities:    
Prepaid expenses and other assets (2,894) (159)
Accounts payable (1,017) 1,283
Accrued expenses and other liabilities 5,176 (1,584)
Operating lease liabilities (1,048) (915)
Net cash used in operating activities (60,265) (28,482)
Cash flows from investing activities:    
Purchases of property and equipment (5,627) (2,376)
Purchases of marketable securities (74,249) (11,176)
Maturities of marketable securities 147,750 43,755
Net cash provided by investing activities 67,874 30,203
Cash flows from financing activities:    
Proceeds from issuance of Series B convertible preferred stock, net 0 93,759
Proceeds from initial public offering, net of underwriting discount 0 285,214
Payment of initial public offering costs 0 (2,765)
Proceeds from exercise of stock options 625 524
Issuance of shares through employee stock purchase plan 325 0
Net cash provided by financing activities 950 376,732
Increase in cash, cash equivalents and restricted cash 8,559 378,453
Cash, cash equivalents and restricted cash—beginning of period 69,567 9,456
Cash, cash equivalents and restricted cash—end of period 78,126 387,909
Supplemental disclosure of noncash investing and financing activities:    
Property and equipment additions included in accounts payable and accrued expenses 1,169 794
Initial public offering costs included in accounts payable and accrued liabilities 0 865
Conversion of convertible preferred stock to common stock upon closing of initial public offering 218,919
Settlement of antidilution rights liability by issuing common stock $ 0 $ 32,490
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.22.2
Nature of the Business and Basis of Presentation
6 Months Ended
Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Nature of the Business and Basis of Presentation

1. Nature of the business and basis of presentation

Organization

Verve Therapeutics, Inc. (the “Company” or “Verve”) is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The Company was incorporated on March 9, 2018 as Endcadia, Inc., a Delaware corporation, and began operations shortly thereafter. In January 2019, the Company amended its certificate of incorporation to change its name to Verve Therapeutics, Inc. The Company’s principal offices are located in Cambridge, Massachusetts.

Liquidity and capital resources

Since its inception, the Company has devoted its efforts principally to research and development and raising capital. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry including, but not limited to, technical risks associated with the successful research, development and manufacturing of product candidates, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Current and future programs will require significant research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.

In connection with the Company's initial public offering, or IPO, in June 2021, the Company effected a one-for-9.2595 reverse stock split of the Company’s issued and outstanding common stock. Accordingly, all shares of common stock and per share amounts, as well as the conversion ratio of the Company’s outstanding convertible preferred stock, for all periods presented in the accompanying condensed consolidated financial statements and notes thereto have been retroactively adjusted, where applicable, to reflect the reverse stock split, including reclassification of par and additional paid-in capital amounts as a result of the reverse stock split.

Subsequent to June 30, 2022, on July 18, 2022, the Company entered into a Strategic Collaboration and License Agreement (the “Vertex Agreement”) with Vertex Pharmaceuticals Incorporated (“Vertex”) for an exclusive, four-year worldwide research collaboration focused on developing in vivo gene editing candidates toward an undisclosed target for the treatment of a single liver disease, as further described in Note 14, “Subsequent events.” Pursuant to the Vertex Agreement, Vertex paid the Company $25.0 million in an upfront payment on July 20, 2022. The Company is eligible to receive (i) success payments of up to $22 million for each product candidate (up to a maximum of $66 million) that achieves the applicable development criteria and (ii) up to an aggregate of $340 million in development and commercial milestone payments. The Company is also eligible to receive tiered single-digit royalties on net sales, subject to specified reductions.

On July 18, 2022, in connection with the execution of the Vertex Agreement, the Company also entered into a stock purchase agreement with Vertex (the “Stock Purchase Agreement”) for the sale and issuance of 1,519,756 shares of the Company’s common stock to Vertex at a price of $23.03 per share, which was equal to the five-day volume-weighted average share price as of July 15, 2022, for an aggregate purchase price of $35.0 million (the “Private Placement”). The Private Placement closed on July 20, 2022.

On July 25, 2022, the Company issued and sold 9,583,334 shares of its common, including an additional 1,250,000 shares its common stock sold pursuant to the underwriters’ full exercise of their option to purchase additional shares of common stock, at a public offering price of $27.00 per share, for aggregate net proceeds of approximately $242.9 million after deducting underwriting discounts and commissions of approximately $15.5 million and offering costs of approximately $0.3 million.

The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company expects that its cash, cash equivalents and marketable securities of $293.6 million as of June 30, 2022, together with the net proceeds of approximately $242.9 million from the July 2022 follow-on public offering, $35.0

million from the Private Placement with Vertex, and $25.0 million upfront payment from Vertex pursuant to the Vertex Agreement, will be sufficient to fund its operations and capital expenditure requirements beyond the next 12 months from the date of issuance of these financial statements. The Company will need additional financing to support its continuing operations and pursue its growth strategy. Until such time as the Company can generate significant revenue from product sales, if ever, it expects to finance its operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. The Company may be unable to raise additional funds or enter into such other agreements when needed on favorable terms or at all. The inability to raise capital as and when needed could have a negative impact on the Company’s financial condition and its ability to pursue its business strategy. The Company will need to generate significant revenue to achieve profitability, and it may never do so.

Basis of presentation

The accompanying condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC"). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations.

The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements. In the opinion of the Company’s management, the accompanying unaudited interim condensed consolidated financial statements contain all adjustments that are necessary to present fairly the Company’s financial position as of June 30, 2022, the results of its operations and other comprehensive loss for the three and six months ended June 30, 2022 and 2021, convertible preferred stock and stockholders’ equity for the three and six months ended June 30, 2022 and 2021 and cash flows for the six months ended June 30, 2022 and 2021. Such adjustments are of a normal and recurring nature. The results for the three and six months ended June 30, 2022 are not necessarily indicative of the results for the year ending December 31, 2022, or for any future period. These interim financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended December 31, 2021, and the notes thereto, included in the Company’s Annual Report on Form 10-K filed with the SEC on March 14, 2022.

XML 20 R9.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of Significant Accounting Policies
6 Months Ended
Jun. 30, 2022
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

2. Summary of significant accounting policies

The Company's significant accounting policies are disclosed in Note 2, "Summary of significant accounting policies," in the audited consolidated financial statements for the year ended December 31, 2021, and notes thereto, included in the Company’s Annual Report on Form 10-K filed with the SEC on March 14, 2022. Since the date of those financial statements, there have been no changes to its significant accounting policies.

Cash, cash equivalents and restricted cash

Restricted cash represents collateral provided for letters of credit issued as security deposits in connection with the Company’s leases of its corporate facilities. A reconciliation of the cash, cash equivalents, and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the statement of cash flows is as follows:

 

 

 

June 30,

 

 

June 30,

 

(in thousands)

 

2022

 

 

2021

 

Cash and cash equivalents

 

$

72,889

 

 

$

387,446

 

Restricted cash

 

 

5,237

 

 

 

463

 

Total cash, cash equivalents and restricted cash

 

$

78,126

 

 

$

387,909

 

Recently adopted accounting pronouncements

During the quarter ended September 30, 2021, the Company early adopted ASC Topic 842, “Leases” (“ASC 842”) using the revised modified retrospective approach as of January 1, 2021. The unaudited interim condensed consolidated financial statements for the three and six months ended June 30, 2021 have been retroactively adjusted to reflect the adoption of ASC 842, including retroactive adjustments to the unaudited interim condensed consolidated statement of cash flows and certain additional footnote disclosures as included herein. The adoption of ASC 842 had no material impact to the Company’s unaudited condensed consolidated statement of operations and comprehensive loss for the three and six months ended June 30, 2021.

At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on specific facts and circumstances, the existence of an identified asset(s), if any, and the Company’s control over the use of the identified asset(s), if applicable. The lease liability is measured at the present value of future lease payments, discounted using the discount rate as of the lease commencement date. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the incremental borrowing rate, which is the rate incurred to borrow, on a collateralized basis over a similar term, an amount equal to the lease payments in a similar economic environment. The Company recognizes a corresponding lease right of use (“ROU”) asset, initially measured as the amount of lease liability, adjusted for any initial lease costs or lease payments made before or at the commencement of the lease, and reduced by any lease incentives.

The Company’s leases consist of only operating leases. Operating leases are recognized on the balance sheet as ROU lease assets, lease liabilities current and lease liabilities non-current. Fixed rents are included in the calculation of the lease balances while certain variable costs paid for certain operating and pass-through costs are excluded. Lease expense is recognized over the expected term on a straight-line basis.

XML 21 R10.htm IDEA: XBRL DOCUMENT v3.22.2
Marketable Securities
6 Months Ended
Jun. 30, 2022
Investments, Debt and Equity Securities [Abstract]  
Marketable Securities

3. Marketable securities

Marketable securities by security type consisted of the following:

 

 

 

June 30, 2022

 

(in thousands)

 

Amortized
cost

 

 

Gross
unrealized
gains

 

 

Gross
unrealized
losses*

 

 

Fair
value

 

U.S. treasury bills and notes

 

$

215,407

 

 

$

 

 

$

(930

)

 

$

214,477

 

U.S. agency securities

 

 

6,203

 

 

 

 

 

 

(8

)

 

 

6,195

 

Total

 

$

221,610

 

 

$

 

 

$

(938

)

 

$

220,672

 

 

 

 

December 31, 2021

 

(in thousands)

 

Amortized
cost

 

 

Gross
unrealized
gains

 

 

Gross
unrealized
losses*

 

 

Fair
value

 

U.S. treasury bills and notes

 

$

277,559

 

 

$

 

 

$

(218

)

 

$

277,341

 

U.S. agency securities

 

 

18,781

 

 

 

 

 

 

(10

)

 

 

18,771

 

Total

 

$

296,340

 

 

$

 

 

$

(228

)

 

$

296,112

 

*The Company reviews its marketable securities for impairment each period whenever the fair value of a marketable security is less than the amortized cost and evidence indicates that a marketable security’s carrying amount is not recoverable. As of June 30, 2022 and December 31, 2021, the Company expected its investments to recover through the remaining term of the security and concluded no impairment existed.

The remaining contractual maturities of all marketable securities were less than one year as of June 30, 2022 and December 31, 2021.

XML 22 R11.htm IDEA: XBRL DOCUMENT v3.22.2
Property and equipment, net
6 Months Ended
Jun. 30, 2022
Property, Plant and Equipment [Abstract]  
Property and equipment, net

4. Property and equipment, net

Property and equipment, net, consist of the following:

 

(in thousands)

 

June 30, 2022

 

 

December 31, 2021

 

Lab equipment

 

$

13,509

 

 

$

8,567

 

Furniture and fixtures

 

 

1,618

 

 

 

566

 

Computer equipment

 

 

448

 

 

 

158

 

Leasehold improvements

 

 

274

 

 

 

266

 

Total property and equipment

 

 

15,849

 

 

 

9,557

 

Less accumulated depreciation

 

 

(3,495

)

 

 

(2,333

)

Property and equipment, net

 

$

12,354

 

 

$

7,224

 

 

Depreciation expense for the three and six months ended June 30, 2022 was $0.6 million and $1.2 million, respectively.

Depreciation expense for the three and six months ended June 30, 2021 was $0.4 million and $0.7 million, respectively.

XML 23 R12.htm IDEA: XBRL DOCUMENT v3.22.2
Fair value of financial instruments
6 Months Ended
Jun. 30, 2022
Fair Value Disclosures [Abstract]  
Fair value of financial instruments

5. fair value of financial instruments

The Company’s financial instruments that are measured at fair value on a recurring basis consist of money market funds, marketable securities, and a derivative liability (success payment liability) pursuant to our license agreements with the President and Fellows of Harvard College, or Harvard, and The Broad Institute, Inc., or Broad, which license agreements are referred to herein as the Harvard/Broad License Agreement and Broad License Agreement.

The following tables set forth the fair value of the Company’s financial instruments by level within the fair value hierarchy:

 

 

 

As of June 30, 2022

 

(in thousands)

 

Fair
value

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

36,302

 

 

$

36,302

 

 

$

 

 

$

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury bills and notes

 

 

214,477

 

 

 

 

 

 

214,477

 

 

 

 

U.S. agency securities

 

 

6,195

 

 

 

 

 

 

6,195

 

 

 

 

Total assets

 

$

256,974

 

 

$

36,302

 

 

$

220,672

 

 

$

 

Liabilities

 

 

 

 

 

 

 

 

 

 

 

 

Success payment liability

 

$

1,756

 

 

$

 

 

$

 

 

$

1,756

 

Total liabilities

 

$

1,756

 

 

$

 

 

$

 

 

$

1,756

 

 

 

 

 

As of December 31, 2021

 

(in thousands)

 

Fair
value

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

58,127

 

 

$

58,127

 

 

$

 

 

$

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury bills and notes

 

 

277,341

 

 

 

 

 

 

277,341

 

 

 

 

U.S. agency securities

 

 

18,771

 

 

 

 

 

 

18,771

 

 

 

 

Total assets

 

$

354,239

 

 

$

58,127

 

 

$

296,112

 

 

$

 

Liabilities

 

 

 

 

 

 

 

 

 

 

 

 

Success payment liability

 

$

4,371

 

 

$

 

 

$

 

 

$

4,371

 

Total liabilities

 

$

4,371

 

 

$

 

 

$

 

 

$

4,371

 

 

Cash Equivalents—Cash equivalents of $36.3 million and $58.1 million as of June 30, 2022 and December 31, 2021, respectively, consisted of money market funds and are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices in active markets.

Marketable Securities—The Company measures its marketable securities at fair value on a recurring basis and classifies those instruments within Level 2 of the fair value hierarchy. Marketable securities are classified within Level 2 of the fair value hierarchy because pricing inputs are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date, and fair value is determined through the use of models or other valuation methodologies.

Antidilution Rights Liability—The antidilution rights liability represented the obligation to issue additional shares of common stock to Harvard and Broad following the completion of (1) a defined aggregate level of preferred stock financing and (2) either a sale of the Company’s preferred stock, an initial public offering, or a company sale meeting a certain value threshold. The antidilution rights liability is stated at fair value and is considered Level 3 in the fair value hierarchy because its fair value measurement is based, in part, on significant inputs not observed in the market. The antidilution rights liability related to meeting a defined aggregate level of preferred stock financing was valued using a probability-weighted present value model that considered the probability of meeting the defined aggregate level of preferred stock financing, as well as the fair value of the Company’s common stock. The antidilution rights liability related to the achievement of a specified valuation through either a sale of the Company’s preferred stock, an initial public offering, or a company sale was valued using a Monte Carlo simulation model, which models the value of the liability based on several key variables, including probability of event occurrence, timing of event occurrence, as well as the fair value of the Company’s common stock.

In June 2021, upon completion of its IPO, the Company settled the antidilution rights liability in full through the issuance of 878,098 shares of the Company's common stock for a settlement amount of $32.5 million. Prior to settlement, the Company remeasured the liability with a corresponding increase of $26.0 million and $25.6 million to other expense for

the three and six months ended June 30, 2021, respectively. As the antidilution rights liability was settled in full in June 2021, there were no amounts for such liability included in the condensed consolidated balance sheet as of June 30, 2022 or December 31, 2021.

Success Payment Liability—The Company is obligated to pay to Harvard and Broad tiered success payments in the event its average market capitalization exceeds specified thresholds for a specified period of time ascending from a high nine-digit dollar amount to $10.0 billion, or sale of the Company for consideration in excess of those thresholds. In the event of a change of control or a sale of the Company, the Company is required to pay success payments in cash within a specified period following such event. Otherwise, the success payments may be settled at the Company’s option in either cash or shares of its common stock, or a combination of cash and shares of its common stock. The maximum aggregate success payments that could be payable by the Company is $31.3 million (after termination of the Broad License Agreement).

The success payments liability is stated at fair value and is considered Level 3 because its fair value measurement is based, in part, on significant inputs not observed in the market. The Company used a Monte Carlo simulation model, which models the value of the liability based on several key variables, including probability of event occurrence, timing of event occurrence, as well as the value of the Company’s common stock. The Company also estimated the likelihood that it would maintain the Harvard/Broad License Agreement based on its ongoing research efforts.

The Company remeasured the liability at fair value with decreases of $0.9 million and $2.6 million recorded to other income for the three and six months ended June 30, 2022, respectively, and increases of $10.0 million and $9.7 million recorded to other expense for the three and six months ended June 30, 2021, respectively.

In September 2021, multiple success payments were triggered and amounts due to Harvard and Broad totaled $6.3 million. These amounts were settled in cash in November 2021. The Company will continue to adjust the remaining success payment liability for changes in fair value until the earlier of the achievement or expiration of the obligation.

The primary inputs used in valuing the success payments liability associated with the Company’s realization of a certain valuation threshold, were as follows:

 

 

 

At
June 30,
2022

 

 

At
December 31,
2021

 

Fair value of common stock (per share)

 

$

15.28

 

 

$

36.87

 

Equity volatility

 

 

88

%

 

 

77

%

 

In February 2021, the Company provided written notice to Broad of its election to terminate the Broad License Agreement, which termination became effective in June 2021.

The reconciliation of changes in the fair value of financial instruments based on Level 3 inputs for the six months ended June 30, 2022 is as follows:

 

(in thousands)

 

Success
payment
liability

 

Balance at December 31, 2021

 

$

4,371

 

Changes in fair value

 

 

(2,615

)

Balance at June 30, 2022

 

$

1,756

 

 

The reconciliation of changes in the fair value of financial instruments based on Level 3 inputs for the six months ended June 30, 2021 is as follows:

 

(in thousands)

 

Antidilution rights liability

 

 

Success
payment
liability

 

 

Total

 

Balance at December 31, 2020

 

$

6,916

 

 

$

2,806

 

 

$

9,722

 

Issuance of common stock

 

 

(32,490

)

 

 

-

 

 

 

(32,490

)

Changes in fair value

 

 

25,574

 

 

 

9,654

 

 

 

35,228

 

Balance at June 30, 2021

 

$

 

 

$

12,460

 

 

$

12,460

 

XML 24 R13.htm IDEA: XBRL DOCUMENT v3.22.2
Accrued expenses
6 Months Ended
Jun. 30, 2022
Payables and Accruals [Abstract]  
Accrued expenses

6. Accrued expenses

Accrued expenses consist of the following:

 

(in thousands)

 

June 30,
2022

 

 

December 31,
2021

 

Accrued external research and development expenses

 

$

6,657

 

 

$

5,041

 

Employee compensation and related benefits

 

 

3,682

 

 

 

6,050

 

License and milestone payments

 

 

3,330

 

 

 

 

Professional fees

 

 

1,961

 

 

 

1,109

 

Other

 

 

2,990

 

 

 

792

 

Total

 

$

18,620

 

 

$

12,992

 

XML 25 R14.htm IDEA: XBRL DOCUMENT v3.22.2
Leases
6 Months Ended
Jun. 30, 2022
Leases [Abstract]  
Leases

7. Leases

The Company’s operating lease activity is comprised of non-cancelable facility leases for office and laboratory space in Cambridge, Massachusetts.

The Company has also entered into multiple contract research and contract manufacturing service agreements with third parties which contain embedded leases within the scope of ASC 842. The embedded leases are considered short term leases, as the contractual terms are 12 months or less. Accordingly, no lease liability or ROU asset has been recorded. The Company has recognized $1.0 million and $1.3 million of short term lease costs associated with the embedded leases during the three and six months ended June 30, 2022, respectively. The Company recognized $0.7 million and $1.2 million of short term lease costs associated with the embedded leases during the three and six months ended June 30, 2021, respectively.

The components of operating lease cost were as follows:

 

 

Three months ended June 30,

 

 

Six months ended June 30,

 

(in thousands)

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Operating lease costs

 

$

505

 

 

$

475

 

 

$

1,010

 

 

$

924

 

Variable lease costs

 

 

198

 

 

 

154

 

 

 

409

 

 

 

343

 

Total

 

$

703

 

 

$

629

 

 

$

1,419

 

 

$

1,267

 

Supplemental cash flow information related to operating leases was as follows:

 

 

Six months ended June 30,

 

(in thousands)

 

2022

 

 

2021

 

Cash paid for amounts included in the measurements of lease liabilities:

 

 

 

 

 

 

Operating cash flows related to operating leases

 

$

1,058

 

 

$

973

 

As of June 30, 2022, the Company’s operating leases were measured using a weighted-average incremental borrowing rate of 1.57% over a weighted-average remaining lease term of 0.4 years. As of June 30, 2021, the Company’s operating leases were measured using a weighted-average incremental borrowing rate of 4.69% over a weighted-average remaining lease term of 1.1 years.

On August 19, 2021, the Company entered into a lease agreement with ARE-MA Region No. 87 Tenant, LLC, a Delaware limited liability company (the “Landlord”), pursuant to which the Company will lease approximately 104,933 square feet of office and laboratory space located at 201 Brookline Avenue, Boston, Massachusetts (the “Boston Lease”), further amended in January 2022 to include an additional 211 square feet, for a total of 105,144 square feet (the “Premises”). In June 2022, the Company entered into a second amendment to specify separate target commencement dates for certain areas of the Premises. The Premises have not been made available to the Company as of June 30, 2022 and therefore the Boston Lease has not commenced.

The term of the Boston Lease will commence on the earlier of (1) the date the Landlord delivers the Premises to the Company, which the parties expect to be on or prior to August 18, 2022 for the initial premises and October 1, 2022, for the second floor premises, or (2) the date the Landlord could have delivered the Premises but for any delays attributable to the Company (the “Commencement Date”). The Company’s obligation for the payment of base rent for the Premises begins 90 days after the Commencement Date (the “Rent Commencement Date”) and will initially be $0.8 million per month, which will increase by approximately 3% per annum. The Boston Lease has a term of 10 years, measured from the Rent Commencement Date. The Company has the option to extend the term of the Boston Lease for a period of an additional five years. Under the terms of the Boston Lease, the Landlord has agreed to make up to $21.0 million in certain

tenant improvements to the Premises to suit the Company’s use (the “Tenant Improvement Allowance”), which amount is included in the base rent set forth in the Boston Lease. In addition to the Tenant Improvement Allowance, the Company may receive up to $5.2 million for additional improvements to the Premises, which amount is subject to an 8% annual interest charge and may be paid in equal monthly installments.

In connection with its entry into the Boston Lease and as a security deposit, the Company has provided the Landlord a letter of credit in the amount of approximately $4.8 million, which may be reduced to approximately $3.5 million on the expiration of the 36-month anniversary of the Rent Commencement Date so long as there are, and have been, no defaults by the Company under the terms of the Boston Lease. The Company also paid a deposit in the amount of $0.8 million, which is equal to the first month of base rent.

The Landlord has the right to terminate the Boston Lease upon customary events of default. The Company may also terminate the Boston Lease if the Premises are not ready for occupancy within a specified time period after September 1, 2022.

The Boston Lease requires the Landlord to perform a scope of work to build-out the base building prior to the construction of the Premises. The Company concluded the accounting commencement date will occur when the Landlord completes the build-out of the base building and control passes to the Company. The Company will assess the classification of the Boston Lease at the accounting commencement date, and measure the ROU asset and lease liability. Payments made by the Company prior to commencement will be treated as prepaid rent which will increase the ROU asset. As of June 30, 2022 the Company has incurred an aggregate of $6.2 million related to the build out of the Premises prior to the Commencement Date.

In October 2021, the Company entered into a sublease for 11,931 square feet of office and laboratory space in Cambridge, Massachusetts. The sublease commenced in December 2021 and has an initial noncancelable term of 12 months. The Company had the option to extend the sublease for one extension term of three months by written notice not less than six months prior to the expiration of the sublease term. The Company did not exercise this option. Therefore, this sublease is treated as a short term lease. The total fixed lease payments over the sublease term are approximately $1.4 million and the Company is also required to pay its proportional share of operating expenses.

Future minimum commitments under non-cancellable leases as of June 30, 2022 were as follows:

Years ending December 31,

 

Amount

 

 

 

(in thousands)

 

Remainder of 2022

 

$

2,337

 

2023

 

 

9,691

 

2024

 

 

9,982

 

2025

 

 

10,281

 

2026

 

 

10,590

 

Thereafter

 

 

65,196

 

Total lease payments

 

$

108,077

 

Less: interest

 

 

(2

)

Present value of operating lease liabilities

 

$

108,075

 

During the three and six months ended June 30, 2022, the Company incurred rent expense of $0.8 million and $1.7 million, respectively. During the three and six months ended June 30, 2021, the Company incurred rent expense of $0.5 million and $0.9 million, respectively.

XML 26 R15.htm IDEA: XBRL DOCUMENT v3.22.2
License Agreements
6 Months Ended
Jun. 30, 2022
License Agreement [Abstract]  
License Agreement

8. License agreements

The Company's significant license agreements are disclosed in Note 8, "License agreements," in the audited consolidated financial statements for the year ended December 31, 2021, and notes thereto, included in the Company’s Annual Report on Form 10-K filed with the SEC on March 14, 2022. Since the date of those financial statements, there have been no changes to its license agreements, except as noted below and as noted in Note 14, "Subsequent events."

Harvard/Broad license agreement and Broad license agreement

In March 2019, the Company simultaneously entered into the Harvard/Broad License Agreement and Broad License Agreement (the “license agreements”) for certain base editing technologies pursuant to which the Company received exclusive, worldwide, sublicensable, royalty-bearing licenses under specified patent rights to develop and commercialize licensed products and nonexclusive, worldwide, sublicensable, royalty-bearing licenses under certain patent rights to research and develop licensed products. The Company agreed to use commercially reasonable efforts to develop licensed products in accordance with the development plans, to introduce any licensed products that gain regulatory approval into the commercial market, to market licensed products that have gained regulatory approval following such

introduction into the market, and to make licensed products that have gained regulatory approval reasonably available to the public. The term of the agreements will continue until the expiration of the last to expire valid claim. The Company may terminate either of the license agreements without cause upon four months’ prior written notice to Harvard and Broad, unless terminated earlier. In February 2021, the Company provided written notice to Broad of its intent to terminate the Broad License Agreement, which termination was effective in June 2021.

As partial consideration for the rights granted under the Harvard/ Broad License Agreement and Broad License Agreement, the Company paid $0.3 million in non-refundable upfront license fees and also issued 276,075 shares of its common stock with a fair value of $0.3 million. Additional consideration under the license agreements is as follows:

Antidilution Rights—The initial shares of common stock issued to Harvard and Broad were subject to antidilution provisions as further described in Note 5, "Fair value of financial instruments." The antidilution rights associated with the Company achieving a defined aggregate level of preferred stock financing were partially satisfied in 2019 and fully satisfied in 2020, which settlement amounts totaled $0.1 million and $0.5 million, respectively, and which amounts were settled through issuances of 121,411 and 187,867 shares of common stock, respectively. The remaining antidilution rights obligation was fully satisfied in the three months ended June 30, 2021 with the Company’s IPO. The settlement amount totaled $32.5 million, and was settled through issuance of 878,098 shares of common stock.

Success Payments—The Company is required to make success payments under the license agreements as further described in Note 5, "Fair value of financial instruments." In September 2021, certain success payments were triggered and amounts due to Harvard and Broad totaled $6.3 million. These amounts were settled in cash in November 2021.

Other Payments—The Company agreed to pay an annual license maintenance fee ranging from low-to-mid five figures to low six figures, depending on the particular calendar year, for each of the license agreements. The Company is responsible for the payment of certain patent prosecution and maintenance costs incurred by Harvard and Broad related to licensed patents. To the extent achieved, the Company is obligated to pay up to an aggregate of $46.2 million and $108 million in development and sales-based milestones, respectively. During the three months ended March 31, 2022, the first milestone was triggered and amounts due to Harvard and Broad totaled $0.3 million. These amounts remain payable as of June 30, 2022 and will be settled in cash. If the Company undergoes a change of control during the term of the license agreements, then certain of the milestone payments would be increased by a mid-double-digit percentage. To the extent there are sales of a licensed product, the Company is required to pay low single digit royalties on net sales, for each of the license agreements. The Company is entitled to certain reductions and offsets on these royalties with respect to a licensed product in a given country.

Beam license agreement

In April 2019, the Company and Beam Therapeutics, Inc. ("Beam") entered into a collaboration and license agreement (the “Beam Agreement”). Pursuant to the Beam Agreement, the Company received an exclusive, worldwide, sublicensable license under certain of Beam’s base editing technology, gene editing, and delivery technologies to develop, make, use, offer for sale, sell and import base editing products and nuclease products using Beam’s CRISPR associated protein 12b, or Cas12b technology, in each case, directed to any of four gene targets, including the PCSK9 and ANGPTL3 genes, that are associated with an increased risk of coronary diseases. In addition, the Company granted Beam an exclusive, worldwide, sublicensable license under certain of its delivery technology to develop, manufacture, sell and import product candidates and products, except for base editor products licensed to Verve.

Both parties may conduct certain activities in accordance with an agreed-upon research and/or development plan. Following the dosing of the final patient in a Phase 1 clinical trial of a given licensed product, Beam has the right to opt in to share 33% of worldwide expenses of the development of such licensed product, as well as jointly commercialize and share profits and expenses of commercializing such licensed product in the United States on a 50/50 basis. If Beam exercises its opt-in right for a given licensed product, which we refer to following such opt-in as a collaboration product, it will be obligated to pay for a specified percentage of the development and commercialization costs of such collaboration product and will have the right to receive a specified percentage of the profits from any sales of such collaboration product. The term of the Beam Agreement continues until the last to expire of any royalty term for any product. The Company has the right to terminate the Beam Agreement as to any licensed product, but not for any collaboration product, by delivering a 90-day termination notice to Beam, provided that Beam has elected not to exercise its opt-in right or the period to exercise such opt-in right has expired. The Company is responsible for all costs and expenses incurred in the conduct of activities under the research plan, any development plan and any costs and expenses for the development of a licensed product for which Beam has not elected to opt-in.

As partial consideration for the license rights granted by Beam under the Beam Agreement, the Company paid a one-time, nonrefundable fee through issuing 276,075 shares of its common stock with a fair value of $0.3 million. To the extent achieved, for each licensed product, the Company is also obligated to pay up to $11.3 million in development and regulatory-based milestones and $15.0 million in sales-based milestones. To the extent there are sales of a licensed

product, the Company is required to pay low-to-mid single digit royalties on net sales. To the extent achieved, for each collaboration product outside of the United States, the Company is obligated to pay up to $5.6 million in development and regulatory-based milestones and $7.5 million in sales-based milestones. To the extent there are ex-U.S. sales of a collaboration product, the Company is required to pay low-to-mid single digit royalties on net sales. Due to the submission of the Company's CTA in New Zealand, a milestone payment of $0.2 million was triggered during the period ending June 30, 2022.

On July 5, 2022, the Company entered into an Amended and Restated Collaboration and License Agreement with Beam (the “Amended Beam Agreement”), which is further described in Note 14, “Subsequent events.”

To the extent there are sales of a delivery technology product, each party will pay the other party low-to-mid single digit royalties based on the annual aggregate worldwide net sales resulting from the sale of each delivery technology product of such paying party; provided, however, that such royalty payments will not apply to net sales of the collaboration products or licensed products. The Company concluded the receipt of any milestone or royalty payments under the Beam Agreement was not probable as of June 30, 2022.

Beam materials exchange letter agreement

In October 2020, the Company and Beam entered into a materials exchange agreement wherein the parties agreed that Beam would provide certain mRNA, gRNA, and protein to the Company and that the Company would provide certain gRNAs to Beam at an agreed upon price per each material provided.

For the three and six months ended June 30, 2022 and 2021, the Company did not purchase any materials from Beam.

For the three and six months ended June 30, 2022, the Company did not sell any materials to Beam. For the three months ended June 30, 2021, the Company did not sell any materials to Beam. For the six months ended June 30, 2021, the Company recognized $0.2 million as a reduction to research and development expense related to reimbursements received for materials sold to Beam.

Acuitas agreements

Development and option agreement

In December 2019, the Company and Acuitas Therapeutics, Inc. ("Acuitas") entered into a development and collaboration agreement, which agreement was amended and restated in October 2020. The Company agreed to reimburse Acuitas on a quarterly basis for its services performed related to the program activities based on an agreed upon number of fulltime employees committed to work on the program at an annual rate per employee, including reimbursement of reasonable external costs. The Company recognized research and development expense of less than $0.1 million and $0.1 million during the three and six months ended June 30, 2022, respectively, and $0.3 million and $0.6 million for the three and six months ended June 30, 2021, respectively, related to the reimbursement of research and development services provided by Acuitas and technology maintenance fees.

License agreement

In October 2020, the Company paid Acuitas a non-refundable, upfront license fee of $2.0 million (less a previously paid target reservation fee) to exercise an option with respect to a licensed product and a licensed genome target and entered into a non-exclusive, worldwide license with Acuitas, with a right to sub-license through multiple tiers, under the licensed LNP technology to research, develop and commercialize the licensed products using the LNP technology in connection with the PCSK9 gene target for all human therapeutic or prophylactic uses.

To the extent achieved, the Company is also obligated to pay up to an aggregate of $9.8 million in clinical and regulatory milestones and $9.5 million in sales-based milestones. The milestones have not been achieved and no expense has been recorded for these milestones as of June 30, 2022.

Third-party license agreements

In October 2021, the Company entered into a license agreement with a third party to obtain a non-exclusive license to certain technology the Company is using for research and development. As consideration for the license and rights granted under the agreement, the Company made a one-time, non-refundable, upfront payment of $0.8 million during the three months ended December 31, 2021. The license agreement provides for specified development milestones relating to the licensed technology and requires the Company to make payments upon achievement of each milestone up to an aggregate amount of $10.0 million. The milestones have not been achieved and no expense has been recorded for these milestones as of June 30, 2022.

In June 2022, the Company amended the agreement to include three additional licensed products to the scope of the non-exclusive license. In consideration of the additional licensed products, the Company was required to make a one-time,

non-refundable upfront payment of $2.8 million to such third party. This amount remained payable as of June 30, 2022 and was settled in cash in July 2022.

XML 27 R16.htm IDEA: XBRL DOCUMENT v3.22.2
Preferred and Common Stock
6 Months Ended
Jun. 30, 2022
Preferred Stock [Abstract]  
Preferred and Common Stock . Preferred and common stock

In January 2021, the Company issued 77,163,022 shares of Series B Preferred Stock at a price of $1.2182 per share for gross proceeds of $94.0 million. The Company incurred issuance costs in connection with this transaction of $0.2 million.

In June 2021, the Company amended and restated its certificate of incorporation to authorize 5,000,000 shares of preferred stock, which shares of preferred stock are currently undesignated, and 200,000,000 shares of common stock, $0.001 par value per share.

In June 2021, the Company completed its IPO, pursuant to which the Company issued and sold 16,141,157 shares of its common stock, including 2,105,368 shares pursuant to the full exercise of the underwriters' option to purchase additional shares, at a public offering price of $19.00 per share, for aggregate gross proceeds of $306.7 million. The Company received approximately $281.6 million in net proceeds, after deducting underwriting discounts and offering expenses payable by the Company.

Upon the closing of the IPO, all outstanding shares of the Company's preferred stock automatically converted into 27,720,923 shares of the Company's common stock.

In June 2021, the Company issued 878,098 shares of its common stock to Harvard and Broad as final settlement of its antidilution rights obligation.

The holders of common stock are entitled to one vote for each share of common stock.

XML 28 R17.htm IDEA: XBRL DOCUMENT v3.22.2
Stock-based compensation
6 Months Ended
Jun. 30, 2022
Share-based Payment Arrangement [Abstract]  
Stock-based compensation

10. Stock-based compensation

The 2018 Equity Incentive Plan, or the 2018 Plan, adopted by the board of directors in August 2018 provided for the grant of qualified incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock and restricted stock units to the Company’s employees, officers, directors, advisors, and outside consultants for the issuance or purchase of shares of the Company’s common stock. The maximum number of shares of common stock that were authorized for issuance under the 2018 Plan was 6,885,653.

In June 2021, the Company's board of directors adopted, and the Company's stockholders approved, the 2021 Stock Incentive Plan, or the 2021 Plan, which became effective on June 16, 2021. The 2021 Plan provides for grant of qualified and nonqualified stock options, stock appreciation rights, restricted and unrestricted stock and stock units, performance awards, and other share-based awards to the Company's employees, directors, advisors and outside consultants. Under the 2021 Plan, the number of shares of common stock initially reserved for issuance was the sum of: (1) 3,466,530; plus (2) the number of shares as was equal to the sum of (x) the number of shares of common stock reserved for issuance under the 2018 Plan that remained available for grant under the 2018 Plan on June 16, 2021 and (y) the number of shares of common stock subject to outstanding awards granted under the 2018 Plan that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right; plus (3) an annual increase, to be added on the first day of each fiscal year, commencing on January 1, 2022 and continuing until, and including, January 1, 2031, equal to the lesser of (i) 5% of the number of shares of common stock outstanding on such date and (ii) the number of shares of common stock determined by the Company’s board of directors.

On January 1, 2022, 2,425,587 shares of the Company's common stock were added to the amount reserved for issuance under the 2021 Plan in accordance with the 2021 Plan described above. As of June 30, 2022, the Company had reserved 7,057,629 shares of the Company's common stock for issuance of equity awards, of which 3,456,180 shares remained available for future grant under the 2021 Plan. Upon effectiveness of the 2021 Plan, the Company ceased granting additional awards under the 2018 Plan.

Stock-based compensation expense recorded in the condensed consolidated statements of operations and comprehensive loss is as follows:

 

 

 

Three months ended June 30,

 

 

Six months ended June 30,

 

(in thousands)

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Research and development

 

$

2,955

 

 

$

708

 

 

$

5,421

 

 

$

1,021

 

General and administrative

 

 

2,694

 

 

 

643

 

 

 

4,432

 

 

 

1,000

 

Total stock-based compensation expense

 

$

5,649

 

 

$

1,351

 

 

$

9,853

 

 

$

2,021

 

 

Stock options

The following table provides a summary of stock option activity during the six months ended June 30, 2022:

 

 

 

Number of
options

 

 

Weighted
average
exercise
price per
share

 

 

Weighted
average
remaining
contractual
life (in years)

 

 

Aggregate
intrinsic
value
(2)
(in thousands)

 

Outstanding at December 31, 2021

 

 

6,119,295

 

 

$

9.44

 

 

 

 

 

 

 

Granted

 

 

2,103,350

 

 

 

27.34

 

 

 

 

 

 

 

Exercised

 

 

(172,699

)

 

 

3.62

 

 

 

 

 

 

 

Forfeited

 

 

(164,729

)

 

 

25.77

 

 

 

 

 

 

 

Outstanding at June 30, 2022

 

 

7,885,217

 

 

$

14.09

 

 

 

8.5

 

 

$

52,868

 

Exercisable at June 30, 2022

 

 

2,301,148

 

 

$

4.40

 

 

 

7.8

 

 

$

25,676

 

Expected to vest after June 30, 2022(1)

 

 

5,584,069

 

 

$

18.08

 

 

 

8.8

 

 

$

27,192

 

 

(1)
This represents the number of unvested options outstanding as of June 30, 2022 that are expected to vest in the future.
(2)
The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the common stock for the options that were in the money as of June 30, 2022.

As of June 30, 2022, there was $66.3 million of unrecognized compensation cost related to unvested stock options, which is expected to be recognized over a weighted-average period of approximately 2.8 years.

Restricted stock units

During the six months ended June 30, 2022, the Company granted 524,875 restricted stock units under the 2021 Plan. These restricted stock units vest annually over a four-year period.

A summary of the status of and change in unvested restricted stock units as of June 30, 2022 was as follows:

 

 

 

Shares

 

 

Weighted-
average grant
date fair
value per share

 

Unvested restricted stock units as of December 31, 2021

 

 

32,000

 

 

$

36.58

 

Restricted stock units granted

 

 

524,875

 

 

$

20.48

 

Restricted stock units forfeited

 

 

(4,500

)

 

$

30.94

 

Unvested restricted stock units as of June 30, 2022

 

 

552,375

 

 

$

21.33

 

 

As of June 30, 2022, there was $11.0 million of unrecognized stock-based compensation expense related to restricted stock units that are expected to vest. These costs are expected to be recognized over a weighted-average remaining vesting period of approximately 3.9 years.

2021 Amended and Restated Employee Stock Purchase Plan

In June 2021, the board of directors adopted, and the Company's stockholders approved, the 2021 Employee Stock Purchase Plan, or the ESPP, as amended and restated, which became effective on June 16, 2021. The Company initially reserved 433,316 shares of common stock for sale under the ESPP. The aggregate number of shares reserved for sale under the ESPP increases automatically on the first day of each fiscal year commencing on January 1, 2022 through January 1, 2031, by the number of shares equal to the least of (a) 1,083,290 shares, (b) 1% of the total outstanding shares of common stock on such date, and (c) a number of shares as may be determined by the board of directors in any particular year. The first offering period under the ESPP commenced on June 16, 2021 and ended on December 13, 2021. On January 1, 2022, 485,117 shares of common stock were added to the amount reserved for sale under the ESPP. As of June 30, 2022, 844,918 shares remained available for issuance under the ESPP. The second offering period ended on May 31, 2022, for which offering period the Company issued 25,218 shares. The next offering period commenced on June 1, 2022 and will end on November 30, 2022.

XML 29 R18.htm IDEA: XBRL DOCUMENT v3.22.2
Net Loss Per Share Attributable to Common Stockholders
6 Months Ended
Jun. 30, 2022
Earnings Per Share [Abstract]  
Net Loss Per Share Attributable to Common Stockholders

11. Net loss per share attributable to common stockholders

 

The Company’s potential dilutive securities, which include convertible preferred stock, unvested restricted stock, unvested restricted stock units and common stock options, have been excluded from the computation of diluted net loss per share as the effects would be anti-dilutive. Therefore, the weighted average number of common shares outstanding used to

calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders for the period indicated because including them would have had an anti-dilutive effect:

 

 

 

As of June 30,

 

 

 

2022

 

 

2021

 

Unvested restricted stock

 

 

 

 

268,816

 

Unvested restricted stock units

 

 

552,375

 

 

 

 

Outstanding options to purchase common stock

 

 

7,885,217

 

 

 

5,720,987

 

Total

 

 

8,437,592

 

 

 

5,989,803

 

XML 30 R19.htm IDEA: XBRL DOCUMENT v3.22.2
Income Taxes
6 Months Ended
Jun. 30, 2022
Income Tax Disclosure [Abstract]  
Income Taxes

12. Income taxes

Deferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using statutory rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized. Due to the uncertainty surrounding the realization of the favorable tax attributes in future tax returns, the Company has recorded a full valuation allowance against the Company’s otherwise recognizable net deferred tax assets.
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.22.2
Related Party Transactions
6 Months Ended
Jun. 30, 2022
Related Party Transactions [Abstract]  
Related Party Transactions

13. Related party transactions

An executive officer of Beam is a board member of the Company. In October 2020, the Company and Beam entered into a materials exchange agreement wherein the parties agreed that Beam would provide certain mRNA, gRNA, and protein to the Company and that the Company would provide certain gRNAs to Beam at an agreed upon price per each material provided. For the three months ended June 30, 2021, the Company did not sell any materials to Beam. For the six months ended June 30, 2021, the Company recognized $0.2 million as a reduction to research and development expense related to reimbursements received for materials sold to Beam. For the three and six months ended June 30, 2022, the Company did not sell any materials to Beam.

In October 2021, the Company entered into a sublease agreement with Beam for laboratory and office space in Cambridge, Massachusetts. The sublease commenced in December 2021. Total expenses incurred under this sublease were $0.5 million and $1.0 million for the three and six months ended June 30, 2022, respectively.

An executive of Broad was a board member of the Company until May 2021. In March 2019, the Company simultaneously entered into the Harvard/Broad License Agreement and Broad License Agreement for certain base editing technologies pursuant to which the Company received exclusive, worldwide, sublicensable, royalty-bearing licenses under specified patent rights to develop and commercialize licensed products and nonexclusive, worldwide, sublicensable, royalty-bearing licenses under certain patent rights to research and develop licensed products. Additional consideration under the license agreements include success payments. See Note 8, "License agreements."
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.22.2
Subsequent Events
6 Months Ended
Jun. 30, 2022
Subsequent Events [Abstract]  
Subsequent Events

14. Subsequent events

Amended and Restated Collaboration and License Agreement

On July 5, 2022, the Company entered into the Amended Beam Agreement.

Pursuant to the Amended Beam Agreement, Beam granted the Company an exclusive, worldwide, sublicensable license under certain of Beam’s base editing technology to develop and commercialize products directed towards an additional liver-mediated, cardiovascular disease target. The Company will be responsible for the development and commercialization of products targeting such gene, subject to Beam’s opt-in right. Following the dosing of the final patient in a Phase 1 clinical trial of a licensed product for such gene, Beam has the right to opt-in to share 35% of worldwide expenses of the development of such licensed product, as well as jointly commercialize and share 35% of the profits and expenses of commercializing such licensed product worldwide. If Beam does not elect to opt-in, Beam would be entitled to receive milestones and royalties on the same basis as other collaboration products as provided in the Beam Agreement.

In exchange, the Company granted to Beam an exclusive, worldwide, sublicensable, fully paid-up license under the Company's intellectual property, including under the Company's GalNAc-LNP delivery technology, relating to a preclinical program developed by the Company.

In addition, the Amended Beam Agreement:

clarifies intellectual property rights with respect to the Company's GalNAc-LNP delivery technology;
grants Beam, on a target-by-target basis, the option to obtain a non-exclusive, worldwide, sublicensable license to the Company's GalNAc-LNP delivery technology for the development and commercialization of certain base editor products, as to which Beam would owe the Company a fee upon exercise of each option, certain regulatory and commercial sale milestones as well as low single-digit royalties on net sales for base editor products using the GalNAc-LNP delivery technology;
terminates the Company's rights and economic obligations under the Beam Agreement with respect to the undisclosed genes, allowing the Company and Beam to independently develop and commercialize products directed to such gene targets; and
concludes other licenses that applied under the Beam Agreement with respect to delivery and other technologies developed by the parties for the development and commercialization of base editor products.

The Amended Beam Agreement also contains representations and warranties, covenants, and other negotiated provisions, including confidentiality obligations, customary for transactions of this nature.

Strategic License and Collaboration Agreement

On July 18, 2022, the Company entered into the Vertex Agreement for an exclusive, four-year worldwide research collaboration focused on developing in vivo gene editing candidates toward an undisclosed target for the treatment of a single liver disease. Additionally, on July 18, 2022, the Company entered into the Stock Purchase Agreement with Vertex, pursuant to which the Company agreed to sell and issue shares of its common stock to Vertex.

Pursuant to the Vertex Agreement, the Company will be responsible for discovery, research and certain preclinical development of novel in vivo gene editing development candidates for the target of interest. The Company’s research activities will be focused on (i) identifying and engineering specific gene editing systems and in vivo delivery systems directed to the target and (ii) evaluating and optimizing development candidates to achieve criteria specified in the Vertex Agreement. Vertex will reimburse the Company’s research expenses consistent with an agreed-upon budget. The research term has an initial term of four years and may be extended by Vertex for up to one additional year.

Vertex will be solely responsible for subsequent development, manufacturing and commercialization of any product candidate resulting from the Company’s research efforts. The Company received an upfront payment from Vertex of $25 million on July 20, 2022. The Company is eligible to receive (i) success payments of up to $22 million for each product candidate (up to a maximum of $66 million) that achieves the applicable development criteria and (ii) up to an aggregate of $340 million in development and commercial milestone payments. The Company is also eligible to receive tiered single-digit royalties on net sales, subject to specified reductions. Such royalty payments will terminate on a country-by-country and product-by-product basis upon the later to occur of (i) the expiration of the last to expire valid claim under the patent rights covering such product in such country, (ii) the period of regulatory exclusivity associated with such product in such country or (iii) ten years after the first commercial sale of such product in such country.

Prior to the first patient dosing of the first Phase 1 clinical trial for the first product candidate developed under the Vertex Agreement, the Company also has the right to opt-in to a profit share arrangement pursuant to which Vertex and the Company would share the costs and net profits for all product candidates emerging from the collaboration. If the Company exercises its opt-in right, in lieu of milestones and royalties, the Company will be obligated to pay for a specified percentage of the development and commercialization costs, and it will have the right to receive a specified percentage of the profits from any sales of any product candidates advanced under the collaboration. At the time the Company exercises the option, it may elect a profit/cost share of up to 40% (with Vertex retaining a minimum of 60%). In order to exercise its opt-in right, the Company is required to pay a fee ranging from $25-70 million, depending on the profit/cost percentage elected by the Company and the licensed technology of the Company included in the most advanced product candidate at the time the Company exercises its opt-in right. Under all profit share scenarios, Vertex will control the worldwide development and commercialization of any product candidates resulting from the collaboration.

The Vertex Agreement includes customary representations and warranties, covenants and indemnification obligations for a transaction of this nature. The Company and Vertex each have the right to terminate the agreement for material breach by, or insolvency of, the other party following notice, and if applicable, a cure period. Vertex may also terminate the Vertex Agreement in its entirety for convenience upon 90 days’ notice.

Stock Purchase Agreement

On July 18, 2022, in connection with the execution of the Vertex Agreement, the Company and Vertex also entered into the Stock Purchase Agreement for the sale and issuance of 1,519,756 shares of the Company’s common stock to Vertex at a price of $23.03 per share, which is equal to the five-day volume-weighted average share price as of July 15, 2022, for an aggregate purchase price of $35.0 million. The sale of the Company’s common stock closed on July 20, 2022.

The Stock Purchase Agreement includes lock-up restrictions with respect to the shares of common stock issued to Vertex. Pursuant to the terms of the Stock Purchase Agreement, Vertex has agreed not to, and to cause its affiliates not to, sell or transfer any of the shares for a period of 12 months following the date of issuance of the shares, subject to specified conditions and exceptions.

Follow-on public offering

On July 25, 2022, the Company issued and sold 9,583,334 shares of its common stock, including 1,250,000 shares of its common stock sold pursuant to the underwriters’ full exercise of their option to purchase additional shares of common stock, at a public offering price of $27.00 per share. The Company received net proceeds of approximately $242.9 million from the sale of shares in the follow-on offering after deducting underwriting discounts and commissions of approximately $15.5 million and offering costs of approximately $0.3 million.

XML 33 R22.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of Significant Accounting Policies (Policies)
6 Months Ended
Jun. 30, 2022
Accounting Policies [Abstract]  
Cash, Cash Equivalents and Restricted Cash

Cash, cash equivalents and restricted cash

Restricted cash represents collateral provided for letters of credit issued as security deposits in connection with the Company’s leases of its corporate facilities. A reconciliation of the cash, cash equivalents, and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the statement of cash flows is as follows:

 

 

 

June 30,

 

 

June 30,

 

(in thousands)

 

2022

 

 

2021

 

Cash and cash equivalents

 

$

72,889

 

 

$

387,446

 

Restricted cash

 

 

5,237

 

 

 

463

 

Total cash, cash equivalents and restricted cash

 

$

78,126

 

 

$

387,909

 

Recently Adopted Accounting Pronouncements

Recently adopted accounting pronouncements

During the quarter ended September 30, 2021, the Company early adopted ASC Topic 842, “Leases” (“ASC 842”) using the revised modified retrospective approach as of January 1, 2021. The unaudited interim condensed consolidated financial statements for the three and six months ended June 30, 2021 have been retroactively adjusted to reflect the adoption of ASC 842, including retroactive adjustments to the unaudited interim condensed consolidated statement of cash flows and certain additional footnote disclosures as included herein. The adoption of ASC 842 had no material impact to the Company’s unaudited condensed consolidated statement of operations and comprehensive loss for the three and six months ended June 30, 2021.

At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on specific facts and circumstances, the existence of an identified asset(s), if any, and the Company’s control over the use of the identified asset(s), if applicable. The lease liability is measured at the present value of future lease payments, discounted using the discount rate as of the lease commencement date. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the incremental borrowing rate, which is the rate incurred to borrow, on a collateralized basis over a similar term, an amount equal to the lease payments in a similar economic environment. The Company recognizes a corresponding lease right of use (“ROU”) asset, initially measured as the amount of lease liability, adjusted for any initial lease costs or lease payments made before or at the commencement of the lease, and reduced by any lease incentives.

The Company’s leases consist of only operating leases. Operating leases are recognized on the balance sheet as ROU lease assets, lease liabilities current and lease liabilities non-current. Fixed rents are included in the calculation of the lease balances while certain variable costs paid for certain operating and pass-through costs are excluded. Lease expense is recognized over the expected term on a straight-line basis.

XML 34 R23.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of Significant Accounting Policies (Tables)
6 Months Ended
Jun. 30, 2022
Accounting Policies [Abstract]  
Reconciliation of Cash, Cash Equivalents and Restricted Cash A reconciliation of the cash, cash equivalents, and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the statement of cash flows is as follows:

 

 

 

June 30,

 

 

June 30,

 

(in thousands)

 

2022

 

 

2021

 

Cash and cash equivalents

 

$

72,889

 

 

$

387,446

 

Restricted cash

 

 

5,237

 

 

 

463

 

Total cash, cash equivalents and restricted cash

 

$

78,126

 

 

$

387,909

 

XML 35 R24.htm IDEA: XBRL DOCUMENT v3.22.2
Marketable Securities (Tables)
6 Months Ended
Jun. 30, 2022
Investments, Debt and Equity Securities [Abstract]  
Schedule of Marketable Securities by Security

Marketable securities by security type consisted of the following:

 

 

 

June 30, 2022

 

(in thousands)

 

Amortized
cost

 

 

Gross
unrealized
gains

 

 

Gross
unrealized
losses*

 

 

Fair
value

 

U.S. treasury bills and notes

 

$

215,407

 

 

$

 

 

$

(930

)

 

$

214,477

 

U.S. agency securities

 

 

6,203

 

 

 

 

 

 

(8

)

 

 

6,195

 

Total

 

$

221,610

 

 

$

 

 

$

(938

)

 

$

220,672

 

 

 

 

December 31, 2021

 

(in thousands)

 

Amortized
cost

 

 

Gross
unrealized
gains

 

 

Gross
unrealized
losses*

 

 

Fair
value

 

U.S. treasury bills and notes

 

$

277,559

 

 

$

 

 

$

(218

)

 

$

277,341

 

U.S. agency securities

 

 

18,781

 

 

 

 

 

 

(10

)

 

 

18,771

 

Total

 

$

296,340

 

 

$

 

 

$

(228

)

 

$

296,112

 

*The Company reviews its marketable securities for impairment each period whenever the fair value of a marketable security is less than the amortized cost and evidence indicates that a marketable security’s carrying amount is not recoverable. As of June 30, 2022 and December 31, 2021, the Company expected its investments to recover through the remaining term of the security and concluded no impairment existed.

XML 36 R25.htm IDEA: XBRL DOCUMENT v3.22.2
Property and equipment, net (Tables)
6 Months Ended
Jun. 30, 2022
Property, Plant and Equipment [Abstract]  
Schedule of Property and Equipment, net

Property and equipment, net, consist of the following:

 

(in thousands)

 

June 30, 2022

 

 

December 31, 2021

 

Lab equipment

 

$

13,509

 

 

$

8,567

 

Furniture and fixtures

 

 

1,618

 

 

 

566

 

Computer equipment

 

 

448

 

 

 

158

 

Leasehold improvements

 

 

274

 

 

 

266

 

Total property and equipment

 

 

15,849

 

 

 

9,557

 

Less accumulated depreciation

 

 

(3,495

)

 

 

(2,333

)

Property and equipment, net

 

$

12,354

 

 

$

7,224

 

XML 37 R26.htm IDEA: XBRL DOCUMENT v3.22.2
Fair Value of Financial Instruments (Tables)
6 Months Ended
Jun. 30, 2022
Fair Value Disclosures [Abstract]  
Schedule of Fair Value of Financial Instruments, Assets and Liabilities

The following tables set forth the fair value of the Company’s financial instruments by level within the fair value hierarchy:

 

 

 

As of June 30, 2022

 

(in thousands)

 

Fair
value

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

36,302

 

 

$

36,302

 

 

$

 

 

$

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury bills and notes

 

 

214,477

 

 

 

 

 

 

214,477

 

 

 

 

U.S. agency securities

 

 

6,195

 

 

 

 

 

 

6,195

 

 

 

 

Total assets

 

$

256,974

 

 

$

36,302

 

 

$

220,672

 

 

$

 

Liabilities

 

 

 

 

 

 

 

 

 

 

 

 

Success payment liability

 

$

1,756

 

 

$

 

 

$

 

 

$

1,756

 

Total liabilities

 

$

1,756

 

 

$

 

 

$

 

 

$

1,756

 

 

 

 

 

As of December 31, 2021

 

(in thousands)

 

Fair
value

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

58,127

 

 

$

58,127

 

 

$

 

 

$

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury bills and notes

 

 

277,341

 

 

 

 

 

 

277,341

 

 

 

 

U.S. agency securities

 

 

18,771

 

 

 

 

 

 

18,771

 

 

 

 

Total assets

 

$

354,239

 

 

$

58,127

 

 

$

296,112

 

 

$

 

Liabilities

 

 

 

 

 

 

 

 

 

 

 

 

Success payment liability

 

$

4,371

 

 

$

 

 

$

 

 

$

4,371

 

Total liabilities

 

$

4,371

 

 

$

 

 

$

 

 

$

4,371

 

Schedule of Fair Value Liabilities Measured on Recurring Basis

The primary inputs used in valuing the success payments liability associated with the Company’s realization of a certain valuation threshold, were as follows:

 

 

 

At
June 30,
2022

 

 

At
December 31,
2021

 

Fair value of common stock (per share)

 

$

15.28

 

 

$

36.87

 

Equity volatility

 

 

88

%

 

 

77

%

Schedule of Reconciliation of Changes in Fair Value of Financial Instruments

The reconciliation of changes in the fair value of financial instruments based on Level 3 inputs for the six months ended June 30, 2022 is as follows:

 

(in thousands)

 

Success
payment
liability

 

Balance at December 31, 2021

 

$

4,371

 

Changes in fair value

 

 

(2,615

)

Balance at June 30, 2022

 

$

1,756

 

 

The reconciliation of changes in the fair value of financial instruments based on Level 3 inputs for the six months ended June 30, 2021 is as follows:

 

(in thousands)

 

Antidilution rights liability

 

 

Success
payment
liability

 

 

Total

 

Balance at December 31, 2020

 

$

6,916

 

 

$

2,806

 

 

$

9,722

 

Issuance of common stock

 

 

(32,490

)

 

 

-

 

 

 

(32,490

)

Changes in fair value

 

 

25,574

 

 

 

9,654

 

 

 

35,228

 

Balance at June 30, 2021

 

$

 

 

$

12,460

 

 

$

12,460

 

XML 38 R27.htm IDEA: XBRL DOCUMENT v3.22.2
Accrued Expenses (Tables)
6 Months Ended
Jun. 30, 2022
Payables and Accruals [Abstract]  
Schedule of Accrued Expenses

Accrued expenses consist of the following:

 

(in thousands)

 

June 30,
2022

 

 

December 31,
2021

 

Accrued external research and development expenses

 

$

6,657

 

 

$

5,041

 

Employee compensation and related benefits

 

 

3,682

 

 

 

6,050

 

License and milestone payments

 

 

3,330

 

 

 

 

Professional fees

 

 

1,961

 

 

 

1,109

 

Other

 

 

2,990

 

 

 

792

 

Total

 

$

18,620

 

 

$

12,992

 

XML 39 R28.htm IDEA: XBRL DOCUMENT v3.22.2
Leases (Tables)
6 Months Ended
Jun. 30, 2022
Leases [Abstract]  
Components of Operating Lease Cost

The components of operating lease cost were as follows:

 

 

Three months ended June 30,

 

 

Six months ended June 30,

 

(in thousands)

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Operating lease costs

 

$

505

 

 

$

475

 

 

$

1,010

 

 

$

924

 

Variable lease costs

 

 

198

 

 

 

154

 

 

 

409

 

 

 

343

 

Total

 

$

703

 

 

$

629

 

 

$

1,419

 

 

$

1,267

 

Supplemental Cash Flow Information Related to Operating Leases

Supplemental cash flow information related to operating leases was as follows:

 

 

Six months ended June 30,

 

(in thousands)

 

2022

 

 

2021

 

Cash paid for amounts included in the measurements of lease liabilities:

 

 

 

 

 

 

Operating cash flows related to operating leases

 

$

1,058

 

 

$

973

 

Schedule of Future Minimum Lease Commitments under Non-Cancellable Leases

Future minimum commitments under non-cancellable leases as of June 30, 2022 were as follows:

Years ending December 31,

 

Amount

 

 

 

(in thousands)

 

Remainder of 2022

 

$

2,337

 

2023

 

 

9,691

 

2024

 

 

9,982

 

2025

 

 

10,281

 

2026

 

 

10,590

 

Thereafter

 

 

65,196

 

Total lease payments

 

$

108,077

 

Less: interest

 

 

(2

)

Present value of operating lease liabilities

 

$

108,075

 

XML 40 R29.htm IDEA: XBRL DOCUMENT v3.22.2
Stock-based compensation (Tables)
6 Months Ended
Jun. 30, 2022
Share-based Payment Arrangement [Abstract]  
Summary of Stock Based Compensation Expense

Stock-based compensation expense recorded in the condensed consolidated statements of operations and comprehensive loss is as follows:

 

 

 

Three months ended June 30,

 

 

Six months ended June 30,

 

(in thousands)

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Research and development

 

$

2,955

 

 

$

708

 

 

$

5,421

 

 

$

1,021

 

General and administrative

 

 

2,694

 

 

 

643

 

 

 

4,432

 

 

 

1,000

 

Total stock-based compensation expense

 

$

5,649

 

 

$

1,351

 

 

$

9,853

 

 

$

2,021

 

Schedule of Stock Option Activity

The following table provides a summary of stock option activity during the six months ended June 30, 2022:

 

 

 

Number of
options

 

 

Weighted
average
exercise
price per
share

 

 

Weighted
average
remaining
contractual
life (in years)

 

 

Aggregate
intrinsic
value
(2)
(in thousands)

 

Outstanding at December 31, 2021

 

 

6,119,295

 

 

$

9.44

 

 

 

 

 

 

 

Granted

 

 

2,103,350

 

 

 

27.34

 

 

 

 

 

 

 

Exercised

 

 

(172,699

)

 

 

3.62

 

 

 

 

 

 

 

Forfeited

 

 

(164,729

)

 

 

25.77

 

 

 

 

 

 

 

Outstanding at June 30, 2022

 

 

7,885,217

 

 

$

14.09

 

 

 

8.5

 

 

$

52,868

 

Exercisable at June 30, 2022

 

 

2,301,148

 

 

$

4.40

 

 

 

7.8

 

 

$

25,676

 

Expected to vest after June 30, 2022(1)

 

 

5,584,069

 

 

$

18.08

 

 

 

8.8

 

 

$

27,192

 

 

(1)
This represents the number of unvested options outstanding as of June 30, 2022 that are expected to vest in the future.
(2)
The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the common stock for the options that were in the money as of June 30, 2022.

As of June 30, 2022, there was $66.3 million of unrecognized compensation cost related to unvested stock options, which is expected to be recognized over a weighted-average period of approximately 2.8 years.

Schedule of Status and Change in Unvested Restricted Stock

A summary of the status of and change in unvested restricted stock units as of June 30, 2022 was as follows:

 

 

 

Shares

 

 

Weighted-
average grant
date fair
value per share

 

Unvested restricted stock units as of December 31, 2021

 

 

32,000

 

 

$

36.58

 

Restricted stock units granted

 

 

524,875

 

 

$

20.48

 

Restricted stock units forfeited

 

 

(4,500

)

 

$

30.94

 

Unvested restricted stock units as of June 30, 2022

 

 

552,375

 

 

$

21.33

 

XML 41 R30.htm IDEA: XBRL DOCUMENT v3.22.2
Net Loss Per Share Attributable to Common Stockholders (Tables)
6 Months Ended
Jun. 30, 2022
Earnings Per Share [Abstract]  
Potential Common Shares, Based on Amounts Outstanding at Period End were Excluded From the Computation of Diluted Net Loss Per Share Attributable to Common Stockholders The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders for the period indicated because including them would have had an anti-dilutive effect:

 

 

 

As of June 30,

 

 

 

2022

 

 

2021

 

Unvested restricted stock

 

 

 

 

268,816

 

Unvested restricted stock units

 

 

552,375

 

 

 

 

Outstanding options to purchase common stock

 

 

7,885,217

 

 

 

5,720,987

 

Total

 

 

8,437,592

 

 

 

5,989,803

 

XML 42 R31.htm IDEA: XBRL DOCUMENT v3.22.2
Nature of the Business and Basis of Presentation - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended
Jul. 25, 2022
Jul. 20, 2022
Jul. 18, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Jun. 21, 2021
Organization Consolidation And Presentation Of Financial Statements [Line Items]                
Common stock shares issued         48,709,652   48,511,735  
Common Stock, Par Value         $ 0.001   $ 0.001  
Issuance of common stock, value         $ 49   $ 49  
Stock Issued During Period, Value, New Issues       $ 281,584   $ (32,490)    
Proceeds from initial public offering, net of underwriting discount         0 $ 285,214    
Net proceeds from sale of common stock         $ 242,900      
Sale of common stock for future issuance         7,057,629      
Cash, cash equivalents, and marketable securities         $ 293,600      
Subsequent Event | Public offering                
Organization Consolidation And Presentation Of Financial Statements [Line Items]                
Common stock shares issued 1,250,000              
Underwriting discounts and commissions $ 15,500              
Offering Costs $ 300              
Shares issued and sold 9,583,334              
Net proceeds from sale of common stock $ 242,900              
Common Stock Offering Price Per Share $ 27.00              
Subsequent Event | Vertex Pharmaceuticals [Member]                
Organization Consolidation And Presentation Of Financial Statements [Line Items]                
Non Refundable Upfront Payment   $ 25,000            
Price Per Share     $ 23.03          
Aggregate purchase price per share     $ 35,000          
Public offering price per share     $ 23.03          
Proceeds from initial public offering, net of underwriting discount   $ 35,000            
Sale of common stock for future issuance     1,519,756          
Subsequent Event | Vertex Pharmaceuticals [Member] | Strategic License and Collaboration Agreement [Member]                
Organization Consolidation And Presentation Of Financial Statements [Line Items]                
Non Refundable Upfront Payment     $ 25,000          
Success payments for each product     22,000          
Development and commercial milestone payments under collaboration agreement     340,000          
Subsequent Event | Vertex Pharmaceuticals [Member] | Maximum | Strategic License and Collaboration Agreement [Member]                
Organization Consolidation And Presentation Of Financial Statements [Line Items]                
Success payments for each product     $ 66,000          
IPO                
Organization Consolidation And Presentation Of Financial Statements [Line Items]                
Reverse stock split         one-for-9.2595      
Shares issued upon conversion of preferred stock               27,720,923
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Jun. 30, 2021
Dec. 31, 2020
Accounting Policies [Abstract]        
Cash and cash equivalents $ 72,889 $ 64,330 $ 387,446  
Restricted cash 5,237   463  
Total cash, cash equivalents and restricted cash $ 78,126 $ 69,567 $ 387,909 $ 9,456
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Operating lease liability $ 108,075  
Operating lease right-of-use assets $ 839 $ 1,839
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.22.2
Marketable securities - Schedule of Marketable Securities (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Marketable Securities [Line Items]    
Debt Securities, Available-for-sale, Amortized Cost, Total $ 221,610 $ 296,340
Gross unrealized gains 0 0
Gross unrealized losses (938) (228)
Fair value 220,672 296,112
U.S. Treasury Bills and Notes [Member]    
Marketable Securities [Line Items]    
Debt Securities, Available-for-sale, Amortized Cost, Total 215,407 277,559
Gross unrealized gains 0 0
Gross unrealized losses (930) (218)
Fair value 214,477 277,341
U.S. Agency Securities [Member]    
Marketable Securities [Line Items]    
Debt Securities, Available-for-sale, Amortized Cost, Total 6,203 18,781
Gross unrealized gains 0 0
Gross unrealized losses (8) (10)
Fair value $ 6,195 $ 18,771
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.22.2
Marketable securities - Additional Information (Details)
6 Months Ended 12 Months Ended
Jun. 30, 2022
Dec. 31, 2021
Marketable Securities [Line Items]    
Remaining contractual maturities of marketable securities term 1 year 1 year
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.22.2
Property and Equipment, net - Schedule of Property and Equipment, net (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Property Plant And Equipment [Line Items]    
Total property and equipment $ 15,849 $ 9,557
Less accumulated depreciation (3,495) (2,333)
Property and equipment, net 12,354 7,224
Lab equipment    
Property Plant And Equipment [Line Items]    
Total property and equipment 13,509 8,567
Leasehold Improvements    
Property Plant And Equipment [Line Items]    
Total property and equipment 274 266
Furniture and Fixtures    
Property Plant And Equipment [Line Items]    
Total property and equipment 1,618 566
Computer Equipment    
Property Plant And Equipment [Line Items]    
Total property and equipment $ 448 $ 158
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.22.2
Property and Equipment, net - Additional Information (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Property, Plant and Equipment [Abstract]        
Depreciation $ 0.6 $ 0.4 $ 1.2 $ 0.7
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.22.2
Fair value of financial instruments - Summary of Assets and Liabilities Measured at Fair Value (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Assets    
Total assets $ 256,974 $ 354,239
Liabilities    
Total liabilities 1,756 4,371
Success Payment Liability    
Liabilities    
Total liabilities 1,756 4,371
U.S. Treasury Bills and Notes    
Assets    
Total assets 214,477 277,341
U.S. Agency Securities    
Assets    
Total assets 6,195 18,771
Level 1    
Assets    
Total assets 36,302 58,127
Liabilities    
Total liabilities 0 0
Level 1 | Success Payment Liability    
Liabilities    
Total liabilities 0 0
Level 1 | U.S. Treasury Bills and Notes    
Assets    
Total assets 0 0
Level 1 | U.S. Agency Securities    
Assets    
Total assets 0 0
Level 2    
Assets    
Total assets 220,672 296,112
Liabilities    
Total liabilities 0 0
Level 2 | Success Payment Liability    
Liabilities    
Total liabilities 0 0
Level 2 | U.S. Treasury Bills and Notes    
Assets    
Total assets 214,477 277,341
Level 2 | U.S. Agency Securities    
Assets    
Total assets 6,195 18,771
Level 3    
Assets    
Total assets 0 0
Liabilities    
Total liabilities 1,756 4,371
Level 3 | Success Payment Liability    
Liabilities    
Total liabilities 1,756 4,371
Level 3 | U.S. Treasury Bills and Notes    
Assets    
Total assets 0 0
Level 3 | U.S. Agency Securities    
Assets    
Total assets 0 0
Money Market Funds    
Assets    
Total assets 36,302 58,127
Money Market Funds | Level 1    
Assets    
Total assets 36,302 58,127
Money Market Funds | Level 2    
Assets    
Total assets 0 0
Money Market Funds | Level 3    
Assets    
Total assets $ 0 $ 0
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.22.2
Fair value of financial instruments - Summary of Assets and Liabilities Measured at Fair Value (Parenthetical) (Details)
$ in Millions
Sep. 30, 2021
USD ($)
Harvard and Board  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Success payment liability, current portion $ 6.3
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.22.2
Fair value of financial instruments - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Mar. 31, 2022
Dec. 31, 2021
Sep. 30, 2021
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]              
Cash equivalents $ 36,300   $ 36,300     $ 58,100  
Common stock shares issued 48,709,652   48,709,652     48,511,735  
Issuance of common stock, value $ 49   $ 49     $ 49  
Other Income              
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]              
Success Payment Liability, Payable 900 $ 10,000 2,600 $ 9,700      
Harvard and Board              
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]              
Success payment liability, payable 10,000,000   10,000,000        
Success payment liability         $ 300   $ 6,300
Success payment liability, current portion             $ 6,300
Harvard | Maximum              
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]              
Success payment liability, payable $ 31,300   $ 31,300        
Broad License Agreement              
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]              
Common stock shares issued 276,075   276,075        
Antidilution Rights Liability              
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]              
Common stock shares issued   878,098   878,098      
Issuance of common stock, value   $ 32,500   $ 32,500      
Antidilution Rights Liability | Other Expense              
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]              
Increase in liabilities   $ 26,000   $ 25,600      
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.22.2
Fair value of financial instruments - Schedule of Fair Value Liabilities Measured on Recurring Basis (Details) - $ / shares
6 Months Ended 12 Months Ended
Jun. 30, 2022
Dec. 31, 2021
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Fair value of common stock (per share) $ 15.28 $ 36.87
Equity Volatility    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Equity volatility 88.00% 77.00%
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.22.2
Fair value of financial instruments - Schedule of Reconciliation of Changes in Fair Value of Financial Instruments (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]      
Beginning balance     $ 9,722
Issuance of common stock $ 281,584   (32,490)
Changes in fair value     35,228
Ending balance 12,460   12,460
Antidilution Rights Liability      
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]      
Beginning balance     6,916
Issuance of common stock     (32,490)
Changes in fair value     25,574
Ending balance 0   0
Success Payment Liability      
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]      
Beginning balance   $ 4,371 2,806
Issuance of common stock     0
Changes in fair value   (2,615) 9,654
Ending balance $ 12,460 $ 1,756 $ 12,460
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.22.2
Accrued expenses - Schedule of Accrued Expenses (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Payables and Accruals [Abstract]    
Accrued external research and development expenses $ 6,657 $ 5,041
Employee compensation and related benefits 3,682 6,050
License and milestone payments 3,330
Professional fees 1,961 1,109
Other 2,990 792
Total $ 18,620 $ 12,992
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.22.2
Leases - Additional Information (Details)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
Aug. 19, 2021
USD ($)
ft²
Oct. 31, 2021
USD ($)
ft²
Jun. 30, 2022
USD ($)
Jun. 30, 2021
USD ($)
Jun. 30, 2022
USD ($)
Jun. 30, 2021
USD ($)
Jan. 31, 2022
ft²
Lessee, Lease, Description [Line Items]              
Operating lease, rent expense     $ 800 $ 500 $ 1,700 $ 900  
Increase in operating lease liability         $ (1,048) $ (915)  
Lease Noncancelable Term   12 months          
Lessee, Operating Lease, Option to Extend   The Company had the option to extend the sublease for one extension term of three months by written notice not less than six months prior to the expiration of the sublease term. The Company did not exercise this option.          
Lease Commencement Date   2021-12          
Operating lease incremental borrowing rate     1.57% 4.69% 1.57% 4.69%  
Weighted average remaining lease term     12 days 1 year 1 month 6 days 12 days 1 year 1 month 6 days  
Lease space build out cost prior to commencement         $ 6,200    
Operating Lease, Payments         $ 1,058 $ 973  
New Amendment [Member]              
Lessee, Lease, Description [Line Items]              
Lease area | ft²             105,144
Additional Lease Area | ft²             211
Premises              
Lessee, Lease, Description [Line Items]              
Lease area | ft² 104,933 11,931          
Lease not yet commenced , lease term 10 years            
Option to extend, lease not yet commenced five years            
Operating lease payment term, lease not yet commenced, terms and conditions         The Company’s obligation for the payment of base rent for the Premises begins 90 days after the Commencement Date (the “Rent Commencement Date”) and will initially be $0.8 million per month, which will increase by approximately 3% per annum.    
Option to terminate, lease not yet commenced true            
Tenant improvements allowance $ 21,000            
Additional tenant improvements allowance $ 5,200            
Improvement allowance interest rate 8.00%            
Prepaid rent     $ 800   $ 800    
Operating Lease, Payments   $ 1,400          
Premises | Letter of Credit              
Lessee, Lease, Description [Line Items]              
Letter of credit issued $ 4,800            
Letter of credit reduced value $ 3,500            
ASC 842              
Lessee, Lease, Description [Line Items]              
Short-term Lease, Cost     $ 1,000 $ 700 $ 1,300 $ 1,200  
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.22.2
Leases - Summary of Components of Operating Lease Cost (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Lease, Cost [Abstract]        
Operating lease costs $ 505 $ 475 $ 1,010 $ 924
Variable lease costs 198 154 409 343
Total $ 703 $ 629 $ 1,419 $ 1,267
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.22.2
Leases - Summary of Supplemental Cash Flow Information Related to Operating Leases (Details) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Cash paid for amounts included in the measurements of lease liabilities [Abstract]    
Operating cash flows related to operating leases $ 1,058 $ 973
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.22.2
Leases - Summary of Future Minimum Commitments under Non-Cancellable Operating Leases (Details)
$ in Thousands
Jun. 30, 2022
USD ($)
Lessee, Operating Lease, Liability, Payment, Due [Abstract]  
Remainder of 2022 $ 2,337
2023 9,691
2024 9,982
2025 10,281
2026 10,590
Thereafter 65,196
Total lease payments 108,077
Less: interest (2)
Present value of operating lease liabilities $ 108,075
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.22.2
License Agreements - Additional Information (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended 10 Months Ended 12 Months Ended
Oct. 31, 2021
Apr. 30, 2019
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Oct. 31, 2020
Dec. 31, 2020
Dec. 31, 2019
Mar. 31, 2022
Dec. 31, 2021
Sep. 30, 2021
Research And Development Arrangement Contract To Perform For Others [Line Items]                        
Research and development expenses     $ 33,125,000 $ 13,423,000 $ 57,614,000 $ 24,768,000            
Common stock shares issued     48,709,652   48,709,652           48,511,735  
Issuance of common stock       281,584,000   (32,490,000)            
Issuance of common stock, value     $ 49,000   $ 49,000           $ 49,000  
Broad License Agreement                        
Research And Development Arrangement Contract To Perform For Others [Line Items]                        
Common stock shares issued     276,075   276,075              
Issuance of common stock         $ 300,000              
Preferred stock financing partially satisfied                 $ 100,000      
Preferred stock financing were fully satisfied               $ 500,000        
Common stock issued for partly satisfying preferred stock financing                 $ 121,411      
Common stock issued for fully satisfying preferred stock financing               187,867        
Payment of milestone development         46,200,000              
Payment of sales based milestone         108,000,000              
Harvard and Board                        
Research And Development Arrangement Contract To Perform For Others [Line Items]                        
Success payment liability                   $ 300,000   $ 6,300,000
Beam License Agreement                        
Research And Development Arrangement Contract To Perform For Others [Line Items]                        
Research and development expenses     $ 0 0 0 0            
Common stock shares issued   276,075                    
Issuance of common stock   $ 300,000                    
Payment of milestone development   11,300,000                    
Payment of sales based milestone   15,000,000.0                    
Payment Received for License Agreement Reimbursement of Costs Incurred           200,000            
Beam License Agreement | Non-US                        
Research And Development Arrangement Contract To Perform For Others [Line Items]                        
Payment of milestone development   5,600,000                    
Payment of sales based milestone   $ 7,500,000                    
Beam License Agreement | NZ                        
Research And Development Arrangement Contract To Perform For Others [Line Items]                        
Payment of sales based milestone         200,000              
Acuitas Agreements                        
Research And Development Arrangement Contract To Perform For Others [Line Items]                        
Research and development expenses     100,000 300,000 100,000 600,000            
sell | Beam License Agreement                        
Research And Development Arrangement Contract To Perform For Others [Line Items]                        
Research and development expenses     $ 0 $ 0 0 $ 0            
License Agreement                        
Research And Development Arrangement Contract To Perform For Others [Line Items]                        
Non-Refundable Upfront License Fees Paid $ 800,000                      
Non Refundable Upfront License Fee         2,800,000   $ 2,000,000.0          
Clinical And Regulatory Milestone         9,800,000              
Sales Based Milestone         9,500,000              
Milestone related expenses $ 10,000,000.0       0              
License Agreement | Broad License Agreement                        
Research And Development Arrangement Contract To Perform For Others [Line Items]                        
Non-Refundable Upfront License Fees Paid         $ 300,000              
Antidilution Rights | Broad License Agreement                        
Research And Development Arrangement Contract To Perform For Others [Line Items]                        
Common stock shares issued     878,098   878,098              
Issuance of common stock, value     $ 32,500,000   $ 32,500,000              
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.22.2
Preferred and Common Stock - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 6 Months Ended
Jan. 31, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Jun. 21, 2021
Subsidiary Sale Of Stock [Line Items]          
Preferred stock, shares issued   0   0  
Preferred stock, value per share   $ 0.001   $ 0.001  
Proceeds from issuance of Preferred Stock, net   $ 0 $ 93,759    
Preferred stock, shares authorized   5,000,000   5,000,000  
Common stock, shares authorized   200,000,000   200,000,000  
Common stock shares issued   48,709,652   48,511,735  
Common Stock, Par Value   $ 0.001   $ 0.001  
Harvard and Board [Member]          
Subsidiary Sale Of Stock [Line Items]          
Common stock shares issued     878,098    
IPO          
Subsidiary Sale Of Stock [Line Items]          
Proceeds from issuance of Preferred Stock, net   $ 281,600      
Additional shares of common stock     2,105,368    
Public price     $ 19.00    
Proceeds from common stock, gross     $ 306,700    
Shares issued upon conversion of preferred stock         27,720,923
Preferred Stock          
Subsidiary Sale Of Stock [Line Items]          
Preferred stock, shares authorized     5,000,000    
Preferred Stock | Series B Preferred Stock          
Subsidiary Sale Of Stock [Line Items]          
Preferred stock, shares issued 77,163,022        
Preferred stock, value per share $ 1.2182        
Proceeds from issuance of Preferred Stock, net $ 94,000        
Transaction costs on issuance $ 200        
Common Stock          
Subsidiary Sale Of Stock [Line Items]          
Common stock, shares authorized     200,000,000    
Common Stock, Par Value     $ 0.001    
Common Stock | IPO          
Subsidiary Sale Of Stock [Line Items]          
Common stock shares issued     16,141,157    
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.22.2
Stock-based compensation - Additional Information (Details) - USD ($)
$ in Millions
6 Months Ended
Jan. 01, 2022
Jun. 30, 2022
Jun. 16, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Shares of common stock reserved for future issuance   7,057,629  
Employee Stock Option      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Unrecognized stock-based compensation cost   $ 66.3  
Weighted average period over which unrecognized compensation is expected to be recognized   2 years 9 months 18 days  
Restricted Stock      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Unrecognized stock-based compensation cost   $ 11.0  
Weighted average period over which unrecognized compensation is expected to be recognized   3 years 10 months 24 days  
Twent Eighteen | Common Stock      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Shares of common stock reserved for future issuance   6,885,653  
ESPP      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Shares of common stock reserved for future issuance   433,316  
Stock available for issuance under ESPP   844,918  
Increase in common stock capital shares, reserved for future issuance 485,117 25,218  
ESPP | Common Stock      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Percentage of outstanding stock, reserved for issuance   1.00%  
Increase in common stock capital shares, reserved for future issuance   1,083,290  
2021 Stock Incentive Plan      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Shares of common stock reserved for future issuance 2,425,587   3,466,530
Share-based Compensation Arrangement by Share-based Payment Award, Description   an annual increase, to be added on the first day of each fiscal year, commencing on January 1, 2022 and continuing until, and including, January 1, 2031, equal to the lesser of (i) 5% of the number of shares of common stock outstanding on such date  
Shares available for future grant   3,456,180  
2021 Stock Incentive Plan | Common Stock      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Percentage of outstanding stock, reserved for issuance 5.00%    
2021 Stock Incentive Plan | Restricted Stock      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Shares available for future grant   524,875  
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.22.2
Stock-based compensation - Summary of Stock Based Compensation Expense (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Total stock-based compensation expense $ 5,649 $ 1,351 $ 9,853 $ 2,021
Research and Development        
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Total stock-based compensation expense 2,955 708 5,421 1,021
General and Administrative        
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Total stock-based compensation expense $ 2,694 $ 643 $ 4,432 $ 1,000
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.22.2
Stock-based compensation - Schedule of Stock Option Activity (Details) - USD ($)
$ / shares in Units, $ in Thousands
6 Months Ended
Jun. 30, 2022
Share-based Payment Arrangement [Abstract]  
Number of options, Outstanding, Beginning balance 6,119,295
Number of options, Granted 2,103,350
Number of options, Exercised (172,699)
Number of options, Forfeited (164,729)
Number of options, Outstanding, Ending balance 7,885,217
Number of options, Exercisable 2,301,148
Number of options, Expected to vest [1] 5,584,069
Weighted average exercise price, Beginning balance $ 9.44
Weighted average exercise price, Granted 27.34
Weighted average exercise price, Exercised 3.62
Weighted average exercise price, Forfeited 25.77
Weighted average exercise price, Ending balance 14.09
Weighted average exercise price, Exercisable 4.40
Weighted average exercise price, Expected to vest [1] $ 18.08
Weighted average remaining contractual life (in years), Outstanding 8 years 6 months
Weighted average remaining contractual life (in years), Exercisable 7 years 9 months 18 days
Weighted average remaining contractual life (in years), Expected to vest [1] 8 years 9 months 18 days
Aggregate intrinsic value, Outstanding [2] $ 52,868
Aggregate intrinsic value, Exercisable [2] 25,676
Aggregate intrinsic value, Expected to vest [1],[2] $ 27,192
[1] This represents the number of unvested options outstanding as of June 30, 2022 that are expected to vest in the future.
[2] The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the common stock for the options that were in the money as of June 30, 2022.
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.22.2
Stock-based compensation - Summary of the Restricted Stock Units (Details) - RSU
6 Months Ended
Jun. 30, 2022
$ / shares
shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]  
Unvested RSUs, beginning balance, Unvested | shares 32,000
Restricted stock units granted | shares 524,875
Restricted stock units forfeited | shares (4,500)
Unvested RSUs, ending balance, unvested | shares 552,375
Weighted-Average Grant Date Fair Value Per Share, beginning balance, Unvested | $ / shares $ 36.58
Weighted-Average Grant-Date Fair Value, Granted | $ / shares 20.48
Weighted-Average Grant-Date Fair Value, forfeited | $ / shares 30.94
Weighted-Average Grant Date Fair Value Per Share, ending balance, Unvested | $ / shares $ 21.33
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.22.2
Net Loss Per Share Attributable to Common Stockholders - Potential Common Shares, Based on Amounts Outstanding at Period End were Excluded From the Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details) - shares
6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Antidilutive securities 8,437,592 5,989,803
Unvested Restricted Stock    
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Antidilutive securities 0 268,816
Unvested restricted stock units    
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Antidilutive securities 552,375 0
Outstanding Options To Purchase Common Stock    
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Antidilutive securities 7,885,217 5,720,987
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.22.2
Net Loss Per Share Attributable to Common Stockholders - Additional Information (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]    
Success payment liability $ 1,756 $ 4,371
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.22.2
Related Party Transactions - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Related Party Transaction [Line Items]        
Research and development expenses $ 33,125 $ 13,423 $ 57,614 $ 24,768
Lease Rent Payment 500   1,000  
Beam License Agreement        
Related Party Transaction [Line Items]        
Research and development expenses $ 0 $ 0 $ 0 0
Beam | Materials Exchange Agreement | Research and Development        
Related Party Transaction [Line Items]        
Research and development expenses       $ 200
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.22.2
Subsequent Events - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 6 Months Ended
Jul. 25, 2022
Jul. 20, 2022
Jul. 18, 2022
Oct. 31, 2021
Jun. 30, 2022
Dec. 31, 2021
Subsequent Event [Line Items]            
Issuance of common stock, value         $ 49 $ 49
Common stock shares issued         48,709,652 48,511,735
Common stock fair value         $ 0.001 $ 0.001
Net proceeds from sale of common stock         $ 242,900  
License Agreement            
Subsequent Event [Line Items]            
Milestone related expenses       $ 10,000 $ 0  
Non-refundable upfront license fees paid       $ 800    
Subsequent Event | Strategic License and Collaboration Agreement            
Subsequent Event [Line Items]            
Non-refundable upfront payment   $ 25,000        
Maximum Success Payments For Each Product     $ 66,000      
Development and commercial milestone payments under collaboration agreement     340,000      
Subsequent Event | Strategic License and Collaboration Agreement | Minimum            
Subsequent Event [Line Items]            
Non-refundable upfront license fees paid     25,000      
Subsequent Event | Strategic License and Collaboration Agreement | Maximum            
Subsequent Event [Line Items]            
Success payments for each product     $ 22,000      
Profit share     40.00%      
Non-refundable upfront license fees paid     $ 70,000      
Subsequent Event | Public offering            
Subsequent Event [Line Items]            
Shares issued and sold 9,583,334          
Common stock shares issued 1,250,000          
Common Stock Offering Price Per Share $ 27.00          
Net proceeds from sale of common stock $ 242,900          
Underwriting discounts and commissions 15,500          
Offering Costs $ 300          
Subsequent Event | Vertex Pharmaceuticals [Member]            
Subsequent Event [Line Items]            
Non-refundable upfront payment   $ 25,000        
Subsequent Event | Vertex Pharmaceuticals [Member] | Strategic License and Collaboration Agreement | Minimum            
Subsequent Event [Line Items]            
Profit share     60.00%      
Subsequent Event | Vertex Pharmaceuticals [Member] | Stock Purchase Agreement            
Subsequent Event [Line Items]            
Agreegate purchase price     $ 35,000      
Common stock shares issued     1,519,756      
Common stock fair value     $ 23.03      
XML 69 verv-20220630_htm.xml IDEA: XBRL DOCUMENT 0001840574 us-gaap:RetainedEarningsMember 2022-06-30 0001840574 verv:VertexPharmaceuticalsMember us-gaap:SubsequentEventMember 2022-07-18 0001840574 us-gaap:GeneralAndAdministrativeExpenseMember 2021-04-01 2021-06-30 0001840574 srt:MinimumMember us-gaap:SubsequentEventMember verv:StrategicLicenseAndCollaborationAgreementMember 2022-07-18 2022-07-18 0001840574 verv:OutstandingOptionsToPurchaseCommonStockMember 2022-01-01 2022-06-30 0001840574 us-gaap:FairValueInputsLevel3Member verv:USTreasuryBillsAndNotesMember 2021-12-31 0001840574 us-gaap:SalesMember verv:BeamLicenseAgreementMember 2022-01-01 2022-06-30 0001840574 us-gaap:AccountingStandardsUpdate201602Member 2022-01-01 2022-06-30 0001840574 2021-10-01 2021-10-31 0001840574 verv:UnvestedRestrictedStockUnitsMember 2021-01-01 2021-06-30 0001840574 verv:AntidilutionRightsLiabilityMember us-gaap:OtherExpenseMember 2021-04-01 2021-06-30 0001840574 us-gaap:FairValueInputsLevel2Member verv:SuccessPaymentLiabilityMember 2021-12-31 0001840574 us-gaap:ResearchAndDevelopmentExpenseMember 2022-04-01 2022-06-30 0001840574 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-06-30 0001840574 us-gaap:IPOMember 2021-06-30 0001840574 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-06-30 0001840574 us-gaap:EquipmentMember 2022-06-30 0001840574 us-gaap:RestrictedStockMember 2022-06-30 0001840574 us-gaap:FairValueInputsLevel1Member verv:SuccessPaymentLiabilityMember 2021-12-31 0001840574 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0001840574 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-06-30 0001840574 verv:AcuitasAgreementsMember 2022-01-01 2022-06-30 0001840574 us-gaap:FairValueInputsLevel1Member verv:USTreasuryBillsAndNotesMember 2021-12-31 0001840574 us-gaap:RetainedEarningsMember 2021-12-31 0001840574 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001840574 verv:VertexPharmaceuticalsMember srt:MinimumMember us-gaap:SubsequentEventMember verv:StrategicLicenseAndCollaborationAgreementMember 2022-07-18 0001840574 us-gaap:LicenseAgreementTermsMember 2020-01-01 2020-10-31 0001840574 us-gaap:GeneralAndAdministrativeExpenseMember 2022-04-01 2022-06-30 0001840574 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001840574 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2022-06-30 0001840574 us-gaap:FairValueInputsLevel2Member 2022-06-30 0001840574 us-gaap:IPOMember 2021-06-21 0001840574 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001840574 us-gaap:FairValueInputsLevel2Member verv:USTreasuryBillsAndNotesMember 2022-06-30 0001840574 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001840574 us-gaap:FairValueInputsLevel3Member verv:SuccessPaymentLiabilityMember 2021-12-31 0001840574 verv:BroadLicenseAgreementMember 2019-01-01 2019-12-31 0001840574 us-gaap:FairValueInputsLevel3Member verv:USAgencySecuritiesMember 2022-06-30 0001840574 verv:AntidilutionRightsMember verv:BroadLicenseAgreementMember 2022-06-30 0001840574 verv:VertexPharmaceuticalsMember verv:StrategicLicenseAndCollaborationAgreementMember us-gaap:SubsequentEventMember 2022-07-18 2022-07-18 0001840574 verv:AntidilutionRightsLiabilityMember 2021-01-01 2021-06-30 0001840574 us-gaap:FairValueInputsLevel3Member verv:USAgencySecuritiesMember 2021-12-31 0001840574 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001840574 us-gaap:MeasurementInputPriceVolatilityMember 2022-01-01 2022-06-30 0001840574 us-gaap:MoneyMarketFundsMember 2022-06-30 0001840574 verv:UnvestedRestrictedStockMember 2022-01-01 2022-06-30 0001840574 2022-01-01 2022-03-31 0001840574 us-gaap:USTreasurySecuritiesMember 2022-06-30 0001840574 us-gaap:CommonStockMember 2022-03-31 0001840574 verv:NewAmendmentMember 2022-01-31 0001840574 2022-06-30 0001840574 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001840574 us-gaap:RestrictedStockMember 2022-01-01 2022-06-30 0001840574 verv:BeamLicenseAgreementMember 2022-01-01 2022-06-30 0001840574 2022-03-31 0001840574 us-gaap:ComputerEquipmentMember 2021-12-31 0001840574 us-gaap:PreferredStockMember 2021-01-01 2021-03-31 0001840574 verv:BroadLicenseAgreementMember 2022-06-30 0001840574 us-gaap:OtherIncomeMember 2022-04-01 2022-06-30 0001840574 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001840574 verv:PremisesMember 2021-08-19 2021-08-19 0001840574 verv:VertexPharmaceuticalsMember us-gaap:SubsequentEventMember 2022-07-20 2022-07-20 0001840574 2022-08-04 0001840574 2022-01-01 2022-06-30 0001840574 us-gaap:FairValueInputsLevel1Member 2021-12-31 0001840574 us-gaap:FairValueInputsLevel1Member verv:SuccessPaymentLiabilityMember 2022-06-30 0001840574 verv:VertexPharmaceuticalsMember us-gaap:SubsequentEventMember verv:StockPurchaseAgreementMember 2022-07-18 0001840574 country:NZ verv:BeamLicenseAgreementMember 2022-01-01 2022-06-30 0001840574 verv:USTreasuryBillsAndNotesMember 2022-06-30 0001840574 us-gaap:FairValueInputsLevel1Member verv:USAgencySecuritiesMember 2022-06-30 0001840574 us-gaap:FairValueInputsLevel2Member verv:USTreasuryBillsAndNotesMember 2021-12-31 0001840574 us-gaap:FairValueInputsLevel2Member 2021-12-31 0001840574 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001840574 verv:PremisesMember 2021-10-31 0001840574 us-gaap:FairValueInputsLevel3Member verv:SuccessPaymentLiabilityMember 2022-06-30 0001840574 us-gaap:FairValueInputsLevel1Member 2022-06-30 0001840574 us-gaap:AccountingStandardsUpdate201602Member 2022-04-01 2022-06-30 0001840574 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001840574 2020-12-31 0001840574 us-gaap:CommonStockMember 2021-06-30 0001840574 2021-01-01 2021-12-31 0001840574 us-gaap:LicenseAgreementTermsMember 2021-10-01 2021-10-31 0001840574 verv:HarvardAndBroadLicenseAgreementMember 2022-06-30 0001840574 verv:AcuitasAgreementsMember 2022-04-01 2022-06-30 0001840574 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-06-30 0001840574 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001840574 verv:HarvardAndBroadLicenseAgreementMember 2021-09-30 0001840574 us-gaap:OtherIncomeMember 2022-01-01 2022-06-30 0001840574 verv:AntidilutionRightsLiabilityMember us-gaap:OtherExpenseMember 2021-01-01 2021-06-30 0001840574 verv:SuccessPaymentLiabilityMember 2022-06-30 0001840574 us-gaap:SalesMember verv:BeamLicenseAgreementMember 2021-04-01 2021-06-30 0001840574 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001840574 verv:UnvestedRestrictedStockMember 2021-01-01 2021-06-30 0001840574 verv:SuccessPaymentLiabilityMember 2022-01-01 2022-06-30 0001840574 verv:SuccessPaymentLiabilityMember 2021-06-30 0001840574 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001840574 verv:PremisesMember 2022-01-01 2022-06-30 0001840574 verv:AcuitasAgreementsMember 2021-01-01 2021-06-30 0001840574 verv:VertexPharmaceuticalsMember us-gaap:SubsequentEventMember 2022-07-18 2022-07-18 0001840574 us-gaap:RestrictedStockMember verv:TwoThousandAndTwentyOneStockIncentivePlanMember 2022-06-30 0001840574 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001840574 us-gaap:AccountingStandardsUpdate201602Member 2021-04-01 2021-06-30 0001840574 us-gaap:CommonStockMember 2022-06-30 0001840574 us-gaap:AccountingStandardsUpdate201602Member 2021-01-01 2021-06-30 0001840574 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2022-06-30 0001840574 verv:BroadLicenseAgreementMember 2020-01-01 2020-12-31 0001840574 us-gaap:PreferredStockMember 2020-12-31 0001840574 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001840574 verv:TwoThousandAndTwentyOneStockIncentivePlanMember 2021-06-16 0001840574 us-gaap:ResearchAndDevelopmentExpenseMember 2021-04-01 2021-06-30 0001840574 srt:MaximumMember us-gaap:SubsequentEventMember verv:StrategicLicenseAndCollaborationAgreementMember 2022-07-18 0001840574 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-06-30 0001840574 verv:AntidilutionRightsLiabilityMember 2021-06-30 0001840574 verv:TwentyTwentyOneEmployeeStockPurchasePlanMember us-gaap:CommonStockMember 2022-01-01 2022-06-30 0001840574 verv:SuccessPaymentLiabilityMember 2021-01-01 2021-06-30 0001840574 us-gaap:OtherIncomeMember 2021-04-01 2021-06-30 0001840574 us-gaap:NonUsMember verv:BeamLicenseAgreementMember 2019-04-01 2019-04-30 0001840574 us-gaap:RestrictedStockUnitsRSUMember 2022-06-30 0001840574 us-gaap:LicenseAgreementTermsMember verv:BroadLicenseAgreementMember 2022-01-01 2022-06-30 0001840574 us-gaap:CommonStockMember us-gaap:IPOMember 2021-06-30 0001840574 srt:MaximumMember verv:HarvardLicenseAgreementMember 2022-06-30 0001840574 us-gaap:PreferredStockMember 2021-03-31 0001840574 us-gaap:MoneyMarketFundsMember 2021-12-31 0001840574 verv:USAgencySecuritiesMember 2021-12-31 0001840574 verv:SuccessPaymentLiabilityMember 2020-12-31 0001840574 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001840574 verv:USAgencySecuritiesMember 2022-06-30 0001840574 us-gaap:FairValueInputsLevel1Member verv:USTreasuryBillsAndNotesMember 2022-06-30 0001840574 us-gaap:FairValueInputsLevel3Member 2022-06-30 0001840574 us-gaap:SubsequentEventMember verv:StrategicLicenseAndCollaborationAgreementMember 2022-07-20 2022-07-20 0001840574 2021-06-30 0001840574 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001840574 2021-01-01 2021-06-30 0001840574 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0001840574 verv:VertexPharmaceuticalsMember us-gaap:SubsequentEventMember verv:StockPurchaseAgreementMember 2022-07-18 2022-07-18 0001840574 us-gaap:LetterOfCreditMember verv:PremisesMember 2021-08-19 0001840574 verv:USTreasuryBillsAndNotesMember 2021-12-31 0001840574 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001840574 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001840574 verv:VertexPharmaceuticalsMember srt:MaximumMember verv:StrategicLicenseAndCollaborationAgreementMember us-gaap:SubsequentEventMember 2022-07-18 0001840574 2022-04-01 2022-06-30 0001840574 verv:OutstandingOptionsToPurchaseCommonStockMember 2021-01-01 2021-06-30 0001840574 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-06-30 0001840574 verv:PremisesMember 2021-10-01 2021-10-31 0001840574 srt:MaximumMember us-gaap:SubsequentEventMember verv:StrategicLicenseAndCollaborationAgreementMember 2022-07-18 2022-07-18 0001840574 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2021-12-31 0001840574 verv:UnvestedRestrictedStockUnitsMember 2022-01-01 2022-06-30 0001840574 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001840574 verv:VertexPharmaceuticalsMember verv:StrategicLicenseAndCollaborationAgreementMember us-gaap:SubsequentEventMember 2022-07-18 0001840574 verv:TwentyTwentyOneEmployeeStockPurchasePlanMember 2022-01-01 2022-06-30 0001840574 us-gaap:IPOMember 2022-01-01 2022-06-30 0001840574 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2021-01-31 0001840574 us-gaap:FairValueInputsLevel2Member verv:USAgencySecuritiesMember 2021-12-31 0001840574 verv:TwentyEighteenMember us-gaap:CommonStockMember 2022-06-30 0001840574 us-gaap:USTreasurySecuritiesMember 2021-12-31 0001840574 verv:HarvardAndBroadLicenseAgreementMember 2022-03-31 0001840574 us-gaap:FurnitureAndFixturesMember 2021-12-31 0001840574 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001840574 us-gaap:FairValueInputsLevel3Member 2021-12-31 0001840574 verv:HarvardAndBoardMember 2021-06-30 0001840574 us-gaap:LeaseholdImprovementsMember 2022-06-30 0001840574 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001840574 verv:TwoThousandAndTwentyOneStockIncentivePlanMember us-gaap:CommonStockMember 2022-01-01 2022-01-01 0001840574 verv:PremisesMember 2022-06-30 0001840574 verv:SuccessPaymentLiabilityMember 2021-12-31 0001840574 us-gaap:CommonStockMember 2021-12-31 0001840574 verv:BroadLicenseAgreementMember 2022-01-01 2022-06-30 0001840574 us-gaap:OtherIncomeMember 2021-01-01 2021-06-30 0001840574 us-gaap:EquipmentMember 2021-12-31 0001840574 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0001840574 us-gaap:IPOMember 2021-01-01 2021-06-30 0001840574 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-06-30 0001840574 verv:BeamLicenseAgreementMember 2022-04-01 2022-06-30 0001840574 us-gaap:FairValueInputsLevel2Member verv:SuccessPaymentLiabilityMember 2022-06-30 0001840574 us-gaap:FairValueInputsLevel1Member verv:USAgencySecuritiesMember 2021-12-31 0001840574 verv:BeamLicenseAgreementMember 2019-04-01 2019-04-30 0001840574 us-gaap:SubsequentEventMember verv:PublicOfferingMember 2022-07-25 0001840574 verv:BeamLicenseAgreementMember 2019-04-30 0001840574 us-gaap:FairValueInputsLevel3Member verv:USTreasuryBillsAndNotesMember 2022-06-30 0001840574 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001840574 us-gaap:SalesMember verv:BeamLicenseAgreementMember 2021-01-01 2021-06-30 0001840574 us-gaap:RetainedEarningsMember 2022-03-31 0001840574 us-gaap:SubsequentEventMember verv:PublicOfferingMember 2022-07-25 2022-07-25 0001840574 2021-03-31 0001840574 us-gaap:ComputerEquipmentMember 2022-06-30 0001840574 us-gaap:EmployeeStockOptionMember 2022-06-30 0001840574 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001840574 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001840574 us-gaap:FairValueInputsLevel2Member verv:USAgencySecuritiesMember 2022-06-30 0001840574 2021-12-31 0001840574 verv:TwoThousandAndTwentyOneStockIncentivePlanMember 2022-01-01 0001840574 verv:TwentyTwentyOneEmployeeStockPurchasePlanMember 2022-01-01 0001840574 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001840574 verv:TwentyTwentyOneEmployeeStockPurchasePlanMember us-gaap:CommonStockMember 2022-06-30 0001840574 us-gaap:SalesMember verv:BeamLicenseAgreementMember 2022-04-01 2022-06-30 0001840574 us-gaap:RetainedEarningsMember 2021-06-30 0001840574 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001840574 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2022-06-30 0001840574 verv:BeamLicenseAgreementMember 2021-01-01 2021-06-30 0001840574 us-gaap:CommonStockMember 2021-03-31 0001840574 verv:TwentyTwentyOneEmployeeStockPurchasePlanMember 2022-06-30 0001840574 verv:AntidilutionRightsLiabilityMember 2020-12-31 0001840574 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-01-31 0001840574 2021-04-01 2021-06-30 0001840574 us-gaap:LicenseAgreementTermsMember 2022-01-01 2022-06-30 0001840574 us-gaap:PreferredStockMember 2021-04-01 2021-06-30 0001840574 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001840574 verv:PremisesMember 2021-08-19 0001840574 us-gaap:FurnitureAndFixturesMember 2022-06-30 0001840574 us-gaap:ResearchAndDevelopmentExpenseMember verv:BeamMember verv:MaterialsExchangeAgreementMember 2021-01-01 2021-06-30 0001840574 verv:AcuitasAgreementsMember 2021-04-01 2021-06-30 0001840574 us-gaap:CommonStockMember 2020-12-31 0001840574 us-gaap:RetainedEarningsMember 2020-12-31 0001840574 verv:TwoThousandAndTwentyOneStockIncentivePlanMember 2022-06-30 0001840574 2021-01-01 2021-03-31 0001840574 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001840574 verv:BeamLicenseAgreementMember 2021-04-01 2021-06-30 0001840574 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0001840574 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001840574 us-gaap:MeasurementInputPriceVolatilityMember 2021-01-01 2021-12-31 0001840574 us-gaap:PreferredStockMember 2021-06-30 0001840574 us-gaap:RetainedEarningsMember 2021-03-31 0001840574 verv:TwoThousandAndTwentyOneStockIncentivePlanMember 2022-01-01 2022-06-30 0001840574 us-gaap:SubsequentEventMember verv:StrategicLicenseAndCollaborationAgreementMember 2022-07-18 2022-07-18 pure utr:sqft shares iso4217:USD shares iso4217:USD 0 --12-31 Q2 true 0 false 0001840574 10-Q true 2022-06-30 2022 false 001-40489 VERVE THERAPEUTICS , INC. DE 82-4800132 500 Technology Square, Suite 901 Cambridge MA 02139 617 603-0070 Common stock, par value $0.001 per share VERV NASDAQ Yes Yes Non-accelerated Filer false true false false 59942339 72889000 64330000 220672000 296112000 5083000 6686000 298644000 367128000 12354000 7224000 5237000 5237000 839000 1839000 7193000 2696000 324267000 384124000 6320000 7077000 18620000 12992000 907000 1955000 25847000 22024000 1756000 4371000 331000 377000 27934000 26772000 0.001 0.001 5000000 5000000 0 0 0 0 0 0 0.001 0.001 200000000 200000000 48709652 48709652 48511735 48511735 49000 49000 555184000 544381000 -938000 -228000 -257962000 -186850000 296333000 357352000 324267000 384124000 33125000 13423000 57614000 24768000 9067000 3541000 16503000 6257000 42192000 16964000 74117000 31025000 -42192000 -16964000 -74117000 -31025000 0 25970000 25574000 -938000 10036000 -2615000 9654000 308000 5000 390000 25000 1246000 -36001000 3005000 -35203000 -40946000 -52965000 -71112000 -66228000 -0.84 -6.66 -1.46 -12.46 48674873 7948110 48623330 5316084 -40946000 -52965000 -71112000 -66228000 -206000 -4000 -710000 -5000 -41152000 -52969000 -71822000 -66233000 179519032 125160000 2585789 3000 2616000 8000 -66536000 -63909000 241000 77163022 93759000 134409 48745 72000 72000 -1000 -1000 670000 670000 -13263000 -13263000 256682054 218919000 2768943 3000 3358000 7000 -79799000 -76431000 -256682054 -218919000 27720923 28000 218891000 218919000 25098000 16141157 16000 281568000 281584000 878098 1000 32489000 32490000 134408 303467 452000 452000 -4000 -4000 1351000 1351000 -52965000 -52965000 47946996 48000 538109000 3000 -132764000 405396000 48511735 49000 544381000 -228000 -186850000 357352000 143506 505000 505000 -504000 -504000 4203000 4203000 -30166000 -30166000 48655241 49000 549089000 -732000 -217016000 331390000 29193 120000 120000 25218 325000 325000 -206000 -206000 5650000 5650000 -40946000 -40946000 48709652 49000 555184000 -938000 -257962000 296333000 -71112000 -66228000 1162000 651000 999000 865000 1231000 356000 9853000 2021000 0 25574000 -2615000 9654000 2894000 159000 -1017000 1283000 5176000 -1584000 -1048000 -915000 -60265000 -28482000 5627000 2376000 74249000 11176000 147750000 43755000 67874000 30203000 0 93759000 0 285214000 0 2765000 625000 524000 -325000 0 950000 376732000 8559000 378453000 69567000 9456000 78126000 387909000 1169000 794000 0 865000 218919000 32490000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">1. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Nature of the business and basis of presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;min-width:fit-content;">Organization</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Verve Therapeutics, Inc. (the “Company” or “Verve”) is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The Company was incorporated on March 9, 2018 as Endcadia, Inc., a Delaware corporation, and began operations shortly thereafter. In January 2019, the Company amended its certificate of incorporation to change its name to Verve Therapeutics, Inc. The Company’s principal offices are located in Cambridge, Massachusetts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;min-width:fit-content;">Liquidity and capital resources</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Since its inception, the Company has devoted its efforts principally to research and development and raising capital. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry including, but not limited to, technical risks associated with the successful research, development and manufacturing of product candidates, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Current and future programs will require significant research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">In connection with the Company's initial public offering, or IPO, in June 2021, the Company effected a </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">one-for-9.2595</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> reverse stock split of the Company’s issued and outstanding common stock. Accordingly, all shares of common stock and per share amounts, as well as the conversion ratio of the Company’s outstanding convertible preferred stock, for all periods presented in the accompanying condensed consolidated financial statements and notes thereto have been retroactively adjusted, where applicable, to reflect the reverse stock split, including reclassification of par and additional paid-in capital amounts as a result of the reverse stock split.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Subsequent to June 30, 2022, on July 18, 2022, the Company entered into a Strategic Collaboration and License Agreement </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(the “Vertex Agreement”) with Vertex Pharmaceuticals Incorporated (“Vertex”) for an exclusive, four-year worldwide research collaboration focused on developing in vivo gene editing candidates toward an undisclosed target for the treatment of a single liver disease, as further described in Note 14, “Subsequent events.” Pursuant to the Vertex Agreement, Vertex paid the Company $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">25.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million in an upfront payment on July 20, 2022. The Company is eligible to receive (i) success payments of up to $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">22</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million for each product candidate (up to a maximum of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">66</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million) that achieves the applicable development criteria and (ii) up to an aggregate of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">340</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million in development and commercial milestone payments. The Company is also eligible to receive tiered single-digit royalties on net sales, subject to specified reductions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">On July 18, 2022, in connection with the execution of the Vertex Agreement</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">, the Company also entered into a stock purchase agreement with Vertex (the “Stock Purchase Agreement”) for the sale and issuance of </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">1,519,756</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> shares of the Company’s common stock to Vertex at a price of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">23.03</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> per share, which was equal to the five-day volume-weighted average share price as of July 15, 2022, for an aggregate purchase price of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">35.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million (the “Private Placement”). The Private Placement closed on July 20, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">On July 25, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">, the Company issued and sold </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">9,583,334</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> shares of its common, including an additional </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">1,250,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> shares its common stock sold pursuant to the underwriters’ full exercise of their option to purchase additional shares of common stock, at a public offering price of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">27.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> per share, for aggregate net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">242.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million after deducting underwriting discounts and commissions of approximately $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">15.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million and offering costs of approximately $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company expects that its cash, cash equivalents and marketable securities of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">293.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> as of June 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">, together with the net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">242.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million from the July 2022 follow-on public offering, $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">35.0</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">from the Private Placement with Vertex, and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">25.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million upfront payment from Vertex pursuant to the Vertex Agreement, will be sufficient to fund its operations and capital expenditure requirements beyond the next 12 months from the date of issuance of these financial statements. The Company will need additional financing to support its continuing operations and pursue its growth strategy. Until such time as the Company can generate significant revenue from product sales, if ever, it expects to finance its operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. The Company may be unable to raise additional funds or enter into such other agreements when needed on favorable terms or at all. The inability to raise capital as and when needed could have a negative impact on the Company’s financial condition and its ability to pursue its business strategy. The Company will need to generate significant revenue to achieve profitability, and it may never do so.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;min-width:fit-content;">Basis of presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">The accompanying condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC"). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements. In the opinion of the Company’s management, the accompanying unaudited interim condensed consolidated financial statements contain all adjustments that are necessary to present fairly the Company’s financial position as of June 30, 2022, the results of its operations and other comprehensive loss for the three and six months ended June 30, 2022 and 2021, convertible preferred stock and stockholders’ equity for the three and six months ended June 30, 2022 and 2021 and cash flows for the six months ended June 30, 2022 and 2021. Such adjustments are of a normal and recurring nature. The results for the three and six months ended June 30, 2022 are not necessarily indicative of the results for the year ending December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">, or for any future period. These interim financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended December 31, 2021, and the notes thereto, included in the Company’s Annual Report on Form 10-K filed with the SEC on March 14, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p> one-for-9.2595 25000000.0 22000000 66000000 340000000 1519756 23.03 35000000.0 9583334 1250000 27.00 242900000 15500000 300000 293600000 242900000 35000000.0 25000000.0 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">2. S</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">ummary of significant accounting policies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">The Company's significant accounting policies are disclosed in Note 2, "Summary of significant accounting policies," in the audited consolidated financial statements for the year ended December 31, 2021, and notes thereto, included in the Company’s Annual Report on Form 10-K filed with the SEC on March 14, 2022. Since the date of those financial statements, there have been no changes to its significant accounting policies.</span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;min-width:fit-content;">Cash, cash equivalents and restricted cash</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Restricted cash represents collateral provided for letters of credit issued as security deposits in connection with the Company’s leases of its corporate facilities. </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">A reconciliation of the cash, cash equivalents, and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the statement of cash flows is as follows: </span></span><span style=""/></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;min-width:fit-content;"/> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:67.013%;"/> <td style="width:1.623%;"/> <td style="width:1.0%;"/> <td style="width:12.871%;"/> <td style="width:1.0%;"/> <td style="width:1.623%;"/> <td style="width:1.0%;"/> <td style="width:12.871%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:10.0pt;"> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">June 30,</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">June 30,</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(in thousands)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Cash and cash equivalents</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">72,889</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">387,446</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Restricted cash</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">5,237</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">463</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Total cash, cash equivalents and restricted cash</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">78,126</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">387,909</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> </table></div></div><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;min-width:fit-content;">Recently adopted accounting pronouncements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">During the quarter ended September 30, 2021, the Company early adopted ASC Topic 842, “Leases” (“ASC 842”) using the revised modified retrospective approach as of January 1, 2021. The unaudited interim condensed consolidated financial statements for the three and six months ended June 30, 2021 have been retroactively adjusted to reflect the adoption of ASC 842, including retroactive adjustments to the unaudited interim condensed consolidated statement of cash flows and certain additional footnote disclosures as included herein. The adoption of ASC 842 had no material impact to the Company’s unaudited condensed consolidated statement of operations and comprehensive loss for the three and six months ended June 30, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on specific facts and circumstances, the existence of an identified asset(s), if any, and the Company’s control over the use of the identified asset(s), if applicable. The lease liability is measured at the present value of future lease payments, discounted using the discount rate as of the lease commencement date. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the incremental borrowing rate, which is the rate incurred to borrow, on a collateralized basis over a similar term, an amount equal to the lease payments in a similar economic environment. The Company recognizes a corresponding lease right of use (“ROU”) asset, initially measured as the amount of lease liability, adjusted for any initial lease costs or lease payments made before or at the commencement of the lease, and reduced by any lease incentives.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">The Company’s leases consist of only operating leases. Operating leases are recognized on the balance sheet as ROU lease assets, lease liabilities current and lease liabilities non-current. Fixed rents are included in the calculation of the lease balances while certain variable costs paid for certain operating and pass-through costs are excluded. Lease expense is recognized over the expected term on a straight-line basis.</span></p></div> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;min-width:fit-content;">Cash, cash equivalents and restricted cash</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Restricted cash represents collateral provided for letters of credit issued as security deposits in connection with the Company’s leases of its corporate facilities. </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">A reconciliation of the cash, cash equivalents, and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the statement of cash flows is as follows: </span></span><span style=""/></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;min-width:fit-content;"/> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:67.013%;"/> <td style="width:1.623%;"/> <td style="width:1.0%;"/> <td style="width:12.871%;"/> <td style="width:1.0%;"/> <td style="width:1.623%;"/> <td style="width:1.0%;"/> <td style="width:12.871%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:10.0pt;"> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">June 30,</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">June 30,</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(in thousands)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Cash and cash equivalents</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">72,889</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">387,446</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Restricted cash</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">5,237</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">463</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Total cash, cash equivalents and restricted cash</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">78,126</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">387,909</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> </table></div> <span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">A reconciliation of the cash, cash equivalents, and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the statement of cash flows is as follows: </span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;min-width:fit-content;"/> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:67.013%;"/> <td style="width:1.623%;"/> <td style="width:1.0%;"/> <td style="width:12.871%;"/> <td style="width:1.0%;"/> <td style="width:1.623%;"/> <td style="width:1.0%;"/> <td style="width:12.871%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:10.0pt;"> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">June 30,</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">June 30,</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(in thousands)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Cash and cash equivalents</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">72,889</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">387,446</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Restricted cash</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">5,237</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">463</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Total cash, cash equivalents and restricted cash</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">78,126</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">387,909</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> </table> 72889000 387446000 5237000 463000 78126000 387909000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;min-width:fit-content;">Recently adopted accounting pronouncements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">During the quarter ended September 30, 2021, the Company early adopted ASC Topic 842, “Leases” (“ASC 842”) using the revised modified retrospective approach as of January 1, 2021. The unaudited interim condensed consolidated financial statements for the three and six months ended June 30, 2021 have been retroactively adjusted to reflect the adoption of ASC 842, including retroactive adjustments to the unaudited interim condensed consolidated statement of cash flows and certain additional footnote disclosures as included herein. The adoption of ASC 842 had no material impact to the Company’s unaudited condensed consolidated statement of operations and comprehensive loss for the three and six months ended June 30, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on specific facts and circumstances, the existence of an identified asset(s), if any, and the Company’s control over the use of the identified asset(s), if applicable. The lease liability is measured at the present value of future lease payments, discounted using the discount rate as of the lease commencement date. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the incremental borrowing rate, which is the rate incurred to borrow, on a collateralized basis over a similar term, an amount equal to the lease payments in a similar economic environment. The Company recognizes a corresponding lease right of use (“ROU”) asset, initially measured as the amount of lease liability, adjusted for any initial lease costs or lease payments made before or at the commencement of the lease, and reduced by any lease incentives.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">The Company’s leases consist of only operating leases. Operating leases are recognized on the balance sheet as ROU lease assets, lease liabilities current and lease liabilities non-current. Fixed rents are included in the calculation of the lease balances while certain variable costs paid for certain operating and pass-through costs are excluded. Lease expense is recognized over the expected term on a straight-line basis.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">3. Marketable securities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Marketable securities by security type consisted of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;min-width:fit-content;"> </span> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:48.469%;"/> <td style="width:1.169%;"/> <td style="width:1.0%;"/> <td style="width:8.734%;"/> <td style="width:1.0%;"/> <td style="width:1.169%;"/> <td style="width:1.0%;"/> <td style="width:10.98%;"/> <td style="width:1.0%;"/> <td style="width:1.169%;"/> <td style="width:1.0%;"/> <td style="width:10.107999999999999%;"/> <td style="width:1.0%;"/> <td style="width:1.169%;"/> <td style="width:1.0%;"/> <td style="width:9.032%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:10.0pt;"> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="14" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">June 30, 2022</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(in thousands)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Amortized<br/>cost</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Gross<br/>unrealized<br/>gains</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Gross<br/>unrealized<br/>losses*</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Fair<br/>value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">U.S. treasury bills and notes</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">215,407</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">930</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">214,477</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">U.S. agency securities</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">6,203</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">8</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">6,195</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Total</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">221,610</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">938</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">220,672</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;min-width:fit-content;"> </span> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:48.469%;"/> <td style="width:1.169%;"/> <td style="width:1.0%;"/> <td style="width:8.734%;"/> <td style="width:1.0%;"/> <td style="width:1.169%;"/> <td style="width:1.0%;"/> <td style="width:10.98%;"/> <td style="width:1.0%;"/> <td style="width:1.169%;"/> <td style="width:1.0%;"/> <td style="width:10.107999999999999%;"/> <td style="width:1.0%;"/> <td style="width:1.169%;"/> <td style="width:1.0%;"/> <td style="width:9.032%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:10.0pt;"> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="14" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">December 31, 2021</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(in thousands)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Amortized<br/>cost</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Gross<br/>unrealized<br/>gains</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Gross<br/>unrealized<br/>losses*</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Fair<br/>value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">U.S. treasury bills and notes</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">277,559</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">218</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">277,341</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">U.S. agency securities</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">18,781</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">10</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">18,771</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Total</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">296,340</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">228</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">296,112</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">*</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">The Company reviews its marketable securities for impairment each period whenever the fair value of a marketable security is less than the amortized cost and evidence indicates that a marketable security’s carrying amount is not recoverable. As of June 30, 2022 and December 31, 2021, the Company expected its investments to recover through the remaining term of the security and concluded no impairment existed.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">The remaining contractual maturities of all marketable securities were less than </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">one year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">June 30, 2022 and December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Marketable securities by security type consisted of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;min-width:fit-content;"> </span> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:48.469%;"/> <td style="width:1.169%;"/> <td style="width:1.0%;"/> <td style="width:8.734%;"/> <td style="width:1.0%;"/> <td style="width:1.169%;"/> <td style="width:1.0%;"/> <td style="width:10.98%;"/> <td style="width:1.0%;"/> <td style="width:1.169%;"/> <td style="width:1.0%;"/> <td style="width:10.107999999999999%;"/> <td style="width:1.0%;"/> <td style="width:1.169%;"/> <td style="width:1.0%;"/> <td style="width:9.032%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:10.0pt;"> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="14" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">June 30, 2022</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(in thousands)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Amortized<br/>cost</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Gross<br/>unrealized<br/>gains</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Gross<br/>unrealized<br/>losses*</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Fair<br/>value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">U.S. treasury bills and notes</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">215,407</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">930</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">214,477</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">U.S. agency securities</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">6,203</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">8</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">6,195</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Total</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">221,610</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">938</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">220,672</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;min-width:fit-content;"> </span> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:48.469%;"/> <td style="width:1.169%;"/> <td style="width:1.0%;"/> <td style="width:8.734%;"/> <td style="width:1.0%;"/> <td style="width:1.169%;"/> <td style="width:1.0%;"/> <td style="width:10.98%;"/> <td style="width:1.0%;"/> <td style="width:1.169%;"/> <td style="width:1.0%;"/> <td style="width:10.107999999999999%;"/> <td style="width:1.0%;"/> <td style="width:1.169%;"/> <td style="width:1.0%;"/> <td style="width:9.032%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:10.0pt;"> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="14" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">December 31, 2021</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(in thousands)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Amortized<br/>cost</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Gross<br/>unrealized<br/>gains</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Gross<br/>unrealized<br/>losses*</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Fair<br/>value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">U.S. treasury bills and notes</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">277,559</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">218</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">277,341</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">U.S. agency securities</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">18,781</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">10</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">18,771</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Total</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">296,340</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">228</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">296,112</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">*</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">The Company reviews its marketable securities for impairment each period whenever the fair value of a marketable security is less than the amortized cost and evidence indicates that a marketable security’s carrying amount is not recoverable. As of June 30, 2022 and December 31, 2021, the Company expected its investments to recover through the remaining term of the security and concluded no impairment existed.</span></p> 215407000 0 930000 214477000 6203000 0 8000 6195000 221610000 0 938000 220672000 277559000 0 218000 277341000 18781000 0 10000 18771000 296340000 0 228000 296112000 P1Y P1Y <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">4. P</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">roperty and equipment, net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Property and equipment, net, consist of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;min-width:fit-content;"/> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.407%;"/> <td style="width:1.605%;"/> <td style="width:1.0%;"/> <td style="width:12.789%;"/> <td style="width:1.0%;"/> <td style="width:1.605%;"/> <td style="width:1.0%;"/> <td style="width:13.596%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:10.0pt;"> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(in thousands)</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">June 30, 2022</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">December 31, 2021</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Lab equipment</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">13,509</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">8,567</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Furniture and fixtures</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">1,618</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">566</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Computer equipment</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">448</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">158</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Leasehold improvements</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">274</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">266</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Total property and equipment</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">15,849</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">9,557</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Less accumulated depreciation</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">3,495</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2,333</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Property and equipment, net</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">12,354</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">7,224</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Depreciation expense for the three and six months ended June 30, 2022 was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">0.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Depreciation expense for the three and six months ended June 30, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million, respectively.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Property and equipment, net, consist of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;min-width:fit-content;"/> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.407%;"/> <td style="width:1.605%;"/> <td style="width:1.0%;"/> <td style="width:12.789%;"/> <td style="width:1.0%;"/> <td style="width:1.605%;"/> <td style="width:1.0%;"/> <td style="width:13.596%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:10.0pt;"> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(in thousands)</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">June 30, 2022</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">December 31, 2021</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Lab equipment</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">13,509</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">8,567</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Furniture and fixtures</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">1,618</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">566</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Computer equipment</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">448</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">158</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Leasehold improvements</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">274</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">266</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Total property and equipment</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">15,849</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">9,557</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Less accumulated depreciation</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">3,495</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2,333</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Property and equipment, net</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">12,354</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">7,224</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> </table> 13509000 8567000 1618000 566000 448000 158000 274000 266000 15849000 9557000 3495000 2333000 12354000 7224000 600000 1200000 400000 700000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">5. f</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">air value of financial instruments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">The Company’s financial instruments that are measured at fair value on a recurring basis consist of money market funds, marketable securities, and a derivative liability (success payment liability) pursuant to our license agreements with the President and Fellows of Harvard College, or Harvard, and The Broad Institute, Inc., or Broad, which license agreements are referred to herein as the Harvard/Broad License Agreement and Broad License Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">The following tables set forth the fair value of the Company’s financial instruments by level within the fair value hierarchy:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;min-width:fit-content;"/> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.951%;"/> <td style="width:1.234%;"/> <td style="width:1.0%;"/> <td style="width:8.984%;"/> <td style="width:1.0%;"/> <td style="width:1.234%;"/> <td style="width:1.0%;"/> <td style="width:8.817%;"/> <td style="width:1.0%;"/> <td style="width:1.234%;"/> <td style="width:1.0%;"/> <td style="width:8.984%;"/> <td style="width:1.0%;"/> <td style="width:1.234%;"/> <td style="width:1.0%;"/> <td style="width:9.326999999999998%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:10.0pt;"> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="14" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">As of June 30, 2022</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(in thousands)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Fair<br/>value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Level 1</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Level 2</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Level 3</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Assets</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Money market funds</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">36,302</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">36,302</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Marketable securities:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">U.S. treasury bills and notes</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">214,477</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">214,477</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">U.S. agency securities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">6,195</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">6,195</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Total assets</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">256,974</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">36,302</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">220,672</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Liabilities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Success payment liability</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">1,756</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">1,756</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Total liabilities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">1,756</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">1,756</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;min-width:fit-content;"/> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.306%;"/> <td style="width:1.215%;"/> <td style="width:1.0%;"/> <td style="width:9.122%;"/> <td style="width:1.0%;"/> <td style="width:1.215%;"/> <td style="width:1.0%;"/> <td style="width:9.122%;"/> <td style="width:1.0%;"/> <td style="width:1.215%;"/> <td style="width:1.0%;"/> <td style="width:9.122%;"/> <td style="width:1.0%;"/> <td style="width:1.215%;"/> <td style="width:1.0%;"/> <td style="width:9.465%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">As of December 31, 2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(in thousands)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Fair<br/>value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Level 1</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Level 2</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Level 3</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Assets</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Money market funds</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">58,127</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">58,127</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Marketable securities:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">U.S. treasury bills and notes</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">277,341</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">277,341</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">U.S. agency securities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">18,771</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">18,771</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Total assets</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">354,239</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">58,127</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">296,112</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Liabilities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Success payment liability</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">4,371</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">4,371</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Total liabilities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">4,371</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">4,371</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Cash Equivalents</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—Cash equivalents of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">36.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">58.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> as of June 30, 2022 and December 31, 2021, respectively, consisted of money market funds and are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices in active markets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Marketable Securities—</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">The Company measures its marketable securities at fair value on a recurring basis and classifies those instruments within Level 2 of the fair value hierarchy. Marketable securities are classified within Level 2 of the fair value hierarchy because pricing inputs are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date, and fair value is determined through the use of models or other valuation methodologies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Antidilution Rights Liability</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—The antidilution rights liability represented the obligation to issue additional shares of common stock to Harvard and Broad following the completion of (1) a defined aggregate level of preferred stock financing and (2) either a sale of the Company’s preferred stock, an initial public offering, or a company sale meeting a certain value threshold. The antidilution rights liability is stated at fair value and is considered Level 3 in the fair value hierarchy because its fair value measurement is based, in part, on significant inputs not observed in the market. The antidilution rights liability related to meeting a defined aggregate level of preferred stock financing was valued using a probability-weighted present value model that considered the probability of meeting the defined aggregate level of preferred stock financing, as well as the fair value of the Company’s common stock. The antidilution rights liability related to the achievement of a specified valuation through either a sale of the Company’s preferred stock, an initial public offering, or a company sale was valued using a Monte Carlo simulation model, which models the value of the liability based on several key variables, including probability of event occurrence, timing of event occurrence, as well as the fair value of the Company’s common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">In June 2021, upon completion of its IPO, the Company settled the antidilution rights liability in full through the issuance of </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">878,098</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> shares of the Company's common stock for a settlement amount of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">32.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million. Prior to settlement, the Company remeasured the liability with a corresponding increase of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">26.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">25.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">to other expense for</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">three and six months ended June 30, 2021, respectively. As the antidilution rights liability was settled in full in June 2021, there were no amounts for such liability included in the condensed consolidated balance sheet as of June 30, 2022 or December 31, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Success Payment Liability</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—The Company is obligated to pay to Harvard and Broad tiered success payments in the event its average market capitalization exceeds specified thresholds for a specified period of time ascending from a high nine-digit dollar amount to $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> billion, or sale of the Company for consideration in excess of those thresholds. In the event of a change of control or a sale of the Company, the Company is required to pay success payments in cash within a specified period following such event. Otherwise, the success payments may be settled at the Company’s option in either cash or shares of its common stock, or a combination of cash and shares of its common stock. The maximum aggregate success payments that could be payable by the Company is $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">31.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million (after termination of the Broad License Agreement).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">The success payments liability is stated at fair value and is considered Level 3 because its fair value measurement is based, in part, on significant inputs not observed in the market. The Company used a Monte Carlo simulation model, which models the value of the liability based on several key variables, including probability of event occurrence, timing of event occurrence, as well as the value of the Company’s common stock. The Company also estimated the likelihood that it would maintain the Harvard/Broad License Agreement based on its ongoing research efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">The Company remeasured the liability at fair value with decreases of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> recorded to other income for the three and six months ended June 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">, respectively, and increases of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">9.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million recorded to other expense for the three and six months ended June 30, 2021, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">In September 2021, multiple success payments were triggered and amounts due to Harvard and Broad totaled $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">6.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million. These amounts were settled in cash in November 2021. The Company will continue to adjust the remaining success payment liability for changes in fair value until the earlier of the achievement or expiration of the obligation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">The primary inputs used in valuing the success payments liability associated with the Company’s realization of a certain valuation threshold, were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;min-width:fit-content;"/> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.364%;"/> <td style="width:1.475%;"/> <td style="width:1.0%;"/> <td style="width:12.834%;"/> <td style="width:1.0%;"/> <td style="width:1.475%;"/> <td style="width:1.0%;"/> <td style="width:13.854000000000001%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:10.0pt;"> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">At<br/>June 30,<br/>2022</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">At<br/>December 31,<br/>2021</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Fair value of common stock (per share)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">15.28</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">36.87</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Equity volatility</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">88</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">%</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">77</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">%</span></p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">In February 2021, the Company provided written notice to Broad of its election to terminate the Broad License Agreement, which termination became effective in June 2021.</span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">The reconciliation of changes in the fair value of financial instruments based on Level 3 inputs for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">six months ended June 30, 2022 is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;min-width:fit-content;"/> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:79.887%;"/> <td style="width:1.791%;"/> <td style="width:1.0%;"/> <td style="width:16.322%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:10.0pt;"> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(in thousands)</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Success<br/>payment<br/>liability</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Balance at December 31, 2021</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">4,371</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Changes in fair value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2,615</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Balance at June 30, 2022</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">1,756</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">The reconciliation of changes in the fair value of financial instruments based on Level 3 inputs for the six months ended June 30, 2021 is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;min-width:fit-content;"/> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:56.67%;"/> <td style="width:1.243%;"/> <td style="width:1.0%;"/> <td style="width:11.562%;"/> <td style="width:1.0%;"/> <td style="width:1.243%;"/> <td style="width:1.0%;"/> <td style="width:11.294%;"/> <td style="width:1.0%;"/> <td style="width:1.243%;"/> <td style="width:1.0%;"/> <td style="width:10.747%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:10.0pt;"> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(in thousands)</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Antidilution rights liability</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Success<br/>payment<br/>liability</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Total</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Balance at December 31, 2020</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">6,916</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2,806</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">9,722</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Issuance of common stock</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">32,490</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">-</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">32,490</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Changes in fair value</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">25,574</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">9,654</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">35,228</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Balance at June 30, 2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">12,460</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">12,460</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> </table></div> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">The following tables set forth the fair value of the Company’s financial instruments by level within the fair value hierarchy:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;min-width:fit-content;"/> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.951%;"/> <td style="width:1.234%;"/> <td style="width:1.0%;"/> <td style="width:8.984%;"/> <td style="width:1.0%;"/> <td style="width:1.234%;"/> <td style="width:1.0%;"/> <td style="width:8.817%;"/> <td style="width:1.0%;"/> <td style="width:1.234%;"/> <td style="width:1.0%;"/> <td style="width:8.984%;"/> <td style="width:1.0%;"/> <td style="width:1.234%;"/> <td style="width:1.0%;"/> <td style="width:9.326999999999998%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:10.0pt;"> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="14" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">As of June 30, 2022</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(in thousands)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Fair<br/>value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Level 1</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Level 2</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Level 3</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Assets</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Money market funds</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">36,302</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">36,302</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Marketable securities:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">U.S. treasury bills and notes</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">214,477</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">214,477</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">U.S. agency securities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">6,195</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">6,195</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Total assets</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">256,974</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">36,302</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">220,672</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Liabilities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Success payment liability</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">1,756</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">1,756</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Total liabilities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">1,756</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">1,756</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;min-width:fit-content;"/> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.306%;"/> <td style="width:1.215%;"/> <td style="width:1.0%;"/> <td style="width:9.122%;"/> <td style="width:1.0%;"/> <td style="width:1.215%;"/> <td style="width:1.0%;"/> <td style="width:9.122%;"/> <td style="width:1.0%;"/> <td style="width:1.215%;"/> <td style="width:1.0%;"/> <td style="width:9.122%;"/> <td style="width:1.0%;"/> <td style="width:1.215%;"/> <td style="width:1.0%;"/> <td style="width:9.465%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">As of December 31, 2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(in thousands)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Fair<br/>value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Level 1</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Level 2</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Level 3</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Assets</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Money market funds</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">58,127</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">58,127</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Marketable securities:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">U.S. treasury bills and notes</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">277,341</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">277,341</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">U.S. agency securities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">18,771</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">18,771</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Total assets</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">354,239</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">58,127</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">296,112</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Liabilities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Success payment liability</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">4,371</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">4,371</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Total liabilities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">4,371</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">4,371</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> </table> 36302000 36302000 0 0 214477000 0 214477000 0 6195000 0 6195000 0 256974000 36302000 220672000 0 1756000 0 0 1756000 1756000 0 0 1756000 58127000 58127000 0 0 277341000 0 277341000 0 18771000 0 18771000 0 354239000 58127000 296112000 0 4371000 0 0 4371000 4371000 0 0 4371000 36300000 58100000 878098 32500000 26000000.0 25600000 10000000000.0 31300000 900000 2600000 10000000.0 9700000 6300000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">The primary inputs used in valuing the success payments liability associated with the Company’s realization of a certain valuation threshold, were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;min-width:fit-content;"/> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.364%;"/> <td style="width:1.475%;"/> <td style="width:1.0%;"/> <td style="width:12.834%;"/> <td style="width:1.0%;"/> <td style="width:1.475%;"/> <td style="width:1.0%;"/> <td style="width:13.854000000000001%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:10.0pt;"> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">At<br/>June 30,<br/>2022</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">At<br/>December 31,<br/>2021</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Fair value of common stock (per share)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">15.28</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">36.87</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Equity volatility</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">88</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">%</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">77</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">%</span></p></td> </tr> </table> 15.28 36.87 0.88 0.77 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">The reconciliation of changes in the fair value of financial instruments based on Level 3 inputs for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">six months ended June 30, 2022 is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;min-width:fit-content;"/> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:79.887%;"/> <td style="width:1.791%;"/> <td style="width:1.0%;"/> <td style="width:16.322%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:10.0pt;"> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(in thousands)</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Success<br/>payment<br/>liability</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Balance at December 31, 2021</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">4,371</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Changes in fair value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2,615</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Balance at June 30, 2022</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">1,756</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">The reconciliation of changes in the fair value of financial instruments based on Level 3 inputs for the six months ended June 30, 2021 is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;min-width:fit-content;"/> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:56.67%;"/> <td style="width:1.243%;"/> <td style="width:1.0%;"/> <td style="width:11.562%;"/> <td style="width:1.0%;"/> <td style="width:1.243%;"/> <td style="width:1.0%;"/> <td style="width:11.294%;"/> <td style="width:1.0%;"/> <td style="width:1.243%;"/> <td style="width:1.0%;"/> <td style="width:10.747%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:10.0pt;"> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(in thousands)</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Antidilution rights liability</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Success<br/>payment<br/>liability</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Total</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Balance at December 31, 2020</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">6,916</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2,806</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">9,722</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Issuance of common stock</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">32,490</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">-</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">32,490</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Changes in fair value</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">25,574</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">9,654</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">35,228</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Balance at June 30, 2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">12,460</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">12,460</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> </table> 4371000 -2615000 1756000 6916000 2806000 9722000 -32490000 0 -32490000 25574000 9654000 35228000 0 12460000 12460000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">6. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Accrued expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Accrued expenses consist of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;min-width:fit-content;"> </span> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.429%;"/> <td style="width:1.475%;"/> <td style="width:1.0%;"/> <td style="width:12.964%;"/> <td style="width:1.0%;"/> <td style="width:1.475%;"/> <td style="width:1.0%;"/> <td style="width:13.658999999999999%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:10.0pt;"> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(in thousands)</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">June 30,<br/>2022</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">December 31,<br/>2021</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Accrued external research and development expenses</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">6,657</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">5,041</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Employee compensation and related benefits</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">3,682</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">6,050</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">License and milestone payments</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">3,330</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_4bf4d863-b79e-4424-8cc1-d9c98df69038;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Professional fees</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">1,961</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">1,109</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Other</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2,990</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">792</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">18,620</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">12,992</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> </table></div> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Accrued expenses consist of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;min-width:fit-content;"> </span> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.429%;"/> <td style="width:1.475%;"/> <td style="width:1.0%;"/> <td style="width:12.964%;"/> <td style="width:1.0%;"/> <td style="width:1.475%;"/> <td style="width:1.0%;"/> <td style="width:13.658999999999999%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:10.0pt;"> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(in thousands)</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">June 30,<br/>2022</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">December 31,<br/>2021</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Accrued external research and development expenses</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">6,657</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">5,041</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Employee compensation and related benefits</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">3,682</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">6,050</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">License and milestone payments</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">3,330</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_4bf4d863-b79e-4424-8cc1-d9c98df69038;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Professional fees</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">1,961</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">1,109</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Other</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2,990</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">792</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">18,620</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">12,992</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> </table> 6657000 5041000 3682000 6050000 3330000 1961000 1109000 2990000 792000 18620000 12992000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">7. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">The Company’s operating lease activity is comprised of non-cancelable facility leases for office and laboratory space in Cambridge, Massachusetts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">The Company has also entered into multiple contract research and contract manufacturing service agreements with third parties which contain embedde</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">d leases within the scope of ASC 842. The embedded leases are considered short term leases, as the contractual terms are 12 months or less. Accordingly, no lease liability or ROU asset has been recorded. The Company has recognized $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">1.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million of short ter</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">m lease costs associated with the embedded leases during the three and six months ended June 30, 2022, respectively. The Company recognize</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">d $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million of sh</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">ort term lease costs associated with the embedded leases during the three and six months ended June 30, 2021, respectively.</span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">The components of operating lease cost were as follows:</span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.121%;"/> <td style="width:1.215%;"/> <td style="width:1.0%;"/> <td style="width:9.083%;"/> <td style="width:1.0%;"/> <td style="width:1.215%;"/> <td style="width:1.0%;"/> <td style="width:9.426%;"/> <td style="width:1.0%;"/> <td style="width:1.215%;"/> <td style="width:1.0%;"/> <td style="width:9.083%;"/> <td style="width:1.0%;"/> <td style="width:1.215%;"/> <td style="width:1.0%;"/> <td style="width:9.426%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:10.0pt;"> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="6" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Three months ended June 30,</span></p></td> <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="6" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Six months ended June 30,</span></p></td> <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(in thousands)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Operating lease costs</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">505</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">475</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">1,010</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">924</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Variable lease costs</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">198</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">154</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">409</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">343</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Total</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">703</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">629</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">1,419</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">1,267</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> </table></div><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Supplemental cash flow information related to operating leases was as follows:</span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.831%;"/> <td style="width:1.614%;"/> <td style="width:1.0%;"/> <td style="width:12.804%;"/> <td style="width:1.0%;"/> <td style="width:1.614%;"/> <td style="width:1.0%;"/> <td style="width:13.138%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:10.0pt;"> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="6" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Six months ended June 30,</span></p></td> <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(in thousands)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Cash paid for amounts included in the measurements of lease liabilities:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Operating cash flows related to operating leases</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">1,058</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">973</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">As of June 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">, the Company’s operating leases were measured using a weighted-average incremental borrowing rate of </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">1.57</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">% over a weighted-average remaining lease term of </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">0.4</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> years. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">June 30, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">, the Company’s operating leases were measured using a weighted-average incremental borrowing rate of </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">4.69</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">% over a weighted-average remaining lease term of </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">1.1 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">On August 19, 2021, the Company entered into a lease agreement with ARE-MA Region No. 87 Tenant, LLC, a Delaware limited liability company (the “Landlord”), pursuant to which the Company will lease approximately </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">104,933</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> square feet of office and laboratory space located at 201 Brookline Avenue, Boston, Massachusetts (the “Boston Lease”), further amended in January 2022 to include an additional </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">211</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> square feet, for a total of </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">105,144</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> square feet (the “Premises”). In June 2022, the Company entered into a second amendment to specify separate target commencement dates for certain areas of the Premises. The Premises have not been made available to the Company as of June 30, 2022 and therefore the Boston Lease has not commenced.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">The term of the Boston Lease will commence on the earlier of (1) the date the Landlord delivers the Premises to the Company, which the parties expect to be on or prior to August 18, 2022 for the initial premises and October 1, 2022, for the second floor premises, or (2) the date the Landlord could have delivered the Premises but for any delays attributable to the Company (the “Commencement Date”). </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">The Company’s obligation for the payment of base rent for the Premises begins 90 days after the Commencement Date (the “Rent Commencement Date”) and will initially be $0.8 million per month, which will increase by approximately 3% per annum.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> The Boston Lease has a term of </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">10</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> years, measured from the Rent Commencement Date. The Company has the option to extend the term of the Boston Lease for a period of an additional </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">. Under the terms of the Boston Lease, the Landlord has agreed to make up to $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">21.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">in certain</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">tenant </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">improvements to the Premises to suit the Company’s use (the “Tenant Improvement Allowance”), which amount is included in the base rent set forth in the Boston Lease. In addition to the Tenant Improvement Allowance, the Company may receive up to $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">5.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million for additional improvements to the Premises, which amount is subject to an </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">% annual interest charge and may be paid in equal monthly installments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">In connection with its entry into the Boston Lease and as a security deposit, the Company has provided the Landlord a letter of credit in the amount of approximately $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">4.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million, which may be reduced to approximately $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">3.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million on the expiration of the 36-month anniversary of the Rent Commencement Date so long as there are, and have been, no defaults by the Company under the terms of the Boston Lease. The Company also paid a deposit in the amount of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million, which is equal to the first month of base rent.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">The Landlord has the right to terminate the Boston Lease upon customary events of default. The Company</span><span style="font-size:10.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_8fff783a-1a1c-44b4-b399-f4fc00cd49da;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> may also terminate</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> the Boston Lease if the Premises are not ready for occupancy within a specified time period after September 1, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">The Boston Lease requires the Landlord to perform a scope of work to build-out the base building prior to the construction of the Premises. The Company concluded the accounting commencement date will occur when the Landlord completes the build-out of the base building and control passes to the Company. The Company will assess the classification of the Boston Lease at the accounting commencement date, and measure the ROU asset and lease liability. Payments made by the Company prior to commencement will be treated as prepaid rent which will increase the ROU asset. As of June 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> the Company has incurred an aggregate of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">6.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million related to the build out of the Premises prior to the Commencement Date.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">In October 2021, the Company entered into a sublease for </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">11,931</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> square feet of office and laboratory space in Cambridge, Massachusetts. The sublease commenced in </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">December 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> and has an initial noncancelable term of </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">12 months</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">. </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">The Company had the option to extend the sublease for one extension term of three months by written notice not less than six months prior to the expiration of the sublease term. The Company did not exercise this option.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> Therefore, this sublease is treated as a sh</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">ort term lease. The total fixed lease payments over the sublease term are approximately $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">1.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million and the Company is also required to pay its proportional share of operating expenses.</span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Future minimum commitments under non-cancellable leases as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">June 30, 2022 were as follows:</span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:68.871%;"/> <td style="width:2.254%;"/> <td style="width:1.0%;"/> <td style="width:26.876%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:10.0pt;"> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Years ending December 31,</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Amount</span></p></td> <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(in thousands)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Remainder of 2022</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2,337</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2023</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">9,691</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2024</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">9,982</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2025</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">10,281</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2026</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">10,590</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Thereafter</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">65,196</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Total lease payments</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">108,077</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Less: interest</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Present value of operating lease liabilities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">108,075</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">During the three and six months ended June 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">, the Company incurred rent expense of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">1.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million, respectively. During the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">three and six months ended June 30, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">, the Company incurred rent expense of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p> 1000000.0 1300000 700000 1200000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">The components of operating lease cost were as follows:</span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.121%;"/> <td style="width:1.215%;"/> <td style="width:1.0%;"/> <td style="width:9.083%;"/> <td style="width:1.0%;"/> <td style="width:1.215%;"/> <td style="width:1.0%;"/> <td style="width:9.426%;"/> <td style="width:1.0%;"/> <td style="width:1.215%;"/> <td style="width:1.0%;"/> <td style="width:9.083%;"/> <td style="width:1.0%;"/> <td style="width:1.215%;"/> <td style="width:1.0%;"/> <td style="width:9.426%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:10.0pt;"> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="6" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Three months ended June 30,</span></p></td> <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="6" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Six months ended June 30,</span></p></td> <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(in thousands)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Operating lease costs</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">505</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">475</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">1,010</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">924</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Variable lease costs</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">198</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">154</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">409</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">343</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Total</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">703</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">629</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">1,419</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">1,267</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> </table> 505000 475000 1010000 924000 198000 154000 409000 343000 703000 629000 1419000 1267000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Supplemental cash flow information related to operating leases was as follows:</span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.831%;"/> <td style="width:1.614%;"/> <td style="width:1.0%;"/> <td style="width:12.804%;"/> <td style="width:1.0%;"/> <td style="width:1.614%;"/> <td style="width:1.0%;"/> <td style="width:13.138%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:10.0pt;"> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="6" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Six months ended June 30,</span></p></td> <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(in thousands)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Cash paid for amounts included in the measurements of lease liabilities:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Operating cash flows related to operating leases</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">1,058</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">973</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> </table> 1058000 973000 0.0157 P0M12D 0.0469 P1Y1M6D 104933 211 105144 The Company’s obligation for the payment of base rent for the Premises begins 90 days after the Commencement Date (the “Rent Commencement Date”) and will initially be $0.8 million per month, which will increase by approximately 3% per annum. P10Y five years 21000000.0 5200000 0.08 4800000 3500000 800000 6200000 11931 2021-12 P12M The Company had the option to extend the sublease for one extension term of three months by written notice not less than six months prior to the expiration of the sublease term. The Company did not exercise this option. 1400000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Future minimum commitments under non-cancellable leases as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">June 30, 2022 were as follows:</span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:68.871%;"/> <td style="width:2.254%;"/> <td style="width:1.0%;"/> <td style="width:26.876%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:10.0pt;"> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Years ending December 31,</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Amount</span></p></td> <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(in thousands)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Remainder of 2022</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2,337</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2023</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">9,691</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2024</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">9,982</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2025</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">10,281</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2026</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">10,590</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Thereafter</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">65,196</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Total lease payments</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">108,077</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Less: interest</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Present value of operating lease liabilities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">108,075</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> </table> 2337000 9691000 9982000 10281000 10590000 65196000 108077000 2000 108075000 800000 1700000 500000 900000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">8.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> License agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">The Company's significant license agreements are disclosed in Note 8, "License agreements," in the audited consolidated financial statements for the year ended December 31, 2021, and notes thereto, included in the Company’s Annual Report on Form 10-K filed with the SEC on March 14, 2022. Since the date of those financial statements, there have been no changes to its license agreements, except as noted below and as noted in Note 14, "Subsequent events."</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;min-width:fit-content;">Harvard/Broad license agreement and Broad license agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">In March 2019, the Company simultaneously entered into the Harvard/Broad License Agreement and Broad License Agreement (the “license agreements”) for certain base editing technologies pursuant to which the Company received exclusive, worldwide, sublicensable, royalty-bearing licenses under specified patent rights to develop and commercialize licensed products and nonexclusive, worldwide, sublicensable, royalty-bearing licenses under certain patent rights to research and develop licensed products. The Company agreed to use commercially reasonable efforts to develop licensed products in accordance with the development plans, to introduce any licensed products that gain regulatory approval into the commercial market, to market licensed products that have gained regulatory approval following such</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">introduction into the market, and to make licensed products that have gained regulatory approval reasonably available to the public. The term of the agreements will continue until the expiration of the last to expire valid claim. The Company may terminate either of the license agreements without cause upon four months’ prior written notice to Harvard and Broad, unless terminated earlier. In February 2021, the Company provided written notice to Broad of its intent to terminate the Broad License Agreement, which termination was effective in June 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">As partial consideration for the rights granted under the Harvard/ Broad License Agreement and Broad License Agreement, the Company paid $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million in non-refundable upfront license fees and also issued </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">276,075</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> shares of its common stock with a fair value of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million. Additional consideration under the license agreements is as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Antidilution Rights</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—The initial shares of common stock issued to Harvard and Broad were subject to antidilution provisions as further described in Note 5, "Fair value of financial instruments." The antidilution rights associated with the Company achieving a defined aggregate level of preferred stock financing were partially satisfied in 2019 and fully satisfied in 2020, which settlement amounts totaled $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million, respectively, and which amounts were settled through issuances of </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">121,411</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">187,867</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> shares of common stock, respectively. The remaining antidilution rights obligation was fully satisfied in the three months ended June 30, 2021 with the Company’s IPO. The settlement amount totaled $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">32.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million, and was settled through issuance of </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">878,098</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> shares of common stock.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Success Payments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—The Company is required to make success payments under the license agreements as further described in Note 5, "Fair</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">value of financial instruments." In September 2021, certain success payments were triggered and amounts due to Harvard and Broad totaled $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">6.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million. These amounts were settled in cash in November 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Other Payments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—The Company agreed to pay an annual license maintenance fee ranging from low-to-mid five figures to low six figures,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">depending on the particular calendar year, for each of the license agreements. The Company is responsible for the payment of certain patent prosecution and maintenance costs incurred by Harvard and Broad related to licensed patents. To the extent achieved, the Company is obligated to pay up to an aggregate of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">46.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">108</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million in development and sales-based milestones, respectively. Durin</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">g the three months ended March 31, 2022, the first milestone was triggered and amounts due to Harvard and Broad totaled $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million. These amounts remain payable as of June 30, 2022 and will be settled in cash. If the Company undergoes a change of control during the term of the license agreements, then certain of the milestone payments would be increased by a mid-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">double-digit percentage. To the extent there are sales of a licensed product, the Company is required to pay low single digit royalties on net sales, for each of the license agreements. The Company is entitled to certain reductions and offsets on these royalties with respect to a licensed product in a given country.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;min-width:fit-content;">Beam license agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">In April 2019, the Company and Beam Therapeutics, Inc. ("Beam") entered into a collaboration and license agreement (the “Beam Agreement”). Pursuant to the Beam Agreement, the Company received an exclusive, worldwide, sublicensable license under certain of Beam’s base editing technology, gene editing, and delivery technologies to develop, make, use, offer for sale, sell and import base editing products and nuclease products using Beam’s CRISPR associated protein 12b, or Cas12b technology, in each case, directed to any of four gene targets, including the PCSK9 and ANGPTL3 genes, that are associated with an increased risk of coronary diseases. In addition, the Company granted Beam an exclusive, worldwide, sublicensable license under certain of its delivery technology to develop, manufacture, sell and import product candidates and products, except for base editor products licensed to Verve.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Both parties may conduct certain activities in accordance with an agreed-upon research and/or development plan. Following the dosing of the final patient in a Phase 1 clinical trial of a given licensed product, Beam has the right to opt in to share 33% of worldwide expenses of the development of such licensed product, as well as jointly commercialize and share profits and expenses of commercializing such licensed product in the United States on a 50/50 basis. If Beam exercises its opt-in right for a given licensed product, which we refer to following such opt-in as a collaboration product, it will be obligated to pay for a specified percentage of the development and commercialization costs of such collaboration product and will have the right to receive a specified percentage of the profits from any sales of such collaboration product. The term of the Beam Agreement continues until the last to expire of any royalty term for any product. The Company has the right to terminate the Beam Agreement as to any licensed product, but not for any collaboration product, by delivering a 90-day termination notice to Beam, provided that Beam has elected not to exercise its opt-in right or the period to exercise such opt-in right has expired. The Company is responsible for all costs and expenses incurred in the conduct of activities under the research plan, any development plan and any costs and expenses for the development of a licensed product for which Beam has not elected to opt-in.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">As partial consideration for the license rights granted by Beam under the Beam Agreement, the Company paid a one-time, nonrefundable fee through issuing </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">276,075</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> shares of its common stock with a fair value of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million. To the extent achieved, for each licensed product, the Company is also obligated to pay up to $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">11.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million in development and regulatory-based milestones and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">15.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">in sales-based milestones. To the extent there are sales of a licensed</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">product, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">the Company is required to pay low-to-mid single digit royalties on net sales. To the extent achieved, for each collaboration product outside of the United States, the Company is obligated to pay up to $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">5.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million in development and regulatory-based milestones and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">7.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million in sales-based milestones. To the extent there are ex-U.S. sales of a collaboration product, the Company is required to pay low-to-mid single digit royalties on net sales. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Due to the submission of the Company's CTA in New Zealand, a milestone payment of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million was triggered during the period ending June 30, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">On July 5, 2022, the Company entered into an Amended and Restated Collaboration and License Agreement with Beam (the “Amended Beam Agreement”), which is further described in Note 14, “Subsequent events.”</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">To the extent there are sales of a delivery technology product, each party will pay the other party low-to-mid single digit royalties based on the annual aggregate worldwide net sales resulting from the sale of each delivery technology product of such paying party; provided, however, that such royalty payments will not apply to net sales of the collaboration products or licensed products. The Company concluded the receipt of any milestone or royalty payments under the Beam Agreement was not probable as of June 30, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;min-width:fit-content;">Beam materials exchange letter agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">In October 2020, the Company and Beam entered into a materials exchange agreement wherein the parties agreed that Beam would provide certain mRNA, gRNA, and protein to the Company and that the Company would provide certain gRNAs to Beam at an agreed upon price per each material provided.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">For the three and six months ended June 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> and 2021, the Company did </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">t purchase any materials from Beam.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">For the three and six months ended June 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">, the Company did </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">t sell any materials to Beam. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">For the three months ended June 30, 2021, the Company did </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">t sell any materials to Beam. For the six months ended June 30, 2021, the Company recognized $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million as a reduction to research and development expense related to reimbursements received for materials sold to Beam.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;min-width:fit-content;">Acuitas agreements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;min-width:fit-content;">Development and option agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">In December 2019, the Company and Acuitas Therapeutics, Inc. ("Acuitas") entered into a development and collaboration agreement, which agreement was amended and restated in October 2020. The Company agreed to reimburse Acuitas on a quarterly basis for its services performed related to the program activities based on an agreed upon number of fulltime employees committed to work on the program at an annual rate per employee, including reimbursement of reasonable external costs. The Company recognized research and development expense of less than $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million during the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">three and six months ended June 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">, respectively, and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">0.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">three and six months ended June 30, 2021, respectively, related to the reimbursement of research and development services provided by Acuitas and technology maintenance fees.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;min-width:fit-content;">License agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">In October 2020, the Company paid Acuitas a non-refundable, upfront license fee of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million (less a previously paid target reservation fee) to exercise an option with respect to a licensed product and a licensed genome target and entered into a non-exclusive, worldwide license with Acuitas, with a right to sub-license through multiple tiers, under the licensed LNP technology to research, develop and commercialize the licensed products using the LNP technology in connection with the PCSK9 gene target for all human therapeutic or prophylactic uses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">To the extent achieved, the Company is also obligated to pay up to an aggregate of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">9.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million in clinical and regulatory milestones and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">9.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million in sales-based milestones. The milestones have not been achieved and </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> expense has been recorded for these milestones as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">June 30, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;min-width:fit-content;">Third-party license agreements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">In October 2021, the Company entered into a license agreement with a third party to obtain a non-exclusive license to certain technology the Company is using for research and development. As consideration for the license and rights granted under the agreement, the Company made a one-time, non-refundable, upfront payment of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million during the three months ended December 31, 2021. The license agreement provides for specified development milestones relating to the licensed technology and requires the Company to make payments upon achievement of each milestone up to an aggregate amount of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million. The milestones have not been achieved and no expense has been recorded for these milestones as of June 30, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">In June 2022, the Company amended the agreement to include three additional licensed products to the scope of the non-exclusive license. In consideration of the additional licensed prod</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">ucts, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">the Company was required to make a one-time,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">non-refundable </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">upfront payment of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million to such third party. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">This amount remained payable as of June 30, 2022 and was settled in cash in July 2022.</span></p> 300000 276075 300000 100000 500000 121411 187867 32500000 878098 6300000 46200000 108000000 300000 276075 300000 11300000 15000000.0 5600000 7500000 200000 0 0 0 0 0 0 0 0 200000 100000 100000 300000 600000 2000000.0 9800000 9500000 0 800000 10000000.0 2800000 <span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Preferred and common stock</span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">In January 2021, the Company issued </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">77,163,022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> shares of Series B Preferred Stock at a price of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">1.2182</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> per share for gross proceeds of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">94.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million. The Company incurred issuance costs in connection with this transaction of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">In June 2021, the Company amended and restated its certificate of incorporation to authorize </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">5,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> shares of preferred stock, which shares of preferred stock are currently undesignated, and </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">200,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> shares of common stock, $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">0.001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> par value per share.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">In June 2021, the Company completed its IPO, pursuant to which the Company issued and sold </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">16,141,157</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> shares of its common stock, including </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2,105,368</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> shares pursuant to the full exercise of the underwriters' option to purchase additional shares, at a public offering price of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">19.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> per share, for aggregate gross proceeds of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">306.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">. The Company received approximately </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">281.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> in net proceeds, after deducting underwriting discounts and offering expenses payable by the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Upon the closing of the IPO, all outstanding shares of the Company's preferred stock automatically converted into </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">27,720,923</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> shares of the Company's common stock.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">In June 2021, the Company issued </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">878,098</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> shares of its common stock to Harvard and Broad as final settlement of its antidilution rights obligation.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">The holders of common stock are entitled to one vote for each share of common stock.</span></p> 77163022 1.2182 94000000.0 200000 5000000 200000000 0.001 16141157 2105368 19.00 306700000 281600000 27720923 878098 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">10. Stock-based compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">The 2018 Equity Incentive Plan, or the 2018 Plan, adopted by the board of directors in August 2018 provided for the grant of qualified incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock and restricted stock units to the Company’s employees, officers, directors, advisors, and outside consultants for the issuance or purchase of shares of the Company’s common stock. The maximum number of shares of common stock that were authorized for issuance under the 2018 Plan was </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">6,885,653</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">In June 2021, the Company's board of directors adopted, and the Company's stockholders approved, the 2021 Stock Incentive Plan, or the 2021 Plan, which became effective on June 16, 2021. The 2021 Plan provides for grant of qualified and nonqualified stock options, stock appreciation rights, restricted and unrestricted stock and stock units, performance awards, and other share-based awards to the Company's employees, directors, advisors and outside consultants. Under the 2021 Plan, the number of shares of common stock initially reserved for issuance was the sum of: (1) </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">3,466,530</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">; plus (2) the number of shares as was equal to the sum of (x) the number of shares of common stock reserved for issuance under the 2018 Plan that remained available for grant under the 2018 Plan on June 16, 2021 and (y) the number of shares of common stock subject to outstanding awards granted under the 2018 Plan that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right; plus (3) </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">an annual increase, to be added on the first day of each fiscal year, commencing on January 1, 2022 and continuing until, and including, January 1, 2031, equal to the lesser of (i) </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">% of the number of shares of common stock outstanding on such date</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> and (ii) the number of shares of common stock determined by the Company’s board of directors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">On January 1, 2022, </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2,425,587</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> shares of the Company's common stock were added to the amount reserved for issuance under the 2021 Plan in accordance with the 2021 Plan described above. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">As of June 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">, the Company had reserved </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">7,057,629</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> shares of the Company's common stock for issuance of equity awards, of which </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">3,456,180</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> shares remained available for future grant under the 2021 Plan. Upon effectiveness of the 2021 Plan, the Company ceased granting additional awards under the 2018 Plan.</span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Stock-based compensation expense recorded in the condensed consolidated statements of operations and comprehensive loss is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;min-width:fit-content;"/> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.121%;"/> <td style="width:1.215%;"/> <td style="width:1.0%;"/> <td style="width:9.083%;"/> <td style="width:1.0%;"/> <td style="width:1.215%;"/> <td style="width:1.0%;"/> <td style="width:9.426%;"/> <td style="width:1.0%;"/> <td style="width:1.215%;"/> <td style="width:1.0%;"/> <td style="width:9.083%;"/> <td style="width:1.0%;"/> <td style="width:1.215%;"/> <td style="width:1.0%;"/> <td style="width:9.426%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:10.0pt;"> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="6" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Three months ended June 30,</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="6" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Six months ended June 30,</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(in thousands)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Research and development</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2,955</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">708</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">5,421</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">1,021</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">General and administrative</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2,694</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">643</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">4,432</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">1,000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Total stock-based compensation expense</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">5,649</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">1,351</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">9,853</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2,021</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;min-width:fit-content;">Stock options</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">The following table provides a summary of stock option activity during the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">six months ended June 30, 2022:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;min-width:fit-content;"/> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:35.878%;"/> <td style="width:1.512%;"/> <td style="width:1.0%;"/> <td style="width:11.217%;"/> <td style="width:1.0%;"/> <td style="width:1.512%;"/> <td style="width:1.0%;"/> <td style="width:12.823%;"/> <td style="width:1.0%;"/> <td style="width:1.512%;"/> <td style="width:1.0%;"/> <td style="width:13.100999999999999%;"/> <td style="width:1.0%;"/> <td style="width:1.512%;"/> <td style="width:1.0%;"/> <td style="width:12.934%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:10.0pt;"> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Number of<br/>options</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Weighted<br/>average<br/>exercise<br/>price per<br/>share</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Weighted<br/>average<br/>remaining<br/>contractual<br/>life (in years)</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Aggregate<br/>intrinsic<br/>value</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;font-family:Arial;position:relative;min-width:fit-content;">(2)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;"><br/>(in thousands)</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Outstanding at December 31, 2021</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">6,119,295</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">9.44</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Granted</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2,103,350</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">27.34</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Exercised</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">172,699</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">3.62</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Forfeited</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">164,729</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">25.77</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Outstanding at June 30, 2022</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">7,885,217</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">14.09</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">8.5</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">52,868</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Exercisable at June 30, 2022</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2,301,148</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">4.40</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">7.8</span></span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">25,676</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Expected to vest after June 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Arial;position:relative;min-width:fit-content;">(1)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">5,584,069</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">18.08</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">8.8</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">27,192</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;min-width:fit-content;"/> </p><div style="text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;min-width:fit-content;text-indent:0;display:inline-flex;font-size:8.0pt;font-family:Arial;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;min-width:fit-content;">This represents the number of unvested options outstanding as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;min-width:fit-content;">June 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;min-width:fit-content;"> that are expected to vest in the future. </span></div></div><div style="text-indent:0.0%;display:flex;margin-top:3.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;min-width:fit-content;text-indent:0;display:inline-flex;font-size:8.0pt;font-family:Arial;justify-content:flex-start;min-width:3.333%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;min-width:fit-content;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the common stock for the options that were in the money as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;min-width:fit-content;">June 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;min-width:fit-content;">.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">As of June 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">, there was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">66.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million of unrecognized compensation cost related to unvested stock options, which is expected to be recognized over a weighted-average period of approximately </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2.8 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;min-width:fit-content;">Restricted stock units</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">During the six months ended June 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">, the Company granted </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">524,875</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> restricted stock units under the 2021 Plan. These restricted stock units vest annually over a four-year period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">A summary of the status of and change in unvested restricted stock units as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">June 30, 2022 was as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;min-width:fit-content;"/> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:62.737%;"/> <td style="width:1.781%;"/> <td style="width:1.0%;"/> <td style="width:14.326%;"/> <td style="width:1.0%;"/> <td style="width:1.781%;"/> <td style="width:1.0%;"/> <td style="width:15.375%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:10.0pt;"> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Shares</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Weighted-<br/>average grant<br/>date fair<br/>value per share</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Unvested restricted stock units as of December 31, 2021</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">32,000</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">36.58</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Restricted stock units granted</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">524,875</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">20.48</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Restricted stock units forfeited</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">4,500</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">30.94</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Unvested restricted stock units as of June 30, 2022</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">552,375</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">21.33</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">As of June 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">, there was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">11.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million of unrecognized stock-based compensation expense related to restricted stock units that are expected to vest. These costs are expected to be recognized over a weighted-average remaining vesting period of approximately </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">3.9 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;min-width:fit-content;">2021 Amended and Restated Employee Stock Purchase Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">In June 2021, the board of directors adopted, and the Company's stockholders approved, the 2021 Employee Stock Purchase Plan, or the ESPP, as amended and restated, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">which became effective on June 16, 2021. The Company initially reserved </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">433,316</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> shares of common stock for sale under the ESPP. The aggregate number of shares reserved for sale under the ESPP increases automatically on the first day of each fiscal year commencing on January 1, 2022 through January 1, 2031, by the number of shares equal to the least of (a) </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">1,083,290</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> shares, (b) </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">% of the total outstanding shares of common stock on such date, and (c) a number of shares as may be determined by the board of directors in any particular year. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">The first offering period under the ESPP commenced on June 16, 2021 and ended on December 13, 2021. On January 1, 2022, </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">485,117</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> shares of common stock were added to the amount reserved for sale under the ESPP. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">As of June 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">844,918</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> shares remained available for issuance under the ESPP. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">The second offering period ended on May 31, 2022, for which offering period the Company issued </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">25,218</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> shares. The next offering period commenced on June 1, 2022 and will end on November 30, 2022.</span></p> 6885653 3466530 an annual increase, to be added on the first day of each fiscal year, commencing on January 1, 2022 and continuing until, and including, January 1, 2031, equal to the lesser of (i) 5% of the number of shares of common stock outstanding on such date 0.05 2425587 7057629 3456180 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Stock-based compensation expense recorded in the condensed consolidated statements of operations and comprehensive loss is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;min-width:fit-content;"/> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.121%;"/> <td style="width:1.215%;"/> <td style="width:1.0%;"/> <td style="width:9.083%;"/> <td style="width:1.0%;"/> <td style="width:1.215%;"/> <td style="width:1.0%;"/> <td style="width:9.426%;"/> <td style="width:1.0%;"/> <td style="width:1.215%;"/> <td style="width:1.0%;"/> <td style="width:9.083%;"/> <td style="width:1.0%;"/> <td style="width:1.215%;"/> <td style="width:1.0%;"/> <td style="width:9.426%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:10.0pt;"> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="6" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Three months ended June 30,</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="6" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Six months ended June 30,</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(in thousands)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Research and development</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2,955</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">708</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">5,421</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">1,021</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">General and administrative</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2,694</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">643</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">4,432</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">1,000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Total stock-based compensation expense</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">5,649</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">1,351</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">9,853</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2,021</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> </table> 2955000 708000 5421000 1021000 2694000 643000 4432000 1000000 5649000 1351000 9853000 2021000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">The following table provides a summary of stock option activity during the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">six months ended June 30, 2022:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;min-width:fit-content;"/> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:35.878%;"/> <td style="width:1.512%;"/> <td style="width:1.0%;"/> <td style="width:11.217%;"/> <td style="width:1.0%;"/> <td style="width:1.512%;"/> <td style="width:1.0%;"/> <td style="width:12.823%;"/> <td style="width:1.0%;"/> <td style="width:1.512%;"/> <td style="width:1.0%;"/> <td style="width:13.100999999999999%;"/> <td style="width:1.0%;"/> <td style="width:1.512%;"/> <td style="width:1.0%;"/> <td style="width:12.934%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:10.0pt;"> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Number of<br/>options</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Weighted<br/>average<br/>exercise<br/>price per<br/>share</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Weighted<br/>average<br/>remaining<br/>contractual<br/>life (in years)</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Aggregate<br/>intrinsic<br/>value</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;font-family:Arial;position:relative;min-width:fit-content;">(2)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;"><br/>(in thousands)</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Outstanding at December 31, 2021</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">6,119,295</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">9.44</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Granted</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2,103,350</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">27.34</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Exercised</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">172,699</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">3.62</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Forfeited</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">164,729</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">25.77</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Outstanding at June 30, 2022</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">7,885,217</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">14.09</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">8.5</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">52,868</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Exercisable at June 30, 2022</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2,301,148</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">4.40</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">7.8</span></span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">25,676</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Expected to vest after June 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Arial;position:relative;min-width:fit-content;">(1)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">5,584,069</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">18.08</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">8.8</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">27,192</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;min-width:fit-content;"/> </p><div style="text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;min-width:fit-content;text-indent:0;display:inline-flex;font-size:8.0pt;font-family:Arial;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;min-width:fit-content;">This represents the number of unvested options outstanding as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;min-width:fit-content;">June 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;min-width:fit-content;"> that are expected to vest in the future. </span></div></div><div style="text-indent:0.0%;display:flex;margin-top:3.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;min-width:fit-content;text-indent:0;display:inline-flex;font-size:8.0pt;font-family:Arial;justify-content:flex-start;min-width:3.333%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;min-width:fit-content;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the common stock for the options that were in the money as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;min-width:fit-content;">June 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;min-width:fit-content;">.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">As of June 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">, there was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">66.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million of unrecognized compensation cost related to unvested stock options, which is expected to be recognized over a weighted-average period of approximately </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2.8 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p> 6119295 9.44 2103350 27.34 172699 3.62 164729 25.77 7885217 14.09 P8Y6M 52868000 2301148 4.40 P7Y9M18D 25676000 5584069 18.08 P8Y9M18D 27192000 66300000 P2Y9M18D 524875 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">A summary of the status of and change in unvested restricted stock units as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">June 30, 2022 was as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;min-width:fit-content;"/> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:62.737%;"/> <td style="width:1.781%;"/> <td style="width:1.0%;"/> <td style="width:14.326%;"/> <td style="width:1.0%;"/> <td style="width:1.781%;"/> <td style="width:1.0%;"/> <td style="width:15.375%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:10.0pt;"> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Shares</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Weighted-<br/>average grant<br/>date fair<br/>value per share</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Unvested restricted stock units as of December 31, 2021</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">32,000</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">36.58</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Restricted stock units granted</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">524,875</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">20.48</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Restricted stock units forfeited</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">4,500</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">30.94</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Unvested restricted stock units as of June 30, 2022</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">552,375</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">21.33</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> </table> 32000 36.58 524875 20.48 4500 30.94 552375 21.33 11000000.0 P3Y10M24D 433316 1083290 0.01 485117 844918 25218 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">11. Net loss per share attributable to common stockholders</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Company’s potential dilutive securities, which include convertible preferred stock, unvested restricted stock, unvested restricted stock units and common stock options, have been excluded from the computation of diluted net loss per share as the effects would be anti-dilutive. Therefore, the weighted average number of common shares outstanding used to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">calculate </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">both basic and diluted net loss per share attributable to common stockholders is the same. </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders for the period indicated because including them would have had an anti-dilutive effect: </span></span><span style=""/></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;min-width:fit-content;"/> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:65.931%;"/> <td style="width:1.596%;"/> <td style="width:1.0%;"/> <td style="width:13.272%;"/> <td style="width:1.0%;"/> <td style="width:1.596%;"/> <td style="width:1.0%;"/> <td style="width:13.606%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:10.0pt;"> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="6" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">As of June 30,</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Unvested restricted stock</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">268,816</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Unvested restricted stock units</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">552,375</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Outstanding options to purchase common stock</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">7,885,217</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">5,720,987</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Total</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">8,437,592</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">5,989,803</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> </table></div> <span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders for the period indicated because including them would have had an anti-dilutive effect: </span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;min-width:fit-content;"/> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:65.931%;"/> <td style="width:1.596%;"/> <td style="width:1.0%;"/> <td style="width:13.272%;"/> <td style="width:1.0%;"/> <td style="width:1.596%;"/> <td style="width:1.0%;"/> <td style="width:13.606%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:10.0pt;"> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="6" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">As of June 30,</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Unvested restricted stock</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">268,816</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Unvested restricted stock units</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">552,375</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Outstanding options to purchase common stock</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">7,885,217</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">5,720,987</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Total</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">8,437,592</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">5,989,803</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p></td> </tr> </table> 0 268816 552375 0 7885217 5720987 8437592 5989803 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">12. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Income taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Deferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using statutory rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized. Due to the uncertainty surrounding the realization of the favorable tax attributes in future tax returns, the Company has recorded a full valuation allowance against the Company’s otherwise recognizable net deferred tax assets.</span> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">13. Related party transactions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">An executive officer of Beam is a board member of the Company. In October 2020, the Company and Beam entered into a materials exchange agreement wherein the parties agreed that Beam would provide certain mRNA, gRNA, and protein to the Company and that the Company would provide certain gRNAs to Beam at an agreed upon price per each material provided. For the three months ended June 30, 2021, the Company did not sell any materials to Beam. For </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">the six months ended June 30, 2021, the Company recognized $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million as a reduction to research and development expense related to reimbursements received for materials sold to Beam. For the three and six months ended June 30, 2022, the Company did not sell any materials to Beam.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">In October 2021, the Company entered into a sublease agreement with Beam for laboratory and office space in Cambridge, Massachusetts. The sublease commenced in December 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">. Total expenses incurred under this sublease were $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million for the three and six months ended June 30, 2022, respectively.</span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">An executive of Broad was a board member of the Company until May 2021. In March 2019, the Company simultaneously entered into the Harvard/Broad License Agreement and Broad License Agreement for certain base editing technologies pursuant to which the Company received exclusive, worldwide, sublicensable, royalty-bearing licenses under specified patent rights to develop and commercialize licensed products and nonexclusive, worldwide, sublicensable, royalty-bearing licenses under certain patent rights to research and develop licensed products. Additional consideration under the license agreements include success payments. See Note 8, "License agreements."</span> 200000 500000 1000000.0 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">14. S</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">ubsequent events</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;min-width:fit-content;">Amended and Restated Collaboration and License Agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">On July 5, 2022, the Company entered into the Amended Beam Agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Pursuant to the Amended Beam Agreement, Beam granted the Company an exclusive, worldwide, sublicensable license under certain of Beam’s base editing technology to develop and commercialize products directed towards an additional liver-mediated, cardiovascular disease target. The Company will be responsible for the development and commercialization of products targeting such gene, subject to Beam’s opt-in right. Following the dosing of the final patient in a Phase 1 clinical trial of a licensed product for such gene, Beam has the right to opt-in to share 35% of worldwide expenses of the development of such licensed product, as well as jointly commercialize and share 35% of the profits and expenses of commercializing such licensed product worldwide. If Beam does not elect to opt-in, Beam would be entitled to receive milestones and royalties on the same basis as other collaboration products as provided in the Beam Agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">In exchange, the Company granted to Beam an exclusive, worldwide, sublicensable, fully paid-up license under the Company's intellectual property, including under the Company's GalNAc-LNP delivery technology, relating to a preclinical program developed by the Company.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">In addition, the Amended Beam Agreement:</span></p><div style="text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">clarifies intellectual property rights with respect to the Company's GalNAc-LNP delivery technology;</span></div></div><div style="text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">grants Beam, on a target-by-target basis, the option to obtain a non-exclusive, worldwide, sublicensable license to the Company's GalNAc-LNP delivery technology for the development and commercialization of certain base editor products, as to which Beam would owe the Company a fee upon exercise of each option, certain regulatory and commercial sale milestones as well as low single-digit royalties on net sales for base editor products using the GalNAc-LNP delivery technology;</span></div></div><div style="text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">terminates the Company's rights and economic obligations under the Beam Agreement with respect to the undisclosed genes, allowing the Company and Beam to independently develop and commercialize products directed to such gene targets; and</span></div></div><div style="text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">concludes other licenses that applied under the Beam Agreement with respect to delivery and other technologies developed by the parties for the development and commercialization of base editor products.</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">The Amended Beam Agreement also contains representations and warranties, covenants, and other negotiated provisions, including confidentiality obligations, customary for transactions of this nature.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;min-width:fit-content;">Strategic License and Collaboration Agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">On July 18, 2022, the Company entered into the Vertex Agreement for an exclusive, four-year worldwide research collaboration focused on developing in vivo gene editing candidates toward an undisclosed target for the treatment of a single liver disease. Additionally, on July 18, 2022, the Company entered into the Stock Purchase Agreement with Vertex, pursuant to which the Company agreed to sell and issue shares of its common stock to Vertex.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Pursuant to the Vertex Agreement, the Company will be responsible for discovery, research and certain preclinical development of novel in vivo gene editing development candidates for the target of interest. The Company’s research activities will be focused on (i) identifying and engineering specific gene editing systems and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> delivery systems directed to the target and (ii) evaluating and optimizing development candidates to achieve criteria specified in the Vertex Agreement. Vertex will reimburse the Company’s research expenses consistent with an agreed-upon budget. The research term has an initial term of four years and may be extended by Vertex for up to one additional year.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Vertex will be solely responsible for subsequent development, manufacturing and commercialization of any product candidate resulting from the Company’s research efforts. The Company received an upfront payment from Vertex of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million on July 20, 2022. The Company is eligible to receive (i) success payments of up to $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">22</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million for each product candidate (up to a maximum of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">66</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million) that achieves the applicable development criteria and (ii) up to an aggregate of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">340</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million in development and commercial milestone payments. The Company is also eligible to receive tiered single-digit royalties on net sales, subject to specified reductions. Such royalty payments will terminate on a country-by-country and product-by-product basis upon the later to occur of (i) the expiration of the last to expire valid claim under the patent rights covering such product in such country, (ii) the period of regulatory exclusivity associated with such product in such country or (iii) ten years after the first commercial sale of such product in such country.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Prior to the first patient dosing of the first Phase 1 clinical trial for the first product candidate developed under the Vertex Agreement, the Company also has the right to opt-in to a profit share arrangement pursuant to which Vertex and the Company would share the costs and net profits for all product candidates emerging from the collaboration. If the Company exercises its opt-in right, in lieu of milestones and royalties, the Company will be obligated to pay for a specified percentage of the development and commercialization costs, and it will have the right to receive a specified percentage of the profits from any sales of any product candidates advanced under the collaboration. At the time the Company exercises the option, it may elect a profit/cost share of up to </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">40</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">% (with Vertex retaining a minimum of </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">60</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">%). In order to exercise its opt-in right, the Company is required to pay a fee ranging from $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">-</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">70</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million, depending on the profit/cost percentage elected by the Company and the licensed technology of the Company included in the most advanced product candidate at the time the Company exercises its opt-in right. Under all profit share scenarios, Vertex will control the w</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">orldwide development and commercialization of any product candidates resulting from the collaboration.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">The Vertex Agreement includes customary representations and warranties, covenants and indemnification obligations for a transaction of this nature. The Company and Vertex each have the right to terminate the agreement for material breach by, or insolvency of, the other party following notice, and if applicable, a cure period. Vertex may also terminate the Vertex Agreement in its entirety for convenience upon 90 days’ notice.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;min-width:fit-content;">Stock Purchase Agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">On July 18, 2022, in connection with the execution of the Vertex Agreement, the Company and Vertex also entered into the Stock Purchase Agreement for the sale and issuance of </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">1,519,756</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">shares of the Company’s common stock to Vertex at a price of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">23.03</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> per share, which is equal to the five-day volume-weighted average share price as of July 15, 2022, for an aggregate purchase price of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">35.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million. The sale of the Company’s common stock closed on July 20, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">The Stock Purchase Agreement includes lock-up restrictions with respect to the shares of common stock issued to Vertex. Pursuant to the terms of the Stock Purchase Agreement, Vertex has agreed not to, and to cause its affiliates not to, sell or transfer any of the shares for a period of 12 months following the date of issuance of the shares, subject to specified conditions and exceptions.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;min-width:fit-content;">Follow-on public offering</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">On July 25, 2022, the Company issued and sold </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">9,583,334</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> shares of its common stock, including </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">1,250,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> shares of its common stock sold pursuant to the underwriters’ full exercise of their option to purchase additional shares of common stock, at a public offering price of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">27.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> per share. The Company received net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">242.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million from the sale of shares in the follow-on offering after deducting underwriting discounts and commissions of approximately $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">15.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million and offering costs of approximately $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million.</span></p> 25000000 22000000 66000000 340000000 0.40 0.60 25000000 70000000 1519756 23.03 35000000.0 9583334 1250000 27.00 242900000 15500000 300000 This represents the number of unvested options outstanding as of June 30, 2022 that are expected to vest in the future. The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the common stock for the options that were in the money as of June 30, 2022. EXCEL 70 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 71 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 72 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 73 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 224 273 1 true 61 0 false 5 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.vervetx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 100030 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 100040 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss Sheet http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss Condensed Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 100050 - Statement - Condensed Consolidated Statement of Convertible Preferred Stock and Stockholders' Equity (Deficit) Sheet http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit Condensed Consolidated Statement of Convertible Preferred Stock and Stockholders' Equity (Deficit) Statements 5 false false R6.htm 100060 - Statement - Condensed Consolidated Statement of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) Sheet http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical Condensed Consolidated Statement of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) Statements 6 false false R7.htm 100070 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 7 false false R8.htm 100080 - Disclosure - Nature of the Business and Basis of Presentation Sheet http://www.vervetx.com/20220630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentation1 Nature of the Business and Basis of Presentation Notes 8 false false R9.htm 100090 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 100100 - Disclosure - Marketable Securities Sheet http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureMarketableSecurities Marketable Securities Notes 10 false false R11.htm 100110 - Disclosure - Property and equipment, net Sheet http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet Property and equipment, net Notes 11 false false R12.htm 100120 - Disclosure - Fair value of financial instruments Sheet http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstruments1 Fair value of financial instruments Notes 12 false false R13.htm 100130 - Disclosure - Accrued expenses Sheet http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureAccruedExpenses Accrued expenses Notes 13 false false R14.htm 100140 - Disclosure - Leases Sheet http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeases Leases Notes 14 false false R15.htm 100150 - Disclosure - License Agreements Sheet http://www.vervetx.com/20220630/taxonomy/role/DisclosureLicenseAgreements License Agreements Notes 15 false false R16.htm 100170 - Disclosure - Preferred and Common Stock Sheet http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosurePreferredAndCommonStock Preferred and Common Stock Notes 16 false false R17.htm 100180 - Disclosure - Stock-based compensation Sheet http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensation Stock-based compensation Notes 17 false false R18.htm 100190 - Disclosure - Net Loss Per Share Attributable to Common Stockholders Sheet http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders Net Loss Per Share Attributable to Common Stockholders Notes 18 false false R19.htm 100200 - Disclosure - Income Taxes Sheet http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureIncomeTaxes Income Taxes Notes 19 false false R20.htm 100210 - Disclosure - Related Party Transactions Sheet http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureRelatedPartyTransactions Related Party Transactions Notes 20 false false R21.htm 100220 - Disclosure - Subsequent Events Sheet http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureSubsequentEvents Subsequent Events Notes 21 false false R22.htm 100230 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies 22 false false R23.htm 100240 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies 23 false false R24.htm 100250 - Disclosure - Marketable Securities (Tables) Sheet http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesTables Marketable Securities (Tables) Tables http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureMarketableSecurities 24 false false R25.htm 100260 - Disclosure - Property and equipment, net (Tables) Sheet http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables Property and equipment, net (Tables) Tables http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet 25 false false R26.htm 100270 - Disclosure - Fair Value of Financial Instruments (Tables) Sheet http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables Fair Value of Financial Instruments (Tables) Tables 26 false false R27.htm 100280 - Disclosure - Accrued Expenses (Tables) Sheet http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureAccruedExpensesTables Accrued Expenses (Tables) Tables 27 false false R28.htm 100290 - Disclosure - Leases (Tables) Sheet http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesTables Leases (Tables) Tables http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeases 28 false false R29.htm 100300 - Disclosure - Stock-based compensation (Tables) Sheet http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationTables Stock-based compensation (Tables) Tables http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensation 29 false false R30.htm 100310 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables) Sheet http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables Net Loss Per Share Attributable to Common Stockholders (Tables) Tables http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders 30 false false R31.htm 100320 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Details) Sheet http://www.vervetx.com/20220630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetails Nature of the Business and Basis of Presentation - Additional Information (Details) Details 31 false false R32.htm 100330 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) Sheet http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) Details 32 false false R33.htm 100340 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) Sheet http://www.vervetx.com/20220630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails Summary of Significant Accounting Policies - Additional Information (Details) Details 33 false false R34.htm 100350 - Disclosure - Marketable securities - Schedule of Marketable Securities (Details) Sheet http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails Marketable securities - Schedule of Marketable Securities (Details) Details 34 false false R35.htm 100360 - Disclosure - Marketable securities - Additional Information (Details) Sheet http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails Marketable securities - Additional Information (Details) Details 35 false false R36.htm 100370 - Disclosure - Property and Equipment, net - Schedule of Property and Equipment, net (Details) Sheet http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails Property and Equipment, net - Schedule of Property and Equipment, net (Details) Details 36 false false R37.htm 100380 - Disclosure - Property and Equipment, net - Additional Information (Details) Sheet http://www.vervetx.com/20220630/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails Property and Equipment, net - Additional Information (Details) Details 37 false false R38.htm 100390 - Disclosure - Fair value of financial instruments - Summary of Assets and Liabilities Measured at Fair Value (Details) Sheet http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails Fair value of financial instruments - Summary of Assets and Liabilities Measured at Fair Value (Details) Details 38 false false R39.htm 100400 - Disclosure - Fair value of financial instruments - Summary of Assets and Liabilities Measured at Fair Value (Parenthetical) (Details) Sheet http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueParentheticalDetails Fair value of financial instruments - Summary of Assets and Liabilities Measured at Fair Value (Parenthetical) (Details) Details 39 false false R40.htm 100410 - Disclosure - Fair value of financial instruments - Additional Information (Details) Sheet http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails Fair value of financial instruments - Additional Information (Details) Details 40 false false R41.htm 100420 - Disclosure - Fair value of financial instruments - Schedule of Fair Value Liabilities Measured on Recurring Basis (Details) Sheet http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails Fair value of financial instruments - Schedule of Fair Value Liabilities Measured on Recurring Basis (Details) Details 41 false false R42.htm 100430 - Disclosure - Fair value of financial instruments - Schedule of Reconciliation of Changes in Fair Value of Financial Instruments (Details) Sheet http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails Fair value of financial instruments - Schedule of Reconciliation of Changes in Fair Value of Financial Instruments (Details) Details 42 false false R43.htm 100440 - Disclosure - Accrued expenses - Schedule of Accrued Expenses (Details) Sheet http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails Accrued expenses - Schedule of Accrued Expenses (Details) Details 43 false false R44.htm 100450 - Disclosure - Leases - Additional Information (Details) Sheet http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails Leases - Additional Information (Details) Details 44 false false R45.htm 100460 - Disclosure - Leases - Summary of Components of Operating Lease Cost (Details) Sheet http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfOperatingLeaseCostDetails Leases - Summary of Components of Operating Lease Cost (Details) Details 45 false false R46.htm 100470 - Disclosure - Leases - Summary of Supplemental Cash Flow Information Related to Operating Leases (Details) Sheet http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfSupplementalCashFlowInformationRelatedToOperatingLeasesDetails Leases - Summary of Supplemental Cash Flow Information Related to Operating Leases (Details) Details 46 false false R47.htm 100480 - Disclosure - Leases - Summary of Future Minimum Commitments under Non-Cancellable Operating Leases (Details) Sheet http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNoncancellableOperatingLeasesDetails3 Leases - Summary of Future Minimum Commitments under Non-Cancellable Operating Leases (Details) Details 47 false false R48.htm 100490 - Disclosure - License Agreements - Additional Information (Details) Sheet http://www.vervetx.com/20220630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails License Agreements - Additional Information (Details) Details 48 false false R49.htm 100500 - Disclosure - Preferred and Common Stock - Additional Information (Details) Sheet http://www.vervetx.com/20220630/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails Preferred and Common Stock - Additional Information (Details) Details 49 false false R50.htm 100510 - Disclosure - Stock-based compensation - Additional Information (Details) Sheet http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails Stock-based compensation - Additional Information (Details) Details 50 false false R51.htm 100520 - Disclosure - Stock-based compensation - Summary of Stock Based Compensation Expense (Details) Sheet http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails Stock-based compensation - Summary of Stock Based Compensation Expense (Details) Details 51 false false R52.htm 100530 - Disclosure - Stock-based compensation - Schedule of Stock Option Activity (Details) Sheet http://www.vervetx.com/20220630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionActivityDetails Stock-based compensation - Schedule of Stock Option Activity (Details) Details 52 false false R53.htm 100540 - Disclosure - Stock-based compensation - Summary of the Restricted Stock Units (Details) Sheet http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsDetails Stock-based compensation - Summary of the Restricted Stock Units (Details) Details 53 false false R54.htm 100550 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Potential Common Shares, Based on Amounts Outstanding at Period End were Excluded From the Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details) Sheet http://www.vervetx.com/20220630/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersPotentialCommonSharesBasedOnAmountsOutstandingAtPeriodEndWereExcludedFromTheCo Net Loss Per Share Attributable to Common Stockholders - Potential Common Shares, Based on Amounts Outstanding at Period End were Excluded From the Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details) Details 54 false false R55.htm 100560 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Additional Information (Details) Sheet http://www.vervetx.com/20220630/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetails Net Loss Per Share Attributable to Common Stockholders - Additional Information (Details) Details 55 false false R56.htm 100570 - Disclosure - Related Party Transactions - Additional Information (Details) Sheet http://www.vervetx.com/20220630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails Related Party Transactions - Additional Information (Details) Details 56 false false R57.htm 100580 - Disclosure - Subsequent Events - Additional Information (Details) Sheet http://www.vervetx.com/20220630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails Subsequent Events - Additional Information (Details) Details 57 false false All Reports Book All Reports verv-20220630.htm verv-20220630.xsd verv-20220630_cal.xml verv-20220630_def.xml verv-20220630_lab.xml verv-20220630_pre.xml verv-ex10_2.htm verv-ex31_1.htm verv-ex31_2.htm verv-ex32_1.htm verv-ex32_2.htm http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 76 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "verv-20220630.htm": { "axisCustom": 0, "axisStandard": 23, "contextCount": 224, "dts": { "calculationLink": { "local": [ "verv-20220630_cal.xml" ] }, "definitionLink": { "local": [ "verv-20220630_def.xml" ] }, "inline": { "local": [ "verv-20220630.htm" ] }, "labelLink": { "local": [ "verv-20220630_lab.xml" ] }, "presentationLink": { "local": [ "verv-20220630_pre.xml" ] }, "schema": { "local": [ "verv-20220630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 504, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 3, "http://www.vervetx.com/20220630": 4, "http://xbrl.sec.gov/dei/2021q4": 4, "total": 11 }, "keyCustom": 67, "keyStandard": 206, "memberCustom": 25, "memberStandard": 34, "nsprefix": "verv", "nsuri": "http://www.vervetx.com/20220630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4f92a9b7-39ba-4393-8cce-78ef5092b413", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.vervetx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4f92a9b7-39ba-4393-8cce-78ef5092b413", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4f92a9b7-39ba-4393-8cce-78ef5092b413", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Marketable Securities", "role": "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureMarketableSecurities", "shortName": "Marketable Securities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4f92a9b7-39ba-4393-8cce-78ef5092b413", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4f92a9b7-39ba-4393-8cce-78ef5092b413", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Property and equipment, net", "role": "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet", "shortName": "Property and equipment, net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4f92a9b7-39ba-4393-8cce-78ef5092b413", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4f92a9b7-39ba-4393-8cce-78ef5092b413", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Fair value of financial instruments", "role": "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstruments1", "shortName": "Fair value of financial instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4f92a9b7-39ba-4393-8cce-78ef5092b413", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4f92a9b7-39ba-4393-8cce-78ef5092b413", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - Accrued expenses", "role": "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureAccruedExpenses", "shortName": "Accrued expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4f92a9b7-39ba-4393-8cce-78ef5092b413", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4f92a9b7-39ba-4393-8cce-78ef5092b413", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - Leases", "role": "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4f92a9b7-39ba-4393-8cce-78ef5092b413", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4f92a9b7-39ba-4393-8cce-78ef5092b413", "decimals": null, "first": true, "lang": "en-US", "name": "verv:LicenseAgreementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100150 - Disclosure - License Agreements", "role": "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLicenseAgreements", "shortName": "License Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4f92a9b7-39ba-4393-8cce-78ef5092b413", "decimals": null, "first": true, "lang": "en-US", "name": "verv:LicenseAgreementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4f92a9b7-39ba-4393-8cce-78ef5092b413", "decimals": null, "first": true, "lang": "en-US", "name": "verv:PreferredAndCommonStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - Preferred and Common Stock", "role": "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosurePreferredAndCommonStock", "shortName": "Preferred and Common Stock", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4f92a9b7-39ba-4393-8cce-78ef5092b413", "decimals": null, "first": true, "lang": "en-US", "name": "verv:PreferredAndCommonStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4f92a9b7-39ba-4393-8cce-78ef5092b413", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - Stock-based compensation", "role": "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensation", "shortName": "Stock-based compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4f92a9b7-39ba-4393-8cce-78ef5092b413", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4f92a9b7-39ba-4393-8cce-78ef5092b413", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - Net Loss Per Share Attributable to Common Stockholders", "role": "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders", "shortName": "Net Loss Per Share Attributable to Common Stockholders", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4f92a9b7-39ba-4393-8cce-78ef5092b413", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4f92a9b7-39ba-4393-8cce-78ef5092b413", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Income Taxes", "role": "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4f92a9b7-39ba-4393-8cce-78ef5092b413", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_e1ae039c-f794-421a-a56c-e9281c374bce", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_e1ae039c-f794-421a-a56c-e9281c374bce", "decimals": "-3", "lang": null, "name": "us-gaap:MarketableSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4f92a9b7-39ba-4393-8cce-78ef5092b413", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100210 - Disclosure - Related Party Transactions", "role": "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureRelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4f92a9b7-39ba-4393-8cce-78ef5092b413", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4f92a9b7-39ba-4393-8cce-78ef5092b413", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Subsequent Events", "role": "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureSubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4f92a9b7-39ba-4393-8cce-78ef5092b413", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4f92a9b7-39ba-4393-8cce-78ef5092b413", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4f92a9b7-39ba-4393-8cce-78ef5092b413", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4f92a9b7-39ba-4393-8cce-78ef5092b413", "decimals": null, "first": true, "lang": "en-US", "name": "verv:ReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100240 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4f92a9b7-39ba-4393-8cce-78ef5092b413", "decimals": null, "first": true, "lang": "en-US", "name": "verv:ReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4f92a9b7-39ba-4393-8cce-78ef5092b413", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - Marketable Securities (Tables)", "role": "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesTables", "shortName": "Marketable Securities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4f92a9b7-39ba-4393-8cce-78ef5092b413", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4f92a9b7-39ba-4393-8cce-78ef5092b413", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Property and equipment, net (Tables)", "role": "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables", "shortName": "Property and equipment, net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4f92a9b7-39ba-4393-8cce-78ef5092b413", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4f92a9b7-39ba-4393-8cce-78ef5092b413", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - Fair Value of Financial Instruments (Tables)", "role": "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables", "shortName": "Fair Value of Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4f92a9b7-39ba-4393-8cce-78ef5092b413", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4f92a9b7-39ba-4393-8cce-78ef5092b413", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Accrued Expenses (Tables)", "role": "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureAccruedExpensesTables", "shortName": "Accrued Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4f92a9b7-39ba-4393-8cce-78ef5092b413", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4f92a9b7-39ba-4393-8cce-78ef5092b413", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - Leases (Tables)", "role": "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4f92a9b7-39ba-4393-8cce-78ef5092b413", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4f92a9b7-39ba-4393-8cce-78ef5092b413", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100300 - Disclosure - Stock-based compensation (Tables)", "role": "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationTables", "shortName": "Stock-based compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4f92a9b7-39ba-4393-8cce-78ef5092b413", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_e1ae039c-f794-421a-a56c-e9281c374bce", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:PreferredStockSharesIssued", "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_e1ae039c-f794-421a-a56c-e9281c374bce", "decimals": "INF", "lang": null, "name": "us-gaap:PreferredStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4f92a9b7-39ba-4393-8cce-78ef5092b413", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)", "role": "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables", "shortName": "Net Loss Per Share Attributable to Common Stockholders (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4f92a9b7-39ba-4393-8cce-78ef5092b413", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_e1ae039c-f794-421a-a56c-e9281c374bce", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100320 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Details)", "role": "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetails", "shortName": "Nature of the Business and Basis of Presentation - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:NatureOfOperations", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_e1ae039c-f794-421a-a56c-e9281c374bce", "decimals": "-5", "lang": null, "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_e1ae039c-f794-421a-a56c-e9281c374bce", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100330 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)", "role": "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails", "shortName": "Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_b7ed037f-1caf-4b8a-92c6-227801fe055b", "decimals": "-3", "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_e1ae039c-f794-421a-a56c-e9281c374bce", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseLiability", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100340 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)", "role": "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R34": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:MarketableSecuritiesTextBlock", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_e1ae039c-f794-421a-a56c-e9281c374bce", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100350 - Disclosure - Marketable securities - Schedule of Marketable Securities (Details)", "role": "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails", "shortName": "Marketable securities - Schedule of Marketable Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:MarketableSecuritiesTextBlock", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_e1ae039c-f794-421a-a56c-e9281c374bce", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4f92a9b7-39ba-4393-8cce-78ef5092b413", "decimals": null, "first": true, "lang": "en-US", "name": "verv:RemainingContractualMaturitiesOfMarketableSecuritiesTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100360 - Disclosure - Marketable securities - Additional Information (Details)", "role": "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails", "shortName": "Marketable securities - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4f92a9b7-39ba-4393-8cce-78ef5092b413", "decimals": null, "first": true, "lang": "en-US", "name": "verv:RemainingContractualMaturitiesOfMarketableSecuritiesTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_e1ae039c-f794-421a-a56c-e9281c374bce", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100370 - Disclosure - Property and Equipment, net - Schedule of Property and Equipment, net (Details)", "role": "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails", "shortName": "Property and Equipment, net - Schedule of Property and Equipment, net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_e1ae039c-f794-421a-a56c-e9281c374bce", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_d474bbb5-fccd-4578-8a76-6667c229934b", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100380 - Disclosure - Property and Equipment, net - Additional Information (Details)", "role": "http://www.vervetx.com/20220630/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails", "shortName": "Property and Equipment, net - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_d474bbb5-fccd-4578-8a76-6667c229934b", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_e1ae039c-f794-421a-a56c-e9281c374bce", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100390 - Disclosure - Fair value of financial instruments - Summary of Assets and Liabilities Measured at Fair Value (Details)", "role": "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails", "shortName": "Fair value of financial instruments - Summary of Assets and Liabilities Measured at Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_e1ae039c-f794-421a-a56c-e9281c374bce", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4e545da7-f74d-4aca-a978-c61a7b4e9d41", "decimals": "-5", "first": true, "lang": null, "name": "verv:SuccessPaymentLiabilityCurrent", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100400 - Disclosure - Fair value of financial instruments - Summary of Assets and Liabilities Measured at Fair Value (Parenthetical) (Details)", "role": "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueParentheticalDetails", "shortName": "Fair value of financial instruments - Summary of Assets and Liabilities Measured at Fair Value (Parenthetical) (Details)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R4": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_d474bbb5-fccd-4578-8a76-6667c229934b", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss", "role": "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_d474bbb5-fccd-4578-8a76-6667c229934b", "decimals": "-3", "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_e1ae039c-f794-421a-a56c-e9281c374bce", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100410 - Disclosure - Fair value of financial instruments - Additional Information (Details)", "role": "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "shortName": "Fair value of financial instruments - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_8cee7062-6e5c-4a65-9089-8429ea93cf48", "decimals": "-5", "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_e1ae039c-f794-421a-a56c-e9281c374bce", "decimals": "2", "first": true, "lang": null, "name": "verv:FairValueOfCommonStockPerShare", "reportCount": 1, "unique": true, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100420 - Disclosure - Fair value of financial instruments - Schedule of Fair Value Liabilities Measured on Recurring Basis (Details)", "role": "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails", "shortName": "Fair value of financial instruments - Schedule of Fair Value Liabilities Measured on Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_e1ae039c-f794-421a-a56c-e9281c374bce", "decimals": "2", "first": true, "lang": null, "name": "verv:FairValueOfCommonStockPerShare", "reportCount": 1, "unique": true, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_d4eefe15-9e3b-4610-8c84-18d5c6645776", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100430 - Disclosure - Fair value of financial instruments - Schedule of Reconciliation of Changes in Fair Value of Financial Instruments (Details)", "role": "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails", "shortName": "Fair value of financial instruments - Schedule of Reconciliation of Changes in Fair Value of Financial Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_d4eefe15-9e3b-4610-8c84-18d5c6645776", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_e1ae039c-f794-421a-a56c-e9281c374bce", "decimals": "-3", "first": true, "lang": null, "name": "verv:AccruedExternalResearchAndDevelopmentExpenses", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100440 - Disclosure - Accrued expenses - Schedule of Accrued Expenses (Details)", "role": "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails", "shortName": "Accrued expenses - Schedule of Accrued Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_e1ae039c-f794-421a-a56c-e9281c374bce", "decimals": "-3", "first": true, "lang": null, "name": "verv:AccruedExternalResearchAndDevelopmentExpenses", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_d474bbb5-fccd-4578-8a76-6667c229934b", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100450 - Disclosure - Leases - Additional Information (Details)", "role": "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "shortName": "Leases - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_d474bbb5-fccd-4578-8a76-6667c229934b", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_d474bbb5-fccd-4578-8a76-6667c229934b", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100460 - Disclosure - Leases - Summary of Components of Operating Lease Cost (Details)", "role": "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfOperatingLeaseCostDetails", "shortName": "Leases - Summary of Components of Operating Lease Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_d474bbb5-fccd-4578-8a76-6667c229934b", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "verv:ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4f92a9b7-39ba-4393-8cce-78ef5092b413", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100470 - Disclosure - Leases - Summary of Supplemental Cash Flow Information Related to Operating Leases (Details)", "role": "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfSupplementalCashFlowInformationRelatedToOperatingLeasesDetails", "shortName": "Leases - Summary of Supplemental Cash Flow Information Related to Operating Leases (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R47": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_e1ae039c-f794-421a-a56c-e9281c374bce", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100480 - Disclosure - Leases - Summary of Future Minimum Commitments under Non-Cancellable Operating Leases (Details)", "role": "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNoncancellableOperatingLeasesDetails3", "shortName": "Leases - Summary of Future Minimum Commitments under Non-Cancellable Operating Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_e1ae039c-f794-421a-a56c-e9281c374bce", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_d474bbb5-fccd-4578-8a76-6667c229934b", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100490 - Disclosure - License Agreements - Additional Information (Details)", "role": "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails", "shortName": "License Agreements - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "verv:LicenseAgreementDisclosureTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_38bd6e5e-054e-4094-b244-a058464ca2d3", "decimals": "-5", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_e1ae039c-f794-421a-a56c-e9281c374bce", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesIssued", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100500 - Disclosure - Preferred and Common Stock - Additional Information (Details)", "role": "http://www.vervetx.com/20220630/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails", "shortName": "Preferred and Common Stock - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_344f3391-d6a2-417c-abbb-245aa4be3888", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_d4eefe15-9e3b-4610-8c84-18d5c6645776", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050 - Statement - Condensed Consolidated Statement of Convertible Preferred Stock and Stockholders' Equity (Deficit)", "role": "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit", "shortName": "Condensed Consolidated Statement of Convertible Preferred Stock and Stockholders' Equity (Deficit)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_25561b81-868f-44fc-8822-ab763a06a70b", "decimals": "-3", "lang": null, "name": "verv:StockIssuedDuringPeriodValueSeriesBConvertiblePreferredStock", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_e1ae039c-f794-421a-a56c-e9281c374bce", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100510 - Disclosure - Stock-based compensation - Additional Information (Details)", "role": "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "shortName": "Stock-based compensation - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_b39632d5-f607-44de-afde-9ff863189fc5", "decimals": "-5", "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_d474bbb5-fccd-4578-8a76-6667c229934b", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100520 - Disclosure - Stock-based compensation - Summary of Stock Based Compensation Expense (Details)", "role": "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails", "shortName": "Stock-based compensation - Summary of Stock Based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_d474bbb5-fccd-4578-8a76-6667c229934b", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_8cee7062-6e5c-4a65-9089-8429ea93cf48", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100530 - Disclosure - Stock-based compensation - Schedule of Stock Option Activity (Details)", "role": "http://www.vervetx.com/20220630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionActivityDetails", "shortName": "Stock-based compensation - Schedule of Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_8cee7062-6e5c-4a65-9089-8429ea93cf48", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_0bb3e20b-0e50-4b71-b178-3ab9b85b7a3c", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100540 - Disclosure - Stock-based compensation - Summary of the Restricted Stock Units (Details)", "role": "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsDetails", "shortName": "Stock-based compensation - Summary of the Restricted Stock Units (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_0bb3e20b-0e50-4b71-b178-3ab9b85b7a3c", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4f92a9b7-39ba-4393-8cce-78ef5092b413", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100550 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Potential Common Shares, Based on Amounts Outstanding at Period End were Excluded From the Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)", "role": "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersPotentialCommonSharesBasedOnAmountsOutstandingAtPeriodEndWereExcludedFromTheCo", "shortName": "Net Loss Per Share Attributable to Common Stockholders - Potential Common Shares, Based on Amounts Outstanding at Period End were Excluded From the Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4f92a9b7-39ba-4393-8cce-78ef5092b413", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_e1ae039c-f794-421a-a56c-e9281c374bce", "decimals": "-3", "first": true, "lang": null, "name": "verv:SuccessPaymentLiability", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100560 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Additional Information (Details)", "role": "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetails", "shortName": "Net Loss Per Share Attributable to Common Stockholders - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R56": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_d474bbb5-fccd-4578-8a76-6667c229934b", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100570 - Disclosure - Related Party Transactions - Additional Information (Details)", "role": "http://www.vervetx.com/20220630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "shortName": "Related Party Transactions - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_d474bbb5-fccd-4578-8a76-6667c229934b", "decimals": "-5", "lang": null, "name": "verv:LeaseRentPayment", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_e1ae039c-f794-421a-a56c-e9281c374bce", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CommonStockValue", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100580 - Disclosure - Subsequent Events - Additional Information (Details)", "role": "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "shortName": "Subsequent Events - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_834c1be4-1b90-4a21-a8bd-acef25fe4c61", "decimals": "-6", "lang": null, "name": "verv:NonRefundableUpfrontPayment", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_b7e8b94a-c7d6-42dc-89c2-50dd227d34af", "decimals": "-3", "first": true, "lang": null, "name": "verv:IssuanceCostsOfSeriesBConvertiblePreferredStock", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100060 - Statement - Condensed Consolidated Statement of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)", "role": "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical", "shortName": "Condensed Consolidated Statement of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_b7e8b94a-c7d6-42dc-89c2-50dd227d34af", "decimals": "-3", "first": true, "lang": null, "name": "verv:IssuanceCostsOfSeriesBConvertiblePreferredStock", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4f92a9b7-39ba-4393-8cce-78ef5092b413", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100070 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4f92a9b7-39ba-4393-8cce-78ef5092b413", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4f92a9b7-39ba-4393-8cce-78ef5092b413", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100080 - Disclosure - Nature of the Business and Basis of Presentation", "role": "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentation1", "shortName": "Nature of the Business and Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4f92a9b7-39ba-4393-8cce-78ef5092b413", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4f92a9b7-39ba-4393-8cce-78ef5092b413", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100090 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "verv-20220630.htm", "contextRef": "C_4f92a9b7-39ba-4393-8cce-78ef5092b413", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 61, "tag": { "country_NZ": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NEW ZEALAND", "terseLabel": "NZ" } } }, "localname": "NZ", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r505" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r506" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r503" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r503" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r516" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r503" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r515" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r503" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r503" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r503" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r503" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r502" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r504" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r50", "r52", "r94", "r95", "r207", "r216" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r206", "r215", "r239", "r241", "r399", "r400", "r401", "r402", "r403", "r404", "r424", "r467", "r470", "r499", "r500" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r206", "r215", "r239", "r241", "r399", "r400", "r401", "r402", "r403", "r404", "r424", "r467", "r470", "r499", "r500" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_OfficerMember": { "auth_ref": [ "r143" ], "lang": { "en-us": { "role": { "label": "Officer [Member]", "terseLabel": "Officer [Member]" } } }, "localname": "OfficerMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r140", "r226", "r227", "r426", "r466", "r468" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r140", "r226", "r227", "r426", "r466", "r468" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r206", "r215", "r229", "r239", "r241", "r399", "r400", "r401", "r402", "r403", "r404", "r424", "r467", "r470", "r499", "r500" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r206", "r215", "r229", "r239", "r241", "r399", "r400", "r401", "r402", "r403", "r404", "r424", "r467", "r470", "r499", "r500" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r51", "r52", "r94", "r95", "r207", "r216" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r108", "r240" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]", "verboseLabel": "Forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r108", "r113", "r240" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r141", "r142", "r226", "r228", "r469", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r141", "r142", "r226", "r228", "r469", "r485", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r108", "r113", "r191", "r240", "r391" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "stpr_MA": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "MASSACHUSETTS", "terseLabel": "Cambridge, Massachusetts" } } }, "localname": "MA", "nsuri": "http://xbrl.sec.gov/stpr/2021", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update 2016-02 [Member]", "terseLabel": "ASC 842" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accrued expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureAccruedExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r36", "r388" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "totalLabel": "Accounts Payable, Current, Total" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "auth_ref": [ "r13", "r14", "r40" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": { "order": 0.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Employee Benefits, Current", "terseLabel": "Employee compensation and related benefits" } } }, "localname": "AccruedEmployeeBenefitsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r40" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Total" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails", "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r13", "r14", "r40" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r34", "r185" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less accumulated depreciation", "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance", "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance", "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r26", "r57", "r58", "r59", "r459", "r478", "r482" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income", "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r56", "r59", "r66", "r67", "r68", "r97", "r98", "r99", "r306", "r473", "r474", "r521" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r24" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance", "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance", "terseLabel": "Additional paid-in capital", "verboseLabel": "Additional common stock issued" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r97", "r98", "r99", "r274", "r275", "r276", "r324" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r101", "r102", "r103", "r104", "r113", "r145", "r146", "r164", "r165", "r166", "r167", "r169", "r170", "r192", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r288", "r289", "r290", "r291", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r338", "r339", "r341", "r342", "r343", "r344", "r345", "r346", "r377", "r427", "r428", "r429", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r517", "r518", "r519", "r520", "r521" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r242", "r244", "r279", "r280" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation", "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r244", "r266", "r278" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Total stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r121" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersPotentialCommonSharesBasedOnAmountsOutstandingAtPeriodEndWereExcludedFromTheCo" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersPotentialCommonSharesBasedOnAmountsOutstandingAtPeriodEndWereExcludedFromTheCo" ], "xbrltype": "stringItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueParentheticalDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r91", "r132", "r134", "r138", "r160", "r193", "r194", "r195", "r197", "r198", "r199", "r200", "r201", "r202", "r204", "r205", "r301", "r307", "r337", "r386", "r388", "r444", "r457" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r9", "r11", "r46", "r91", "r160", "r193", "r194", "r195", "r197", "r198", "r199", "r200", "r201", "r202", "r204", "r205", "r301", "r307", "r337", "r386", "r388" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r327" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "terseLabel": "Total assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r152" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails": { "order": 0.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross unrealized gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r153" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Gross unrealized losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r150", "r176" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Amortized Cost", "terseLabel": "Amortized cost", "totalLabel": "Debt Securities, Available-for-sale, Amortized Cost, Total" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r148", "r151", "r176", "r447" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Fair value", "totalLabel": "Debt Securities, Available-for-sale, Total" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r245", "r268" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r6", "r32", "r86" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 }, "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance", "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance", "terseLabel": "Cash and cash equivalents", "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails", "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r16", "r87", "r443" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash, Cash Equivalents and Restricted Cash" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "auth_ref": [ "r32" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.", "label": "Cash, Cash Equivalents, and Short-term Investments", "terseLabel": "Cash, cash equivalents, and marketable securities", "totalLabel": "Cash, Cash Equivalents, and Short-term Investments, Total" } } }, "localname": "CashCashEquivalentsAndShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r81", "r86", "r88" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash\u2014end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash\u2014beginning of period", "totalLabel": "Total cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails", "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r81", "r347" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Increase in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r32" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash Equivalents, at Carrying Value", "terseLabel": "Cash equivalents", "totalLabel": "Cash Equivalents, at Carrying Value, Total" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental disclosure of noncash investing and financing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": { "auth_ref": [ "r0", "r1", "r97", "r98", "r100", "r145", "r146", "r161", "r162", "r163", "r164", "r165", "r192", "r270", "r271", "r272", "r288", "r314", "r316", "r317", "r338", "r340", "r341", "r342", "r345", "r346", "r357", "r377", "r427", "r428", "r471", "r472", "r517" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether accounting standards update was adopted.", "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]", "terseLabel": "Change in accounting principle, accounting standards update, adopted" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": { "auth_ref": [ "r0", "r1", "r97", "r98", "r107", "r145", "r146", "r161", "r162", "r163", "r164", "r165", "r192", "r270", "r271", "r272", "r288", "r314", "r316", "r317", "r318", "r321", "r338", "r340", "r341", "r342", "r345", "r346", "r357", "r377", "r427", "r428", "r471", "r472", "r517" ], "lang": { "en-us": { "role": { "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format.", "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date", "terseLabel": "Change in accounting principle, accounting standards update, adoption date" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": { "auth_ref": [ "r101", "r112", "r147", "r168", "r277", "r292" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.", "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]", "terseLabel": "Change in accounting principle, accounting standards update, immaterial effect" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r90", "r91", "r114", "r115", "r116", "r118", "r120", "r127", "r128", "r129", "r160", "r193", "r198", "r199", "r200", "r204", "r205", "r213", "r214", "r217", "r218", "r337", "r507" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersPotentialCommonSharesBasedOnAmountsOutstandingAtPeriodEndWereExcludedFromTheCo", "http://www.vervetx.com/20220630/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets", "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r42", "r190", "r448", "r463" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (See Note 7 and Note 8)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r43" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Shares of common stock reserved for future issuance", "verboseLabel": "Sale of common stock for future issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r97", "r98", "r324" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock fair value", "verboseLabel": "Common Stock, Par Value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common Stock, Shares Authorized", "verboseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock shares issued", "totalLabel": "Common Stock, Shares, Issued, Total" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r23", "r221" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning Balance (in shares)", "terseLabel": "Common Stock, Shares, Outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r23", "r388" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "periodEndLabel": "Common Stock, Value, Issued, Ending Balance", "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance", "terseLabel": "Common stock, $0.001 par value; 200,000,000 and 255,000,000 shares authorized, 48,655,241 and 48,511,735 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively", "totalLabel": "Common Stock, Value, Issued, Total", "verboseLabel": "Issuance of common stock, value" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r62", "r64", "r65", "r70", "r450", "r465" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer Equipment" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertiblePreferredStockMember": { "auth_ref": [ "r213", "r214", "r217" ], "lang": { "en-us": { "role": { "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.", "label": "Convertible Preferred Stock [Member]", "terseLabel": "Convertible Preferred Stock" } } }, "localname": "ConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersPotentialCommonSharesBasedOnAmountsOutstandingAtPeriodEndWereExcludedFromTheCo", "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets", "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "auth_ref": [ "r21", "r22", "r219", "r222", "r223" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.", "label": "Convertible Preferred Stock, Shares Issued upon Conversion", "terseLabel": "Shares issued upon conversion of preferred stock" } } }, "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r84", "r183" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation", "totalLabel": "Depreciation, Total" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r84", "r183" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation", "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r47", "r52", "r53", "r311", "r406" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Liability, Fair Value, Gross Liability", "terseLabel": "Success payment liability, payable", "totalLabel": "Derivative Liability, Fair Value, Gross Liability, Total", "verboseLabel": "Success payments due" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r48", "r49", "r52", "r336" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "terseLabel": "Success payment liability", "totalLabel": "Derivative Liability, Total" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Stock-based compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r119" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Basic and Diluted", "terseLabel": "Net loss per common share attributable to common stockholders, basic and diluted", "totalLabel": "Earnings Per Share, Basic and Diluted, Total" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]" } } }, "localname": "EarningsPerShareBasicLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r121", "r122", "r123", "r125" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss Per Share Attributable to Common Stockholders" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted average period over which unrecognized compensation is expected to be recognized" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r267" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized stock-based compensation cost" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r267" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized stock-based compensation cost" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r264" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Employee Stock Option" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Equipment", "verboseLabel": "Lab equipment" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r2", "r66", "r67", "r68", "r97", "r98", "r99", "r102", "r109", "r111", "r126", "r167", "r221", "r224", "r274", "r275", "r276", "r290", "r291", "r324", "r348", "r349", "r350", "r351", "r352", "r353", "r473", "r474", "r475", "r521" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueParentheticalDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r327", "r328", "r329", "r335" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueParentheticalDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r208", "r211", "r212", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r238", "r328", "r396", "r397", "r398" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r333", "r335" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]", "terseLabel": "Liability Class" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r333" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair value of financial instruments" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstruments1" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r208", "r230", "r231", "r236", "r238", "r328", "r396" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r208", "r211", "r212", "r230", "r231", "r236", "r238", "r328", "r397" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r208", "r211", "r212", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r238", "r328", "r398" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r327", "r328" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.", "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Fair Value Liabilities Measured on Recurring Basis" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r331" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]", "terseLabel": "Fair Value by Liability Class" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r331", "r335" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r331", "r335" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Schedule of Reconciliation of Changes in Fair Value of Financial Instruments" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r208", "r211", "r212", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r238", "r396", "r397", "r398" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings": { "auth_ref": [ "r332", "r334" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from derivative asset (liability) after deduction of derivative liability (asset), measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings", "terseLabel": "Changes in fair value" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs": { "auth_ref": [ "r327", "r334" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r154", "r155", "r157", "r158", "r159", "r171", "r172", "r173", "r174", "r175", "r177", "r178", "r179", "r180", "r210", "r220", "r315", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r507", "r508", "r509", "r510", "r511", "r512", "r513" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails", "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialLiabilitiesFairValueDisclosure": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.", "label": "Financial Liabilities Fair Value Disclosure", "terseLabel": "Total liabilities", "totalLabel": "Financial Liabilities Fair Value Disclosure, Total" } } }, "localname": "FinancialLiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and Fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r73" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative", "totalLabel": "General and Administrative Expense, Total", "verboseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r71" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and Administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO [Member]", "terseLabel": "IPO" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r187", "r189" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r189" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r92", "r285", "r286", "r287", "r293", "r294", "r295", "r296", "r297" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r83" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable", "totalLabel": "Increase (Decrease) in Accounts Payable, Total" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r83" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "terseLabel": "Accrued expenses and other liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r83", "r369" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Increase (Decrease) in Operating Lease Liability", "negatedLabel": "Operating Lease Liabilities", "terseLabel": "Operating lease liabilities", "verboseLabel": "Increase in operating lease liability" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": { "auth_ref": [ "r83" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current liabilities classified as other.", "label": "Increase (Decrease) in Other Current Liabilities", "terseLabel": "Increase in liabilities" } } }, "localname": "IncreaseDecreaseInOtherCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r83" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets", "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions": { "auth_ref": [ "r452" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of fees and commissions from banking, advisory, brokerage, and securities underwriting activities. Activities include, but are not limited to, underwriting securities, private placements of securities, investment advisory and management services, merger and acquisition services, sale and servicing of mutual funds, and other related consulting fees.", "label": "Investment Banking, Advisory, Brokerage, and Underwriting Fees and Commissions", "terseLabel": "Underwriting discounts and commissions", "totalLabel": "Investment Banking, Advisory, Brokerage, and Underwriting Fees and Commissions, Total" } } }, "localname": "InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r156", "r442", "r455", "r484", "r514" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Marketable Securities" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureMarketableSecurities" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r372", "r375" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfOperatingLeaseCostDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "terseLabel": "Lease payment", "totalLabel": "Total" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfOperatingLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease, Cost [Abstract]" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Components of Operating Lease Cost" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseExpirationDate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.", "label": "Lease Expiration Date", "terseLabel": "Lease expiration date" } } }, "localname": "LeaseExpirationDate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r184" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold Improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether lessee has option to extend operating lease not yet commenced.", "label": "Lessee, Operating Lease, Lease Not yet Commenced, Existence of Option to Extend [true false]", "terseLabel": "Option to extend true/false, lease not yet commenced" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToTerminate": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether lessee has option to terminate operating lease not yet commenced.", "label": "Lessee, Operating Lease, Lease Not yet Commenced, Existence of Option to Terminate [true false]", "terseLabel": "Option to terminate, lease not yet commenced" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToTerminate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "Description of terms and conditions of option to extend lessee's operating lease that has not yet commenced. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.", "label": "Lessee, Operating Lease, Lease Not yet Commenced, Option to Extend", "terseLabel": "Option to extend, lease not yet commenced" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract", "terseLabel": "Lease not yet commenced , lease term" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedVariableLeasePaymentTermsAndConditions": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "Description of basis, terms, and conditions on which variable lease payment for lessee's operating lease that has not yet commenced is determined.", "label": "Lessee, Operating Lease, Lease Not yet Commenced, Variable Lease Payment, Terms and Conditions", "terseLabel": "Operating lease payment term, lease not yet commenced, terms and conditions" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedVariableLeasePaymentTermsAndConditions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r373" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNoncancellableOperatingLeasesDetails2": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNoncancellableOperatingLeasesDetails3": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNoncancellableOperatingLeasesDetails3" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r373" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNoncancellableOperatingLeasesDetails3": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNoncancellableOperatingLeasesDetails3" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r373" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNoncancellableOperatingLeasesDetails3": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNoncancellableOperatingLeasesDetails3" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r373" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNoncancellableOperatingLeasesDetails3": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNoncancellableOperatingLeasesDetails3" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r373" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNoncancellableOperatingLeasesDetails3": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNoncancellableOperatingLeasesDetails3" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r373" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNoncancellableOperatingLeasesDetails3": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "Remainder of 2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNoncancellableOperatingLeasesDetails3" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r373" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNoncancellableOperatingLeasesDetails2": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: interest", "terseLabel": "Less: interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNoncancellableOperatingLeasesDetails3" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseOptionToExtend": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.", "label": "Lessee, Operating Lease, Option to Extend" } } }, "localname": "LesseeOperatingLeaseOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Remaining Lease Term", "terseLabel": "Lease term remaining" } } }, "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Operating lease renewal term" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Lease term" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter of Credit [Member]", "terseLabel": "Letter of Credit" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r38", "r91", "r135", "r160", "r193", "r194", "r195", "r198", "r199", "r200", "r201", "r202", "r204", "r205", "r302", "r307", "r308", "r337", "r386", "r387" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r29", "r91", "r160", "r337", "r388", "r446", "r461" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities, convertible preferred stock, and stockholders' equity (deficit)" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities, convertible preferred stock, and stockholders\u2019 deficit" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r41", "r91", "r160", "r193", "r194", "r195", "r198", "r199", "r200", "r201", "r202", "r204", "r205", "r302", "r307", "r308", "r337", "r386", "r387", "r388" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LicenseAgreementTermsMember": { "auth_ref": [ "r283", "r284" ], "lang": { "en-us": { "role": { "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others.", "label": "License Agreement Terms [Member]", "terseLabel": "License Agreement" } } }, "localname": "LicenseAgreementTermsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LicenseMember": { "auth_ref": [ "r227" ], "lang": { "en-us": { "role": { "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.", "label": "License [Member]", "terseLabel": "License Agreement [Member]" } } }, "localname": "LicenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [ "r7", "r39" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable Securities, Current", "terseLabel": "Marketable securities", "totalLabel": "Marketable Securities, Current, Total" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Marketable Securities [Line Items]", "terseLabel": "Marketable Securities [Line Items]" } } }, "localname": "MarketableSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecuritiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in marketable security.", "label": "Marketable Securities [Table]", "terseLabel": "Marketable Securities [Table]" } } }, "localname": "MarketableSecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecuritiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.", "label": "Marketable Securities [Table Text Block]", "terseLabel": "Schedule of Marketable Securities by Security" } } }, "localname": "MarketableSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_MeasurementInputDefaultRateMember": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using likelihood loan will not be repaid as proportion of outstanding loan.", "label": "Measurement Input, Default Rate [Member]", "terseLabel": "Probability of Termination" } } }, "localname": "MeasurementInputDefaultRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input, Expected Term [Member]", "terseLabel": "Expected Term" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]", "terseLabel": "Equity Volatility" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r230" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money Market Funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r130", "r131" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "Nature of the Business and Basis of Presentation" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentation1" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r81" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r81" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r81", "r82", "r85" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r5", "r60", "r63", "r68", "r69", "r85", "r91", "r101", "r105", "r106", "r107", "r108", "r110", "r111", "r117", "r132", "r133", "r136", "r137", "r139", "r160", "r193", "r194", "r195", "r198", "r199", "r200", "r201", "r202", "r204", "r205", "r326", "r337", "r449", "r464" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 0.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net loss attributable to common stockholders" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Adopted Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]", "terseLabel": "Non-US" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingGainsLossesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Gains (Losses) [Abstract]", "terseLabel": "Other income (expense):" } } }, "localname": "NonoperatingGainsLossesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r74" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense), net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": { "auth_ref": [ "r249" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.", "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]", "terseLabel": "Schedule of Status and Change in Unvested Restricted Stock" } } }, "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r132", "r133", "r136", "r137", "r139" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r366", "r375" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfOperatingLeaseCostDetails": { "order": 0.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease costs" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfOperatingLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r360" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Operating lease, rent expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r359" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNoncancellableOperatingLeasesDetails2": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Present value of operating lease liabilities", "totalLabel": "Operating Lease, Liability, Total", "verboseLabel": "Operating lease liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNoncancellableOperatingLeasesDetails3", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r359" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease obligations, current portion" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r361", "r369" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows related to operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfSupplementalCashFlowInformationRelatedToOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r358" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r371", "r375" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r13", "r14", "r15", "r40" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r35" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other long term assets", "totalLabel": "Other Assets, Noncurrent, Total" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "auth_ref": [ "r54", "r55", "r57" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax", "terseLabel": "Unrealized loss on marketable securities", "totalLabel": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Comprehensive Loss:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r61", "r64", "r299", "r300", "r305" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Unrealized gain on available-for-sale securities", "totalLabel": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent, Total", "verboseLabel": "Unrealized loss on available-for-sale securities" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive loss:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherExpenseMember": { "auth_ref": [ "r312" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other expense.", "label": "Other Expense [Member]", "terseLabel": "Other Expense" } } }, "localname": "OtherExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherIncomeMember": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other revenue.", "label": "Other Income [Member]", "terseLabel": "Other Income" } } }, "localname": "OtherIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r75" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Interest and other income, net", "totalLabel": "Other Nonoperating Income (Expense), Total" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over-Allotment Option [Member]", "terseLabel": "Underwriters Option" } } }, "localname": "OverAllotmentOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsForRepurchaseOfInitialPublicOffering": { "auth_ref": [ "r78" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the repurchase of amount received from entity's first offering of stock to the public.", "label": "Payments for Repurchase of Initial Public Offering", "negatedLabel": "Payment of initial public offering costs" } } }, "localname": "PaymentsForRepurchaseOfInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r79" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "terseLabel": "Transaction costs on issuance" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r149" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedLabel": "Purchases of marketable securities", "totalLabel": "Payments to Acquire Marketable Securities, Total" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r76" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment", "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r245", "r268" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Preferred Stock [Member]", "verboseLabel": "Preferred Stock" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r22", "r213" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, value per share" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r22", "r213" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued", "totalLabel": "Preferred Stock, Shares Issued, Total" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance", "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance", "terseLabel": "Preferred Stock, Shares Outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r22", "r388" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance", "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance", "terseLabel": "Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively", "totalLabel": "Preferred Stock, Value, Issued, Total" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r9", "r30", "r31" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidRent": { "auth_ref": [ "r8", "r10", "r181", "r182" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Rent", "terseLabel": "Prepaid rent" } } }, "localname": "PrepaidRent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r77" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds from Issuance Initial Public Offering", "terseLabel": "Proceeds from initial public offering, net of underwriting discount" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": { "auth_ref": [ "r77" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.", "label": "Proceeds from Issuance of Preferred Stock and Preference Stock", "terseLabel": "Proceeds from issuance of Series B convertible preferred stock, net", "verboseLabel": "Proceeds from issuance of Preferred Stock, net" } } }, "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r77", "r269" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r5", "r60", "r63", "r68", "r80", "r91", "r101", "r110", "r111", "r132", "r133", "r136", "r137", "r139", "r160", "r193", "r194", "r195", "r198", "r199", "r200", "r201", "r202", "r204", "r205", "r299", "r303", "r304", "r309", "r310", "r326", "r337", "r453" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss", "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r34", "r186" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r188", "r487", "r488", "r489" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r33", "r184" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": { "order": 0.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance", "terseLabel": "Total property and equipment", "totalLabel": "Property, Plant and Equipment, Gross, Total" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property Plant And Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r17", "r18", "r186", "r388", "r456", "r462" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails", "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r17", "r186" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of Property and Equipment, net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r17", "r184" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProvisionForLeaseLosses": { "auth_ref": [ "r451" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense related to estimated loss to be realized from lease transactions.", "label": "Provision for Lease Losses", "verboseLabel": "Non-cash lease expense" } } }, "localname": "ProvisionForLeaseLosses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r237", "r380", "r381" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": { "auth_ref": [ "r380" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "Related Party Transaction, Expenses from Transactions with Related Party", "terseLabel": "Related party transaction, expenses from transactions with related party" } } }, "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r237", "r380", "r383", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r378", "r379", "r381", "r384", "r385" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureRelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": { "auth_ref": [ "r283", "r284" ], "lang": { "en-us": { "role": { "documentation": "Information by form of arrangement related to research and development.", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]", "terseLabel": "Research And Development Arrangement Contract To Perform For Others [Line Items]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": { "auth_ref": [ "r283", "r284" ], "lang": { "en-us": { "role": { "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r282", "r425", "r501" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 0.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development", "totalLabel": "Research and Development Expense, Total", "verboseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r6", "r16", "r86", "r88" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents, Current", "terseLabel": "Restricted cash", "totalLabel": "Restricted Cash and Cash Equivalents, Current, Total" } } }, "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r12", "r19", "r88", "r486" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r121" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "RSU" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r25", "r224", "r277", "r388", "r460", "r477", "r482" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance", "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance", "terseLabel": "Accumulated deficit", "totalLabel": "Retained Earnings (Accumulated Deficit), Total" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r2", "r97", "r98", "r99", "r102", "r109", "r111", "r167", "r274", "r275", "r276", "r290", "r291", "r324", "r473", "r475" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromRelatedParties": { "auth_ref": [ "r72", "r196", "r198", "r199", "r203", "r204", "r205", "r483" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.", "label": "Revenue from Related Parties", "terseLabel": "Revenue from related parties" } } }, "localname": "RevenueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r370", "r375" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for new operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Net proceeds from sale of common stock" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Shares issued and sold" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Public offering price per share", "verboseLabel": "Price Per Share" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SalesMember": { "auth_ref": [ "r312" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.", "label": "Sales [Member]", "terseLabel": "sell" } } }, "localname": "SalesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accrued Expenses" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureAccruedExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r121" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersPotentialCommonSharesBasedOnAmountsOutstandingAtPeriodEndWereExcludedFromTheCo" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r121" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Potential Common Shares, Based on Amounts Outstanding at Period End were Excluded From the Computation of Diluted Net Loss Per Share Attributable to Common Stockholders" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": { "auth_ref": [ "r114", "r115", "r118", "r120", "r124" ], "lang": { "en-us": { "role": { "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share.", "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]" } } }, "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r244", "r265", "r278" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Summary of Stock Based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r327", "r328" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Fair Value of Financial Instruments, Assets and Liabilities" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.", "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]", "terseLabel": "Schedule of Future Minimum Lease Commitments under Non-Cancellable Leases" } } }, "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r34", "r186" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Schedule Of Property Plant And Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r382", "r383" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": { "auth_ref": [ "r283", "r284" ], "lang": { "en-us": { "role": { "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.", "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]", "terseLabel": "Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]" } } }, "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r245", "r268" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsDetails", "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r250", "r260", "r261" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SeriesBPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series B Preferred Stock [Member]", "terseLabel": "Series B Preferred Stock" } } }, "localname": "SeriesBPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r83" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation", "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r247" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": { "auth_ref": [ "r243", "r246" ], "lang": { "en-us": { "role": { "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Description", "terseLabel": "Awards description" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r255" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Restricted stock units forfeited", "terseLabel": "Restricted stock units forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r258" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Restricted stock units granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Unvested RSUs, ending balance, unvested", "periodStartLabel": "Unvested RSUs, beginning balance, Unvested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted-Average Grant Date Fair Value Per Share, ending balance, Unvested", "periodStartLabel": "Weighted-Average Grant Date Fair Value Per Share, beginning balance, Unvested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r259" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Unvested RSUs, Vested", "terseLabel": "Unvested RSUs, Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r259" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-Average Grant Date Fair Value Per Share, Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsDetails", "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Additional shares of common stock" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r268" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Shares available for future grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r253" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Number of options, Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r256" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period", "negatedLabel": "Number of options, Forfeited", "terseLabel": "Forfeited", "totalLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Total" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r256" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Stock option granted during period", "verboseLabel": "Number of options, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r252", "r268" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Number of options, Outstanding, Ending balance", "periodStartLabel": "Number of options, Outstanding, Beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r251" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted average exercise price, Ending balance", "periodStartLabel": "Weighted average exercise price, Beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "auth_ref": [ "r263" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "terseLabel": "Aggregate intrinsic value, Expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "auth_ref": [ "r263" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "terseLabel": "Number of options, Expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r263" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, Expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum", "terseLabel": "Percentage of outstanding stock, reserved for issuance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r243", "r248" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding", "terseLabel": "Aggregate intrinsic value, Outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r268" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Aggregate intrinsic value, Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r268" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual life (in years), Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual life (in years), Outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual life (in years), Expected to vest" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShortTermBorrowings": { "auth_ref": [ "r20", "r388", "r445", "r458" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.", "label": "Short-term Debt", "terseLabel": "Letter of credit issued", "totalLabel": "Short-term Debt, Total" } } }, "localname": "ShortTermBorrowings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermLeaseCommitmentAmount": { "auth_ref": [ "r374" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease commitment.", "label": "Short-term Lease Commitment, Amount", "terseLabel": "Lease Commitment Amount", "verboseLabel": "Lease Rent Payment" } } }, "localname": "ShortTermLeaseCommitmentAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r367", "r375" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-term Lease, Cost" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r89", "r96" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r21", "r22", "r23", "r90", "r91", "r114", "r115", "r116", "r118", "r120", "r127", "r128", "r129", "r160", "r193", "r198", "r199", "r200", "r204", "r205", "r213", "r214", "r217", "r218", "r221", "r337", "r507" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersPotentialCommonSharesBasedOnAmountsOutstandingAtPeriodEndWereExcludedFromTheCo", "http://www.vervetx.com/20220630/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets", "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r2", "r45", "r66", "r67", "r68", "r97", "r98", "r99", "r102", "r109", "r111", "r126", "r167", "r221", "r224", "r274", "r275", "r276", "r290", "r291", "r324", "r348", "r349", "r350", "r351", "r352", "r353", "r473", "r474", "r475", "r521" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets", "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r97", "r98", "r99", "r126", "r426" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets", "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r44", "r209", "r221", "r222", "r224" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "terseLabel": "Conversion of convertible preferred stock to common stock upon closing of initial public offering (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r22", "r23", "r221", "r224" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Issuance of common stock under Employee Stock Purchase Plan, shares" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r22", "r23", "r221", "r224" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Stock Issued During Period, Shares, New Issues", "verboseLabel": "Issuance of common stock from initial public offering, net of issuance costs (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r221", "r224" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "terseLabel": "Vesting of restricted common stock (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r22", "r23", "r221", "r224", "r254" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Number of options, Exercised", "terseLabel": "Exercise of stock options (in shares)", "verboseLabel": "Exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionActivityDetails", "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r45", "r221", "r224" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "terseLabel": "Conversion of convertible preferred stock to common stock upon closing of initial public offering" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r22", "r23", "r221", "r224" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "negatedLabel": "Issuance of shares through employee stock purchase plan", "terseLabel": "Issuance of common stock under Employee Stock Purchase Plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r22", "r23", "r221", "r224" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock from initial public offering, net of issuance costs of $25,098", "verboseLabel": "Issuance of common stock" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "auth_ref": [ "r22", "r23", "r221", "r224" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross", "terseLabel": "Vesting of restricted common stock" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r45", "r221", "r224" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r23", "r27", "r28", "r91", "r144", "r160", "r337", "r388" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "totalLabel": "Total stockholders equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets", "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity (deficit):" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityReverseStockSplit": { "auth_ref": [ "r225" ], "lang": { "en-us": { "role": { "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.", "label": "Stockholders' Equity, Reverse Stock Split", "terseLabel": "Reverse stock split" } } }, "localname": "StockholdersEquityReverseStockSplit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r354", "r390" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r354", "r390" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r354", "r390" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r354", "r390" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r389", "r392" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureSubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Different names of stock transactions and the different attributes of each transaction.", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]", "terseLabel": "Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary, Sale of Stock [Line Items]", "terseLabel": "Subsidiary Sale Of Stock [Line Items]" } } }, "localname": "SubsidiarySaleOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of new stock classified as temporary equity issued during the period.", "label": "Temporary Equity, Stock Issued During Period, Value, New Issues", "negatedLabel": "Issuance of Series A Preferred Stock", "terseLabel": "Issuance of Series A Preferred" } } }, "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r154", "r155", "r157", "r158", "r159", "r210", "r220", "r315", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r507", "r508", "r509", "r510", "r511", "r512", "r513" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails", "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r101", "r102", "r103", "r104", "r113", "r145", "r146", "r164", "r165", "r166", "r167", "r169", "r170", "r192", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r288", "r289", "r290", "r291", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r338", "r339", "r341", "r342", "r343", "r344", "r345", "r346", "r377", "r427", "r428", "r429", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r517", "r518", "r519", "r520", "r521" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Accounting Standards Update [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r298" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueParentheticalDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r93", "r230", "r454" ], "lang": { "en-us": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "U.S. Agency Securities [Member]" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r93", "r230", "r238", "r454" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "US Treasury Securities [Member]", "terseLabel": "U.S. Treasury Bills and Notes [Member]" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r368", "r375" ], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfOperatingLeaseCostDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease costs" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfOperatingLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted", "terseLabel": "Weighted-average common shares used in net loss per share attributable to common stockholders, basic and diluted" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "sharesItemType" }, "verv_AccruedExternalResearchAndDevelopmentExpenses": { "auth_ref": [], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued external research and development expenses", "label": "Accrued External Research And Development Expenses", "terseLabel": "Accrued external research and development expenses" } } }, "localname": "AccruedExternalResearchAndDevelopmentExpenses", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "verv_AcuitasAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Acuitas agreements.", "label": "Acuitas Agreements [Member]", "terseLabel": "Acuitas Agreements" } } }, "localname": "AcuitasAgreementsMember", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "verv_AdditionalLesseeOperatingLeaseArea": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additional Lessee Operating Lease Area", "label": "Additional Lessee Operating Lease Area", "terseLabel": "Additional Lease Area" } } }, "localname": "AdditionalLesseeOperatingLeaseArea", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "areaItemType" }, "verv_AdditionalTenantImprovementsAllowance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Additional tenant improvements allowance.", "label": "Additional Tenant Improvements Allowance", "terseLabel": "Additional tenant improvements allowance" } } }, "localname": "AdditionalTenantImprovementsAllowance", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "verv_AggregatePurchasePricePerShare": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate purchase price per share", "label": "Aggregate purchase price per share" } } }, "localname": "AggregatePurchasePricePerShare", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "verv_AgreegatePurchasePrice": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Agreegate purchase price.", "label": "Agreegate Purchase Price", "terseLabel": "Agreegate purchase price" } } }, "localname": "AgreegatePurchasePrice", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "verv_AmortizationOfPremiumOnMarketableSecurities": { "auth_ref": [], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortization of premium on marketable securities.", "label": "Amortization Of Premium On Marketable Securities", "terseLabel": "Amortization of premium on marketable securities" } } }, "localname": "AmortizationOfPremiumOnMarketableSecurities", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "verv_AmountRecievedUnderCollaborationAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount recieved under collaboration agreement", "label": "Amount Recieved Under Collaboration Agreement", "terseLabel": "Amount recieved under collaboration agreement" } } }, "localname": "AmountRecievedUnderCollaborationAgreement", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "verv_AntidilutionRightsLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Antidilution rights liability.", "label": "Antidilution Rights Liability [Member]", "terseLabel": "Antidilution Rights Liability" } } }, "localname": "AntidilutionRightsLiabilityMember", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "verv_AntidilutionRightsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Antidilution rights.", "label": "Antidilution Rights Member", "terseLabel": "Antidilution Rights" } } }, "localname": "AntidilutionRightsMember", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "verv_BeamLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Beam license agreement.", "label": "Beam License Agreement [Member]", "terseLabel": "Beam License Agreement" } } }, "localname": "BeamLicenseAgreementMember", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "verv_BeamMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Beam [Member].", "label": "Beam [Member]", "terseLabel": "Beam" } } }, "localname": "BeamMember", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "verv_BroadLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Broad License Agreement [Member]", "label": "Broad License Agreement [Member]", "terseLabel": "Broad License Agreement" } } }, "localname": "BroadLicenseAgreementMember", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "verv_CambridgeLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cambridge lease.", "label": "Cambridge Lease [Member]", "terseLabel": "Cambridge Lease" } } }, "localname": "CambridgeLeaseMember", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "verv_CashPaidForAmountsIncludedInTheMeasurementsOfLeaseLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash paid for amounts included in the measurements of lease liabilities.", "label": "Cash paid for amounts included in the measurements of lease liabilities [Abstract]" } } }, "localname": "CashPaidForAmountsIncludedInTheMeasurementsOfLeaseLiabilitiesAbstract", "nsuri": "http://www.vervetx.com/20220630", "xbrltype": "stringItemType" }, "verv_ChangeInFairValueOfAntidilutionRights": { "auth_ref": [], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 0.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 }, "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in fair value of antidilution rights.", "label": "Change In Fair Value Of Antidilution Rights", "negatedLabel": "Change in fair value of antidilution rights liability", "terseLabel": "Change in fair value of antidilution rights" } } }, "localname": "ChangeInFairValueOfAntidilutionRights", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "verv_ChangeInFairValueOfSuccessPaymentsLiabilities": { "auth_ref": [], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 }, "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in fair value of success payments liabilities.", "label": "Change In Fair Value Of Success Payments Liabilities", "negatedLabel": "Change in fair value of success payment liability", "terseLabel": "Change in fair value of success payments liabilities" } } }, "localname": "ChangeInFairValueOfSuccessPaymentsLiabilities", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "verv_ClinicalAndRegulatoryMilestone": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Clinical and regulatory milestone.", "label": "Clinical And Regulatory Milestone" } } }, "localname": "ClinicalAndRegulatoryMilestone", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "verv_CommonStockIssuedForFullySatisfyingPreferredStockFinancing": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock issued for fully satisfying preferred stock financing", "label": "Common Stock Issued For Fully Satisfying Preferred Stock Financing", "terseLabel": "Common stock issued for fully satisfying preferred stock financing" } } }, "localname": "CommonStockIssuedForFullySatisfyingPreferredStockFinancing", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "verv_CommonStockIssuedForPartlySatisfyingPreferredStockFinancing": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Common stock issued for partly satisfying preferred stock financing", "label": "Common Stock Issued For Partly Satisfying Preferred Stock Financing", "terseLabel": "Common stock issued for partly satisfying preferred stock financing" } } }, "localname": "CommonStockIssuedForPartlySatisfyingPreferredStockFinancing", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "verv_CommonStockOfferingPrice": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Common stock offering price", "label": "Common stock offering price", "terseLabel": "Common stock offering price" } } }, "localname": "CommonStockOfferingPrice", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "verv_CommonStockOfferingPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock Offering Price Per Share", "label": "Common Stock Offering Price Per Share" } } }, "localname": "CommonStockOfferingPricePerShare", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "verv_CumulativeProbabilityOfTriggeringEvent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cumulative probability of triggering event.", "label": "Cumulative Probability Of Triggering Event", "terseLabel": "Cumulative probability of triggering event" } } }, "localname": "CumulativeProbabilityOfTriggeringEvent", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "percentItemType" }, "verv_DevelopmentAndCommercialMilestonePaymentsUnderCollaborationAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Development and commercial milestone payments under collaboration agreement", "label": "Development and Commercial Milestone Payments Under Collaboration Agreement", "terseLabel": "Development and commercial milestone payments under collaboration agreement" } } }, "localname": "DevelopmentAndCommercialMilestonePaymentsUnderCollaborationAgreement", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "verv_FairValueAssumptionOfEquityVolatilityRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fair value assumption of equity volatility rate.", "label": "Fair Value Assumption Of Equity Volatility Rate", "terseLabel": "Equity volatility" } } }, "localname": "FairValueAssumptionOfEquityVolatilityRate", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "percentItemType" }, "verv_FairValueAssumptionsExpectedTerm1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fair value assumptions expected term 1.", "label": "Fair Value Assumptions Expected Term1", "terseLabel": "Expected term (in years)" } } }, "localname": "FairValueAssumptionsExpectedTerm1", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "durationItemType" }, "verv_FairValueInputsProbabilityOfTermination": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fair value inputs probability of termination.", "label": "Fair Value Inputs Probability Of Termination", "terseLabel": "Fair value inputs probability of termination" } } }, "localname": "FairValueInputsProbabilityOfTermination", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "verv_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSuccessPaymentEarned": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value net derivative asset liability measured on recurring basis unobservable inputs reconciliation success payment earned.", "label": "Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Success Payment Earned", "terseLabel": "Success payment earned" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSuccessPaymentEarned", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "verv_FairValueOfCommonStockPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fair value of common stock per share.", "label": "Fair value of common stock per share", "terseLabel": "Fair value of common stock (per share)" } } }, "localname": "FairValueOfCommonStockPerShare", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "perShareItemType" }, "verv_FirstAmendmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First Amendment Member.", "label": "First Amendment [Member]", "terseLabel": "First Amendment" } } }, "localname": "FirstAmendmentMember", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "verv_HarvardAndBoardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Harvard and Board.", "label": "Harvard And Board [Member]", "terseLabel": "Harvard and Board [Member]" } } }, "localname": "HarvardAndBoardMember", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "verv_HarvardAndBroadLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Harvard and Broad license agreement.", "label": "Harvard And Broad License Agreement [Member]", "terseLabel": "Harvard and Board" } } }, "localname": "HarvardAndBroadLicenseAgreementMember", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueParentheticalDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "verv_HarvardLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Harward.", "label": "Harvard License Agreement [Member]", "terseLabel": "Harvard", "verboseLabel": "Harvard License Agreement" } } }, "localname": "HarvardLicenseAgreementMember", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "verv_IncreaseDecreaseInOperatingLeaseRightOfUseOfAsset": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase Decrease In Operating Lease Right Of Use Of Asset", "label": "Increase Decrease In Operating Lease Right Of Use Of Asset", "terseLabel": "Increase in Right-Of-Use assets" } } }, "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseOfAsset", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "verv_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Increase in common stock capital shares, reserved for future issuance.", "label": "Increase In Common Stock Capital Shares Reserved For Future Issuance", "terseLabel": "Increase in common stock capital shares, reserved for future issuance" } } }, "localname": "IncreaseInCommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "verv_InitialPublicOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Initial Public Offering Costs Included In Accounts Payable And Accrued Liabilities", "label": "Initial Public Offering Costs Included In Accounts Payable And Accrued Liabilities", "terseLabel": "Initial public offering costs included in accounts payable and accrued liabilities" } } }, "localname": "InitialPublicOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "verv_InterestRateForAdditionalImprovementsAllowance": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate for additional improvements allowance.", "label": "Interest Rate For Additional Improvements Allowance", "terseLabel": "Improvement allowance interest rate" } } }, "localname": "InterestRateForAdditionalImprovementsAllowance", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "verv_IssuanceCostsOfCommonStockFromInitialPublicOffering": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Issuance Costs Of Common Stock from Initial Public Offering", "label": "Issuance Costs Of Common Stock From Initial Public Offering", "terseLabel": "Issuance Costs Of Common Stock from Initial Public Offering" } } }, "localname": "IssuanceCostsOfCommonStockFromInitialPublicOffering", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "monetaryItemType" }, "verv_IssuanceCostsOfSeriesA1ConvertiblePreferredStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Issuance Costs of Series A-1 Convertible Preferred Stock", "label": "Issuance Costs Of Series A1 Convertible Preferred Stock", "terseLabel": "Issuance Costs of Series A-1 Convertible Preferred Stock" } } }, "localname": "IssuanceCostsOfSeriesA1ConvertiblePreferredStock", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "monetaryItemType" }, "verv_IssuanceCostsOfSeriesAConvertiblePreferredStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Issuance Costs of Series A Convertible Preferred Stock", "label": "Issuance Costs Of Series A Convertible Preferred Stock", "terseLabel": "Issuance Costs of Series A Convertible Preferred Stock" } } }, "localname": "IssuanceCostsOfSeriesAConvertiblePreferredStock", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "monetaryItemType" }, "verv_IssuanceCostsOfSeriesBConvertiblePreferredStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Issuance Costs Of Series B Convertible Preferred Stock", "label": "Issuance Costs Of Series B Convertible Preferred Stock", "terseLabel": "Issuance Costs Of Series B Convertible Preferred Stock" } } }, "localname": "IssuanceCostsOfSeriesBConvertiblePreferredStock", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "monetaryItemType" }, "verv_IssuanceOfShareUnderEmployeeStockPurchasePlan": { "auth_ref": [], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance Of Share Under Employee Stock Purchase Plan", "label": "Issuance Of Share Under Employee Stock Purchase Plan", "negatedLabel": "Issuance of shares through employee stock purchase plan" } } }, "localname": "IssuanceOfShareUnderEmployeeStockPurchasePlan", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "verv_JefferiesLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Jefferies LLC [Member]", "label": "Jefferies LLC [Member]", "terseLabel": "Jefferies LLC [Member]" } } }, "localname": "JefferiesLlcMember", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "verv_LeaseCommencementDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease Commencement Date.", "label": "Lease Commencement Date" } } }, "localname": "LeaseCommencementDate", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "gYearMonthItemType" }, "verv_LeaseNoncancelableTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease Noncancelable Term.", "label": "Lease Noncancelable Term" } } }, "localname": "LeaseNoncancelableTerm", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "verv_LeaseRentPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Lease rent payment", "label": "Lease Rent Payment", "terseLabel": "Lease Rent Payment" } } }, "localname": "LeaseRentPayment", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "verv_LesseeOperatingLeaseArea": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee operating lease area.", "label": "Lessee Operating Lease Area", "terseLabel": "Lease area" } } }, "localname": "LesseeOperatingLeaseArea", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "areaItemType" }, "verv_LesseeOperatingLeaseIncrementalBorrowingRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee operating lease incremental borrowing rate.", "label": "Lessee Operating Lease Incremental Borrowing Rate", "terseLabel": "Operating lease incremental borrowing rate" } } }, "localname": "LesseeOperatingLeaseIncrementalBorrowingRate", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "verv_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": { "auth_ref": [], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNoncancellableOperatingLeasesDetails3": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee operating lease liability payments due after year four.", "label": "Lessee Operating Lease Liability Payments Due After Year Four", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNoncancellableOperatingLeasesDetails3" ], "xbrltype": "monetaryItemType" }, "verv_LicenseAgreementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License Agreement Abstract", "label": "License Agreement [Abstract]" } } }, "localname": "LicenseAgreementAbstract", "nsuri": "http://www.vervetx.com/20220630", "xbrltype": "stringItemType" }, "verv_LicenseAgreementDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License agreement", "label": "License Agreement Disclosure [Text Block]", "terseLabel": "License Agreement" } } }, "localname": "LicenseAgreementDisclosureTextBlock", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLicenseAgreements" ], "xbrltype": "textBlockItemType" }, "verv_LicenseAndMilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "License and milestone payments", "label": "License and milestone payments" } } }, "localname": "LicenseAndMilestonePayments", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "verv_MaterialsExchangeAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Materials Exchange Agreement [Member].", "label": "Materials Exchange Agreement [Member]", "terseLabel": "Materials Exchange Agreement" } } }, "localname": "MaterialsExchangeAgreementMember", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "verv_MaturitiesOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Maturities of marketable securities.", "label": "Maturities Of Marketable Securities", "terseLabel": "Maturities of marketable securities" } } }, "localname": "MaturitiesOfMarketableSecurities", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "verv_MaximumSuccessPaymentsForEachProduct": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum Success Payments For Each Product", "label": "Maximum Success Payments For Each Product" } } }, "localname": "MaximumSuccessPaymentsForEachProduct", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "verv_MilestoneRelatedExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Milestone related expenses.", "label": "Milestone Related Expenses", "terseLabel": "Milestone related expenses" } } }, "localname": "MilestoneRelatedExpenses", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "verv_NewAmendmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "New Amendment [Member]", "label": "New Amendment [Member]" } } }, "localname": "NewAmendmentMember", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "verv_NonRefundableUpfrontLicenseFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non refundable upfront license fee.", "label": "Non Refundable Upfront License Fee" } } }, "localname": "NonRefundableUpfrontLicenseFee", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "verv_NonRefundableUpfrontLicenseFeesPaid": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non-refundable upfront license fees paid", "label": "Non-Refundable Upfront License Fees Paid", "terseLabel": "Non-refundable upfront license fees paid" } } }, "localname": "NonRefundableUpfrontLicenseFeesPaid", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "verv_NonRefundableUpfrontPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non refundable upfront payment", "label": "Non Refundable Upfront Payment", "terseLabel": "Non-refundable upfront payment" } } }, "localname": "NonRefundableUpfrontPayment", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "verv_NumberOfInstallmentsForRestrictedSharesVested": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of installments for restricted shares vested.", "label": "Number of Installments for Restricted Shares Vested" } } }, "localname": "NumberOfInstallmentsForRestrictedSharesVested", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "verv_OfferingCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Offering Costs", "label": "Offering Costs", "terseLabel": "Offering Costs" } } }, "localname": "OfferingCosts", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "verv_OpenMarketSaleAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Open Market Sale Agreement [Member]", "label": "Open Market Sale Agreement [Member]", "terseLabel": "Open Market Sale Agreement" } } }, "localname": "OpenMarketSaleAgreementMember", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "verv_OperatingLeaseRelatedExpensesPriorToCommencement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating lease related expenses prior to commencement.", "label": "Operating Lease Related Expenses Prior To Commencement", "terseLabel": "Lease space build out cost prior to commencement" } } }, "localname": "OperatingLeaseRelatedExpensesPriorToCommencement", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "verv_OptionLicenseAgreementAndPatentLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Option License Agreement and Patent License Agreement [Member].", "label": "Option License Agreement And Patent License Agreement [Member]", "terseLabel": "Option License Agreement And Patent License Agreement" } } }, "localname": "OptionLicenseAgreementAndPatentLicenseAgreementMember", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "verv_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organization consolidation and presentation of financial statements.", "label": "Organization Consolidation And Presentation Of Financial Statements [Line Items]", "terseLabel": "Organization Consolidation And Presentation Of Financial Statements [Line Items]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "verv_OrganizationConsolidationAndPresentationOfFinancialStatementsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organization consolidation and presentation of financial statements.", "label": "Organization Consolidation And Presentation Of Financial Statements [Table]", "terseLabel": "Organization Consolidation And Presentation Of Financial Statements [Table]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsTable", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "verv_OtherLongTermLiabilities": { "auth_ref": [], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other long term liabilities", "label": "Other long term liabilities" } } }, "localname": "OtherLongTermLiabilities", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "verv_OutstandingOptionsToPurchaseCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding Options to Purchase Common Stock", "label": "Outstanding Options To Purchase Common Stock [Member]", "terseLabel": "Outstanding Options To Purchase Common Stock" } } }, "localname": "OutstandingOptionsToPurchaseCommonStockMember", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersPotentialCommonSharesBasedOnAmountsOutstandingAtPeriodEndWereExcludedFromTheCo" ], "xbrltype": "domainItemType" }, "verv_PaymentOfMilestoneDevelopment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment of milestone development.", "label": "Payment of Milestone Development", "terseLabel": "Payment of milestone development" } } }, "localname": "PaymentOfMilestoneDevelopment", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "verv_PaymentOfSalesBasedMilestone": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment of sales based milestone.", "label": "Payment of Sales Based Milestone", "terseLabel": "Payment of sales based milestone" } } }, "localname": "PaymentOfSalesBasedMilestone", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "verv_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Payment received for license agreement reimbursement of costs incurred", "label": "Payment Received for License Agreement Reimbursement of Costs Incurred" } } }, "localname": "PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "verv_PreferredAndCommonStockTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred and common stock disclosure text block.", "label": "Preferred And Common Stock [Text Block]", "terseLabel": "Preferred and Common Stock" } } }, "localname": "PreferredAndCommonStockTextBlock", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosurePreferredAndCommonStock" ], "xbrltype": "textBlockItemType" }, "verv_PreferredStockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred stock abstract.", "label": "Preferred Stock [Abstract]" } } }, "localname": "PreferredStockAbstract", "nsuri": "http://www.vervetx.com/20220630", "xbrltype": "stringItemType" }, "verv_PreferredStockFinancingFullySatisfied": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Preferred stock financing fully satisfied", "label": "Preferred Stock Financing Fully Satisfied", "terseLabel": "Preferred stock financing were fully satisfied" } } }, "localname": "PreferredStockFinancingFullySatisfied", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "verv_PreferredStockFinancingPartiallySatisfied": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Preferred stock financing partially satisfied", "label": "Preferred Stock Financing Partially Satisfied", "terseLabel": "Preferred stock financing partially satisfied" } } }, "localname": "PreferredStockFinancingPartiallySatisfied", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "verv_PreferredStockTrancheLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred stock tranche liability.", "label": "Preferred Stock Tranche Liability [Member]", "terseLabel": "Preferred Stock Tranche Liability" } } }, "localname": "PreferredStockTrancheLiabilityMember", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "verv_PreferredStockTrancheLiabilityTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred stock tranche liability disclosure text block.", "label": "Preferred Stock Tranche Liability [Text Block]", "terseLabel": "Preferred Stock Tranche Liability" } } }, "localname": "PreferredStockTrancheLiabilityTextBlock", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosurePreferredStockTrancheLiability" ], "xbrltype": "textBlockItemType" }, "verv_PremisesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Premises.", "label": "Premises [Member]", "terseLabel": "Premises" } } }, "localname": "PremisesMember", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "verv_ProceedsFromIssuanceOfCommonStockUnderIPOGross": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Issuance Of Common Stock Under IPO, Gross.", "label": "Proceeds From Issuance Of Common Stock Under I P O Gross", "terseLabel": "Proceeds from common stock, gross" } } }, "localname": "ProceedsFromIssuanceOfCommonStockUnderIPOGross", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "verv_ProceedsFromSaleOfCommonStockPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Proceeds From sale Of Common Stock Percentage", "label": "Proceeds From sale Of Common Stock Percentage" } } }, "localname": "ProceedsFromSaleOfCommonStockPercentage", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "verv_ProfitCostShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Profit cost share", "label": "Profit cost share", "terseLabel": "Profit share" } } }, "localname": "ProfitCostShare", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "verv_PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Property and equipment additions included in accounts payable and accrued expenses.", "label": "Property And Equipment Additions Included In Accounts Payable And Accrued Expenses", "terseLabel": "Property and equipment additions included in accounts payable and accrued expenses" } } }, "localname": "PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "verv_PublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Public offering [Member]", "label": "Public offering [Member]", "terseLabel": "Public offering" } } }, "localname": "PublicOfferingMember", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "verv_PublicPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Public price.", "label": "Public Price", "terseLabel": "Public price" } } }, "localname": "PublicPrice", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "verv_ReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reconciliation of cash, cash equivalents and restricted cash.", "label": "Reconciliation Of Cash Cash Equivalents And Restricted Cash Table [Text Block]", "terseLabel": "Reconciliation of Cash, Cash Equivalents and Restricted Cash" } } }, "localname": "ReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "verv_RemainingContractualMaturitiesOfMarketableSecuritiesTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Remaining contractual maturities of marketable securities term.", "label": "Remaining Contractual Maturities Of Marketable Securities Term", "terseLabel": "Remaining contractual maturities of marketable securities term" } } }, "localname": "RemainingContractualMaturitiesOfMarketableSecuritiesTerm", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "verv_RestrictedStockUnitsForfeited": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Restricted stock units forfeited", "label": "Restricted stock units forfeited" } } }, "localname": "RestrictedStockUnitsForfeited", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsDetails" ], "xbrltype": "monetaryItemType" }, "verv_SalesBasedMilestone": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sales based milestone", "label": "Sales Based Milestone" } } }, "localname": "SalesBasedMilestone", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "verv_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of supplemental cash flow information related to operating leases.", "label": "Schedule of Supplemental Cash Flow Information Related to Operating Leases [Table Text Block]", "terseLabel": "Supplemental Cash Flow Information Related to Operating Leases" } } }, "localname": "ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "verv_SecondAmendmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second Amendment Member.", "label": "Second Amendment [Member]", "terseLabel": "Second Amendment" } } }, "localname": "SecondAmendmentMember", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "verv_SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Settlement of Antidilution Rights Liability By Issuing Common Stock", "label": "Settlement of Antidilution Rights Liability By Issuing Common Stock", "terseLabel": "Settlement of antidilution rights liability by issuing common stock" } } }, "localname": "SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "verv_SettlementOfTrancheRightLliability": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Settlement of tranche right liability.", "label": "Settlement Of Tranche Right Lliability", "terseLabel": "Settlement of tranche right liability" } } }, "localname": "SettlementOfTrancheRightLliability", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "verv_ShortTermBorrowingsReducedValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Short term borrowings reduced value.", "label": "Short Term Borrowings Reduced Value", "terseLabel": "Letter of credit reduced value" } } }, "localname": "ShortTermBorrowingsReducedValue", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "verv_StockAvailableForIssuanceUnderEmployeeStockPurchasePlan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Available For Issuance Under Employee Stock Purchase Plan", "label": "Stock Available For Issuance Under Employee Stock Purchase Plan", "terseLabel": "Stock available for issuance under ESPP" } } }, "localname": "StockAvailableForIssuanceUnderEmployeeStockPurchasePlan", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "verv_StockIssuedDuringPeriodShareLicensorInstitutions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance of common stock to licensor institutions (in shares)", "label": "Stock Issued During Period Share Licensor Institutions", "terseLabel": "Issuance of common stock to licensor institutions (in shares)" } } }, "localname": "StockIssuedDuringPeriodShareLicensorInstitutions", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "verv_StockIssuedDuringPeriodSharesSeriesA1ConvertiblePreferredStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance of Series A-1 convertible preferred stock, net of issuance costs (in shares)", "label": "Stock Issued During Period Shares Series A1 Convertible Preferred Stock", "terseLabel": "Issuance of Series A-1 convertible preferred stock, net of issuance costs (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesSeriesA1ConvertiblePreferredStock", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "verv_StockIssuedDuringPeriodSharesSeriesAConvertiblePreferredStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance of Series A convertible preferred stock, net of issuance costs (in shares)", "label": "Stock Issued During Period Shares Series A Convertible Preferred Stock", "terseLabel": "Issuance of Series A convertible preferred stock, net of issuance costs (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesSeriesAConvertiblePreferredStock", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "verv_StockIssuedDuringPeriodSharesSeriesBConvertiblePreferredStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance of Series B convertible preferred stock, net of issuance costs (in shares)", "label": "Stock Issued During Period Shares Series B Convertible Preferred Stock", "terseLabel": "Issuance of Series B convertible preferred stock, net of issuance costs (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesSeriesBConvertiblePreferredStock", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "verv_StockIssuedDuringPeriodValueLicensorInstitutions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period Value Licensor Institutions", "label": "Stock Issued During Period Value Licensor Institutions", "terseLabel": "Issuance of common stock to licensor institutions" } } }, "localname": "StockIssuedDuringPeriodValueLicensorInstitutions", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "verv_StockIssuedDuringPeriodValueSeriesA1ConvertiblePreferredStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of Series A-1 convertible preferred stock, net of issuance costs of $112", "label": "Stock Issued During Period Value Series A1 Convertible Preferred Stock", "terseLabel": "Issuance of Series A-1 convertible preferred stock, net of issuance costs of $112" } } }, "localname": "StockIssuedDuringPeriodValueSeriesA1ConvertiblePreferredStock", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "verv_StockIssuedDuringPeriodValueSeriesAConvertiblePreferredStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares series a convertible preferred stock.", "label": "Stock Issued During Period Value Series A Convertible Preferred Stock", "terseLabel": "Issuance of Series A convertible preferred stock, net of issuance costs of $22" } } }, "localname": "StockIssuedDuringPeriodValueSeriesAConvertiblePreferredStock", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "verv_StockIssuedDuringPeriodValueSeriesBConvertiblePreferredStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance of Series B convertible preferred stock, net of issuance costs", "label": "Stock Issued During Period Value Series B Convertible Preferred Stock", "terseLabel": "Issuance of Series B convertible preferred stock, net of issuance costs of $241" } } }, "localname": "StockIssuedDuringPeriodValueSeriesBConvertiblePreferredStock", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "verv_StockPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Purchase Agreement [Member]", "label": "Stock Purchase Agreement [Member]", "terseLabel": "Stock Purchase Agreement" } } }, "localname": "StockPurchaseAgreementMember", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "verv_StrategicLicenseAndCollaborationAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Strategic License and Collaboration Agreement [Member]", "label": "Strategic License and Collaboration Agreement [Member]", "terseLabel": "Strategic License and Collaboration Agreement" } } }, "localname": "StrategicLicenseAndCollaborationAgreementMember", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "verv_SubleaseExpirationDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sublease expiration date.", "label": "Sublease Expiration Date", "terseLabel": "Sublease expiration date" } } }, "localname": "SubleaseExpirationDate", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "gYearMonthItemType" }, "verv_SuccessPaymentLiability": { "auth_ref": [], "calculation": { "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Success payment liability.", "label": "Success Payment Liability", "terseLabel": "Success payment liability", "verboseLabel": "Success payment liability, net of current portion (See Notes 5, 8 and 14)" } } }, "localname": "SuccessPaymentLiability", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "verv_SuccessPaymentLiabilityCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Success Payment Liability Current", "label": "Success Payment Liability Current", "terseLabel": "Success payment liability, current portion" } } }, "localname": "SuccessPaymentLiabilityCurrent", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueParentheticalDetails" ], "xbrltype": "monetaryItemType" }, "verv_SuccessPaymentLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Success payment liability.", "label": "Success Payment Liability [Member]", "terseLabel": "Success Payment Liability" } } }, "localname": "SuccessPaymentLiabilityMember", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "verv_SuccessPaymentLiabilityPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Success payment liability, payable", "label": "Success Payment Liability, Payable", "terseLabel": "Success Payment Liability, Payable" } } }, "localname": "SuccessPaymentLiabilityPayable", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "verv_SuccessPaymentRecievedUnderCollaborationAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Success payment recieved under collaboration agreement", "label": "Success Payment Recieved Under Collaboration Agreement", "terseLabel": "Success payment recieved under collaboration agreement" } } }, "localname": "SuccessPaymentRecievedUnderCollaborationAgreement", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "verv_SuccessPaymentsForEachProduct": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Success payments for each product", "label": "Success payments for each product", "terseLabel": "Success payments for each product" } } }, "localname": "SuccessPaymentsForEachProduct", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "verv_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Temporary equity, Conversion of convertible preferred stock to common stock upon closing of initial public offering", "label": "Temporary Equity Conversion Of Convertible Preferred Stock To Common Stock Upon Closing Of Initial Public Offering", "terseLabel": "Conversion of convertible preferred stock to common stock upon closing of initial public offering" } } }, "localname": "TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://www.vervetx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "verv_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOfferingInShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary equity, Conversion of convertible preferred stock to common stock upon closing of initial public offering (in shares)", "label": "Temporary Equity Conversion Of Convertible Preferred Stock To Common Stock Upon Closing Of Initial Public Offering In Shares", "terseLabel": "Temporary equity Conversion of convertible preferred stock to common stock upon closing of initial public offering (in shares)" } } }, "localname": "TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOfferingInShares", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "verv_TenantImprovementsAllowance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Tenant improvements allowance.", "label": "Tenant Improvements Allowance", "terseLabel": "Tenant improvements allowance" } } }, "localname": "TenantImprovementsAllowance", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "verv_ThirdAmendmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third Amendment Member.", "label": "Third Amendment [Member]", "terseLabel": "Third Amendment" } } }, "localname": "ThirdAmendmentMember", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "verv_TwentyEighteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Twenty eighteen", "label": "Twenty Eighteen [Member]", "terseLabel": "Twent Eighteen" } } }, "localname": "TwentyEighteenMember", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "verv_TwentyTwentyOneEmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Twenty twenty one employee stock purchase plan member", "label": "Twenty Twenty One Employee Stock Purchase Plan [Member]", "terseLabel": "ESPP" } } }, "localname": "TwentyTwentyOneEmployeeStockPurchasePlanMember", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "verv_TwoThousandAndTwentyOneStockIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand And Twenty One Stock Incentive Plan [Member]", "label": "Two Thousand And Twenty One Stock Incentive Plan [Member]", "terseLabel": "2021 Stock Incentive Plan" } } }, "localname": "TwoThousandAndTwentyOneStockIncentivePlanMember", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "verv_USAgencySecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "U.S. agency securities.", "label": "U S Agency Securities [Member]", "terseLabel": "U.S. Agency Securities" } } }, "localname": "USAgencySecuritiesMember", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "verv_USTreasuryBillsAndNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "U.S. treasury bills and notes.", "label": "U S Treasury Bills And Notes [Member]", "terseLabel": "U.S. Treasury Bills and Notes" } } }, "localname": "USTreasuryBillsAndNotesMember", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "verv_UnvestedRestrictedStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unvested Restricted Stock.", "label": "Unvested Restricted Stock [Member]", "terseLabel": "Unvested Restricted Stock" } } }, "localname": "UnvestedRestrictedStockMember", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersPotentialCommonSharesBasedOnAmountsOutstandingAtPeriodEndWereExcludedFromTheCo" ], "xbrltype": "domainItemType" }, "verv_UnvestedRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unvested Restricted Stock Units [Member]", "label": "Unvested Restricted Stock Units [Member]", "terseLabel": "Unvested restricted stock units" } } }, "localname": "UnvestedRestrictedStockUnitsMember", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersPotentialCommonSharesBasedOnAmountsOutstandingAtPeriodEndWereExcludedFromTheCo" ], "xbrltype": "domainItemType" }, "verv_VerilyLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Verily License Agreement [Member]", "label": "Verily License Agreement [Member]", "terseLabel": "Verily License Agreement" } } }, "localname": "VerilyLicenseAgreementMember", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "verv_VertexPharmaceuticalsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vertex pharmaceuticals member.", "label": "Vertex Pharmaceuticals [Member]", "terseLabel": "Vertex Pharmaceuticals [Member]" } } }, "localname": "VertexPharmaceuticalsMember", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.vervetx.com/20220630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "verv_WeightedAverageGrantDateFairValueForfeited": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted-Average Grant-Date Fair Value, forfeited", "label": "Weighted-Average Grant-Date Fair Value, forfeited" } } }, "localname": "WeightedAverageGrantDateFairValueForfeited", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "verv_WeightedAverageGrantDateFairValueGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted-Average Grant-Date Fair Value, Granted", "label": "Weighted-Average Grant-Date Fair Value, Granted" } } }, "localname": "WeightedAverageGrantDateFairValueGranted", "nsuri": "http://www.vervetx.com/20220630", "presentation": [ "http://www.vervetx.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31010-122693" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r125": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r131": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(1)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563" }, "r156": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r188": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S65", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.C)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r281": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r297": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "4F", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624186-113959" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL77916155-209984" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL120154346-209984" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918705-209980" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r376": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r385": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.2)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r392": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r442": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "http://asc.fasb.org/subtopic&trid=2176304" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.11)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.13(b))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803" }, "r455": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/subtopic&trid=2209399" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.1(c))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272" }, "r484": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "http://asc.fasb.org/subtopic&trid=2324412" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r502": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r503": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r504": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r505": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r506": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r507": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r508": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r509": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r510": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r511": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r512": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r513": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r514": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403" }, "r515": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r516": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(e))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(3)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r96": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" } }, "version": "2.1" } ZIP 77 0000950170-22-015737-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-22-015737-xbrl.zip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�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

_U('IO M)_Z\^:9$FO.OY<-?MJL^@'Z=CL?639<9Y?E)N[4ZMFH[E!>MSYNMZSJ<-[]N ME&PH!R*W+MP>\;J ZSZ/2HFK,>T71\!5$HWL56BP?YZ$M=GS?LX6?]PMJR> M,(97SJZWRT[8(J$.7C]KOK,M?-R:$_Q:%&NN M$'8&6AC6=!ELR"N<=Q[R2=HR\SD(01#M6'4YE_:+!$!K,=M#MY5!\/!=*?C4$6U%JW6IHTSY-8WA\YJ8 M:],"K_Q/\ 9C/.6)0=F^/ZAN ;[*J.4.%\. M9J-RK'VS=,M?I[.=HBGGS0_KJB2EJ,JTZ(DE:LJ;B.,<@1SEZPM^^?4B,R1I M/% G=VK(?J,==W"NPS:[H*Y(W85M;\X?9\:=7I5'PJ>2D] P]G5^S%H>5Y5] MV]5H-L<.7^4B*GM>9O/>3Y:WMOFO*5B;\?6M&CHE!%#>"/>DT5)C;KYL\_I5 MN9:]<"Z/ZI^34K[MW;S(<39FCC92I< MD?.[5Z_+5/Z8T^FR.8#UVBXDLWJ6;7?LZOH9@)177M!.?+A[^T8YHC6&W[?P MMVL2=2_J@MLKHNP=Q(TK5JI+;+'"TB[_R3!6Y"J;+J6PU,J3N/NMNW4HMO'! MN@Q%NU&'XE;5B\6 M\UP08OVZ.\@+;N/2('7GCPQ&8:,B1KYVHZP$O/[LINY$,;IK"8WCSISGEY85 MZ)AVEV=7>R'E%.76I9L\V5U;'ES6,OSI!HLMI4':VU*YWC=92MU**6;:W.C# MF[24M=[+2NZLK-UMU=?%NKRE9V$KM,Y2U6*&U6^4M0#(*76XXXW/^02E<84&)1S2'E3S+E00V"@GDG=_-O,TL M;"<0_DQ"<\:$1-80G]-5(K+."H29,S1IPHC827%)6"10Z@IY+37B!&/D,+'Y M3_B!4JSE3@7PQ^5LXEHUX 2K!G 2-34, 9,%Q!U/R$3%4+1466*4X72W"X(A MCENCD)'!(!YM0,YPC(1WT7BK%5:Z5@UX_,O'K1AV-=P9RV>^]3BN71C.6OQW%H\]]DY< U+AZ-3_SQI8I6??H_< MB7M ^/WQW>EBGN,RJSCK5ES\OEG*)X&OHJ=WNDK94-6O[_AF+*\F< M!@%T)D")^^F?>^2!! %(I B)"2#;NB@2R",.#_>?W]Y0R)S.\OZP M[FK65VM[6U15K_#\IOG7][^]CGF#@'3^OV!FP "F,4;S03CGI5A>I3'>2<4) MUTX2Z4Q&5"HX<2RW-%=9+L*.Y55JER56I81F0A"9NI08903Q3IN?AXH>AC[NE]J-C)WHJMX(@V^<="(9L8T6*CQ5@J'OCU<_; MUQZO?M9(),\ADD=8LO8%$'8R.6I9Z.^^KR-F4!#C Q=Q3^LO/BV8:[309,4V M"BV(J#$?Y1$,RV)VF"V8= M'^)"L5RUL3T;<0X/VAG6H>"!R']QN/!&>R@%Y:+Y[1>*\0>Q'O ^#"MJ,G5F M806?C5'_1XOZ?^-6BZ9.!CT0]_\@IG_/KFR"^=\C$RQZ&?JH3#=5%[H(M#HC MJN$97<#K[:^_O)Y.KN//)DXZ!JDWX+T_K/BH_H?[GXC/JMI8N D&G;=1LW4S MJ&6)L7( HFJVUTZLXV9CN/794/I/3?Q8G3D;8X.+#X?K3?(3TA)P,KL-QWQQ M$65DE3 ^"R80F2@'.JBH1X33,,6I-$FY03 MJJBT0B58-N9AA-"O3:#IZ[GO65A_K -)/RL1GU3!H;X* ,U787[00J44:<2RV1 BUT0F>$)T)EB?<^XSLA M4"\V09%2R;5/"6,P8ADX3#!C@7#CK;;2('AUTWSI/, MY38/\&-/NZ(7FZ /2,&YE)J_P+3'"^V&-.^8P/3H6WKK!3M(NI,'7[R1;Y1+T)4<5% MP_Y1+!^>V45*8\-TGAM@X[G 2DPJ [:5 6M/LUQD0?-@Z ZK\TD:\BR3!&0U ML$=)!='*.9)1FG!OI7(Y/PZK$UNL3GP.+\^ES75(%>&>I0 W #]8'Q3)T]1Z M85VBDMT2(3Y0RYTB3AF/$EP38YPEWCBIE/*:IT?BY4^:X.-X^:DJFV&>+@>_D6R%^U,MVL'!FA?8L M$<0!"R*26SA]7!F2I%:GG'H RD>"BD=@+RH%3,\C/\E0FV&*Z!1K$5FMM:1Y M2-(=;29(R[/<"%A8X;$,F0;^F<%\-57.:\68W.F2.+*7H[*7]M!^%+NPG1H5 MB^LY#.8R DT2YESF$T]HDH&RKD!C-X8'4-N,E(PY(>U.0X"G*$%]?_*O3?D/ MV);&Y=:9\G\-Q:U=EU6H_<[?8TKHSTW.Z>AQ[M5PQ"3SKBI2G;N]J3"P%4K5 M)-/VBYJ6_56N-N58,+)PU6\,55:\DUR6O[^/) M\_$K_,.#P,;%L@XY&'UD1_*1_0 ,K"DFOZ\X5DOA!^MC-1?L+Y&U6W5C*VYD MD\'>M#+<\DJ;7N1)V4:>%-M>O6W_^*8$>L>ENPG$JB;_7)L2!CB[KRN;1*:- M&>-Y :N+PL(S4>C;#)/Q) MN%W.%O.H,>VFL;F!0EX#E?$H39[0CP?H$C2"&*%"_ MB!$9J& V2V2^4_A84V]!#Y-$6,5 #0,0:*D 72QU5.84M!2QTPOC& ;ML>ON M&1%>DC%K@E$D48G$WJ,4?6$)25Q(;,HR4"9VK&]I+E*N$BP.ST&3R$"=T#+/ M2*Z!ZCS+F&9Z)+S/)+Q>*.KIC/X87@RHWP=X/ M^F!58Y3#D4TV?QNKEW^U..98[:\C=*SU1S;%_J:3]3(OX4%=94&L_GW6]=4C M9R_OFG*8(?QQJQHK3+(Q^SZB0T6LB+KY^#K,%[=M&?>Z0.JVB1*/S+Y2ZMV9 MB>]LCMBT+5?8E<6MUI:T5[9U-6\Q 6DY@P^*4,(].YV&_>1OO[Q]4':]E6W3 M5K#ME"D.VX]X4!8?OWOP5&P2LYC/@]NLW:9V?:^Z?5>T]F8-G#/F>C6FWDE= ML7UYV8_Q8^4,+[$IH\FK8!/5NDG!B> MY4[[S&9F-U8'%*G)HXK+@4FS U9,MWS?5Z4$_^K6K MYG'<%')]=2[]\;I2_MO%3RZQ[(FWJ79&"T*UHT0:R= 1D1)GC3)+Z/#3FAI_._,8L]B\7^_3;35%ZTA1RV&E->,EK?6R;#_M8A98]3><:'76% M&]14VL >'K9NO;2M\7:W]SI&]A73;46@5C61-1PRQ5Y-7E>?:&\1(=IVBXN- MAFSV=[6X-3X\[&JQU])U8:6LM!4@\K@C(:$.!&B2$,VY(9H:PQ(O:.9V\R]M M0G.M)3'28RFK1!-#@R4^]5KX7(3NC#I(;=-3JN_VZ$GFZ#J)KUULFXEZA[G6C6)MO&KK=,$]V+*Q M5RT&X]@:,-H>I[J,1%=D9H_V7_A:VY:?H5//%YT'>$4@>%=S$Y=RM/==&_&X! 60S M==!KETK=]$Q%/;+6ZC52:RP\]_W2.1MV"]73&NU7N MR&Q7<(V2J0?]ANI]&/LF/+=O@AC[)NQ_Z=@WX>M0X+92>4+\\T*UWY *:YV1 MQ,E8X1TK5@BJB><:6SK1-.3NV>;CKQ+C<1:*;PR'<#=]P],IE:?X[09=W;4. M6P8,$T3<9^X/546MNT$;S!Y;K69U;IHSU0W^&^LK[^@*S1[_LKX-9>'@;U_< MH:3[7+S A\"KX]VKTLPKI/!7ZR5VO395.(Z=FC]Q$W6?WEJVT2QXZR"E/G-4 M..(S3->72A/MJ"0BY]P$KCD-.UQ#YIH;;3,B-!9E$UH0Y5P@F0IY0C6WDHGM M=/W8Z1P@[.NY[S6%_0T>^9<9_/+-) "C6.*6E^OP3=?#V[]>/7:,_\E.>:.^ M'F=X[DB[K>PBLMKFM=W9?GBN^S#VSW#(GR!_:UG7D(/I^_4?2Q(C[OL"Y\IDE M NL02>8LT8DRA*?"Y]Q2&IOL;&=^= ?JJ7VR?_[EIX_WRLFF+!73F-]VNG!J MTRS['; 3^.TODPT+BDL6D\2;"L\7 O5U2"VG"3 ^K0#J^]P295U"4ZDDIK8 MD"G"..,Y8X;G^4ZG(:>=,AG0M\^!OJ65";%.!Y)K$[S+M1#I3LVSM\VZ_E0N M;I&38G+3FWR;E@&(UA\$^#)^:;:D[ M5C<;JYIMZ'?T21[))\GV^R2WJQ !+\!HJ2('45_G/0#+6)3+MK01AD:L5S>+ M$M-V+H ;"".YL!DCP2JL61IR8GFF26:T2*CUTIF=H'.7!9F+/!"54;B':LRV MXY(PN#VS+A>69H]1'5ZW"_U<]2&94DKQOU/F!QOM8=DI#=%8T1;9.GA!;.\5 MY=Y\-;N/,7D5G&(D^.FE!*1SY26S:4Y"RCRH#'E&=)JF) ?E(0E)FE*QT]C8 MQKJV&0@T!E?*/$M!JJ49R87*/'<4#L-.^:>>2?#(1,QK$CX?,NX;W*87 :V$ M3:6B@*H,S9"9"FRJP5*BE&%64AETMF.@?B81'DO1?3R=PE+1DZX3M33EY [7 M:J/ICB#L"X$PX '+66B1U\]OWTRQ>0EJ C$\K!9L>XRVL00)EN*] *X!QYQ[ M0[&9DC/ !@""*<4- 7U+JD09T*UVK+>:&1Y< O>P5&%-=D^,5HX(:U*>)3G.U4\TP<)D8E<$]EJ((LR N>/W>E/Z76*05I%@7ZWEL'#9E-)F*]*0C.QIZ M[O-:Y+)8UW93GJ.)FHTY/.]+&%19_6M;L -+!71=IC9AM?5SIXT?8VUG6&HB M!V4DMMV])+\&XT B(@BB3 [@C:>.Z."QE$#.@#M3PW;;?IC$..:8)308N$=Q M.%PY_'!2)"ZS:9(D;CL8(:[P6US7+P?HF+XZ;96C@W'3NB!*E]>RZ[LXG5E= MPAFR"KO!<$6HST'8*%#?C;&,Y-9($UC.5+*3!/<48=,$].QSL?3 T._(_P": M_A6IY2B6:4'3JY.&0XUM^G1&O%,HO>[M899P^#\4V-YC=C\>_D$=?N8L2XV0 MQ*6HPC#C0.V1GECF@@1]*-'Y;@]9BW;G-)# ,9@@RT#\YE2 JF2PT+8SJ=HQ MEKR@BQ6 ]%E4,CVA$1?SR3RL.ID/2!5S3F#+8M<@ *D=VL4_?%$Y#!NNBPQU M0+;)-*RZ(&*[E5 _UE$[&\O5[\NFBX>;+6*)A$8GBI8JK*RW6*^J%1 '?K:>@U@ M+4V-$3EF>>RH1BQ);.XTX0X[(C#)B'4L >$@A15."Y>Z78-67-D"3NCAR$3< MX?K""D;X7-M -LTXG6I^TH71#]%QW^PU6L2_D$7\4Z7R(EKY8EY4FY!81'BT*GPQ6\?M M;6H -75%QQBFY^>OA+51V;&RN[U*&Z M#^[;R5[KYZ7T\M?VI[@<2K3Y9G]>5A8T"&RI26:5)-*+C!ANX >E*@N.0V:$BLQLG#':5 =RMSZ[&3_023OO4A"%2Q& MG$G]B?&+Y:KNW('?V 5*%>!'OBB#6RW*&'W]>GV]KE;U;5VOC[; 7*PFA[?\ M:; 6RQ^+IZDOE0W*YO>[TK]P=@ M82/(U>1] %'1Q;?6&] -95/+K]O,@P213Q# I2 B9 MUBYA+M5^QQ8I1.H#E<1C]5MI7$:4]1Q^Y"IA7&;>F8] U>_-$NMTUHCUU]A% M(38'_VF] @'7&BJ?"6+3J5+)-$U.65T=K6UG(UL.:L7_6NT3&XU@J;GI]M61 MI[68.7IYNO8'^/ FV_*@[((KZD_J #0;G,%FOWE>M[3"UKYQH"SMEWKL[MLN M\;A'>M45Z^:;#SY+3N%3UO.]@JLGK:9M[^/(Q W&R+0""!N"U/*@ 6SUMP_D MV[]N";8]XNR0-+N:_-X3&=V:QL)MGQ)'!0R]B/;1LN%]V\((!4\L!P>R;9&_ MFGS+_G@1@D@GJ75>$,VQ$61F#-$V!]TH!(,E;C3C.\TCN?6Y2#0:5I0@DIJ< MZ"QPDG+).$MTQO,7%T1B*M-TFHA3CC/Y;K*FF$57U88C[;OK(6.+1_O;^T>.KEK; M_VH:./7](@U7V:T)_6"TX<.RP""=52AAC6/Z51D-')%1O<>0M"IFL7@LDSV= M.)S\;(:_PJSR@#%/DUC"NH7,_H%G#N/2X,\")@'\--JRND6LH]/Z$7$F'B0D MQ-BRO7MJS8O;[1:?S7@.F4M4+K0)<+QUT'#&M20V-2G12N8N >PHLMV,>),D M+J2>F!S-)>A-,5[G1/!$2)UDF70[\;Z?'6+Y0ZA<6419=1*P FL9S^>XAZ U ME@&F,\7MM3%R$4FF=O'E10D:J#?W75'DO$"G_N0^F'):=^R:N^@$W)058;V2 M48T-K?8BKXI9+66[\.#I]DU8)GJ+%V CM?IX?5MDGO (#8U(0CO"T#^\03%$Q9[?^B*\7Y*//1E GZ( M)>4\L/E/5%L:_A+44K(H'BDF?:@EW(YXVAAR=K6=4.(I2[UQ6CFG=C(-F E4:$=R5-$D9X:8)'4D:*Z8$YFTR%I>EC=E M4YIDTY3KL^=-6YP'%;C:/=G:.^&3VI9[ <1,/7,N9#E&58+0-(DD6EE&G)!) M9M)4";E3G(R;5#+& A'>@7B5(1!MI24B4<$GBBS18N_O8F_S6XQ?4-O M8>"+.JKHV#%$EZP='0H@ZOH[=6V=BB8T?X&K6E\^KQ:SPIO:&0;_U%W/@/87 MRZ874-46>X;AW\!ML7$0IH$6T4*?+V"OWU>OSDO;IE^%GC[1$"5]JG![V 6E M;ATS^?,JLZF*VNG?4#ZL1^.+)ZIZ=P:TO)[^R=WE23)M_X/5V-[F40R,8F!0YWF(8N!=\6$4 D,FFJ_+'IZEIGU)_>OQ M>SRD'7VI5,JG$L6WT;BY6%=F[JL_/NKH#_%,CQ+_DQ*??S/H'3P5KCS$0]R/ M #FYHWLJ&_^".MD0MVWDN"/'O6B.RT:..W+..'/?\#MY .>Z(<4>..W+< MD>.>X<$;*,<=,>YY<=SC&_DYS:9"3*LPZU&F8@,^;TF-+=Q(!C'^[" M;+'$>.3//[M'V]3F! ]]7X<&>YZ\_O/%":_^9YRJXQZ@?QG.23E!"79F26TV M$=*HQ)',4TFD\(P8;14QL,69P_1PLU,M'*Y4J95PI=49D58E!)Z [3.5H<;G M"<,RX-NI04VN3_#[4X%^K)-0#K9_$5OM7\0G$L=U/LZ>3DD.C')X ME,.C'![E\!G(X5R91#N1D5B616:2$AV<(&F0J7&)RZ3?22ZGF5=!YHH(:2V1 MDAJB9)H1[(\:O)-.^N0%Y7!&#[?Q&)G3*(4'LM2C%!ZE\"B%1RF,4EBRQ%,; M%/$N 6TX"P&$J7;$&I9HDV>Y18GZH'1FRG(6,DX2IRF1SH#D3BC>HPU-C?1 M)B\HA9.I1+_&*(='.3SLI1[E\"B'1SD\RN%8-S H1H7-2,@H(U(I;#BN.3%, M9#;+,JVEV6D,1%.?ICH0T)93(E-GB0V>$Q]\CE5-$R_L"\IA-J6C'!Z>'!YL M'N#0=V28[.2O81Y*K*XW]Q/CX:JB6F&!LKLPA-">H>_IT"#8$U;^H]SM?')J M3V,S+CG"[@[=!J;,8KULQ'K M'L0P9\R1$)0FTFF0Z)Y3D@J1B=39/.<[C@ZA-/.K,MF,4ZD/?H=/8C%&HGXU0=]JI+$\L,=ID M1$HCB*(Y_"9 BY>I%;G9\9H(X;E--,8=&D-DR%*B@V$D3T20DN42U/P7%.IR M*@4?Q?K(I4:Q/O@]&@_,@#9C%.MG(]:M]R"]@R4T\0F1RDAB>9H0Q32W+% E M]4X_[Y!9ZF3"B4P" ("@-=$"Q'KJ@V1&Z<3F+QF4R*:4'NXD-W*I 7.I+UY3 MH;^:3,:GO41%Y7X#K&880]SG83*RWQ8K,YM4GV@Y-YR(O_,Y]T/#C\<-4SN? M?1KC;4

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

0YI/ G6/8T._W2E7I#&;9 ;)#"[(# YE1RG L0V2 M>1(F'[$VDI.&)/: );2/::?[-B\@X'80F?=A%U(>7I&QSKR,QA%7(KQ%S!F0B!=VAE*Z4"*9@?\J MNW8X"AUW+9&7%TB:?=#T",.F$]Z,J+2*I1V'=D/2!ZIA/W<@1;(8T)P71A+6 M[:T(#\%AAN[N91/ /DL7'[]^6ZU[VS(5+E&AFM63>)Y9QTBTD9+1Y;7"/F0W M]A)6;5-S:Q?5/+=*.(3+-S^2#_+K1JU^7"[N6'JU-0H[E*9E&GS;L1SH:?S^XE<[WT4WA>$7D!UIQ+ M6 !YN]S+/\O7CL]>'!=M.WWLR,ZZL&Q\>88 W5ZD9_R4.6C[GC8BMT2.-^?Z M/ ZIJ,@+$LE_A3#2OWSZ"3Z9W*6_*:G5T=5XQ](+W);QLE"+L9,_# MAU" )Q?(@2S-3L7T\*G M8=/B'#QSA4%>-7@EJU/ ?\_!DLB.QLADQ%=4TUTE;0P7M3'< 8D(=NG;DIF! M260KXN=A'#'M".W.1J#7J\\G((NP-12$ENC*KG=^&2HXR!*W@(6ZO"7X'-IF M,:JXP9%)57?U@C87^!6V6TM*DW#:AV4U^V96#$7D6(B*85K,DT.3C%M'K#*< M?]&Q4=D$[PGS.PX 1YUF5J#Q B(6TT/+\ 'WEY>$J_!?S5;08Y8X)_U$T@ZT[:4!-3^/6SH M/9+**;Q\Q+CH.$)IM)(A?U._.NVX]ZL3 M1/#X87BOP_',.U"&DCL ,UY'=0;U0KU*>*R45]R4LCO1_LR6-']J-[>#8296 MV&:T/K/ I+0E4I/0N2:/>K*)#&'L#^6F;=8DAGA3MDP_Q5^(E@$'0O#E#5*& M<#BUW)3V&=(\;B&(M9[)_M!"Q0$L'H?B%>&>0@:0BO98?E<"N,7'!$N%); U M#@K21D[0KP=7G)1,RRY^NVUY!?E9-54V9I(?#LL K'3H51FCR \0K7+0,W?3 M=6%Q@H'A:3S&P4F@NT-_V6@,R_+=J#=9QI-$/#FW:1[BTN8AGJ5YB#0/\<>O M.\TKI>(4/%&OXXKJT3&OUEGJTVJ=0UQ 14NBBU0M,2H.>FG[>CBLP06",QY5 MN-!]"N).V.LG"2RGTO"Y ]XI[2'YD<*TZ'#D)KFX?7$N\4->E\B&*8.B%/'[ M )?C%RPZ:,3GWI2,><;A3@;]Q\O-E% HB- Z%CG_ECE&R?8 MEP(>)'+725!'D'#6F*MFGIW MA9VDJ"I'%T"1I F/=:!6T>BC)Y77=D(7:_%X(6$H=>U6HPDJNO51+$B5;TLU MN!9Z3I45%$_1X6PI:45J5&:Y2>-+N]TW\B*C;&JA$">7"PG,0*I_,LTL*0GW M#N#%E6B(Y?:DB'F6V)0?3U+TYWO4A;*.IUX1[Q%:=)R7UHNWD7S4)?DHS!;$ M,TB* %EO>:31*+$SPQ'//(K4%GK+@0^+)2;-['%)SA@V?! N)%6# <'EK>\T)Q4/*!*_],)F=&8)EYWQFO%4 M[49:*ZAU:\HFY[LL_ST>SM7/4;5%#S'#I0,JA544\1[%QTKQNN('0BK,PE\ 1(3VZ4&D>27>7=W0K*10E M.6JE6KG?/8T]6>R"%%PSY\#0>=$MGT8L*KJD]+@%JH(.]52&P4XJO\6C%1\X MSS S6J[^G-JZ#HMM"AA2R(U\=3R^)$]I%(GL7,TE Y:.%I90J,$U6.+1E$- MA4G1-T4BC\CO_BXJ/+10J,)+/0^*;*LJ7S=M[OO;A6#P@O9%F T;?_K,7+:* M5V0Q%]08)#+KKCW!TJQ6A!)G=6YT/=XI!?*'+%[YRHPT20=2#/*8;>$!2F-= M5/XBL5"W.V6^@'3&**27KL(/G7.OQ^HP2Q:R9"!-36WG0Q/EL&?7?"2B4M:K M%\>VK%8??_3L,[J)Z/K1_CYW^6'UPE=9\(+?;"HPA!M<]8JAV;B6:MAP$?@% M0HT_^^QYAZDI'!1O"[, W'7T)RT'P8$02^DV^QI;\UA_R[%][H^YR=NBA!RX M@_@B!Z> X8@T[P;&KRY6HF@C-"4B+*H=N/TIFQ>3J< Q_C' [1#4'7_Z?M,W M6#Z'7WPT_UQ>; :PMBY^-/HXJ'VMG\#=]9OO?IB[U^>*K_!GGS_9+_ HW!MS M+J:[V,*-7YW /:YNF[8J4,P\B/U$*P@^NAD$:25^E!%QJYORIHG?BPUCFUMX M^%A5 SLL.^DD\QOP'KI'VCQR6/\J'.&DUW3W%OA@ \WN="RMI7'X02Q#]*'OWG!AA@4[#RN@: MU8'(L26IB\B8M%!.X$A%!2(D"'84SI[@+P\*;^,]THU+&-4 M)N.R,9UB2^1WG(++JMR[_*;TS!E*Y,!?"4)H.IT0+5[4Z(FN"$&NX!E#2W;, MC<"+&+[4W":FA#3IER;]WG_AQEL>\\@$@#5A]EI'NQL-0/$LH)KB[)YJ7?98SCB,#[-FB>KNB2K&BL:3YF_\\YS8:;%GQ;_12[^H>V&41)U M#DY ^1XRL=.W+2T=89AJ>-:S)/'K7/)W4W*?:08(K)T)6S.KQ<(X[KDD2\I8 MY8;+! 2R3-]V]V,L*@/NE_>4%J']E95! M9K]#%3;U&3#CF!._2IP+"*\2\ I3*D1 A-CYP+M:NWD?1.S\01<9K3@4 MZD'=U@OE]\"B%+27F9\D/C;6TWB\H$$+;PC3Y)N^C7J,^R*EDADG,W[:9IQ' M!D)V,R?G/*4;G) ?AH!^(O%L8/TCL:&()V AQP[FGJ7$XH?"L)Y[HCDEIZ M3#_/\*CL<7<<*;N.YG;YN('P$0^R\X\A;]=EWPI!842O>ZO3>DB?@>^O&PY6 MI[7&8:;DCI([>MKN: %\0HX%:V?$,I?Y:?5LY;"HO<% &YQ'78CKZ975YBW\ MDU;WA\[30LVI#;%B!2(\5K?(I4,1A">@PG%"\1GX^ =)V"O(%BH>_7?H2GUM M$(WZ7ZXY8B[Q&]/OUIY#^-XW8"^/("DTK#'$EV9<3?(3R4\\;3_AC8OXK-JR MT@V\_1M9KJWPKZ!G#0N MBR7WG =-WJ)AW91-19.VJ*#Q-OOI=MP9"]7J:(LR,3"UO,R.)>WK)-R7#/"2 M#)!R56D.:?XJ]/;"5,_">QNOKF.--_.L7^&[Q+G@*5TBCM4?HD$OA[#(5;3E]-C'RN\4Y5#B_FT'0]3H9* M;10>(41-F27G?K5$&S=:TD)W',H;A"KR0(/H.L\Q'C%N@6G.J!:\G>F<^L7/ M]"0C%MTAL/CR)3$K*=Z&7+MG&5$T)Y5G*M?U4GYNFU->P?9VS$_\V -K1G3? M]'QN7;A[/I60.M"A<92?9@C#,3JCS=DQ-]/]YJ^\E0MCI*7L(,F,N%H5ZMP* M6EGBP7A1>=50&NZ';U>L"&7J65%%;J[H/O]>"]=MVG+-S7(("[K5__O_?/*7 MYS_">59?\>0$_0)U>WFU5UT332*/* LFZR'Q87PPKD^!RX.2* ZD?'L%E@<> M2LNBPL:S1ZX=KF,'%L$:+/^*/A6XSZF,"I:#VFD9:<61BO0@:G\R#5@-4IGQ MM/$63)D915'Z%+R4G E;F)A'53!C#BOB=G9O1%I-C7!,S7/+"G9@0Q___6_9 M1W__ZZJ#F[/F<#@T-5\//ACZOA>_ J>^"> 4X@,9GW!,T21!!5XC84EQ*.F& M"!<]HSD=3+YG$VBI6OLK?I;]]=EGV=__^K<[KID/-6+@#'[W9=Y]MOI&&*IF M'\VS3S[-/OKD[W<]FK;)V7'^;][>Y&UQ/?T5NZ!]SL3<5_3J0YLR.WN[,P>K MK5_^Y*//LH___NFYJY3=,]_M$&O0&VX5C_2K7-@SM7?"7]["QEAOL-)(G$]T M)W)IG_X='M!GG]JK"5=QYW/BI4H7P'AGO?97/WP?/9'EM\57U,I5_?_LO6N3 MV\:U-?Q76,^MDBK,'$O)RUQ>5Y<2?0;))P@(!!I>AF%__]+[V M;J#!H:2Q,N*@ZM2)/"2!1J-[][ZLO19WVI.OZD]:^)\P9S*3?@?BPS')C9[( M/$E U$3[+0=%@*U*^+*O*Z>0>P<)V':!XG*; G5*_9.C0.,B;U>.VSH TITO M=OY%+RHPO^MB6_C-#S:I$6(-/\[_!69MX4/4$I^>2B B5#+(KT@ILZ*[T$R$>.;X\[(FS@B@%F&'^'Q M/IY5-!=YN\.]#9HN9KI8<"LL14R%XTAO%S](RB"S?E]X61SPM*[K0)4MIS=6 M'W1."K+8<&^8R\F]0;XI_&FIVN<;^AV*K4[^$.?VC3OX*)Z9\9[A#('^)SY? M8N7M\LM7%B\H-[7 Z&WZ>7=WL$WV_CSJ"5&T4-7 L.%'$RC:G^\*H+?UGM'_ M^L/M[\!GA?7GIW:5[T':Y(21V05&4XR6O!%Y\?Y_OZ_OPAQ=GVOUU)M@?SD!+H6ULKTKO_766YD!T&+Z M\#*!DV!QV1'A(ZOPD PLP;!7Z?##LNMEX B _X.'%IR4VY8]>3PN@..]E5!^ MF,(+Y+(A0AST[14F) M20PDHZ'RTHK,F^!Z.%+-8)2CB;0#TK3Q?O9+)LOW?ZX\JFYH6&-] 7V?;+ M7[@N#+E"0:)!%4?>4F[IU-49S4;;G6%? M:V]%#KN\9:B')C O9K!-[C[9I:2VT4&;24\[^.-3I]X@KN&:B,15@0PT!-3G MM2"*EJBCA36C_&9#/6JRZ+B]K>H"AZBLJ-Q7E&7Y)*STCV5_SI(,L3@4FW>K MI0+LYGZ#4D0HL*]AV0&%7&2[E!#8YFW-9P2G?BGX@:.F;+_'K#)!OEG8FBRK66 MMA_EP"D];A6+TL -\>N8;5JR5*:)%\64VG/C8L$=V\3HMX2?%4B6($B\;Q?K M7IC:"Q]I^GG/C/V/7> M,F$U::75]!9%95]5.H]2QV&L^)!X)L$0J72PM",/ M[ Y]!7X^%[Z(C1U1G"-O&,[9GW<.(X"C2P42^4#N8-@G^LC#B0^+)NRJUHCB M)\QS\G^*+AZJ(9#W([,\S>5&#X%-[,6NKM>:#X.RX_*$GW[SU8ML\?5W+P+O MFZU1]MV.2=7H6@%JQ%D]06"(OYA@W:&Y%RU8CBFU+!F+?1EY$$V6COTW3,EV M!=6!XV%12EXIX:3MEZHW/JH1B$A?,>M(=QH!(3'):H&001I"=;;RBJ['- ,- M%#(H[^R-!J2>*=;:F0O!;8 XA#HAM8_*/VFGBTI_;]TMW8C4FRKV&U4MB#24(%?\TTBW7 M.F?2\M$6_JS(B63 MPG#7YQ\_<3?#GOJ&<(@2^PG5[&8YSMQ%>JD#[D0MN,(=I,01^R$9 MKW@BF0*F2G"G$F3JB[1T7CT"\@I;_O2#9:31PJUU=JAP!J43:-BX/\*VKSE=QAE@R,^(!RP;QC#M24(=EM+U MF>PYMQO;\""41^**-Y2G\(L6F@D%?6@W@#GVXE 5#1_R=8.G_L]$T@6FSM[>!NKKGST9>P13>LP]>X/3'! M:MT@&YEJ2%ZN"NJBPVN>5$R=D,J.+/E I(O-[\$_^@YE$(!=KHKP?Y34I*.E M$FU2*GGCQ8H6KX)L'#Z\%"([%&!@S^18-V\E\T"XB9Z(.::F'H0!\V.8XLQ, M?K9XZTZ"T7!:!:2D\K:NURWW!;:-J >1/>@?@@U'D/ MOI>DX!RF(2&[E3>D',SIHXQ;'5 />.-W#1:(*OS+0E4:-O)^<'WU2Q]_=WUG MEY=DR^_\ I4LYU*=22 *L9EE?<<5-#F;I.GCD$4Z(;4WTXT^&)>MH39^S M*5>W:)\Z#OCW,PYXQ@%_^G67] 00=R=]*EF48UAA;IH<1?_YZBW4^T*R3G,0 M!4(JIFUNZA,^W27AXV_WK][/)S9O4+00&@ZCSMI163DTP<;F-K1#AR2)]S< M.E#X@1\I%TC)$ 8XY6M_1W!="V "P+MP+$.N#CNE[Q79M$0I9STK\G(*@Y2S;Q&_;3V*4.#C6R=VH:#)WWEE"5G+253G1F MX_>A2T$W-[=&UY&RL'L,**;*HU?H#@D]\*I5& MGV.0XF:Q#BV>8$F(;L'LA&A\<61@IRD1$Y)"4+""[L-LE,LA4R@1P#!9[R:& MURI9#$_>!7]T\)YP5FJ.SGM%\__I2#?*$TL5+6 M%L]W!@+D32>5MY$K,=ZN6;Q?S2[:G&$FXX@9:H=M7>+*\U?YI2ZJ(+X#'IFR M?PJ&!ET6^B@C K.5=_> @Y3V,:8C\<;_J%!HZTVGFCV2:NVK#G*.*6I@Y4J[ M?^\Y;P#OAID?]=&A MM*$WO.0._QM1&X;_C>9TG[]%E;2>Q-*\-2A)2M=;A(83H_#'#/R]NA&(4Z"C ML_8'/TP7&N-<";FME(O#)*_8P^ ;%[)&P4HKRP'F46**!TSS\$E!6"QD;+7K MDQQ:6BB8NV^\0P]D(HV+CQ?F =+JZO7YJ$_9_OT<(CN[-^W^/]0D#PWEFTV! ME0%V%)AD38L<:5N3HY\P=(0GQ1( V(O;RO"<1EU92P@%;\@*,F0PU3<0W^X" M^Y+&UG#<:%M[QF[2T'QR1H:%7#F9)GN0GOE%*,SRY/ZTT?+L67QK2+#!V+AUMTKOH..H+&=Y@/JFLZJ'Z* MXE/=J(9.034FLC/,"N><2+_.7*97=XEXW'18Y0!P4'@:)BG;HC%>57PZPL:T M39_@$E,Q=YA+',"4D[$'9U+Y/#KOVTE4 \<4MWA@+K( ;]:AD5ZZ[NA]/M 5..??T(5A$L(04 M^F].]H(Y'V\,'%%63*I)&A!EWQUZ>*4;@)L6>,NNK@EA8-VD6+DUD):+%3/V?;:6,_46RT ?*C;UV+O[-9OU*S+G$& M[(_+6S"TO0YV._#A^7]IKV$F7!BM]HZ,/=9_]7Z=J<6#EHZB0HI>W^P 3@/[@7- MV;;18=?O02VZ7I^H#0%;%N/1P!W6-=C&;ZC\F?EG7?A7C]57_,$/JZZ&UIYG M&?#-/3>CC*PDGF5M[2?>='0R12@D;+9-+HR)]!"05@)>O)H\%1P8>!0<&W!* M!ZZZ# N&9_R7OBG:=1$E&0>_?^G?4[?X#;5!K[[\Q^N7R&'\6UBN1:L7SF.N M .)R]&MB^"H.V/>Y+%_0F_ 6I#Y=(5N!F[LV-S$,_0)EDCPHS]D.#)13VAXL^"8: T?-O&J8258N MA3=@@*4--VWB 3PE4\V5H M*;]C-Q?MU.YT />KY)._%W85[Q/X8.W9G_QY6G4[_UU WW&TPSUV'$0AQCW^ ML;20F2BD8EI=I+D=ELJ!^.%MY<-.4OX,'!*\]\-OZ:=7MW.>.@#TOV< Z P M_?3K+EB@HVM8*J5HVHYR-&]%;$S38.A_B'B(B_(H$^X1E/S16(K7M0 S1^83 M;X<]-YEV5@TMW>+<$"$S@\YV(B1DZM(P>'3GI;Y#(24X4)#[RBBXS"C+Z,.M M+&09*?R*$3?PO3[T>M_O6^)),XS;;4;NS'68#!^#>6I02DUU$-B1@HZ\G*7# MP@+YBA1JV?CV7N0#I@N/N[ID753T5;.%]M$[Q!!1.=\O4V++)S"'N)L14, R ME$U5+/W+>HGQ66L(Z8T33C%W,U*PWHR^=#$Z!%$*4 .#%BGX2?2.[4J?0,KP MI-Z#< L7T["CRIO&[XDHQV&^9A9U#O@;C.\U(22H7.X@,0-O[KLPW7_VPJ_) MH >+DK*@HOP0,BQY%-SY08E)A"_M_7^HL(F41S@M$V\H3L3 0O\),#; )K#X M 2)0,NW_>//ZIQ_P7Y@%Z;\A-[CLFMZ=]&X8X99+"[&\KPT9_4#G.I+=+7%N8Y18A%IV(= M&?6@5TK'!W2<"E;5+PPA2Q9R3^@WA1,^+-3,W)K*F"IH*AT@(T*5+!;[SE(& MFBJ",8@.2V)G$+@I"$R@*G30#5TT?A,*_!')GIG*3P1@F 9;R1BED23J^;#] MBP."%7^/IM^V>EW6F:4\I-GUT7$ "$L4/F08]V1 DSG7^P6_AVA6#C51"WO M@S,R&9I#-A591;%N1H2%IGD6$3#R3!/5 7F89<0QC9I.XT+@$;RP8 MT-*CG\V[Y]JYS13WC(P&@[IW?I-56] (M> X<>MM!X1-)9L]&&&$4[=($A13 M85%]#U,ZDJ8,_SI798_%P[P5_0#IR@,BU%$,A_BW*(H+#1;GIE?=)&5-U7@7 MZSGXC#RX&EV<>W&AMXLW<%+I!=L!]H[P=E @I6?DT6^\U[.ND9Z)T) A L.[ MR])%0-^I% 6"Y#>WZED_:88R7 M;G-)]\1D=%3#_1"STS>I8"X.[2\*7'G6K3N"V)QX[BV;!@*6X&+2:&H+ADBP M0?T(8T%)MS^4]B'8?J%G2TP6K>Y'=U$UC(;A=_0U@G)KIC-@\5 MBY-Z8B3ZVCDB'J7Q&LX.].\ DL)U#*;BZ MZ;!MJ!,27>O<-'%7 )RJ;RTQQ3XL(E*,+<\%X1&4@E!VJ-1[BALT:6V% R6 MFV6,B;(+P2'CYE90*C4>D0#3HB31O:880)R;NBQJBQV(;)XIQ 4H 6YT "R< MR9.\;PL9Z@]>NC6NSL%Y CVXEX>8/T2XE?-=@^_954G(:\P?9.'HX*3 %+$] M[YJ6D"$$\NYQ$W.D-[[KFDL(HN0TSKCOF,?N1YZV# 4YC+V MIXU^AX(01]'B*T&7P3H<49/%N8ZAZ[/F3WR[(*Q.]P3&$8TS;9&&,'Y09B*C MG>K)&N^LU,J"JH$"_MFJ#WB5W__0&$ ?A2UF0>DGOLM09;T[HY@+G[U8]=YR MM^'/IJHS9N"?D@D/94F"Q4)XN6*O&UD2[\EI22?7Q(1DBV^_?WW)!/UD;8/5 M!H!7 TR&WEI &]?:!V-;AR5+OY2\C8-6)\X79HNF/GG_]P0'<^O#J(IQ]30I MUMKY!=2WY\PCV2KSDRQA@L== D%*+WQ;PLU"%*JQ'8+(?N+>%).S8X61TI;:V0R@L M28@KD6Z6A<41*8\><,]#X&\ ]1/$P(R'4WL$0SIB ;J>SF!_@-<>@2UN%V\@ M%1$<$3A?Q.B)P8L]=;#7[IU_06T+3?NA?JC'$!3H6 F%9P_S3KP-Q6[@PXC4 M2=RP$\7=Z=ZUR32D204,@YPAXL#F (SHBKX-[/*$MR;640I/W,H5E@8N"P[D MU_*J43?1'J#C5Y>FJM%&-YLDB7*DDYSX<1\4"?;JW.*BK!LT<[6P"CLS8]E M*RN2%3A#R)QX/SP@%E=2);R*B#!E4!^&DZ:F1,M-K(;>2RW.7@:&ZJ_#381 <#?*> U& M>&["[-8&AE)&MT:NG_3>$AZ3NNZC(8W\M5'119J9AL)G$UB?L.N)/E\[(X,; MF9C; F #?H ^Y)= >0+)F0I9+@1FXZS;BA9:P=&*FFW1-=FBGV.&!VH71^D, M8G<07/^8X"'P'S!=$A+V$'B>H06:A$/83VL 6[8 D#*J'UJ#3:@487,(0Z:/+/A".1HZ_PO0+US'RPA[Z' MECEBJ@FKI@._UFA<%77N-1[<3WTQ0X:28@22CX]GR(#P/$Y)2AXS26Z3X!FQ M+Y- *'4;&]+:S$8 _<2$)IK_#%9532J_9@&,01(<@"Y2*)(J[?DBK:GKWZ]% M<SY6KNE8^2%=&FC\:G=8];5P M8Z2L*B'N82DE(QE+:IHLFYBH6'%R:VC7*>U6$X ,"&;)Q5/GB-328T19&]=_ MUF10N-'(WA,?)>BM!_M Q>(1-BFSY>%!'M7;O+@#^;B3IC:8%B>T&:OZ!N^( MZ$>;3B0' MPN[YQ^V;V\46 HP*'7TX5?S?T0%N8 OP^@W'2"#9)J&;X$?SC9#YS]31 <,# MMPJ5%[Y)QC:Z%=Y#[RL3BS:85',-_Y6V7A4(UE:/_;WL#E)R,>]M/?2)C3)+ M$4, D&6=Y?=R1:#'C5D&-:XL5%K:Y9*J8XEP!R>&,NX$9-[,Q 2*77;E6L M'0-ZP6&GZV@0D3$](_5E<^"*:VP+S2=05VWQ/AA^YZN.T/C^ORK+N;RN$>-< MTZL>#$)"VE:F%-XK45!"V;*#(4!X0?2[W#_?

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